PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Acetazolamide
Diamox
Injection 500mg
Syrup 25mg/mL
Tablet 250mg
Acetyl Salicylic Acid
Aspirin
Aspirin Pedia
Juspirin
Tablet 81mg
Tablet 300mg
Acetylcholine Chloride
Miochol
Injection 1%
Acetylcysteine
Parvolex
Inj. 2g/10mL
Actinomycin
Dactinomycin
Cusiviral
Acyclovir
Cyclovax
Zovirax
PRODUCT INFORMATION
THERAPEUTIC USE: Anticonvulsant, Antiglaucoma, Carbonic Anhydrase Inhibitor, Cardiovascular Agent, Musculoskeletal Agent, RenalUrologic Agent Sulfonamide,
Urinary Stone Agent
DOSE: Adult - 250 to 1000 mg ORALLY divided 1 to 4 times daily, extended-release: 500 mg ORALLY twice daily & max. dose of 1000
mg/day is recommended. Injection - Acute Angle-Closure Glaucoma, Intravenous therapy may be used for rapid relief of ocular tension in
acute cases. The recommended dose for acute congestive glaucoma is 250 mg every 4 hours. Some patients may respond to 250 mg 2 times
daily on a short-term basis. Pedia - initial, 4 mg/kg ORALLY daily maintenance, 8 to 30 mg/kg ORALLY daily, divided every 6 to 8 hours.
Injection - Glaucoma; Adjunct, recommended dose for glaucoma in children is 5 to 10 mg/kg/dose every 6 hours or 20 to 40 mg/kg/day.
CONTRA-INDICATIONS: Adrenal gland failure, chronic noncongestive angle-closure glaucoma, cirrhosis, hyponatremia/hypokalemia,
hyperchloremic acidosis, hypersensitivity to acetazolamide and severe hepatic or renal disease
ADVERSE EFFECTS: Angle-closure glaucoma, Metabolic acidosis, Sulfonamide adverse reaction, Including anaphylaxis, blood dyscrasias,
erythema multiforme, fulminant hepatic necrosis, Stevens-Johnson syndrome, toxic epidermal necrolysis & Tinnitus
THERAPEUTIC USE: Analgesic, Antipyretic, Antirrheumatic ,Central Nervous System Agent, NSAID, Platelet Aggregation Inhibitor Salicylate,
DOSE: Adult - 50 to 325 mg ORALLY once daily; maximum of up to 4 g ORALLY per day in divided doses. Pedia - 12 years and older, 325
to 650 mg ORALLY every 4 hours; MAX: 3.9 grams/24 hours
CONTRA-INDICATIONS: hypersensitivity to NSAIDs, children and teenagers with chickenpox or flu symptoms (risk of Reye's syndrome),
syndrome of asthma, rhinitis, & nasal polyps
ADVERSE EFFECTS: Angioedema, Bleeding, Bronchospasm, Gastrointestinal ulcer, Reye's syndrome and Tinnitus
THERAPEUTIC USE: Cholinergic, Direct Acting Miotic
DOSE: Adult - Miosis induction - 0.5 to 2mL instilled INTRAOCULARLY into the anterior chamber before or after securing one or more
sutures; Pedia - safety and effectiveness in pediatric patients have not been established
CONTRA-INDICATIONS: hypersensitivity to acetylcholine chloride or any component of the product
ADVERSE EFFECTS: Bradyarrhythmia, With systemic absorption, Cataract, Transient, Corneal decompensation, Corneal edema,
Endophthalmitis, Hypotension, With systemic absorption, Optic atrophy
THERAPEUTIC USE: Acetaminophen Antidote, Amino Acid Supplement, Diagnostic Agent, Bronchial, Mucolytic
DOSE: Adult & Pedia- Acetaminophen overdose, initial, 140 mg/kg ORALLY, then 70 mg/kg every 4 h for 17 doses starting 4 hr after loading
dose; initial, 150 mg/kg IV in 200 mL of 5% dextrose over 60 minutes, then 50 mg/kg IV in 500mL 5% dextrose over 4 hours, followed by 100
mg/kg IV in 1000mL of 5% dextrose over 16 hours. Nebulization into a face mask, mouth piece, or tracheostomy: 1 to 10mL of the 20%
solution or 2 to 20mL of the 10% solution every 2 to 6 h; usual dose 3 to 5mL of the 20% solution or 6 to 10mL of the 10% solution 3-4 times
daily.
ADVERSE EFFECTS: Anaphylaxis, Bronchospasm
Injection 0.5mg
THERAPEUTIC USE: Antibiotic
DOSE: Adult & Pedia - Ewing's sarcoma of bone - 15 mcg/kg IV every day for 5 days (in combination with other chemotherapy); Gestational
trophoblastic neoplasm - 12 mcg/kg IV every day for 5 days (single agent); 500 mcg IV days 1, 2 (in combination with etoposide,
methotrexate, folinic acid, vincristine, cyclophosphamide, and cisplatin);
CONTRA-INDICATIONS: chickenpox or herpes zoster infection; increased risk for severe generalized disease which could result in death,
Hypersensitivity to dactinomycin
ADVERSE EFFECTS: Anaphylaxis, Hepatotoxicity, Liver failure, Myelosuppression, Veno-occlusive disease of the liver
Cream 5%
Eye Oint. 3%
Injection 250mg
Tablet 200mg
THERAPEUTIC USE: Antiviral, Guanosine Nucleoside Analog, Viral DNA Polymerase Inhibitor
DOSE: Adult - Genital herpes simplex initial episode, 400 mg ORALLY 3 times a day or 200 mg ORALLY 5 times a day, for 7 to 10 days;
Herpes simplex, mucosal and cutaneous - Patient immunocompromised - 5 mg/kg IV every 8 hr for 7 days; apply ointment TOPICALLY every
3 hours (6 times per day) for 7 days in sufficient quantities to adequately cover lesions. Pedia - congenital herpes simplex - birth to 3 mos of
age, 10 mg/kg IV every 8 h for 10 days; doses of 15 to 20 mg/kg IV have been used; CDC recommends 20 mg/kg IV every 8 h, for 21 days for
disseminated disease or 14 days for disease of the skin and mucous membranes.
CONTRA-INDICATIONS:Hypersensitivity to acyclovir or valacyclovir
ADVERSE EFFECTS: Agitation, Confusion, Encephalopathic changes, Hemolytic uremic syndrome, Immunocompromised patients; some
fatal cases, Lethargy, Encephalopathic changes, Renal impairment, Thrombotic thrombocytopenic purpura, Immunocompromised patients;
some fatal cases and Tremor.
1
PRODUCT
DESCRIPTION
Adenosine
TRADE
NAME
Adenocor
Adrenaline
(Epinephrine)
Albendazole
DOSAGE
FORM/STRENGTH
Injection 6mg/2mL
Injection 1:1000
Inj. 1:10,000
Albenda
Tablet 200mg
Alzental
Albumin Solution
Injection 20%
Alfacalcidol
One Alpha
Cap. 0.25mcg
Capsule 1mcg
Drops 2mcg/mL
Alfuzosin
Xatral XL
Tablet 10mg
Allopurinol
No Uric
Syrup 20mg/mL
Tablet 100mg
Tablet 300mg
PRODUCT INFORMATION
THERAPEUTIC USE: Antiarrhythmic, Nutriceutical
DOSE: Adult - Advanced cardiac life support - Supraventricular tachycardia - initial 6 mg IV peripheral bolus over 1 to 2 seconds, increase to
12 mg every 1 to 2 min as needed for 2 doses; MAX 12 mg/dose. Pedia - Advanced cardiac life support - Supraventricular tachycardia initial, 0.1 mg/kg/dose IV or IO, MAX 6 mg/dose; may repeat at 0.2 mg/kg increments as needed; MAX 12 mg/dose
CONTRA-INDICATIONS: hypersensitivity to adenosine, second or third degree AV block, sinus node dysfunction, such as sick sinus
syndrome or symptomatic bradycardia
ADVERSE EFFECTS: Bradyarrhythmia, Bronchospasm, In asthmatics, Cardiac dysrhythmia, Partial atrioventricular block
THERAPEUTIC USE: Adrenergic, Alkylarylamine, Anaphylaxis Agent, Anesthetic Adjunct, Antiglaucoma, Bronchodilator, Decongestant,
Sympathomimetic, Vasopressor
DOSE: Adult – Anaphylaxis (auto-injector) 0.3mg IM (0.3mL of a 1:1000 solution); may be repeated if severe anaphylaxis persists, (injectable
solution) 0.2 to 1mg SUBQ. Pedia – Anaphylaxis (auto-injector) 0.15 to 0.3mg IM depending on body weight, a dosage of 0.01 mg/kg is
recommended
CONTRA-INDICATIONS: Cardiac dilatation & coronary insufficiency, concurrent use with cyclopropane or halogenated hydrocarbon
anesthetic; may sensitize the heart to the arrhythmic action of sympathomimetic drugs,concurrent use with local anesthetics for injection of
certain areas (eg; fingers, toes, ears); increased risk of vasoconstriction and sloughing of tissue, hypersensitivity to sympathomimetic amines,
ADVERSE EFFECTS: Cardiac dysrhythmia, Hypertensive crisis, Pulmonary edema
THERAPEUTIC USE: Anthelmintic, Benzimidazole
DOSE: Adult & Pedia - Ancylostomiasis and necatoriasis 400 mg ORALLY as a single dose
ADVERSE EFFECTS: Acute renal failure, Agranulocytosis, Aplastic anemia, Erythema multiforme, granulocytopenic disorder, Hepatotoxicity,
With elevated liver enzymes Leukopenia, Pancytopenia, Stevens-Johnson syndrome, Thrombocytopenia
THERAPEUTIC USE: Volume Expander
DOSE: Adult - Cardiopulmonary bypass operation 5%, adjust albumin and crystalloid pump prime to achieve a hematocrit of 20% and a
plasma albumin concentration of 2.5 g/100mL; Hypovolemic shock - IV, 500mL of 5% solution as rapidly as tolerated, may repeat in 30
minutes; IV, 100 to 200mL of 25% solution, may repeat in 15-30 minutes. Pedia - Hypovolemic shock - IV, 10 to 20mL/kg of 5% solution, may
repeat in 30 minutes, MAX 6 g/kg/day; IV, 2.5 to 5mL of 25% solution, may repeat in 15-30 minutes
CONTRA-INDICATIONS: Hypersensitivity to albumin, patients at risk for acute circulatory overload
ADVERSE EFFECTCS: Immune hypersensitivity reaction
THERAPEUTIC USE: Nutritive Agent, Vitamin D (class)
DOSE: Adults - once daily with food. Pedia - 1mcg daily have been administered to children 2 to 17 years of age for control of secondary
hyperparathyroidism; Addition of oral alfacalcidol 10 to 20 ng/kg daily to standard therapy
CONTRA-INDICATIONS: Prior hypersensitivity to alfacalcidol, vitamin D (cholecalciferol, ergocalciferol), or other vitamin D metabolites (eg,
calcitriol, calcifediol, calcipotriol) Hypercalcemia (exacerbation with enhanced toxicity) Other evidence of hypervitaminosis D (exacerbation)
THERAPEUTIC USE: Alpha-1 Adrenergic Blocker, Benign Prostatic Hypertrophy Agent
DOSE: Adult -Benign prostatic hyperplasia extended-release: 10mg ORALLY once daily. Pedia - safety and effectiveness not established in
children
CONTRA-INDICATIONS: concomitant use of potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir; increases blood
levels of alfuzosin, hepatic insufficiency, moderate or severe; may lead to increased alfuzosin levels in the blood,
and hypersensitivity to alfuzosin or to any component of the product
ADVERSE EFFECTS: Angina ,Intra-operative floppy iris syndrome, Orthostatic hypotension, Prolonged QT interval, Tachycardia
THERAPEUTIC USE: Anti-gout, Urinary Stone Agent, Xanthine Oxidase Inhibitor
DOSE: Adult - Calcium renal calculus, recurrent 200 to 300mg ORALLY as a single or divided dose (2-3 times daily); maximum dose: 300
mg/dose; 800 mg/day.
Pedia - Hyperuricemia Tumor lysis syndrome - (under 6 yrs) 50 mg ORALLY 3 times daily; (6-10 yrs) 100 mg ORALLY 3 times daily OR 300
mg ORALLY once daily ; 200 mg/m(2)/day IV starting 24-48 hours prior to initiation of chemotherapy as a single infusion OR in equally divided
infusions at 6-, 8-, or 12-hour intervals
ADVERSE EFFECTCS: Agranulocytosis, Anemia, Hepatotoxicity, Myelosuppression,
Stevens-Johnson syndrome
2
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Alprostadil
Prostin VR
Injection
500mcg
Alteplase
Actilyse
Injection 50mg
Alum Hydroxide/
Magnesium Hydroxide
Moxal
Rialox
Suspension
Amethocaine HCl
(Tetracaine)
Amethocaine
Eye Minims
0.5%
Amikacin Sulphate
Miacin
Injection 100mg
Injection 500mg
AmilorideHCl/
Hydrochlorothiazide
Moduretic
Tablet
PRODUCT INFORMATION
THERAPEUTIC USE: Endocrine-Metabolic Agent, Erectile Dysfunction Agent, Prostaglandin
DOSE: Adult - Erectile dysfunction, initial dose of 2.5mcg INTRACAVERNOSAL INJECTION, average dose of 2.5-60mcg; no more than 3
doses weekly with at least 24 hours between doses; or 125-1000mcg urethral SUPPOSITORY; no more than 2 doses in 24 hours; Pedia –
Cyanotic congenital heart disease initial, 0.05-0.1mcg/kg/min continuous IV, maintenance 0.01-0.4mcg/kg/min
CONTRA-INDICATIONS: anatomical deformation of the penis, hypersensitivity to alprostadil, leukemia, myeloma, neonatal respiratory
distress syndrome, penile implant MUSE® is contraindicated for use with pregnant sexual partners unless a condom is used
ADVERSE EFFECTS: Apnea in the newborn, Congestive heart failure, Disorder of bone development, Cortical proliferation of long bones,
Disseminated intravascular coagulation, Prostin, Partial atrioventricular block, Priapism, Seizure, Supraventricular tachycardia, Ventricular
fibrillation
THERAPEUTIC USE: Thrombolytic, Tissue Plasminogen Activator
DOSE: Adult - Acute myocardial infarction, Accelerated infusion: patients over 67 kg- total dose 100 mg IV, give 15 mg IV bolus, 50 mg over
30 minutes, then 35 mg over 60 minutes. Pedia - Venous catheter occlusion, Central, 30 kg of weight or greater) 2 mg/ 2 mL instilled into
occluded catheter; up to 2 doses may be used, separated by 120 minutes.
CONTRA-INDICATIONS: active internal bleeding, hypersensitivity to alteplase, severe uncontrolled hypertension, recent intracranial or
intraspinal surgery or trauma, intracranial neoplasm, arteriovenous malformation, or aneurysm
known bleeding diathesis, history of cerebrovascular accident, evidence of intracranial hemorrhage, suspicion of subarachnoid hemorrhage,
history of intracranial hemorrhage, seizure at the onset of stroke, platelet count less than 100,000/mm(3), administration of heparin with 48
hours preceding the onset of stroke and have an elevated activated partial thromboplastin time at presentation
ADVERSE EFFECTS: Cardiac dysrhythmia, Reperfusion, Cholesterol embolus syndrome, Gastrointestinal hemorrhage, After catheter
clearance, Immune hypersensitivity reaction, Intracranial hemorrhage, Sepsis, After catheter clearance, Venous thrombosis, After catheter
clearance
THERAPEUTIC USE: Antacids
DOSE: Adult - Oral doses are 15 to 30 mL or 250 mg to 1.5 g 4 times a day depending on the formula; pediatric oral doses are 0.5 to 5 mL or
150 to 250 mg/kg/day in 4 to 6 divided doses. Pedia – 0.5mL/kg are recommended for infants with reflux disease. Best results, as determined
by serial intragastric pH monitoring, obtained when antacid was given prior to and after formula feedings
CONTRA-INDICATIONS: Antacids are contraindicated in patients with a history of hypersensitivity to the components of the product.
THERAPEUTIC USE: Amino Ester, Anesthetic, Local
DOSE: Adult – direct application: apply 0.25% or 0.5% solution to larynx, trachea, or esophagus (add 0.06mL of epinephrine to each mL of
anesthetic solution minor surgical procedures, instill 1-2 drops of 0.5% ophthalmic solution into eyes every 5-10 min for 1-3 instillations. Pedia
- not FDA approved in pediatric patients
CONTRA-INDICATIONS: hypersensitivity to tetracaine hydrochloride/ester-type anesthetics or aminobenzoic acid or its derivatives, topical
application to inflamed/infected tissue, when spinal anesthesia contraindicated.
ADVERSE EFFECTS: Apnea, Injection or excessive systemic absorption of topical Cardiac arrest, Injection or excessive systemic absorption
of topical, Central nervous system finding, Depression or excitation, injection or excessive systemic absorption of topical, Contact dermatitis,
Topical, Drug-induced keratoconjunctivitis (Severe), Ophthalmic
THERAPEUTIC USE: Aminoglycoside Antibiotic
DOSE: Adult – 15mg/kg/day IV/IM divided every 8 to 12 hr; depending on type and severity of infection; total daily dose should not exceed
15mg/kg/day; for heavier patients the total daily dose should not exceed 1.5g/day. Pedia – (neonates) 10mg/kg IV/IM loading dose followed
with 7.5mg/kg IV/IM every 12 hr; total daily dose should not exceed 15 mg/kg/day; (infants and children) 15 mg/kg/day IV/IM divided every 8
to 12 hrs; total daily dose should not exceed 15 mg/kg/day
ADVERSE EFFECT: Nephrotoxicity, Neuromuscular blockade finding, Ototoxicity, Respiratory tract paralysis, Concomitant anesthesia,
muscle relaxants
THERAPEUTIC USE: Diuresis
DOSE: Diuresis: 1 tab ORALLY daily, may increase to 2 tabs ORALLY daily
CONTRA-INDICATIONS: antikaliuretic therapy (potassium-conserving agents or supplementation), hypersensitivity to amiloride, HCTZ or
sulfonamides, hyperkalemia
impaired renal function (Cr over 1.5 mg/100 mL or BUN over 30 mg/100 mL)
ADVERSE EFFECTS: Dermatologic: Erythema multiforme, Rash (3-8%), Scaling eczema (less than 1%), Endocrine metabolic: Hyperkalemia
(1-2%), Gastrointestinal: Loss of appetite (3-8%), Nausea (3-8%), Neurologic: Asthenia (3-8%), Dizziness (3-8%), Headache (3-8%)
3
PRODUCT
DESCRIPTION
TRADE
NAME
Aminophyllin
DOSAGE
FORM/STRENGTH
Injection 250mg
Amiodarone
Cordarone
Injection 150mg
Susp. 5mg/mL
Tablet 200mg
Amitriptyline HCl
Tryptizol
Tablet 10mg
Tablet 25mg
Amlodipine
Amoxycillin
Amlor
Lowvasc
Amoxil
Amoxydar
Flemoxin
Hiconcil
Hymox
Julphamox
Ospamox
Amoclan
Amoxycillin /
Clavulanic Acid
Augmentin
Klavox
Tablet 5mg
Capsule 500mg
Drops 100mg
Susp.250mg/5mL
Injection 600mg
Injection 1200mg
Susp. 156mg/5mL
Susp. 457mg/5mL
Tablet 375mg
Tablet 625mg
PRODUCT INFORMATION
THERAPEUTIC USE: Asthma, chronic obstructive pulmonary disease
DOSE: Adult - Asthma: aminophylline dose equals theophylline dose divided by 0.8; Asthma: IV, loading dose for acute bronchodilation,
theophylline 4.6mg/kg (aminophylline 5.7mg/kg) of ideal body weight IV over 30 min. Pedia – Asthma IV, loading dose for acute
bronchodilation, theophylline 4.6 mg/kg (aminophylline 5.7 mg/kg) of lean (ideal) body weight IV over 30 min.
ADVERSE EFFECTS: Cardiovascular: Atrial fibrillation, Bradyarrhythmia, Too quick
Administration, Cardiac arrest, Tachyarrhythmia,
Dermatologic: Erythroderma Gastrointestinal: Necrotizing enterocolitis in fetus or newborn, Immunologic: Immune hypersensitivity reaction,
Neurologic: Intracranial hemorrhage, Seizure
THERAPEUTIC USE: Antiarrhythmic, Group III, Benzofuran
DOSE: Adult – Advanced cardiac life support 300mg IV/IO by rapid infusion; if necessary, a supplementary dose of 150mg IV/IO by rapid
infusion may be considered; MAX daily dose 2.2 g;Supraventricular arrhythmia – IV/ORAL regimen; 300mg IV for 1 hr, then 20 mg/kg for 24
hrs, then 600 mg ORALLY daily for 1 wk, then 400 mg ORALLY daily
Pedia – safety and efficacy have not been established in children;Advanced cardiac life support perfusing tachycardias, 5 mg/kg IV over 2060 min; repeat up to MAX daily dose 15 mg/kg; MAX single dose 300 mg
CONTRA-INDICATIONS: Cardiogenic shock, Hypersensitivity to amiodarone or to any of its components, including iodine,Second or third
degree AV block, Severe sinus bradycardia, Severe sinus node dysfunction
ADVERSE EFFECTS: Cardiac dysrhythmia, Congestive heart failure, Disorder of thyroid gland, Hepatotoxicity, Immune hypersensitivity
reaction, Pulmonary toxicity, Shock, Stevens-Johnson syndrome, Thrombocytopenia
THERAPEUTIC USE: Antidepressant, Tricyclic, Urinary Enuresis Agent
DOSE: Adult – Depression 1)outpatients: 75 mg ORALLY (divided into 1-3 doses per day); may increase up to a max of 150 mg/day
2)inpatients: 100 mg ORALLY (divided into 1-3 doses per day); may increase up to a max of 300 mg/day 3)maintenance: 50-100 mg ORALLY
at bedtime 4) 20-30 mg IM 4 times a day; switch to ORAL dosing as soon as possible. Pedia – Safety and effectiveness in children below 12
years have not been established
CONTRA-INDICATIONS: co-administration with cisapride; may cause QT interval prolongation and increase the risk of arrhythmia, coadministration with a MAOI or use within 14 days of discontinuing a MAOI; may cause serious reactions (eg, hyperpyretic crisis, severe
convulsions, death) hypersensitivity to amitriptyline hydrochloride myocardial infarction (MI), during the acute recovery period
ADVERSE EFFECTS: Agranulocytosis, Aplastic anemia, Atrioventricular conduction pattern – finding, Cardiac dysrhythmia, Cerebrovascular
accident, Decreased liver function, Depression, worsening, Drug-induced eosinophilia, Hypertension, Jaundice, Leukopenia, Myocardial
infarction, Orthostatic hypotension, Pancytopenia, Purpuric disorder, Seizure, Suicidal thoughts, Suicide, Syncope,Thrombocytopenia
THERAPEUTIC USE: Antianginal, Antihypertensive, Calcium Channel Blocker, Cardiovascular Agent, Dihydropyridine
DOSE: Adult – Hypertension initial, 5 mg ORALLY once daily; maintenance 5-10 mg ORALLY once daily; Stable angina 5-10 mg ORALLY
once daily. Pedia – safety and efficacy not established in pediatric patients younger than 6 years of age, Hypertension, 6 to 17 years of age:
2.5-5 mg ORALLY once daily
CONTRA-INDICATIONS: Hypersensitivity to amlodipine
ADVERSE EFFECTS: Angina, Cardiac dysrhythmia, Myocardial infarction
THERAPEUTIC USE: Antibiotic Penicillin, Amino-penicillin
DOSE: Adult - Infection of skin &/or subcutaneous tissue mild to moderate infections, 500 mg ORALLY every 12 hr or 250 mg ORALLY every
8 hr oral capsules, oral tablets, chewable oral tablets, oral suspension, severe infections, 875 mg ORALLY every 12hr or 500 mg ORALLY
every 8 hr. Pedia – 50 mg/kg ORALLY 1 hr prior to procedure; maximum 2 g/dose.
CONTRA-INDICATIONS: Hypersensitivity to penicillins
ADVERSE EFFECTS: Immune hypersensitivity reaction
THERAPEUTIC USE: Antibiotic
DOSE: Adult – Infection of skin &/or subcutaneous tissue a)mild to moderate infections, 500 mg ORALLY every 12 hr or 250 mg ORALLY
every 8 hr b) severe infections, 875 mg ORALLY every 12 hr or 500 mg ORALLY every 8 hr. Pedia – (125mg/5mL) infants less than 3
months of age, 30 mg/kg/day ORALLY divided every 12 hr; (200 mg and 400 mg/5mL, 200 mg and 400 mg chewable tab) 3 months and older
and under 40 kg, 25-45 mg/kg/day ORALLY divided every 12 hr; depending on type and severity of infection; (125 mg and 250 mg/5mL, 125
mg and 250 mg chewable tab) 3 months and older and under 40 kg, 20-40 mg/kg/day ORALLY divided every 8 hr; depending on type and
severity of infection
CONTRA-INDICATIONS: hypersensitivity to penicillins, clavulanic acid, history of Augmentin-associated jaundice/hepatic dysfunction
4
PRODUCT
DESCRIPTION
Amphotericin
Ampicillin
Amylase/Lipase/Protease
/Dimethylpolysiloxane/
Pancreatin
Antazoline/Naphazolin
Benzethonium
TRADE
NAME
Abelect
Fungizone
Epicocillin
Pentrexyl
Pankreoflat
Noscam
DOSAGE
FORM/STRENGTH
Injection 50mg
Lipid Complex –
Injection 100mg
Injection 500mg
Injection 1gram
PRODUCT INFORMATION
ADVERSE EFFECTS: Hepatotoxicity
THERAPEUTIC USE: Antifungal, Antiprotozoal, Polyene
DOSE: Adult test dose: 1mg in 20mL D5W IV over 20-30 min; American mucocutaneous leishmaniasis 0.25-1mg/kg/day IV over 2-6 hours.
Pedia test dose: 1mg in 20mL D5W IV over 20-30 min; INTRATHECAL neonatal doses have ranged from 0.5mg/day in 2mL of D5W to 0.6
mg/day in 0.5mL of D5W (total doses were 0.15 mg to 8.6 mg); doses of 0.125 to 0.25 mg have been administered to children via an
Ommaya reservoir.
ADVERSE EFFECTS: Anaphylaxis, Anemia, Blurred vision, Cardiac dysrhythmia, Diplopia, Hypokalemia, Hypotension, Nephrotoxicity,
Seizure, Tachypnea, Thrombocytopenia, Thrombophlebitis
THERAPEUTIC USE: Antibiotic, Penicillin, Aminopenicillin
DOSE: Adult – Respiratory tract infection 250 mg ORALLY every 6 hr; 250-500 mg IV/IM every 6 hr. Pedia – Respiratory tract infection 50
mg/kg/day ORALLY divided every 6 hr
CONTRA-INDICATIONS: Hypersensitivity to ampicillin products/penicillins
ADVERSE EFFECTS: Immune hypersensitivity reaction
Tablet
THERAPEUTIC USE: Digestant, Enzyme
DOSE: Adult – Exocrine pancreatic insufficiency 2 tablets (1000 mg) ORALLY with each meal and 2 tablets (1000 mg) taken with food eaten
between meals.
Pedia – safety and effectiveness in children have not been established
CONTRA-INDICATIONS: Hypersensitivity to pancreatin or to pork protein
Nasal Drops
THERAPEUTIC USE: Allergic conjunctivitis
DOSE: Adult – Allergic conjunctivitis: 1-2 drops 0.5% ophthalmic solution in each EYE up to 4 times daily (with 0.05% naphazoline). Pedia –
Not FDA approved in children under 6 y of age; Allergic conjunctivitis: (6 y and older) 1-2 drops 0.5% ophthalmic solution in each EYE up to 4
times daily (with 0.05% naphazoline)
CONTRA-INDICATIONS: concurrent use of contact lens, narrow angle glaucoma
ADVERSE EFFECTS: Ophthalmic: Excessive tear production, Transient, Intraocular pressure finding, Increase or decrease, Mydriasis, Pain
in eye, Transient
Antazoline/Tetryzoline
Spersallerg
Eye Drops
Anti-Haemophilic Factor IX
Octanine F
Injection 500iu
Anti-Haemophilic Factor VII
Novoseven
Injection 1.2mg
Anti-Haemophilic Factor VIII
Octavi
Injection 250iu
Injection 500iu
THERAPEUTIC USE: Inflammatory conditions of the conjunctiva of allergic origin, especially hay fever and vernal conjunctivitis, and in drug
hypersensitivity reactions, excessive lacrimal secretion and stenosis of the lacrimal canal
DOSE: Adult – Acute cases 1drop every three hours; Protracted treatment, 1drop 2-3times daily is sufficient. In severe cases apply hourly.
Pedia – only 1-2 drops per day.
THERAPEUTIC USE: Antihemophilic Agent, Hemostatic
DOSE: Adult – Hemophilia B – Hemorrhage; number of Factor IX IU required = body weight (kg) times desired Factor IX increase (%) times
1 IU/kg; mild hemorrhage (20% to 30% of normal Factor IX level), 20-30 IU/kg IV twice daily until hemorrhage stops and healing is achieved
(1 to 2 days). Pedia – Hemophilia B – Hemorrhage; dose required = body weight (kg) times desired Factor IX increase (%) times 1 IU/kg
CONTRA-INDICATIONS: Hypersensitivity to hamster protein, Disseminated intravascular coagulation, fibrinolysis, Hypersensitivity to mouse
proteins
THERAPEUTIC USE: Antihemophilic Agent, Hemostatic
DOSE: Adult & Pedia – Bleeding; Prophylaxis – Factor VII deficiency – Procedure 15-30 mcg/kg IV bolus over 2-5 minutes, every 4-6 hours
until hemostasis achieved; adjust dose and frequency as necessary.
CONTRA-INDICATIONS: Hypersensitivity to mouse, hamster, or bovine proteins, hypersensitivity to recombinant coagulation factor VIIa or
any of its components
ADVERSE EFFECTS: Acute renal failure, Anaphylaxis, Arterial thromboembolism, Bleeding, Blood coagulation disorder, Cerebral artery
occlusion, Cerebral ischemia, Disseminated intravascular coagulation, Ischemic heart disease, acute, Myocardial infarction, Pulmonary
embolism, Supraventricular tachycardia, Venous thromboembolism
THERAPEUTIC USE: Antihemophilic Agent
DOSE: Adult & Pedia; Bleeding – Hemophilia A – dosage calculation: body weight (kg) X factor VIII activity increase desired (%) divided by
2% per international unit per kg = dose required (international units).
CONTRA-INDICATIONS: History of anaphylactic or severe systemic response to antihemophilic factor VIII, Hypersensitivity to antihemophilic
factor VIII
ADVERSE EFFECTS: Hemolytic anemia, Hyperfibrinogenemia, Immune hypersensitivity reaction, Pulmonary thromboembolism,
Thromboembolic disorder, Viral disease, Transmission
5
PRODUCT
DESCRIPTION
TRADE
NAME
Anti-Rho(D) Immunoglobulin
Rhesonativ
Apraclonidine
Iopidine
Aprotinin
Trasylol
Artificial Tears
DOSAGE
FORM/STRENGTH
Inj. 250mcg
Eye Drops 5mg/mL
Inj. 500,000u
Eye Drops
Ascorbic Acid
+ Ca Sandoz
Ca-C
Ca-Sandoz
Cal-C-Vita
Calcitec
Tablet
Asparaginase
Erwinase
Inj. 10,000u
Cardol
Atenolol
Hypoten
Tenormin
Inj. 5mg/10mL
Tablet 50mg
Tablet 100mg
PRODUCT INFORMATION
THERAPEUTIC USE: Immune Serum
DOSE: Adult & Pedia – Abortion, Isoimmuinization affecting pregnancy, abortion or other obstetric condition – Rhesus isoimmunization
affecting pregnancy, Sensitization of Rho(D) negative females to Rho(D) positive blood; Prophylaxis a)IV or IM; abortion, amniocentesis after
34 weeks gestation, or any other manipulation late in pregnancy associated with increased risk of Rh isoimmunization, 600 IU (120 mcg) IM
OR IV immediately b)IV or IM; threatened abortion, amniocentesis before 34 weeks gestation, or chorionic villus sampling, 1500 IU (300
mcg) ( IM OR IV immediately, repeat every 12 weeks for duration of pregnancy.
CONTRA-INDICATIONS: Anaphylaxis or severe systemic reaction to human globulin, IgA deficiency; potential for IgA antibody development
and anaphylactic reactions, infants; do not administer to infants when used for the suppression of Rh isoimmunization
ADVERSE EFFECTS: Acute renal failure, Anaphylaxis, Intravascular hemolysis
THERAPEUTIC USE: Alpha-2 Adrenergic Agonist, Anti-glaucoma
DOSE: Adult - Laser surgery – Ocular hypertension, Postsurgical; Treatment and Prophylaxis – 1 drop (1% solution) in operative eye(s) 1 h
before surgery and 1 drop immediately upon completion of surgery; Raised intraocular pressure; Adjunct 1 to 2 drops (0.5% solution) instilled
to affected eye(s) 3 times daily. Pedia – safety and efficacy have not been determined in pediatric patients
CONTRA-INDICATIONS: hypersensitivity to apraclonidine or clonidine, patients receiving MAO inhibitors
ADVERSE EFFECTS: Cardiac dysrhythmia, Immune hypersensitivity reaction, Peripheral edema
THERAPEUTIC USE: Hemostatic
DOSE: Adult – Cardiopulmonary bypass operation, At increased risk for blood loss and blood transfusion – Hemorrhage, Perioperative;
Prophylaxis-initial dose: 10,000 kallikrein inhibitory units IV (10 minutes prior to the loading dose); loading dose: 1 million to 2 million kallikrein
inhibitory units IV (over 20 to 30 minutes and prior to sternotomy). Pedia – safety and efficacy not established in pediatric patients
CONTRA-INDICATIONS: hypersensitivity to aprotinin or any product component, known or suspected previous aprotinin exposure (including
aprotinin containing fibrin sealant) within the last 12 months; risk of anaphylactic, and potentially fatal reactions, even among patients who
tolerate an initial test dose
ADVERSE EFFECTS: Anaphylaxis, Cerebral artery occlusion, Heart failure, Myocardial infarction, Renal failure, Shock, Thrombotic disorder
THERAPEUTIC USE: Diagnostic Agent, Lubricant, Surgical Aid, Ocular
DOSE: Adult & Pedia – Xerophthalmia instill 1 drop 0.3% to 1% OPHTHALMIC solution into affected eye(s) 3 to 4 times daily, as needed
CONTRA-INDICATIONS: Hypersensitivity to hypromellose
THERAPEUTIC USE: Calcium Supplement, Nutritive Agent, Urinary Acidifier, Vitamin Combination, Adult Formula
DOSE: Adult – mild to moderate deficiency, 100 to 250 mg IM/IV/SC or ORALLY once or twice daily. Pedia - Ascorbic acid deficiency 100
mg 3 times/day IM/IV/SC or ORALLY for 1 wk, then 100 mg daily for several wk until tissue saturation is reached; recommended dietary
allowance, age 0 to 6 months, 40 mg/day; 7 to 12 months, 50 mg/day; 1 to 3 y, 15 mg/day; 4 to 8 y, 25 mg/day; 9 to 13 y, 45 mg/day; males
14 to 18 y, 75 mg/day; females 14 to 18 mg/day 65 mg/day
CONTRA-INDICATIONS: Hypersensitivity to any component of the preparation
THERAPEUTIC USE: Antineoplastic Agent
DOSE: Adult & Pedia – 1)desensitization therapy, administer 1 International Unit IV and double the dose every 10 minutes, provided no
reaction has occurred, until the accumulated total amount equals the planned dose for that day 2)skin test, prepare by reconstituting the
contents of a 10,000 International Units vial with 5 mL of diluent. From this solution (2,000 International Units/mL) 0.1 mL is withdrawn and
injected into another vial containing 9.9 mL diluent, giving a skin test solution of approximately 20 International Units/mL. For the intradermal
skin test, 0.1 mL of this solution (approximately 2 International Units) is utilized.
CONTRA-INDICATIONS: acute hemorrhagic pancreatitis, history of pancreatitis, pancreatitis, hypersensitivity reactions/anaphylaxis
ADVERSE EFFECTS: Acute hemorrhagic pancreatitis, Acute renal failure, Anaphylaxis, Body temperature above normal, Hyperglycemia,
Hypofibrinogenemia, Factors V, VII, VIII & IX, Pancreatitis, Pharyngitis, Phlebitis, Pseudocyst of pancreas, Rash, Respiratory distress,
Urticaria
THERAPEUTIC USE: Antianginal, Antiarrhythmic, Group II, Antihypertensive, Antimigraine, Beta-Adrenergic Blocker, Cardioselective,
Cardiovascular Agent
DOSE: Adult – Acute myocardial infarction – 5 mg IV over 5 min, give second 5 mg IV dose 10 min later; if IV dose was tolerated, begin 50
mg ORALLY 10 min after last IV dose, then 50 mg ORALLY 12 h later, then 100 mg ORALLY once daily or 50 mg ORALLY twice daily for 6 to
9 further days; Angina pectoris, chronic 50 mg ORALLY once daily; if inadequate response after 1 week, increase to 100 mg ORALLY once
daily; maximum dose, 200 mg ORALLY once daily. Pedia – Not FDA-approved in children Hypertension – initial, 0.5 to 0.1 mg/kg/day
ORALLY in 1 to 2 divided doses; MAX 2 mg/kg/day ORALLY up to 100 mg/day in 1 to 2 divided doses
CONTRA-INDICATIONS: cardiogenic shock, hypersensitivity to atenolol, overt cardiac failure, second and third degree AV block, severe
sinus bradycardia,
ADVERSE EFFECTS: Lupus erythematosus
6
PRODUCT
DESCRIPTION
Atosiban Acetate
TRADE
NAME
Tractocile
DOSAGE
FORM/STRENGTH
Inj. 37.5mg/5mL
Inj. 6.75mg/0.9mL
Eye Drops 0.5%
Eye Oint. 1%
Inj. 0.5mg/mL
Syr. 0.1mg/mL
Atropine Sulphate
Azathioprine
Imuran
Tablet 50mg
Aztreonam
Azactam
Injection 1gram
Baclofen
Lioresal
Syrup 5mg/mL
Tablet 10mg
Balanced Salt
BSS
Eye Solution
BCG Live Attenuated
Mycobacterum Tuberculosis
Injection
PRODUCT INFORMATION
THERAPEUTIC USE: Effective in the treatment of preterm labor, Intravenous atosiban effectively inhibits uterine contractions
DOSE: Preterm labor – Optimal doses have not been established. Atosiban is given via a continuous intravenous infusion. An initial
intravenous bolus is recommended to shorten the time to cessation of uterine contractions. For women with preterm labor and intact
membranes, an effective intravenous (IV) dosing regimen has begun with a 6.75 milligram bolus, followed immediately by infusion of 300
micrograms/minute for 3 hours and then a 100 micrograms/minute infusion
CONTRA-INDICATIONS: hypersensitivity to atosiban, Preeclampsia or eclampsia, suspected chorioamnionitis, bruption placentae,
undiagnosed vaginal bleeding, multiple gestation, intrauterine fetal distress or fetal death
THERAPEUTIC USE: Anesthetic Adjunct, Antimuscarinic, Cholinergic Antagonist, Gastrointestinal Agent, Mydriatic-Cycloplegic, Nerve Gas
Antidote, Urinary Antispasmodic
DOSE: Adult – Bradyarrhythmia, acute symptomatic, 0.5 mg IV every 3 to 5 min to MAX total dose of 3 mg; Cardiac dysrhythmia, Increased
vagal activity during intra-abdominal surgical traction - General anesthesia, 0.4 to 0.6 mg IV; Cycloplegic refraction - 1 drop of 1% or 2%
ophthalmic solution instilled in eye(s) up to 3 times a day. Pedia – Cardiac dysrhythmia, Increased vagal activity during intra-abdominal
surgical traction - General anesthesia - a)up to 12 y, 0.1 to 0.6 mg IV b)12 y and older, 0.4 to 0.6 mg IV c)with cyclopropane anesthetic, less
than 0.4 mg IV slowly;
Amblyopia - 1 drop of 1% ophthalmic solution instilled in eye(s) once daily
CONTRA-INDICATIONS: Hypersensitivity to atropine or anticholinergics, Narrow-angle glaucoma, Reflux esophagitis, Obstructive
gastrointestinal disease, Ulcerative colitis or toxic megacolon, Obstructive uropathy, Unstable cardiovascular status in acute hemorrhage or
thyrotoxicosis, Paralytic ileus or intestinal atony, Myasthenia gravis
ADVERSE EFFECTS: Cardiac dysrhythmia, Coma, Immune hypersensitivity reaction, Raised intraocular pressure, Respiratory depression
THERAPEUTIC USE: Antimetabolite, Antirheumatic, Cytotoxic, Gastrointestinal Agent
DOSE: Adult – Inflammatory bowel disease 2-3 mg/kg/day ORALLY; maintenance, 1 to 2.5 mg/kg/day ORALLY OR IV as single dose or
divided twice daily; may lower dose 0.5 mg/kg/day every 4 weeks until lowest effective dose is reached.
Pedia – safety & efficacy not established in pediatric patients
CONTRA-INDICATIONS: history of treatment with alkylating agents, hypersensitivity to azathioprine, pregnancy
ADVERSE EFFECTS: Cancer, Hepatotoxicity, Infectious disease, In renal transplant patients, Leukopenia, Megaloblastic anemia,
Pancreatitis, Thrombocytopenia
THERAPEUTIC USE: Antibiotic, Monobactam
DOSE: Adult - Infection of skin &/or subcutaneous tissue (moderately severe systemic infections) 1 or 2 g IV every 8 or 12 h (MAX dose, 8
g/day) Pedia – Endometritis (mild to moderate infections) age 9 months and older, 30 mg/kg IV every 8 h (MAX dose, 120 mg/kg/day)
ADVERESE EFFECTS: Anaphylaxis, Hepatotoxicity, Neutropenia, Pancytopenia, Pseudomembranous enterocolitis, Thrombophlebitis
THERAPEUTIC USE: Analgesic, Gamma Aminobutyric Acid (class), Skeletal Muscle Relaxant, Centrally Acting
DOSE: Adult – Spasticity 5mg ORALLY 3 times a day; may increase dosage by 15 mg/day increments every 3 days to a MAX dose of 80
mg/day (3 to 4 divided doses)
Pedia – Safety and effectiveness of oral baclofen use in children under 12 years of age have not been established. Spasticity a)(2 to 7 y old)
10 to 15 mg/day ORALLY (2 to 3 divided doses); may increase by 5 to 15 mg/day increments every 3 days to a MAX dose of 40 mg/day (3 to
4 divided doses) b)(8 y and older), 10 to 15 mg/day ORALLY (2 to 3 divided doses); may increase by 5 to 15 mg/day increments every 3 days
to a MAX dose of 60 mg/day (3 to 4 divided doses)
ADVERSE EFFECTS: Aseptic meningitis, with intrathecal administration, Coma, Death, abrupt withdrawal, Seizure
THERAPEUTIC USE: For irrigation during various surgical procedures of the eyes, ears, nose and/or throat.
DOSE: This ocular irrigating solution should be used according to standard format for each surgical procedure.
ADVERSE EFFECTS: When the corneal endothelium is abnormal, irrigation or any other trauma may result in bullous keratopathy.
Postoperative inflammatory reactions as well as incidents of corneal edema and corneal decompensation have been reported
THERAPEUTIC USE: Vaccine
DOSE: Adult - Tuberculosis; Prophylaxis 0.2-0.3 mL PERCUTANEOUSLY x 1.
Pedia –Tuberculosis; Prophylaxis a)1 month of age and older, 0.2-0.3 mL PERCUTANEOUSLY x 1; b)less than 1 month of age, one-half of
adult dose (by reconstituting vial with 2 mL of sterile water)
CONTRA-INDICATIONS: immunocompromised status including HIV infection, urinary tract infection or hematuria, acute febrile illness, 7 to
14 days following biopsy, transurethral resection, or traumatic catheterization; increased risk for systemic BCG infection, active tuberculosis,
hypersensitivity to BCG products
ADVERSE EFFECTS: Caseous lesion, Puncture site, percutaneous, Disseminated mycobacteriosis, Intravesical and percutaneous, Infection
due to Mycobacterium bovis, Intravesical and percutaneous, Injection site ulcer, Percutaneous, Purulent discharge from wound, Suppurative
lymphadenopathy, With draining sinuses, percutaneous
7
PRODUCT
DESCRIPTION
TRADE
NAME
Beclomethasone
Dipropionate
Becloforte
Beconase
Becotide
Benzathine Penicillin
Retarpen
DOSAGE
FORM/STRENGTH
Inhaler 50mcg
Nasal Spray
50mcg
Inj. 1.2million units
Benzoic Acid
Powder
Benzoin Tincture
Solution
Benztropine Mesylate
Cogentin
Inj. 1mg/mL
Benzyl Penicillin Sodium
Specillin
Inj. 1million unit
Beractant
Survanta
Suspension
Betahistine Dihydrochloride
Betaserc
Tablet 8mg
Betamethasone
+ Cinchocaine
Supraproct-S
Suppository
Betamethasone
Dipropionate
Betasone
Cream 0.1%
Betnovate
PRODUCT INFORMATION
THERAPEUTIC USE: Adrenal Glucocorticoid, Anti-Inflammatory
DOSE: Adult - Asthma, maintenance treatment and prophylaxis Oral Inhalation, previously treated with bronchodilators alone, initial, 40 to 80
mcg twice a day; MAX 320 mcg twice daily. Pedia - Safety and efficacy not established in children under age 5; Asthma, maintenance
treatment and prophylaxis Oral Inhalation, ages 5 to 11 yr, 40 mcg twice a day; MAX 80 mcg twice a day
CONTRA-INDICATIONS: Acute asthma exacerbations, hypersensitivity to beclomethasone, status asthmaticus
ADVERSE EFFECTS: Cataract, Glaucoma, Osteoporosis, Long-term treatment, Secondary hypocortisolism
THERAPEUTIC USE: Treatment & prophylaxis of infections caused by organisms with high penicillin sensitivity
DOSE: Adult – 1 to 2dose of Retarpen 1.2mu at intervals of 4weeks. Pedia – under 12years old 1dose of Retarpen 0.6mu at intervals of 14
days.
CONTRA-INDICATIONS: Hypersensitivity to to Penicillins, cephalosphorins.
ADVERSE EFFECTS: Stomatitis, glossitis, neuropathy, nephropathy, urticaria.
THERAPEUTIC USE: Benzoic Acid (class), Scabicide
DOSE: Adult – Apply benzoic acid and salicylic acid ointment to affected area 1 or 2 times daily. Duration of therapy may be weeks to
months depending on the infection being treated. Pedia - Benzyl benzoate is diluted with water to 12.5% in children and 8.3% in infants prior
to application. It is applied topically to the entire body from the neck down. The lotion should be left on skin for 24 hours, then washed off
THERAPEUTIC USE: Aromatic Inhalation, Inhalations are used for the relief of nasal obstruction in acute rhinitis or sinusitis.
DOSE: Add one teaspoonful to a pint of hot, not boiling water and inhale the vapour. The use of strong aromatic decongestants (applied as
rub or to pillows) is not advised for infants under the age of 3 months.
THERAPEUTIC USE: Anticholinergic, Antiparkinsonian
DOSE: Adult & Pedia – Extrapyramidal disease – Medication-induced movement disorder, 1 to 4 mg IM/IV/ORAL once or twice a day;
Parkinsonism 1 to 2 mg/day IM/IV/ORAL (range 0.5 to 6 mg/day)
CONTRA-INDICATIONS: hypersensitivity to benztropine or any component, less than age 3 years
ADVERSE EFFECTS: Confusion, Drug-induced psychosis, Heat stroke, Hyperpyrexia, Paralytic ileus, Raised intraocular pressure
THERAPEUTIC USE: Antibiotic, Penicillin, Natural
DOSE: Adult - Bacteremia, Gram-negative usual doses range from 5 to 24 million units/day IV in divided doses every 4 to 6 h. Pedia Meningitis (Pneumococcus, Neisseria eningitides/Meningococcus) 250,000 units/kg/day IV/IM in equally divided doses every 4 h for 7 to 14
days; MAX dose, 12 to 20 million units/day)
CONTRA-INDICATIONS: History of penicillin hypersensitivity
ADVERSE EFFECTS: Hemolytic anemia, With large IV doses, Hyperkalemia, High doses, decreased renal function, Immune hypersensitivity
reaction, Interstitial nephritis, With rash, fever, eosinophilia, Seizure, Patients with renal failure, infants, elderly, meningitis, history of seizures
THERAPEUTIC USE: Lung Surfactant
DOSE: Pedia – Respiratory distress syndrome in the newborn first dose; 100 mg/kg (4mL SurvantaI/kg) INTRATRACHEALLY; slowly inject
one quarter of dose (over 2 to 3 seconds) via catheter into endotracheal tube, remove catheter and manually ventilate at 60 breaths/min for
30 seconds or until stable, reattach catheter and instill next 3 quarter doses using the same procedure; do not suction infant for 1 hour after
dosing unless significant airway obstruction occurs; during rescue strategy use mechanical ventilator rather than manual ventilation
CONTRA-INDICATIONS: None known.
ADVERSE EFFECTS: Blocked endotracheal tube, Bradyarrhythmia, Transient, Desaturation of blood, Reflux, Endotracheal tube
THERAPEUTIC USE: Cerebrovascular disease, vertigo, retinal detachment, sensorineural hearing loss
DOSE: Adult – In MENIERE'S DISEASE and other audiovestibular disorders, betahistine has been given in doses of 8 to 16 milligrams orally
3 times daily (total, 24 to 48 milligrams/day). It is recommended that the drug be taken with meals; Oral doses of 8 to 16 milligrams 3 times
daily have been used in patients with cerebrovascular disease
THERAPEUTIC USE: External & internal haemorrhoids.
DOSE: Adult – 1suppository or a little smear of the ointment should be applied morning and evening until the acute symptoms have
disappeared, can be reduced to one application per day or according to the instructions of the Doctor.
CONTRA-INDICATIONS: Hypersensitivity to the preparation.
THERAPEUTIC USE: Adrenal Glucocorticoid, Corticosteroid, Diagnostic Agent, Endocrine-Metabolic Agent, Immune Suppressant
DOSE: Adult & Pedia (13years & older) – Topical (0.5% Lotion, Cream or Ointment), apply to affected area once or twice daily, Max 50 g/wk
(ointment) or 50mL/wk (lotion) for no more than 2 wk
CONTRA-INDICATIONS: hypersensitivity to betamethasone products, hypersensitivity to other corticosteroids, systemic fungal infections
ADVERSE EFFECTS: Cataract, Cushing's syndrome, Glaucoma, Hyperglycemia, Osteoporosis, Primary adrenocortical insufficiency,
Pulmonary tuberculosis
8
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Betaxolol
Betoptic
Eye Soln 0.5%
Bevacizumab
Avastin
Inj. 100mg/4mL
Bisacodyl
Dulcolax
Supp. 5mg
Supp. 10mg
Tablet 5mg
Bisoprolol Fumarate
Concor
Tablet 2.5mg
Tablet 5mg
Tablet 10mg
Bleomycin HCl
Bleocina
Injection 15mg
Botulinum Toxin
Botox
Inj. 100units
Bretylium Tosylate
Bretylol
Inj. 50mg/mL
Bromazepam
Lexotanil
Tablet 3mg
PRODUCT INFORMATION
THERAPEUTIC USE: Antiglaucoma, Antihypertensive, Beta-Adrenergic Blocker, Cardioselective, Cardiovascular Agent
DOSE: Adult & Pedia – Ocular hypertension & primary open angle glaucoma (0.25% suspension) 1 drop in the affected eye(s) twice daily;
(0.5% solution) 1 to 2 drops in the affected eye(s) twice daily. Safety and efficacy not established in children for the 0.5% ophthalmic solution
CONTRA-INDICATIONS: cardiogenic shock, hypersensitivity to betaxolol, overt cardiac failure, second and third degree AV block, severe
sinus bradycardia
ADVERSE EFFECTS: Anemia, Cardiac dysrhythmia, Heart failure, Myocardial infarction Thrombocytopenia
THERAPEUTIC USE: Immunological Agent, Monoclonal Antibody
DOSE: Adult - Metastatic breast cancer, HER2-negative disease, first-line therapy in combination with paclitaxel The dose of bevacizumab
used in the phase III clinical trial was 10 milligrams/kilogram (mg/kg) intravenously on days 1 and 15 every 28 days. Paclitaxel was
administered at a dose of 90 mg/square meter intravenously on days 1, 8, and 15, of the same 28-day cycle for a maximum of 18 cycles, or
until disease progression or unacceptable toxicity. Pedia - the safety and effectiveness of bevacizumab in pediatric patients has not been
established
ADVERSE EFFECTS: Arterial thromboembolism, Asthenia, Bleeding, Complication of infusion (Severe), Congestive heart failure, Deep
venous thrombosis, Diarrhea, Gastrointestinal hemorrhage, Gastrointestinal perforation, Hemoptysis, Hypertension, Hyponatremia, Impaired
wound healing, Leukopenia, Nephrotic syndrome, Neutropenia, Pulmonary hemorrhage, Reversible posterior leukoencephalopathy
syndrome, Thrombocytopenia, Thromboembolic disorder, Tracheoesophageal fistula, Venous thromboembolismWound dehiscence
THERAPEUTIC USE: Laxative, Stimulant
DOSE: Adult – use for more than 7 days is not recommended; Constipation 5-15 mg ORALLY once daily up to 30 mg/day10 mg suppository
RECTALLY once daily. Preparation of bowel for procedure 10 to 15 mg ORALLY once daily up to 30 mg/day;10 mg suppository RECTALLY
once daily. Pedia – use for more than 7 days is not recommended. Constipation (6-11 yrs) 5 mg ORALLY once daily; (6-11 yrs) 5 mg
suppository RECTALLY once daily (under 6 yrs) consult physician
CONTRA-INDICATIONS: appendicitis, intestinal obstruction, gastroenteritis
ADVERSE EFFECTS: Atony of colon
THERAPEUTIC USE: Antianginal, Antihypertensive, Beta-Adrenergic Blocker,, Cardioselective, Cardiovascular Agent
DOSE: Adult – initial, 2.5-5 mg ORALLY once daily; maintenance, 2.5-20 mg ORALLY once daily; maximum dose, 40 mg ORALLY once
daily. Pedia –safety and efficacy not established in children
CONTRA-INDICATIONS: cardiogenic shock, hypersensitivity to bisoprolol, overt cardiac failure, second and third degree AV block, severe
sinus bradycardia
THERAPEUTIC USE: Antibiotic
DOSE: Adult – Hodgkin's disease treatment, 10 to 20 units/m(2) (0.25 to 0.5 units/kg) IV/IM/SC once or twice weekly ; maintenance, following
a 50% response, use a maintenance dose of 1 unit once daily or 5 units once weekly IV/IM. Pedia - safety and efficacy have not been
established in pediatric patients; protocol-specific, adult doses have been used on a case-by-case basis
CONTRA-INDICATIONS: hypersensitivity / idiosyncratic reactions to bleomycin products
ADVERSE EFFECTS: Hepatotoxicity, Hypotension, Idiosyncratic drug effect, Myelosuppression, Nephrotoxicity, Pneumonitis, Possibly
progressing to pulmonary fibrosis, Pulmonary fibrosis, Usually higher in elderly population and with > 400 units total dose, Vascular disorder,
MI, CVA, Raynaud's, Wheezing
THERAPEUTIC USE: Musculoskeletal Agent, Neuromuscular Blocker, Non-Depolarizing
DOSE: Adult & Pedia – Blepharospasm 1.25-2.5 Units injected into orbicularis oculi muscle; 30 day cumulative MAX 200 Units.
CONTRA-INDICATIONS: Hypersensitivity to botulinum A toxin products, Infection at the proposed injection site(s)
ADVERSE EFFECTS: Anaphylaxis, Cardiac dysrhythmia, Hepatotoxicity, Hypertension, Myocardial infarction, Syncope, Strabismus patients
THERAPEUTIC USE: Adrenergic Blocker, Antiarrhythmic, Group III
DOSE: Adult – Ventricular arrhythmia; Treatment and Prophylaxis initial, 5-10 mg/kg IV bolus, may repeat up to MAX loading dose of 30
mg/kg IV; continuous suppression, 1-2 mg/min IV or 5-10 mg/kg over 8 min every 6 hr; 5-10 mg/kg IM, may repeat at 1-2 hr intervals,
thereafter every 6-8 hr. Pedia – not FDA approved in children
CONTRA-INDICATIONS: all contraindications are relative to the seriousness of the arrhythmia, digitalis-induced arrhythmias, hypersensitivity
to bretylium
ADVERSE EFFECTS: Cardiac dysrhythmia, Kidney disease
THERAPEUTIC USE: Benzodiazepine, Short or Intermediate Acting, Sedative-Hypnotic
DOSE: Adult – oral doses of 6 to 30 milligrams daily (single or divided doses) has proven effective in anxiety-neurosis. Usual doses for the
treatment of anxiety range from 3 to 18 milligrams daily in divided doses. Single daily doses of 1.5 to 6 milligrams administered in the evening
have produced good results in anxious patients
CONTRA-INDICATIONS: Hypersensitivity to bromazepam, Narrow-angle glaucoma
9
PRODUCT
DESCRIPTION
Bromocriptine Mesylate
Budesonide
Bupivacaine HCl
TRADE
NAME
DOSAGE
FORM/STRENGTH
Parlodel
Tablet 2.5mg
Entocort
Enema
2mg/100mL
Nebs. 0.5mg/mL
Pulmicort
Marcaine
Marcaine Heavy
Injection 0.25%
Injection 0.5%
Injection 0.75%
Inj. Heavy 0.5%
Busulphan
Myleran
Tablet 2mg
Cabergoline
Dostinex
Tablet 0.5mg
Calcipotriol
Daivonex
Cream 30grams
Oint. 30grams
PRODUCT INFORMATION
THERAPEUTIC USE: Antiparkinsonian, Dopamine Agonist, Prolactin Secretion Inhibitor
DOSE: Adult – Acromegaly initial, 1.25 to 2.5 mg ORALLY at bedtime; increase 1.25 to 2.5 mg every 3 to 7 days as needed; usual
maintenance dose, 20 to 30 mg ORALLY daily; MAX 100 mg daily. Pedia –safety & effectiveness not established in pediatric patients age
younger than 15 years; Prolactinoma a)(11 to 15 y old) 1.25 to 2.5 mg ORALLY daily, gradual dose adjustment to therapeutic response; usual
dose range, 2.5 to 10 mg daily b)(16 y and older) initial, 1.25 to 2.5 mg ORALLY daily, increase dose by 2.5 mg every 2 to 7 days as needed
until optimal therapeutic response achieved; usual dose range, 2.5 to 15 mg daily
CONTRA-INDICATIONS: during postpartum period in women with history of coronary artery disease or other severe cardiovascular
conditions unless withdrawal is considered medically contraindicated, hypersensitivity to bromocriptine products, sensitivity to ergot alkaloids,
uncontrolled hypertension
ADVERSE EFFECTS: Cerebral ischemia, Cerebrovascular accident, Confusion, Disorder of lower respiratory system, Pleuropulmonary, longterm use, Dyskinesia, Hallucinations, Myocardial infarction, Postpartum, Psychotic disorder, Seizure
THERAPEUTIC USE: Adrenal Glucocorticoid, Anti-Inflammatory, Endocrine-Metabolic Agent
DOSE: Adult – Asthma, Maintenance treatment Oral Inhalation, initial, 360 mcg twice daily, 180 mcg twice daily initially may be sufficient in
some patients; MAX 720 mcg twice daily. Pedia – oral inhalation powder, not recommended for age 6 years or younger; Asthma,
Maintenance treatment Oral Inhalation, (6 yr and older) initial, 180 mcg twice daily, 360 mcg twice daily may be required initially in some
patients; MAX 360 mcg twice daily.
CONTRA-INDICATIONS: hypersensitivity to budesonide products, status asthmaticus or other acute episodes of asthma
ADVERSE EFFECTS:Cataract,Cushing's syndrome,Glaucoma, Secondary hypocortisolism
THERAPEUTIC USE: Amino Amide, Anesthetic, Local
DOSE: Adult – Administration of analgesic, Local 1)INTRAPLEURAL, 10-30 mL bolus of 0.25%, 0.375%, or 0.5% every 4-8 hr; 2)
INTRAPLEURAL, continuous infusion 0.375% bupivacaine with epinephrine at 6 mL/hr after 20 mL loading dose. Pedia - administration in
children under 12 years of age is not recommended; bupivacaine spinal with dextrose not recommended in children under 18 years of age;
Administration of analgesic, Local
INTRAPLEURAL, continuous infusion 0.25% bupivacaine with epinephrine at 0.5 mL/kg/hr CONTRA-INDICATIONS: hypersensitivity to
bupivacaine products or to other amide-type anesthetics, local infection at the site of proposed lumbar puncture (spinal anesthesia),
obstetrical paracervical block anesthesia, septicemia (spinal anesthesia), severe hemorrhage, severe hypotension or shock and arrhythmias,
such as complete heart block, which severely restrict cardiac output (spinal anesthesia), sulfite allergy (epinephrine containing solutions only)
ADVERSE EFFECTS: Bradyarrhythmia, CNS depression, Possibly proceeding to respiratory arrest, CNS stimulation, Possibly proceeding to
convulsions, Hypotension, Up to 10% in spinal anesthesia, Respiratory arrest, Tinnitus, Ventricular arrhythmia
THERAPEUTIC USE: Alkylating Agent, Antineoplastic Agent
DOSE: Adult – Chronic myeloid leukemia, palliative, induction, 60 mcg/kg or 1.8 mg/m(2) ORALLY every day; usual dose is 4 to 8 mg;
maintenance, 1 to 3 mg ORALLY every day. Pedia – Although ORAL busulfan is indicated for the treatment of chronic myelogenous leukemia
in children, the safety and efficacy of IV busulfan in pediatric patients have not been determined; Chronic myeloid leukemia, palliative,
induction, 60 mcg/kg or 1.8 mg/m(2) ORALLY every day; usual dose is 4 to 8 mg
CONTRA-INDICATIONS: hypersensitivity to busulfan products, patients in whom a definitive diagnosis of chronic myelogenous leukemia has
not been established
ADVERSE EFFECTS: Amenorrhea, Aplastic anemia, Cardiac tamponade, Cataract, Complete atrioventricular block, Third degree, Disorder
of adrenal gland, Addisonian-like Fibrosis of pericardium, Graft versus host disease, Hemorrhagic cystitis, Hypertension, Hypotension,
Immune hypersensitivity reaction, Left heart failure, Leukemia, Male infertility, Myelosuppression, Leukopenia, thrombocytopenia, anemia,
Neoplastic disease, Ovarian dysfunction, Pulmonary fibrosis, Seizure, Veno-occlusive disease of the liver
THERAPEUTIC USE: Antiparkinsonian, Dopamine Agonist, Prolactin Secretion Inhibitor
DOSE: Adult – Hyperprolactinemia initial, 0.25 mg ORALLY twice weekly, increase by 0.25 mg twice weekly at 4 wk intervals; MAX 1 mg
twice weekly; Lactation suppression, Puerperal 1 mg ORALLY given within 24 to 27 h of delivery. Pedia – safety and efficacy not established
in pediatric patients
CONTRA-INDICATIONS: hypersensitivity to ergot derivatives, uncontrolled hypertension
ADVERSE EFFECTS: Abdominal pain, Heart valve disorder, Orthostatic hypotension, Pleural effusion, Pulmonary fibrosis, Valvular
regurgitation, Vertigo
THERAPEUTIC USE: Antipsoriatic, Vitamin D3, Synthetic
DOSE: Adult – Plaque psoriasis, cream; apply thin layer topically twice daily for up to 8 weeks; ointment; apply thin layer topically once or
twice daily for up to 8 weeks.
Pedia - safety and efficacy in children have not been established
CONTRA-INDICATIONS: do not apply to face, hypercalcemia, hypersensitivity to calcipotriene or any ingredient, vitamin D toxicity
10
PRODUCT
DESCRIPTION
Calcitonin
Calcium Carbonate
TRADE
NAME
Miacalcic
Caltrate
DOSAGE
FORM/STRENGTH
Inj. 100units
Inj. 200units
Nasal Spray
100units
Tablet 500mg
Oscal
Calcium Chloride
Injection 10%
Calcium Folinate
(Ca Leucovorin)
Capsule 15mg
Inj.100mg/10mL
Inj. 50mg/5mL
Calcium Glubionate
Ca-Sandoz
Calcium Gluconate
Syrup
1.2grams/5mL
Injection 10%
Calcium Polystyrene
Sulphonate
Calcium
Resonium
Powder
Capecitabine
Xeloda
Tablet 500mg
PRODUCT INFORMATION
THERAPEUTIC USE: Hypercalcemia, Paget's disease, Postmenopausal osteoporosis
DOSE: Adult – Hypercalcemia, initial, 4 international units/kg SUBQ or IM every 12 h; may increase after 1 to 2 days to 8 international
units/kg every 12 h; may increase after another 2 days to a maximum of 8 international units/kg every 6 h; Paget's disease initial, 100
international units SUBQ or IM daily. Pedia – Safety and effectiveness not established in children
CONTRA-INDICATIONS: hypersensitivity to synthetic calcitonin-salmon
ADVERSE EFFECTS: Anaphylaxis, Anemia, Bronchospasm, Few cases, Cerebrovascular accident, Myocardial infarction, Thrombophlebitis
THERAPEUTIC USE: Antacid, Calcium Regulator & Supplement, Dental Agent, Dermatological Agent, Hemostatic, Nutriceutical, Parenteral
Mineral-Trace Mineral, Phosphate Binder
DOSE: Adult – Calcium deficiency; Prophylaxis 500 mg (as elemental calcium) ORALLY 2 to 3 times daily with food.
ADVERSE EFFECTS: Bradyarrhythmia, Hypercalciuria, Hypotension, Muscle weakness, Vasodilatation
THERAPEUTIC USE: Antacid, Calcium Regulator & Supplement, Dental Agent, Dermatological Agent, Hemostatic, Nutriceutical, Parenteral
Mineral-Trace Mineral, Phosphate Binder
DOSE: Adult - Hypocalcemia, calcium chloride 500 mg to 1 g (5 to 10mL of a 10% solution) IV every 1 to 3 days depending on patient
response; MAX rate, 1mL/min.
CONTRA-INDICATIONS: digitalis toxicity, IM/SC injection of calcium chloride, ventricular fibrillation
ADVERSE EFFECTS: Bradyarrhythmia, Cardiac arrest, With rapid IV injection, Cardiac dysrhythmia, Hypercalcemia, Hypercalciuria,
Hypertension, Hypomagnesemia, Hypotension, Milk alkali syndrome, Muscle weakness, Vasodilatation
THERAPEUTIC USE: Methotrexate Rescue, Nutritive Agent
DOSE: Adult & Pedia – Antimetabolite overdose, Folic acid antagonist, 15 mg (10 mg/m(2)) IM/IV/ORAL every 6 hr until serum methotrexate
(MTX) level below 0.01 micromolar (mcmol); if 24 hr serum creatinine 50% above baseline, 24 hr MTX level above 5 mcmol, OR 48 hr MTX
level above 0.9 mcmol, increase dose to 100 mg/m(2) IV every 3 hr until serum MTX less than 0.01 mcmol.
CONTRA-INDICATIONS: hypersensitivity to leucovorin, megaloblastic anemias due to vitamin B12 deficiency, pernicious anemias due to
vitamin B12 deficiency
ADVERSE EFFECTS: Allergy
THERAPEUTIC USE: Antacid, Calcium Regulator & Supplement, Dental Agent, Dermatological Agent,, Hemostatic, Nutriceutical, Parenteral
Mineral-Trace Mineral, Phosphate Binder
DOSE: Adult – Calcium deficiency; Prophylaxis 500 mg (as elemental calcium) orally 2 to 3 times daily with food.
ADVERSE EFFECTS: Bradyarrhythmia, Hypercalciuria, Hypotension, Muscle weakness, Vasodilatation
THERAPEUTIC USE: Antacid, Calcium Regulator & Supplement, Dental Agent, Dermatological Agent, Hemostatic, Nutriceutical, Parenteral
Mineral-Trace Mineral, Phosphate Binder
DOSE: Adult – Allergic disorder,calcium gluconate 500 mg to 2 grams (10% solution) IV administered at a rate not to exceed 200 mg/min.
Pedia – Hyperkalemia (children) calcium gluconate 200 to 500 mg (10% solution) IV at a rate not to exceed 200 mg/min; (infants) calcium
gluconate up to 200 mg (10% solution) IV at a rate not to exceed 200 mg/min
CONTRA-INDICATIONS: digitalis toxicity, IM/SC injection of calcium gluonate, ventricular fibrillation
ADVERSE EFFECTS: Bradyarrhythmia, Cardiac arrest, With rapid IV injection, Cardiac dysrhythmia, Hypercalcemia, Hypercalciuria,
Hypertension, Hypomagnesemia, Hypotension, Milk alkali syndrome, Muscle weakness, Vasodilatation
THERAPEUTIC USE: Exchange Resin, Hyperkalemia
DOSE: Adult – Hyperkalemia, 15 g ORALLY 1 to 4 times daily as a slurry in water or syrup; 30 to 50 g RECTALLY every 6 hr as a warm
emulsion in 100 mL aqueous vehicle (sorbitol), retain 30-60 min and follow with a cleansing enema. Pedia – Hyperkalemia, 1 g/kg/dose
ORALLY every 6 hr; do not use ORALLY in neonates;1 g/kg/dose RECTALLY every 2-6 hr
CONTRA-INDICATIONS: hypersensitivity to sodium polystyrene sulfonate, hypokalemia, neonates with reduced GI motility (postoperatively
or drug-induced), obstructive bowel disease, oral administration in neonates
ADVERSE EFFECTS: Bronchopneumonia, Electrolytes abnormal, Fecal impaction, Rectal administration, Gastrointestinal necrosis, Colonic,
Hypocalcemia, Hypokalemia
THERAPEUTIC USE: Antimetabolite, Antineoplastic Agent
DOSE: Adult – Colon cancer, Adjuvant therapy, Duke's Stage C, when treatment with a fluoropyrimidine alone is preferred 1,250 mg/m(2)
ORALLY twice daily for 2 wks followed by 1 wk off, given as 3 wk cycles for a total of 8 cycles (6 mo).
Pedia – safety and effectiveness in children have not been established
CONTRA-INDICATIONS: dihydropyrimidine dehydrogenase (DPD) deficiency, hypersensitivity to capecitabine products or 5-FU, severe renal
impairment
ADVERSE EFFECTS: Anemia, Diarrhea, Hand-foot syndrome in sickle cell anemia, Hyperbilirubinemia, Myocardial infarction, Neutropenia,
Thrombocytopenia
11
PRODUCT
DESCRIPTION
Captopril
Carbamazepine
Carbimazole
TRADE
NAME
Capocard
Capoten
Carbatol
Castor Oil
Syrup 1mg/mL
Tablet 25mg
Tablet 50mg
Tegretol
Syrup
100mg/5mL
Tablet 200mg
Neo-Mercazole
Tablet 5mg
Carboplatin
Carvedilol
DOSAGE
FORM/STRENGTH
Inj. 10mg/mL
Dilatrend
Tablet 6.25mg
Tablet 25mg
Oil
PRODUCT INFORMATION
THERAPEUTIC USE: ACE Inhibitor, Antihypertensive, Cardiovascular Agent, Renal Protective Agent
DOSE: Adult – Congestive heart failure, usually in combination with diuretics and digitalis, initial, 6.25 to 12.5mg orally 3 times a day, initial,
25 mg 3 times a day, maintenance, 50 to 100 mg 3 times a day, Max. 450 mg daily. Pedia – Safety and efficacy have not been established in
pediatric patients
CONTRA-INDICATIONS: history of angioedema, hypersensitivity to captopril/other ACE inhibitors
ADVERSE EFFECTS: Agranulocytosis, Angioedema, Angioedema face, lips, throat (1 in 1000 patients; more frequent in Black patients),
Intestinal angioedema, Neutropenia
THERAPEUTIC USE: Anticonvulsant, Dibenzazepine Carboxamide, Neuropathic Pain Agent
DOSE: Adult – Bipolar I disorder, acute manic and mixed episodes a)ORAL; (extended-release capsules) initial, 400 mg/day ORALLY in 2
divided doses, may increase dosage in increments of 200 mg/day up to a max of 1600 mg/day as needed; Epilepsy, Partial, generalized, and
mixed types. ORAL; (suspension) initial, 1 teaspoon (100 mg) ORALLY 4 times a day for the first week, may increase dosage by 200 mg/day
at weekly intervals (usual max dosage 1000 mg/day in children 12-15 years of age, 1200 mg/day in patients above 15 years of age, and up to
1600 mg/day in adults). Pedia – Epilepsy, Partial, generalized, and mixed types; ORAL; children up to 6 years of age (suspension), initial, 1020 mg/kg/day ORALLY in 4 divided doses, may increase dosage by 100 mg/day at weekly intervals as needed, do not exceed 35 mg/kg/day.
CONTRA-INDICATIONS: bone marrow depression, history of previous, concomitant use of an MAOI, or use within 14 days of discontinuing
an MAOI, concomitant use of nefazodone; decreased nefazodone plasma levels may reduce drug effectiveness, hypersensitivity to
carbamazepine or tricyclic compounds
ADVERSE EFFECTS: Acute intermittent porphyria, Acute renal failure, Agranulocytosis, Angioedema, Aplastic anemia, Atrioventricular block,
Bone marrow depression, Cardiac dysrhythmia, Congestive heart failure, Drug-induced eosinophilia, Hepatitis, Hypocalcemia, Hyponatremia,
Leukocytosis, Leukopenia, Nephrotoxicity, Pancytopenia, Stevens-Johnson syndrome, Syncope, Syndrome of inappropriate antidiuretic
hormone secretion, Systemic lupus erythematosus, Aggravation, Thrombocytopenia, Toxic epidermal necrolysis
THERAPEUTIC USE: Antithyroid Agent, Thionamide
DOSE: Adult – Hyperthyroidism, Monotherapy, Usual starting doses of oral carbimazole for the treatment of hyperthyroidism are 20 to 60
milligrams daily, in 3 or 4 divided doses. Pedia - Oral doses of 0.75 to 1 milligram/kilogram/day in divided doses has been suggested for the
initial treatment of hyperthyroidism in CHILDREN. NEONATES-Neonatal hyperthyroidism patients should receive 2.5 milligrams every 8 hours
with a gradual reduction as symptoms are controlled
CONTRA-INDICATIONS: Hypersensitivity to carbimazole or methimazole, Pregnancy; associated with congenital malformations but could be
used during pregnancy, if medically necessary
THERAPEUTIC USE: Antineoplastic Agent, Platinum Coordination Complex
DOSE: Adult – Ovarian cancer, Advanced (as initial treatment in combination with other approved chemotherapy agents), 300 mg/m(2) on
day 1 every 4 weeks for 6 cycles in combination with cyclophosphamide 600 mg/m(2) IV on day 1 every 4 weeks for 6 cycles. Pedia – safety
and effectiveness in pediatric patients have not been established; 175-600 mg/m(2) IV has been used in various protocols
CONTRA-INDICATIONS: hypersensitivity to cisplatin/platinum products or mannitol, severe myelosuppression/significant bleeding
ADVERSE EFFECTS: Electrolyte imbalance, Immune hypersensitivity reaction, Myelosuppression, Peripheral neuropathy, Visual disturbance
THERAPEUTIC USE: Alpha/Beta-Adrenergic Blocker, Antianginal, Antihypertensive, Cardiovascular Agent
DOSE: Adult – Hypertension initial, 6.25 mg orally twice daily; dose may be doubled every 1-2 wks; max. dose, 25 mg orally twice daily.
Pedia – Not FDA approved in children. Congestive heart failure, initial, 0.09 mg/kg orally twice daily; dose may be increased at 2-wk intervals
as tolerated; maximum dose, 50 mg orally daily
CONTRA-INDICATIONS: atrioventricular block, second- or third-degree, bronchial asthma or related bronchospastic condition; status
asthmaticus resulting in death has been reported in 2 cases, cardiogenic shock, decompensated cardiac failure, with IV inotropic therapy,
hepatic impairment, clinically manifest, hypersensitivity to carvedilol or any component of the product, sick sinus syndrome, sinus bradycardia,
severe, patient without permanent pacemaker
ADVERSE EFFECTS: Aplastic anemia, Asthma with status asthmaticus, Atrioventricular block, Erythema multiforme, Heart failure,
Worsening, Stevens-Johnson syndrome, Toxic epidermal necrolysis
THERAPEUTIC USE: Laxative, Stimulant
DOSE: Adult – Constipation & Preparation of bowel for procedure, Preoperative- 15 to 60 mL ORALLY, dose varies depending on product.
Pedia –a)(less than 2 yrs) 1 to 2mL ORALLY, up to 5mL, dose varies depending on product b)(2 to 12 yrs) 5 to 15mL ORALLY, dose varies
depending on product c)(age 12 yrs and older) 15-60 mL ORALLY, dose varies depending on product
CONTRA-INDICATIONS: abdominal pain, intestinal obstruction, nausea, vomiting, symptoms of appendicitis
12
PRODUCT
DESCRIPTION
Cefaclor
TRADE
NAME
Biodroxil
Ceclor
Cloracef
Tabiclor
Ultracef
DOSAGE
FORM/STRENGTH
Capsule 250mg
Susp.
250mg/5mL
Cefazolin
Cefamizin
Injection 500mg
Injection 1gram
Cefepime HCl
Maxipime
Injection 1gram
Injection 2grams
Cefotaxime
Claforan
Injection 1gram
Ceftazidime
Fortum
Magnacef
Negacef
Injection 1gram
Injection 2grams
Ceftriaxone
Enoxirt
Rocephin
Samixon
Injection 1gram
Cefuroxime Axetil
Cefuzime
Zinacef
Zinnat
Susp.
125mg/5mL
Tablet 250mg
Cefuroxime Sodium
Cefuzime
Zinacef
Zinnat
Injection 750mg
Inj. 1.5grams
PRODUCT INFORMATION
THERAPEUTIC USE: 2nd Generation Cephalosporin, Antibiotic
DOSE: Adult – Infection of skin &/or subcutaneous tissue, 375 mg extended-release ORALLY every 12 hr for 7 to 10 days; 250 to 500 mg
regular-release ORALLY every 8 hr. Pedia – Infection of skin &/or subcutaneous tissue a)(1 month and older) 20 to 40 mg/kg/day regularrelease ORALLY divided every 8 hr, MAX 1 g/day b)(16 years and older) 375 mg extended-release ORALLY every 12 hr for 7 to 10 days.
CONTRA-INDICATIONS: Hypersensitivity to cefaclor products/cephalosporins
ADVERSE EFFECTS: Arthralgia, Arthritis, Erythema multiforme, Fever, More common in children, Rash, Serum sickness due to drug
THERAPEUTIC USE: 1st Generation Cephalosporin, Antibiotic
DOSE: Adult - Infection of skin &/or subcutaneous tissue a)(mild) 250 to 500 mg IV/IM every 8 h, depending on severity and type of infection
b)(moderate to severe) 0.5 to 1 g IV/IM every 6 to 8 h, depending on severity and type of infection.
Pedia – Infection of skin &/or subcutaneous tissue (1 month of age and older) 25 to 50 mg/kg/day IV/IM divided every 6 to 8 h, depending on
severity of infection; dose may be increased to 100 mg/kg/day for severe infections.
ADVERSE EFFECTS: Hepatotoxicity, Leukopenia, Pseudomembranous enterocolitis, Stevens-Johnson syndrome, Thrombocytopenia
THERAPEUTIC USE: 4th Generation Cephalosporin, Antibiotic
DOSE: Adult - Infection of skin &/or subcutaneous tissue (Moderate to Severe) 2 g IV every 12 hr for 10 days. Pedia - Infection of skin &/or
subcutaneous tissue, (2 months of age and older, 40 kg or less), 50 mg/kg IV every 12 hr; maximum 2 g/dose
ADVERSE EFFECTS: Encephalopathy, Myoclonus, Seizure, Renally impaired without dose adjustment
THERAPEUTIC USE: 3rd Generation Cephalosporin, Antibiotic
DOSE: Adult – Infection of skin &/or subcutaneous tissue a)(life-threatening) 2 g IV every 4 h b)(requiring higher doses) 2 g IV every 6 to 8
h; depending on type and severity of infection c)(moderate to severe) 1 to 2 g IV/IM every 8 h; depending on type and severity of infection
d)(uncomplicated) 1 g IV/IM every 12 h; depending on type and severity of infection. Pedia - Infection of skin &/or subcutaneous tissue
a)(neonates, premature and normal gestational age) 0 to 1 week of age, 50 mg/kg IV every 12 h; 1 to 4 weeks of age, 50 mg/kg IV every 8 h;
depending on type and severity of infection b)(1 month to 12 years and under 50 kg) 50 to 180 mg/kg/day IV/IM divided into 4 or 6 equal
doses depending on type and severity of infection; maximum 12 g/day; c)(life-threatening) over 12 years or 50 kg, 2 g IV every 4 h; maximum
12 g/day d)(requiring higher doses) over 12 years or 50 kg, 2 g IV every 6 to 8 h; depending on type and severity of infection e)(moderate to
severe) over 12 years or 50 kg, 1 to 2 g IV/IM every 8 h; maximum 12 g/day; depending on type and severity of infection f)(uncomplicated)
over 12 years or 50 kg, 1 g IV/IM every 12 h; maximum 12 g/day; depending on type and severity of infection
ADVERESE EFFECTS: Agranulocytosis, Long-term therapy, Granulocytopenic disorder, Stevens-Johnson syndrome
THERAPEUTIC USE: 3rd Generation Cephalosporin, Antibiotic
DOSE: Adult – Infection of skin &/or subcutaneous tissue, mild, 0.5 g to 1 g IV/IM every 8 h severe life-threatening infections, 2 g IV every 8
h. Pedia – Infection of skin &/or subcutaneous tissue a)neonates (0 to 4 weeks), 30 mg/kg IV every 12 h b)1 month – 12 years, 30 to 50
mg/kg IV every 8 h; MAX 6 g/day
ADVERSE EFFECTS: Asterixis, Disorder of neuromuscular transmission, Encephalopathy, Seizure
THERAPEUTIC USE: 3rd Generation Cephalosporin, Antibiotic
DOSE: Adult – Infection of skin &/or subcutaneous tissue,1 to 2 g IV/IM every 24 h or in divided doses twice a day; maximum 4 g/day. Pedia
- Infection of skin &/or subcutaneous tissue,50 to 75 mg/kg/day IV/IM once daily or in divided doses every 12 h; maximum 2 g/day
CONTRA-INDICATIONS: concurrent administration of calcium-containing solutions or products in newborns; risk of fatal salt precipitation in
lungs and kidneys, hypersensitivity to cephalosporins, neonates, hyperbilirubinemic; increased risk of bilirubin encephalopathy (kernicterus),
especially in premature neonates
ADVERSE EFFECTS: Disorder of gallbladder, Reversible, Hemolysis, Immune-mediated, Kernicterus of newborn, Kidney finding, Lung
finding
THERAPEUTIC USE: 2nd Generation Cephalosporin, Antibiotic
DOSE: Adult – Infection of skin &/or subcutaneous tissue, Uncomplicated, 250 mg or 500 mg orally twice a day for 10 days. Pedia - Infection
of skin &/or subcutaneous tissue, Uncomplicated, 250 mg or 500 mg ORALLY twice a day for 10 days
ADVERSE EFFECTS: Erythema multiforme, Hepatotoxicity, Hypersensitivity reaction, Stevens-Johnson syndrome, Toxic epidermal
necrolysis
THERAPEUTIC USE: 2nd Generation Cephalosporin, Antibiotic
DOSE: Adult – Infection of skin &/or subcutaneous tissue 750 mg IV/IM every 8 hr.
Pedia – Infection of skin &/or subcutaneous tissue 50 to 100 mg/kg/day in equally divided doses every 6 to 8 hours
ADVERSE EFFECTS: Anaphylaxis, Erythema multiforme, Hypersensitivity reaction, Interstitial nephritis, Stevens-Johnson syndrome,
Thrombocytopenia, Toxic epidermal necrolysis
13
PRODUCT
DESCRIPTION
Cephalexin
Cetirizine HCl
TRADE
NAME
Cefrin
Cephadar
Ceporex
Keflex
DOSAGE
FORM/STRENGTH
Capsule 250mg
Capsule 500mg
Susp.
250mg/5mL
Finallerg
Zyrtec
Syrup 5mg/5mL
Charcoal Activated
Powder
Chloral Hydrate
Crystals
Syrup
100mg/mL
(50mL & 100mL)
Chlorambucil
Leukeran
Tablet 2mg
Chloramphenicol
Chloroptic
Riachol
Spersanicol
Eye Drops 0.5%
Eye Oint. 1%
Chloroquine
Nivaquine
Resochin
Injection 200mg
Syrup
50mg/5mL
Tablet 250mg
PRODUCT INFORMATION
THERAPEUTIC USE: 1st Generation Cephalosporin, Antibiotic
DOSE: Adult - Infection of skin &/or subcutaneous tissue, 250 mg ORALLY every 6 hr OR 500 mg ORALLY every 12 hr. Pedia – Infection of
skin &/or subcutaneous tissue a)MILD TO MODERATE: 25 to 50 mg/kg/day ORALLY divided every 6 hr; maximum 4 g/day; depending on
type and severity of infection b)SEVERE: 50 to 100 mg/kg/day ORALLY divided every 6 hr; depending on type and severity of infection c)total
daily dose may be administered in two divided doses every 12 hr
CONTRA-INDICATIONS: Hypersensitivity to cephalexin products/cephalosporins
THERAPEUTIC USE: Antihistamine, Less-Sedating, Respiratory Agent
DOSE: Adult – 5 -10 mg orally once daily. Pedia – Perennial allergic rhinitis a)(12 yrs and older) 5-10 mg orally once daily b)(6-11 yrs) 5-10
mg orally once daily (1-2 tsp (5 mg/5 mL solution) c)(2-5 yrs) 2.5-5 mg orally once daily (0.5-1 tsp (5 mg/5 mL solution) or 2.5 mg orally twice
daily d)(6-23 months) 2.5 mg (0.5 tsp (5 mg/5 mL solution)) orally once daily; the dose in children 12 to 23 months of age can be increased to
a max. dose of 5 mg per day given as 2.5 mg every 12 hr
CONTRA-INDICATIONS: hypersensitivity to cetirizine or components, hypersensitivity to hydroxyzine
THERAPEUTIC USE: Adsorbent, Gastrointestinal Agent, Nutriceutical
DOSE: Adult - Diarrhea & Indigestion-520 mg ORALLY after meals or at the first sign of discomfort, MAX 4160 mg/day; Poisoning –
Selective decontamination of the digestive tract, initial, ORAL, 30-100 g or 1-2 g/kg; repeat initial dose as soon as possible or 20-50 g every 26 hr. Pedia - Poisoning – Selective decontamination of the digestive tract a)to 1 yr of age, ORAL, as slurry in water 1 g/kg; may repeat half the
initial dose every 2-6 hr as needed b)1-12 yr, ORAL, as slurry in water, 25-50 g or 1-2 g/kg; may repeat half the initial dose every 2-6 hr as
needed c)13 yr and older, same as adult dosage d)continuous ORAL infusion, 0.25 to 0.5 g/kg/hr (up to 50 g/hr)
CONTRA-INDICATIONS: absence of bowel sounds, gastrointestinal perforation, intestinal obstruction, recent surgery, risk of gastrointestinal
hemorrhage
ADVERSE EFFECTS: Electrolyte imbalance, GI obstruction, Hypotension
THERAPEUTIC USE: Nonbarbiturate Hypnotic
DOSE: Adult – Administration of analgesic; Adjunct – Preoperative care, 250 mg ORALLY 3 times a day after meals (max dose 2 g/day).
Pedia – Administration of analgesic; Adjunct – Preoperative care 8 mg/kg body weight or 250 mg/m(2) of body surface area ORALLY 3 times
a day (max dose 500 mg/dose)
CONTRA-INDICATIONS: hypersensitivity to chloral hydrate, severe or marked hepatic or renal impairment
ADVERSE EFFECTS: Confusion, Cutaneous hypersensitivity, Excitement, Unusual, Hallucinations
THERAPEUTIC USE: Alkylating Agent, Antineoplastic Agent, Nitrogen Mustard
DOSE: Adult - Chronic lymphoid leukemia a)0.1-0.2 mg/kg/day ORALLY for 3-6 wk
b)continuous therapy, 0.03-0.1 mg/kg/day ORALLY c)intermittent, biweekly, or once-monthly pulse course, single dose of 0.4 mg/kg
ORALLY, increase dose by 0.1 mg/kg to produce mild hematologic toxicity, until control of lymphocytosis or toxicity d)high dose therapy, 30
mg/m(2) ORALLY once every 2 wk has been used. Pedia – not FDA approved for use in children. Nephrotic syndrome – 100-200 mcg (0.1 to
0.2 mg) per kg of body weight per day ORALLY, in a single dose, for eight to twelve weeks
ADVERSE EFFECTS: Drug fever, Erythema multiforme, Hallucinations, Hepatotoxicity, Immune hypersensitivity reaction, Infertility,
Reversible or permanent, Leukemia, Myelosuppression, Peripheral neuropathy, Pneumonitis, acute, Secondary malignant neoplastic disease,
Seizure, Skin reaction – finding, Stevens-Johnson syndrome, Toxic epidermal necrolysis
THERAPEUTIC USE: Antibacterial, Antibiotic
DOSE: Adult – Bacterial meningitis, 50 to 100 mg/kg/day IV divided every 6 h; depending on type and severity of infection. Pedia – Bacterial
meningitis a)(neonates 14 days of age and younger) 25 mg/kg/day IV divided every 6 h b)(neonates over 14 days of age) up to 50 mg/kg IV
divided every 6 h; depending on type and severity of infection c)(infants and children) 50 to 100 mg/kg/day IV divided every 6 h; depending on
type and severity of infection
ADVERSE EFFECTS: Aplastic anemia, Irreversible, Disorder of hematopoietic structure, Serious, some fatal, Gray syndrome from
chloramphenicol administration in newborn, Newborns
THERAPEUTIC USE: Amebicide, Extraintestinal, Aminoquinoline, Antimalarial, Antirheumatic
DOSE: Adult - Malaria, acute-1000 mg chloroquine phosphate (600 mg as chloroquine base) ORALLY, then 500 mg chloroquine phosphate
(300 mg as chloroquine base) ORALLY after 6 to 8 h, then 500 mg chloroquine phosphate (300 mg as chloroquine base) ORALLY once daily
for 2 consecutive days; total dose, 2500 mg chloroquine phosphate (1500 mg as chloroquine base) in 3 days. Pedia - Malaria, acute-4 total
doses: first dose, 10 mg/kg of chloroquine base (MAX, 600 mg base) ORALLY as a single dose followed by 5 mg/kg per dose ORALLY of
chloroquine base (MAX, 300 mg base per dose) administered for 3 additional doses at 6 h, 24 h, and 36 h after the first dose
CONTRA-INDICATIONS: hypersensitivity to 4-aminoquinoline compounds, retinal/visual field changes
14
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Chlorpheniramine Maleate
Allerfin
Inj. 10mg/mL
Chlorpheniramine Maleate
/ Phenylephrine
Sine-Up
Syrup
Chlorpromazine HCl
Largactil
Inj. 25mg/5mL
Tablet 25mg
Tablet 100mg
Chlorzoxazone
/Paracetamol
Parafon
Capsule
Cholecalciferol
Vi-De3
Drops 4500 iu
Cholestyramine
Questran
Powder 4grams
Cinnarizine
Stugeron
Tablet 25mg
Ciprobay
Eye Drops 0.3%
Injection 200mg
Tablet 250mg
Tablet 500mg
Ciprofloxacin
Ciprogen
Cipromax
PRODUCT INFORMATION
THERAPEUTIC USE: Alkylamine, Antihistamine, Cold/Cough Agent, Respiratory Agent
DOSE: Adult - Allergic rhinitis-4 mg ORALLY every 4-6 hrs; maximum dose: 24 mg/day; sustained-release, 8 or 12 mg ORALLY every 8-12
hours; maximum dose: 24 mg/day; 5-40 mg IM, IV, SC as a single dose; maximum dose: 40 mg/day. Pedia –not recommended in children
less than 6 yrs of age. Allergic rhinitis a)(6-11 yrs) 2 mg ORALLY every 4-6 hrs; maximum dose: 12 mg/day b)(12 yrs and over) sustainedrelease, 8 mg ORALLY every 12 hrs c)87.5 mcg/kg or 2.5 mg/m(2) SC 4 times daily
CONTRA-INDICATIONS: hypersensitivity to chlorpheniramine
THERAPEUTIC USE: For the symptomatic relief of upper respiratory tract disorders, includes allergic rhinitis, vasomotor rhinitis, common
cold & influenza.
DOSE: Adult – 10mL Three times daily. Pedia – 6-12 years old, 5mL 3 times daily; 2-5years old, 2.5mL 3 times daily; 6months-under 2years
old, 1.25mL 3 times daily.
CONTRA-INDICATIONS: Severe hypertension, monoamine oxidase inhibitors, who have previously exhibited intolerance to it or to any of its
constituents.
THERAPEUTIC USE: Aliphatic, Antiemetic, Antipsychotic, Gastrointestinal Agent, Phenothiazine
DOSE: Adult - Nausea and vomiting a)ORAL; 10-25 mg ORALLY every 4-6 hr as needed b)RECTAL; 100 mg suppository every 6-8 hours as
needed c)IM; 25 mg IM; if no hypotension occurs, give 25-50 mg IM every 3-4 hr as needed until vomiting stops, then switch to oral dosage
d)IM; (during surgery) 12.5 mg IM repeated in 30 min if necessary and if no hypotension occurs e)IV; (during surgery) 2 mg IV per fractional
injection (dilute to 1 mg/mL, i.e., 1 mL (25 mg) mixed with 24 mL of saline) at 2-minute intervals, do not exceed 25 mg. Pedia - Nausea and
vomiting a)ORAL; 0.25 mg/pound of body weight b)RECTAL; 0.5 mg/pound of body weight every 6-8 hours as needed c)IM; 0.25 mg/pound
of body weight IM every 6-8 hours as needed, max dose 40 mg/day for patients 6 months to 5 years (or 50 pounds) or 75 mg/day for patients
5-12 years (or 50-100 pounds) d)IM; (during surgery) 0.125 mg/pound body weight, repeat in 30 minutes if necessary and if no hypotension
occurs e)IV (during surgery); 1 mg IV per fractional injection (dilute to 1 mg/mL, i.e., 1 mL (25 mg) mixed with 24 mL of saline) at 2-minute
intervals, not to exceed recommended IM dosage
CONTRA-INDICATIONS: hypersensitivity to chlorpromazine products, phenothiazines, myelosuppression, coma, severe CNS depression
ADVERSE EFFECTS: Agranulocytosis, Cholestatic jaundice syndrome, Disorder of hematopoietic structure, Drug-induced lupus
erythematosus, Systemic, Ineffective thermoregulation, Heatstroke or hypothermia, Leukopenia, Neuroleptic malignant syndrome,
Obstipation, Paralytic ileus, Priapism, Prolonged QT interval, Seizure, Thrombocytopenia, Torsades de pointes
THERAPEUTIC USE: Skeletal Muscle Relaxant, Centrally Acting
DOSE: Adult - Musculoskeletal pain – 500 to 750 mg ORALLY 3 to 4 times daily
CONTRA-INDICATIONS: hypersensitivity to chlorzoxazone products
ADVERSE EFFECTS: Anaphylaxis, Gastrointestinal hemorrhage, Hepatotoxicity
THERAPEUTIC USE: Nutritive Agent, Vitamin D (class)
DOSE: Adult – Vitamin D deficiency; Prophylaxis-200 international units/day; ages 50-70, 400 international units/day; over age 70, 600
international units/day.
Pedia – Vitamin D deficiency; Prophylaxis 200 international units/day
CONTRA-INDICATIONS: Hypersensitivity to cholecalciferol, ergocalciferol, or vitamin D metabolites (eg, calcitriol, calcifediol, alfacalcidol,
calcipotriol), Hypercalcemia (exacerbation with enhanced toxicity), Hypervitaminosis D (worsening of condition; pretherapy 25hydroxycholecalciferol levels should be considered in selected patients)
THERAPEUTIC USE: Antihyperlipidemic, Bile Acid Sequestrant, Exchange Resin, Urinary Stone Agent
DOSE: Adult - Hypercholesterolemia; Adjunct initial, 4 g ORALLY once or twice daily; maintenance, 8 to 16 g in divided doses, MAX 24 g
daily; Pruritus of skin, Associated with partial biliary obstruction. Pedia – Hypercholesterolemia; Adjunct, 80 mg/kg anhydrous cholestyramine
ORALLY 3 times a day
CONTRA-INDICATIONS: complete biliary obstruction, hyperlipidemia types III, IV, or V, hypersensitivity to bile-sequestering resins
THERAPEUTIC USE: Antihistamine, Calcium Channel Blocker
DOSE: Adult – 75mg once or twice daily, followed by a maintenance dose of 75mg once daily. Pedia – 1mg/kg orally (maximum dose = 40
mg) relieved symptoms only during mild exposure to pollen.
CONTRA-INDICATIONS: Prior history of hypersensitivity to cinnarizine or any of its components
THERAPEUTIC USE: Antibiotic, Antitubercular, Fluoroquinolone
DOSE: Adult – Anthrax, Postexposure; Prophylaxis, 400 mg IV every 12 hr for 60 days; 500 mg ORALLY every 12 hr for at least 60 days.
Pedia - Cystic fibrosis, 30 mg/kg/day IV divided every 8 hr, MAX 1.2 g/day; 40 mg/kg/day ORALLY divided every 12 hr, MAX 2 g/day
CONTRA-INDICATIONS: hypersensitivity to ciprofloxacin or other quinolones, concomitant tizanidine administration
ADVERSE EFFECTS: Drug-induced psychosis, Immune hypersensitivity reaction, Serious, Peripheral neuropathy, Raised intracranial
pressure, Seizure, Tendinitis, Traumatic or non-traumatic rupture of tendon
15
PRODUCT
DESCRIPTION
Cisatracurium Besylate
TRADE
NAME
Nimbex
DOSAGE
FORM/STRENGTH
Inj. 20mg/10mL
Cisplatin
Inj. 50mg/100mL
Citric Acid
Powder
Citric Acid/Tartaric Acid
/ Na Bicarbonate
Fawar Fruit
Sachet 5grams
Clarithromycin
Klacid
Susp.
125mg/5mL
Tablet 250mg
Clidinium Bromide/
Chlordiazepoxide
Librax
Tablet
Clindamycin
Dalacin - C
Capsule 150mg
Inj. 300mg/2mL
Clobetasol Propionate
Cloderm
Dermovate
Cream 0.05%
PRODUCT INFORMATION
THERAPEUTIC USE: Musculoskeletal Agent, Neuromuscular Blocker, Non-Depolarizing
DOSE: Adult - dosage must be individualized, initial, 0.15 to 0.20 mg/kg IV bolus as components of a propofol/nitrous oxide/oxygen
induction-intubation technique.
Pedia - dosage must be individualized a)(age 1 to 23 mo) initial, 0.15 mg/kg IV over 5 to 10 s during either halothane or opioid anesthesia
b)(age 2 to 12 y) initial, 0.1 to 0.15 mg/kg IV over 5 to 10 s during either halothane or opioid anesthesia c)(age 2 to 12 y) maintenance, initial
IV infusion of 3 mcg/kg/min; then decrease to 1 to 2 mcg/kg/min IV infusion
CONTRA-INDICATIONS: hypersensitivity to cisatracurium/bis-benzylisoquinolinium agents, hypersensitivity to benzyl alcohol (preservative in
multi-dose vials)
ADVERSE EFFECTS: Bradyarrhythmia, Bronchospasm
THERAPEUTIC USE: Antineoplastic Agent, Platinum Coordination Complex
DOSE: Adult – Gastric cancer docetaxel 75 mg/m(2) IV over 1 h followed by cisplatin 75 mg/m(2) IV over 1 to 3 h, both on day 1 only,
followed by fluorouracil 750 mg/m(2)/day IV over 24 h daily for 5 d; repeat every 3 weeks. Pedia - safety and effectiveness not established in
pediatric patients
CONTRA-INDICATIONS: allergy to cisplatin/platinum-containing products, myelosuppression, pre-existing renal/hearing impairment
ADVERSE EFFECTS: Cerebral herniation, Encephalopathy, Immune hypersensitivity reaction, Myelosuppression, Nausea, Nephrotoxicity,
Ototoxicity, Reversible posterior leukoencephalopathy syndrome, Seizure, Vomiting
THERAPEUTIC USE: Urinary Alkalinizer, Urinary Stone Agent and mild astringent
THERAPEUTIC USE: Flatulence & indigestion associated with hyperchlorhydria. To render the urine alkaline in the treatment of inflammatory
conditions of the urinary tract associated with acidic urine. In gout therapy, as an adjuvant with uricosuric agents. For the prevention of
crystalluria during treatment with sulphonamides.
DOSE: Adult – The contents of one sachet to be added to half a glass of water and taken while effervescing after meals. Pedia – (3 to
12years old) Half the adults dose
THERAPEUTIC USE: Antibiotic, Macrolide
DOSE: Adult - Acute exacerbation of chronic obstructive pulmonary disease - Bacterial infectious disease, 250-500 mg ORALLY twice daily
for 7-14 days; extended-release tablets, 1000 mg ORALLY once daily for 7 days. Pedia - Infection of skin &/or subcutaneous tissue,
Uncomplicated 15 mg/kg/DAILY (divided every 12 hours) for 10 days, MAX 1 g/day.
CONTRA-INDICATIONS: concomitant cisapride, pimozide, astemizole, terfenadine, ergotamine, or dihydroergotamine; hypersensitivity to
clarithromycin, erythromycin, or any macrolide antibiotics
ADVERSE EFFECTS: Immune hypersensitivity reaction (Severe), Anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, Liver
failure
THERAPEUTIC USE: Antianxiety, Benzodiazepine, Long Acting
DOSE: Adult – Anxiety mild to moderate anxiety; 5 or 10 mg ORALLY 3 to 4 times daily; severe anxiety; 20 or 25 mg ORALLY 3 to 4 times
daily; geriatric patients or in the presence of debilitating disease: 5 mg ORALLY 2 to 4 times daily. Pedia - not recommended in pediatric
patients under 6 yr of age, Anxiety about treatment, Preoperative, (6 y and older) 5 mg ORALLY 2 to 4 times daily; may be increased to 10
mg ORALLY 2 to 3 times daily
ADVERSE EFFECTS: Agranulocytosis, Decreased liver function, Disorder of hematopoietic structure
THERAPEUTIC USE: Antiacne, Antibacterial, Antibiotic , Antimalarial, Lincosamide
DOSE: Adult - Infection of skin &/or subcutaneous tissue; serious infections: 150 to 300 mg ORALLY every 6 hours; depending on type of
infection; more severe infections: 300 to 450 mg ORALLY every 6 hours; depending on type of infection. Pedia - Infection of skin &/or
subcutaneous tissue serious infections: 8 to 16 mg/kg/day ORALLY divided every 6 to 8 hr; depending on type of infection; more severe
infections: 16 to 20 mg/kg/day ORALLY divided every 6 to 8 hr; depending on type of infection
CONTRA-INDICATIONS: Hypersensitivity to clindamycin or lincomycin, Clindamycin /benzoyl peroxide topical gel, clindamycin topical
solution, gel and lotion, and clindamycin vaginal cream and suppositories: patients with a history of regional enteritis, ulcerative colitis, or
antibiotic-associated colitis
ADVERSE EFFECTS: Increased liver function test, Jaundice, Pseudomembranous enterocolitis
THERAPEUTIC USE: Adrenal Glucocorticoid, Corticosteroid, Very Strong
DOSE: Adult - Disorder of skin, Corticosteroid responsive (gel, cream, ointment, lotion, foam and scalp application), apply a thin layer
TOPICALLY to affected area twice daily for a maximum of 2 wk, MAX 50 g/wk or 50 mL/wk. Pedia - TOPICAL, cream, gel, foam, ointment,
scalp solution, safety and efficacy in children under 12 years of age have not been established
ADVERSE EFFECTS: Secondary hypocortisolism
16
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Clomipramine HCl
Anafranil
Inj. 25mg/2mL
Tablet 25mg
Clonazepam
Rivotril
Drops 2.5mg/mL
Tablet 0.5mg
Tablet 2mg
Clonidine
Catapres
Syrup 0.1mg/mL
Tablet 150mcg
Clopidogrel
Plavix
Tablet 75mg
Canesten
Cream 1%
Ear Drops 10mg
Vag.Tab. 500mg
Clotrimazole
Micoter
Cloxacillin
Prostaphlin – A
Capsule 250mg
Injection 250mg
Susp.
125mg/5mL
Co-Trimoxazole
Bactrim
Bactrim DS
Septrin
Septrin DS
Trimol
Inj. 480mg/5mL
Susp.
240mg/5mL
Tablet 480mg
Tablet 960mg
Colchicine
Tablet 500mcg
PRODUCT INFORMATION
THERAPEUTIC USE: Antidepressant, Tricyclic, Central Nervous System Agent
DOSE: Adult – Depression initial, 75 mg/day ORALLY (3 divided doses); may increase dosage slowly as needed and tolerated to a range of
100-250 mg/day (3 divided doses); Pedia - safety and effectiveness in children up to 10 years of age have not been established. Depression,
20-30 mg/day ORALLY; may increase dosage by 10 mg/day at 4-5 day intervals as needed and tolerated
CONTRA-INDICATIONS: coadministration with an MAOI or use within 14 days of discontinuing an MAOI; may cause serious reactions,
hypersensitivity to clomipramine hydrochloride or other tricyclic antidepressant, myocardial infarction, during the acute recovery period
ADVERSE EFFECTS: Agranulocytosis, Depression, worsening, Hepatotoxicity, Leukopenia, Myocardial infarction, Orthostatic hypotension,
Pancytopenia, Seizure, Suicidal thoughts, Suicide, Thrombocytopenia
THERAPEUTIC USE: Antianxiety, Anticonvulsant, Benzodiazepine, Short or Intermediate Acting
DOSE: Adult – Seizure initial, 0.5 mg orally 3 times a day, maintenance, may increase daily dose by 0.5 to 1 mg orally every 3 days to a MAX
total daily dose of 20 mg (divided into 3 daily doses). Pedia – Seizure up to 10 y of age or up to 30 kg, initial, 0.01 to 0.03 mg/kg/day orally
divided into 2 to 3 daily doses; up to 10 y of age or up to 30 kg, maintenance, may increase daily dose by 0.25 to 0.5 mg orally every 3 days
to MAX total daily dose of 0.1 to 0.2 mg/kg/day (divided into 3 daily doses)
CONTRA-INDICATIONS: acute narrow angle glaucoma, hypersensitivity to clonazepam or benzodiazepines, severe liver disease
THERAPEUTIC USE: Alpha-2 Adrenergic Agonist, Analgesic, Anesthetic Adjunct
Antihypertensive, Antimigraine, Cardiovascular Agent, Diagnostic Agent, Pheochromocytoma
DOSE: Adult - Essential hypertension, initial, 0.1 mg orally twice daily (morning and bedtime); increase in increments of 0.1 mg daily orally at
weekly intervals, usual daily dose is 0.2-0.6 mg in divided doses; MAX 2.4 mg/day. Pedia - Attention deficit hyperactivity disorder initial,
50mcg orally daily, increased in 50mcg increments; maintenance, 5 mcg/kg/day orally in 4 divided doses (200-600 mcg/day)
ADVERSE EFFECT: Atrioventricular block
THERAPEUTIC USE: ADP-Induced Aggregation Inhibitor, Platelet Aggregation Inhibitor
DOSE: Adult - Acute coronary syndrome, Non-ST segment elevation - Thrombotic disorder; Prophylaxis initial, 300 mg ORALLY once; with
aspirin 75 mg to 325 mg ORALLY; maintenance, 75 mg ORALLY once daily with aspirin 75 mg to 325 mg ORALLY once daily. Pedia - safety
and efficacy in pediatric patients not established
CONTRA-INDICATIONS: bleeding, active (such as peptic ulcer or intracranial hemorrhage) hypersensitivity to clopidogrel or any component
of the product
ADVERSE EFFECTS: Abnormal renal function, Acute renal failure, Agranulocytosis, Anaphylaxis, Atrial fibrillation, Congestive heart failure,
Epidural hematoma, Erythema multiforme, Gastrointestinal hemorrhage, Gastrointestinal ulcer, Hepatitis, Intracranial hemorrhage, Intraocular
hemorrhage, Liver function tests abnormal, Non-cardiogenic pulmonary edema, Thrombotic thrombocytopenic purpura
THERAPEUTIC USE: Antifungal, Imidazole
DOSE: Adult - Candidal vulvovaginitis, insert 1 500 mg tablet INTRAVAGINALLY at bedtime for 1 dose; TOPICAL, apply thin layer of 1%
cream twice daily for up to 4 wks; Ear Drops – Instill 1 to 2 drops in the ear 3 or 4 times daily, continue for 2weeks after signs of infection
disappears. Pedia- Candidal vulvovaginitis,12 yr and older, insert 1 applicatorful of 2% cream INTRAVAGINALLY at bedtime for 3 days;
Candidiasis, topical apply thin layer of 1% cream twice daily for up to 4 wks
THERAPEUTIC USE: Antibiotic, Penicillin, Penicillinase-Resistant
DOSE: Adult - 250 to 500 mg IV/ORALLY every 6 hours; maximum 6 g/day; depending on type and severity of infection. Pedia - over 20 kg:
250 to 500 mg IV/ORALLY every 6 hours; maximum 6 g/day; depending on type and severity of infection; less than 20 kg: 25 to 50 mg/kg/day
IV/ORALLY (in equally divided doses every 6 hours); dose may be increased in severe infections
CONTRA-INDICATIONS: hypersensitivity to cloxacillin or other penicillins
ADVERSE EFFECTS: Agranulocytosis, Hepatotoxicity, Immune hypersensitivity reaction, Myelosuppression, Neutropenia,
Pseudomembranous enterocolitis
THERAPEUTIC USE: Antibiotic, Sulfonamide Combination
DOSE: Adult - 1 double-strength tablet or 2 single-strength tablets or 20 mL suspension ORALLY every 12 hours for 10 to 14 days. Pedia (2 months of age and older) 8 mg/kg TMP component/day ORALLY divided every 12 hours for 10 days.
CONTRA-INDICATIONS: hypersensitivity to sulfonamides or trimethoprim, infants less than 2 months; PCP prophylaxis can begin at 1 month
of age, pregnant patients at term, nursing mothers, megaloblastic anemia due to folate deficiency
ADVERSE EFFECTS: Agranulocytosis, Aplastic anemia, Disorder of hematopoietic structure, Hepatic necrosis, Fulminant, Immune
hypersensitivity reaction (Severe), Stevens-Johnson syndrome, toxic epidermal necrolysis
THERAPEUTIC USE: Antigout
DOSE: Adult - Gout; Treatment and Prophylaxis a)(Treatment)ORAL, initial, 0.5-1.2 mg, then 0.5-0.6 mg every hr or 1-1.2 mg every 2 hr until
symptoms abate or diarrhea occurs (usual dose 4-8 mg); MAX 8 mg ORALLY per attack; a 3-day colchicine-free interval should follow each
ORAL course b)(Treatment) IV, initial, 2 mg over 2-5 min, then 0.5 mg every 6 hr or 1 mg every 6-12 hr until satisfactory response; MAX IV 4
17
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Colomycin
Injection
500,000iu
Conjugated Oestrogens
Premarin
Tablet 0.625mg
Tablet 1.25mg
Vaginal Cream 0.625mg/g
Crotamiton
Eurax
Cream 10%
Lotion 10%
Cyclopentolate HCl
Cyclogyl
Eye Minims 0.5%
Eye Minims 1%
Endoxan
Injection 200mg
Injection 500mg
Injection 1gram
Tablet 50mg
Sandimmun
Capsule 25mg
Capsule 50mg
Capsule 100mg
Inj. 50mg/mL
Colistimethate
Cyclophosphamide
Cyclosporin
PRODUCT INFORMATION
mg/24 hr or per attack; a 7-day colchicine-free interval should follow each full IV course (4 mg) c)(prophylaxis) ORAL, less than 1 acute
attack/yr, 0.5-0.6 mg/day 3-4 times/wk; more than 1 acute attack/yr, 0.5-0.6 mg/daily up to 1.5-1.8 mg/day d)(prophylaxis) IV, 0.5-1 mg once
or twice daily e)(preoperative prophylaxis) ORAL, 0.5-0.6 mg 3 times daily, 3 days before through 3 days after surgery. Pedia - not FDA
approved in children. Familial Mediterranean fever; initial, 0.5 mg/day ORALLY; maintenance, (5 yr or younger) 0.5 mg/day ORALLY;
maintenance, (5 yr or older) 0.5 mg twice a day ORALLY; MAX 2 mg/day
CONTRA-INDICATIONS: blood dyscrasias, cardiac disease, severe, gastrointestinal disease, severe, hepatic failure, hypersensitivity to
colchicine, renal disease, severe
ADVERSE EFFECTS: Myelosuppression, Neuromyopathy
THERAPEUTIC USE: Antibiotic
DOSE: Adult & Pedia - Disease due to Gram-negative bacteria, Pseudomonas aeruginosa, Enterobacter aerogenes, Escherichia coli, and
Klebsiella pneumoniae, 2.5 to 5 mg/kg/day IM or IV in 2 to 4 divided doses, depending on severity of infection; MAX 5 mg/kg/day
CONTRA-INDICATIONS: history of sensitivity to colistimethate or its components
ADVERSE EFFECTS: Acute respiratory failure, Nephrotoxicity, Neurotoxicity, Respiratory tract paralysis
THERAPEUTIC USE: Contraceptive, Endocrine-Metabolic Agent, Estrogen, Female Reproductive Agent, Musculoskeletal Agent
DOSE: Adult - Postmenopausal osteoporosis; Prophylaxis, initial, 0.3 mg ORALLY daily given continuously or in cyclical regimens (25 days
on, 5 days off); adjust dose based upon the individual clinical and bone mineral density responses of the patient; adjust to lowest level that will
provide effective control. Pedia - safety and efficacy in children not established; however, estrogen therapy has been used for the induction
of puberty in adolescents with some forms of pubertal delays
CONTRA-INDICATIONS: arterial thromboembolic disease, breast cancer, known, suspected or history of; except in appropriately selected
patients being treated for metastatic disease,deep vein thrombosis/pulmonary embolism, genital bleeding, undiagnosed abnormal,
hypersensitivity to conjugated estrogens or product ingredients, liver dysfunction or disease, pregnancy
ADVERSE EFFECTS: Anaphylaxis, Body fluid retention, Breast cancer, Breast cancer, Cerebrovascular accident, Cervical cancer, Cervical
cancer, Dementia, Diabetes mellitus, Disorder of gallbladder, Heart disease, Hypercalcemia, Hypertension, Impaired cognition, Malignant
neoplasm of endometrium of corpus uteri, Myocardial infarction, Ovarian cancer, Pancreatitis, Pulmonary embolism, Thrombosis of retinal
vein, Venous thromboembolism
THERAPEUTIC USE: Scabicide
DOSE: Adult- Pruritus of skin completely rub lotion into affected areas, repeat as necessary; Scabies apply cream or lotion topically to entire
body from the chin down (do not rinse off), 24 h later apply cream or lotion a second time and leave on the skin for 48 h; a cleansing bath
should be taken 48 h after the last application. Pedia - not FDA approved in pediatric patients
CONTRA-INDICATIONS: hypersensitivity to crotamiton
THERAPEUTIC USE: Antimuscarinic, Mydriatic-Cycloplegic
DOSE: Adult - Cycloplegic refraction, 1 to 2 drops of 0.5% to 2% solution in eye(s); may repeat after 5 to 10 min if needed. Pedia Cycloplegic refraction a)(children) 1 to 2 drops of 0.5% to 2% solution in eye(s); may repeat with 0.5% or 1% solution after 5 to 10 min if
needed b)(small infants) single instillation of 1 drop of 0.5% solution in the eye; apply pressure to nasolacrimal sac for 2 to 3 min; observe
infant closely for at least 30 min for signs or symptoms of systemic absorption
CONTRA-INDICATIONS: narrow-angle glaucoma or anatomical narrow angles, hypersensitivity to cyclopentolate products
ADVERSE EFFECTS: Ataxia, Confusion, Conjunctivitis, Psychotic disorder, Raised intraocular pressure, Seizure, Tachyarrhythmia,
Vasodilatation
THERAPEUTIC USE: Alkylating Agent, Antineoplastic Agent, Antirheumatic, Cytotoxic, Nitrogen Mustard
DOSE: Adult & Pedia – (single agent) 40 to 50 mg/kg IV in divided doses over 2 to 5 days or 10 to 15 mg/kg IV every 7 to 10 days OR 3 to 5
mg/kg IV twice weekly; (single agent) oral cyclophosphamide is usually administered at dosages in the range of 1 to 5 mg/kg/day for both
initial and maintenance dosing.
CONTRA-INDICATIONS: hypersensitivity to cyclophosphamide products, severely depressed bone marrow function
ADVERSE EFFECTS: Azoospermia, Cardiomyopathy, Hemorrhagic cystitis, Infectious disease, Interstitial pneumonia, Oligozoospermia,
Stevens-Johnson syndrome, Toxic epidermal necrolysis
THERAPEUTIC USE: Anti-Inflammatory, Immune Suppressant
DOSE: Adult - Cardiac transplant rejection; Treatment and Prophylaxis, initial, (preoperative): 15 mg/kg ORALLY 4-12 hr before transplant;
continue same dose as daily dose for 1-2 wk; initial, (preoperative): 5-6 mg/kg/day IV 4-12 hr before transplant; continue same initial dose as
daily dose until patient can tolerate oral formulation; maintenance, decrease by 5% per week to 5-10 mg/kg/day ORALLY; doses are then
adjusted to attain center-defined trough blood concentrations.
Pedia - 6 mo and older, initial, (preoperative): 15 mg/kg ORALLY 4-12 hr before transplant; continue dose for 1-2 wk; 6 mo and older, initial,
(preoperative): 5-6 mg/kg/day IV 4-12 hr before transplant; continue dose until patient can tolerate oral formulation.
18
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Cytarabine
Cytosar
Injection 100mg
Injection 500mg
Injection 1gram
D-Penicillamine
Artamine
Capsule 250mg
Dacarbazine
Deticene
Injection 100mg
Injection 200mg
Dantrolene Sodium
Dantrium
Injection 20mg
Daunorubicin
Daunoblastina
Injection 20mg
Desferrioxamine Mesylate
Desferal
Injection 500mg
PRODUCT INFORMATION
ADVERSE EFFECTS: Anaphylaxis, With IV use, Gingival enlargement, Hemolytic uremic syndrome, Hepatotoxicity, Hyperkalemia,
Hypertension, Hypomagnesemia, Infectious disease, Nephrotoxicity, Pancreatitis, Paresthesia, Post-transplant lymphoproliferative disorder
THERAPEUTIC USE: Antimetabolite, Antineoplastic Agent
DOSE: Adult & Pedia - Acute myeloid leukemia, In combination with other approved chemotherapy agents for remission induction a)100
mg/m(2)/day continuous IV infusion for 7 days or 100 mg/m(2) IV every 12 hr for 7 days b)high dose induction therapy, 3 g/m(2) IV infused
over 1-3 hr every 12 hr for 2-6 days
ADVERSE EFFECTS: Anaphylaxis, Anemia, Bleeding, Infectious disease, Kidney disease, Leukopenia, Neuropathy, Sepsis,
Thrombocytopenia
THERAPEUTIC USE: Antirheumatic, Heavy Metal Chelator-Antagonist, Renal-Urologic Agent
DOSE: Adult - Rheumatoid arthritis (Severe), Active disease that has failed to respond to conventional therapy a)initial, 125 to 250 mg/day
ORALLY; increase dose at 1 to 3 month intervals by 125 or 250 mg/day, as patient response and tolerance indicate; if no improvement and
no serious toxicity after 2 to 3 months, increases of 250 mg/day at 2 to 3 month intervals may be continued until remission or toxicity;
b)maintenance, 500 to 1500 mg/day; typical range 500 to 750 mg/day. Pedia - Copper measurement, urine 500 mg ORALLY immediately
before the second (post-baseline) 24-h urine sample collection and 12 h later, during the second (post-baseline) 24-h urine sample collection
CONTRA-INDICATIONS: breastfeeding, during pregnancy, except for treatment of Wilson's disease and certain cases of cystinuria,
hypersensitivity to penicillamine products, penicillamine-related aplastic anemia/agranulocytosis, rheumatoid arthritis patients with history or
evidence of renal insufficiency
ADVERSE EFFECTS: Agranulocytosis, Aplastic anemia, Goodpasture's syndrome, Myasthenia gravis, Obliterative bronchiolitis, Optic
neuritis, Oral lichenoid reaction, Pemphigus, Peripheral motor neuropathy, Proteinuria, Renal glomerular disease, Renal vasculitis, Sensory
neuropathy, Thrombocytopenia, Tinnitus
THERAPEUTIC USE: Alkylating Agent, Antineoplastic Agent, Imidazole Carboxamide
DOSE: Adult - Hodgkin's disease, Second line, in combination with other effective agents a)150 mg/m(2)/day for 5 days in combination with
other effective drugs; may repeat every 4 wks b) 375 mg/m(2) on day 1 in combination with other effective drugs; repeat every 15 days.
Pedia - not FDA approved for children
CONTRA-INDICATIONS: hypersensitivity to dacarbazine products
ADVERSE EFFECTS: Anaphylaxis, Cerebral hemorrhage, Hepatic necrosis, Hepatic vein thrombosis, Hepatotoxicity, Myelosuppression,
Photosensitivity, Seizure
THERAPEUTIC USE: Skeletal Muscle Relaxant, Direct Acting
DOSE: Adult & Pedia - Malignant hyperthermia, 1 mg/kg IV by continuous rapid intravenous push and continue until symptoms subside or to
a max cumulative dose of 10 mg/kg; discontinue all anesthetic agents and administer 100% oxygen (recommended).
CONTRA-INDICATIONS: active hepatic disease (acute hepatitis, active cirrhosis), no contraindications for the use of dantrolene sodium IV in
the treatment of malignant hyperthermia crisis, not for use where spasticity is utilized to sustain upright balance/posture in ambulation or when
spasticity is utilized to obtain or maintain increased function
ADVERSE EFFECTS: Abnormal blood pressure, Aplastic anemia, Disease of liver, Fatal and non-fatal, Heart failure, Leukopenia, Malignant
lymphoma - small lymphocytic, Phlebitis, Tachyarrhythmia, Thrombocytopenia
THERAPEUTIC USE: Anthracycline, Antineoplastic Agent
DOSE: Adult - Acute lymphoid leukemia, For remission induction in combination with other chemotherapy agents, 45 mg/m(2)/day IV on days
1, 2, and 3 and vincristine 2 mg IV on days 1, 8, and 15. On days 1 through 22, prednisone 40 mg/m(2)/day ORALLY is administered, then
tapered between days 22 to 29; L-asparaginase 500 International Units/kg/day IV on days 22 to 32. Pedia - Acute lymphoid leukemia, For
remission induction in combination with other chemotherapy agents, 25 mg/m(2) IV and vincristine 1.5 mg/m(2) IV on day 1 of every week
along with daily administration of prednisone 40 mg/m(2) ORALLY; four to six 7-day courses are generally required to produce a complete
remission
ADVERSE EFFECTS: Cardiotoxicity, Hyperuricemia, Myelosuppression
THERAPEUTIC USE: Heavy Metal Chelator-Antagonist
DOSE: Adult - Iron toxicity, chronic - Thalassemia major a)0.5 to 1 g IM daily, plus 2 g IV per unit of transfused blood; MAX rate, 15 mg/kg/h;
MAX dose, 1 g/day with no transfusion, 6 g/day if 3 or more units of transfused blood or packed red blood cells b)1 to 2 g (20 to 40
mg/kg/day) subQ over 8 to 24 h. Pedia - Iron toxicity, chronic - Thalassemia major (age 3 years and older) 20 to 40 mg/kg per day SC over 8
to 24h
CONTRA-INDICATIONS: anuria, severe renal disease
ADVERSE EFFECTS: Deferoxamine Mesylate, Cardiac complication, Eye / vision finding, Hypotension, Immune hypersensitivity reaction,
Mucormycosis, Ototoxicity, Shock, Tachyarrhythmia
19
PRODUCT
DESCRIPTION
TRADE
NAME
Desflurane
Desmopressin
DOSAGE
FORM/STRENGTH
Inhalation
Minirin
Decadron
Inj. 4mcg/mL
Nasal Drops
100mcg
Nasal Spray 0.1mg
Spersadex
Eye Drops
1mg/mL
Inj. 8mg/2mL
Tablet 0.5mg
Tablet 1.5mg
Dexmedetomidine HCl
Precedex
Inj. 100mcg/mL
Dexpanthenol
Bepanthen
Dexipan
Panthenol
Cream 5%
Dexamethasone
Dextromethorphan HBr
Oradoxon
Kafosed
Romin
Syrup
15mg/5mL
PRODUCT INFORMATION
THERAPEUTIC USE: General Anesthesia, Haloalkane, Volatile Liquid
DOSE: Adult - General anesthesia a)induction, usually delivered at an initial inspired concentration of 3% in oxygen or nitrous oxide/oxygen
and increased by 0.5%-1% every 2-3 breaths or as tolerated (up to 11%), until loss of consciousness b)maintenance, inhaled in
concentrations of 2.5%-8.5% with or without concomitant nitrous oxide. Pedia - General anesthesia, maintenance, inhaled in concentrations
of 5.2%-10% with or without concomitant nitrous oxide
CONTRA-INDICATIONS: hypersensitivity to desflurane or other halogenated agent, malignant hyperthermia, known or suspected genetic
susceptibility
ADVERSE EFFECTS: Apnea, Bradyarrhythmia, Cardiac dysrhythmia, Complication of anesthesia, During induction, Desaturation of blood,
Hepatic necrosis, Hepatitis, Hyperkalemia, Perioperative, Hypertension, Interrupted breathing, Laryngeal spasm, Liver failure, Malignant
hyperthermia, Nephrotoxicity, Pharyngitis, Sinus arrhythmia, Tachycardia
THERAPEUTIC USE: Endocrine-Metabolic Agent, Hemostatic, Vasopressin (class)
DOSE: Adult - Hemophilia A, With factor VIII levels greater than 5%, 0.3 mcg/kg diluted in 50 mL sterile physiological saline, infused IV
slowly over 15 to 30 minutes; monitor patient to determine necessity of further doses, tachyphylaxis may occur if given more often than every
48 hours; Primary nocturnal enuresis -initial, 20 mcg (0.2 mL) INTRANASALLY at bedtime; maintenance 10 to 40 mcg INTRANASALLY at
bedtime for 4 to 8 weeks. Pedia - von Willebrand disease type 1 (Mild to Moderate), With factor VIII levels greater than 5%, 3 months and
older: 0.3 mcg/kg diluted in sterile physiological saline, infused IV slowly over 15 to 30 minutes; dilute in 50 mL for children over 10 kg and in
10 mL for children 10 kg or less; monitor patient to determine necessity of further doses, tachyphylaxis may occur if given more often than
every 48 hours; Primary nocturnal enuresis - 6 years of age and older: initial, 20 mcg (0.2 mL) INTRANASALLY at bedtime; maintenance 10
to 40 mcg INTRANASALLY at bedtime for 4 to 8 weeks
CONTRA-INDICATIONS: hypersensitivity to desmopressin or any components of desmopressin products, patients with moderate to severe
renal impairment
ADVERSE EFFECTS: Abnormal blood pressure, Anaphylaxis, Hyponatremia, Palpitations, Seizure, Tachyarrhythmia, Thrombotic disorder,
Water intoxication syndrome
THERAPEUTIC USE: Adrenal Glucocorticoid, Antiemetic, Anti-Inflammatory, Corticosteroid, Weak, Diagnostic Agent, Adrenocortical
Function, Endocrine-Metabolic Agent, Immune Suppressant, Ophthalmologic Agent, Otic Agent
DOSE: Adult - Allergic disorder a)ORAL; 0.75 to 9 mg/day, vary dose according to patient response b)IV or IM; 0.5 to 9 mg/day; vary dose
depending on patient response c)IM followed by ORAL; first day, dexamethasone sodium phosphate 4-8 mg IM; second and third days, 4
tablets (0.75 mg each) in 2 divided doses each day; fourth day, 2 tablets in 2 divided doses; fifth and sixth days, 1 tablet each day; seventh
day, no treatment. Pedia - Allergic disorder a)ORAL; 0.02 to 0.3 mg/kg/day in 3 or 4 divided doses, vary dose according to patient response
b)IV or IM; 0.5 to 9 mg/day; vary dose depending on patient response
CONTRA-INDICATIONS: acute infectious stages of vaccinia, varicella, and many other viral, diseases of the cornea and conjunctiva,
epithelial herpes simplex keratitis (dendritic keratitis), fungal diseases of ocular or auricular structures, hypersensitivity to dexamethasone,
mycobacterial infection of the eye, perforation of a drum membrane, systemic fungal infections, Serious Adverse Effects, Glaucoma,
HyperglycemiaPrimary adrenocortical insufficiency
THERAPEUTIC USE: Alpha-2 Adrenergic Agonist, Analgesic, Anesthetic Adjunct Sedative
DOSE: Adult - Sedation, Intubated/mechanically ventilated ICU patients, initial, 1 mcg/kg IV over 10 min; followed by 0.2 to 0.7 mcg/kg/hr
continuous IV infusion for a max of 24 hr. Pedia - safety and effectiveness in children less than 18 years of age have not been established
CONTRA-INDICATIONS: hypersensitivity to dexmedetomidine
ADVERSE EFFECTS: Acidosis, Anemia, Apnea, Atrial fibrillation, Atrioventricular block, Bradyarrhythmia, Bronchospasm, Cardiac arrest,
Dyspnea, Hypercapnia, Hyperkalemia, Hypertension, Aggravated, Hypotension, Hypoventilation, Hypoxia, Infectious disease, Leukocytosis,
Oliguria, Pleural effusion, Pulmonary congestion, Pulmonary edema, Respiratory acidosis, Supraventricular tachycardia,Ventricular
arrhythmia, Ventricular tachycardia
THERAPEUTIC USE: Emollient, Stimulant, Gastrointestinal
DOSE: Adult - Topical application route, Dexpanthenol is used topically in 2% to 5% creams, lotions, solutions or ointments for the treatment
of minor skin disorders such as itching, mild eczema, stings, bites, poison ivy, poison oak, and diaper rash and to improve wound healing
CONTRA-INDICATIONS: Hemophilia, Ileus due to mechanical obstruction, Paraben sensitivity (dexpanthenol inj. may contain parabens)
THERAPEUTIC USE: Antitussive
DOSE: Adult – Cough 10-20 mg ORALLY every 4hrs or 30 mg ORALLY every 6-8hrs; (sustained-release) 60 mg ORALLY twice daily,
maximum dose, 120 mg/day. Pedia – Cough a)(6-12yrs) 5-10 mg ORALLY every 4hrs or 15 mg ORALLY every 6-8hrs; maximum dose: 60
mg/day b)(2-6yrs) 2.5-5 mg ORALLY every 4hrs or 7.5 mg ORALLY every 6-8hrs; maximum dose: 30 mg/day c)(sustained-release) 6-12yrs:
30 mg ORALLY twice daily d)(sustained-release) 2-6yrs: 15 mg ORALLY twice daily
CONTRA-INDICATIONS: hypersensitivity to dextromethorphan, Co-administration with monoamine oxidase inhibitors
20
PRODUCT
DESCRIPTION
Dextromethorphan/
Amm. Chloride/Citric Acid
TRADE
NAME
Romilar
Dextrose
Diazepam
Digoxin
Syrup
15mg/5mL
Injection 50%
Stesolid
Valium
Diazoxide
Diclofenac Sodium
DOSAGE
FORM/STRENGTH
Inj. 10mg/2mL
Syrup 1mg/mL
(50mL & 100mL)
Tablet 5mg
Tablet 50mg
Clofen
Diclogesic
Diclogesic
Retard
Ocugesic, Olfen
Rofenac
Voltaren
Voltaren
EmuGel
Votrex
Eye Drops 0.1%
Gel 1%
Inj. 75mg/3mL
Supp. 12.5mg
Supp. 50mg
Supp. 100mg
Tablet 25mg
Tablet 50mg
Tablet 100mg
Lanoxin
Elixir 0.05mg/mL
Inj. 0.5mg/2mL
Tablet
0.0625mg
Tablet 0.25mg
PRODUCT INFORMATION
THERAPEUTIC USE: For relief of lesion related or nonproductive cough associated with tracheitis or bronchitis; for habit cough as a sequel
of whooping cough or in measles.
DOSE: Adult – 1 to 2 teaspoonfuls two to four times daily. Pedia – over 2years old, 1/2 teaspoonful two to four times daily (according to age).
May be taken undiluted or in water, tea, milk, fruit juice, etc., and should preferably be taken after meals.
CONTRA-INDICATIONS: Hypersensitivity to one or more ingredients, severely impaired hepatic or renal function, monoamine oxidase
inhibitors.
ADVERSE EFFECTS: Mild & transient tiredness, nausea & dizziness may occur after intake, urticaria, skin skin rashes.
THERAPEUTIC USE: Diagnostic Agent, Nutritive Agent, Osmotherapy Agent, Parenteral Solution
DOSE: Adult - Glucose tolerance test a)Diabetes mellitus (diagnosis): 75 g anhydrous glucose (dextrose) dissolved in water ORALLY, as
one-time dose for oral glucose tolerance test b)Gestational diabetes mellitus (diagnosis), one-step approach: 100 g anhydrous glucose
(dextrose) dissolved in water ORALLY, as one-time dose for oral glucose tolerance test c)Gestational diabetes mellitus (diagnosis), two-step
approach: 50 g anhydrous glucose (dextrose) dissolved in water ORALLY as one-time dose for glucose challenge test, then perform the 100g oral glucose tolerance test on those who exceeded the threshold value on the glucose challenge test
CONTRA-INDICATIONS: a)Do not use concentrated solutions of dextrose in patients with: anuria, diabetic coma and hyperglycemia,
intracranial or intraspinal hemorrhage, delirium tremens in dehydrated patients, glucose-galactose malabsorption syndrome b)Allergy to corn
or corn products
THERAPEUTIC USE: Antianxiety, Anticonvulsant, Benzodiazepine, Long Acting, Skeletal Muscle Relaxant
DOSE: Adult – Anxiety a)2 to 10 mg ORALLY 2 to 4 times a day depending on symptom severity b)2 to 10 mg IM or IV every 3 to 4 h if
needed depending on symptom severity . Pedia – Anxiety,initial, 1 to 2.5 mg ORALLY 3 to 4 times daily; increase gradually as needed
CONTRA-INDICATIONS: acute narrow angle glaucoma, hypersensitivity to diazepam products, patients less than 6 months of age, untreated
open angle glaucoma
THERAPEUTIC USE: Antihypertensive, Gastrointestinal Agent, Glucose Regulation, Antihypoglycemic, Thiazide Related
DOSE: Adult & Pedia - Malignant hypertension 1-3 mg/kg (MAX 150 mg) IV bolus every 5-15 min; MAX 1.2 grams per day.
CONTRA-INDICATIONS: functional hypoglycemia, hypersensitivity to diazoxide, other thiazides, or sulfonamides, hypertension associated
with aortic coarctation or arteriovenous shunt
ADVERSE EFFECTS: Body fluid retention, Bowel obstruction, Cardiac arrest, Congestive heart failure, Diabetic ketoacidosis, Extrapyramidal
disease, Hypernatremia, Neutropenia, Pancreatitis, Thrombocytopenia
THERAPEUTIC USE: Analgesic, Antirheumatic, Central Nervous System Agent Musculoskeletal Agent, NSAID, Ophthalmologic Agent
DOSE: Adult - Rheumatoid arthritis, Delayed-release, 100-200 mg/day orally in 3 or 4 divided doses (Max. 225mg/day); Extended- release,
75 mg orally twice a day or 100 mg orally once or twice a day; Enteric-coated 150-200 mg/day in divided doses; Light intolerance - Pain in eye
- Refractive keratoplasty, instill 1-2 drops into affected eye before surgery and four times a day beginning within 15 minutes after surgery and
continued up to 3 days post-op. Pedia - safety and efficacy in children have not been established
CONTRA-INDICATIONS: asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, history; severe, rarely fatal,
anaphylactic-like reactions have been reported, hypersensitivity to diclofenac, aspirin, or other NSAIDs topical gel, use during peri-operative
period in setting of coronary artery bypass graft (CABG) surgery; increased risk of myocardial infarction and stroke during the first 10 to 14
days following surgery
ADVERSE EFFECTS: Acute renal failure, Agranulocytosis, Anaphylactoid reaction, Anemia, Angioedema, Aplastic anemia, Aseptic
meningitis, Blurred vision, Bronchospasm, Cerebrovascular accident, Cirrhosis of liver, Congestive heart failure, Erythema multiforme,
Gastrointestinal hemorrhage, Gastrointestinal perforation, Gastrointestinal ulcer, Generalized exfoliative dermatitis, Hearing loss, Hemolytic
anemia, Hepatic necrosis, Hepatitis, Hypertension, Inflammatory disorder of digestive tract, Interstitial nephritis, Jaundice, Leukopenia, Liver
failure, Melena, Myocardial infarction, Nephrotic syndrome, Pancreatitis, Proteinuria, Purpuric disorder, Seizure, Stevens-Johnson syndrome,
Thrombocytopenia, Thrombotic tendency observations, Toxic epidermal necrolysis,Vomiting
THERAPEUTIC USE: Antiarrhythmic, Cardiac Glycoside, Cardiovascular Agent, Digitalis Glycoside
DOSE: Adult - Congestive heart failure a)(intravenous and/or oral capsule) for rapid digitalization, give loading dose of 0.4 to 0.6 mg ORALLY
or IV; additional doses of 0.1 to 0.3 mg ORALLY or IV may be given cautiously at 6 to 8 h intervals if necessary to achieve response (a 70-kg
person typically requires 0.6 to 1 mg); for daily maintenance doses or for gradual digitalization, give 0.1 to 0.4 mg ORALLY once daily, titrate
every 2 weeks b)(tablet) for rapid digitalization, give loading dose of 0.5 to 0.75 mg ORALLY, additional doses of 0.125 to 0.375 mg ORALLY
may be given cautiously at 6 to 8 h intervals if necessary to achieve response (a 70-kg person typically requires 0.75 to 1.25 mg); for daily
maintenance doses or for gradual digitalization, give 0.125 to 0.5 mg ORALLY once daily, titrate every 2 weeks. Pedia - Congestive heart
failure a)(intravenous and/or oral capsule) for rapid digitalization, give ORALLY or IV in divided doses; (premature) 15 to 25 mcg/kg; (full-term)
21
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Digoxin Antibody
Digibind
Injection 38mg
Dihydrocodeine Tartrate
DF 118
Tablet 30mg
Injection 25mg
Susp. 12mg/mL
Tablet 60mg
Monotildiem SR
SR Tablet 90mg
SR Tablet 200mg
Tildiem
Dilzem
Diltiazem
Dimenhydrinate
Dizinil
Tablet 50mg
Dramamine
PRODUCT INFORMATION
20 to 30 mcg/kg; (1 to 24 mo) 30 to 50 mcg/kg; (2 to 5 y) 25 to 35 mcg/kg; (5 to 10 y) 15 to 30 mcg/kg; (over 10 y) 8 to 12 mcg/kg; for daily
maintenance doses or for gradual digitalization, give 20% to 30% of IV digitalizing dose for premature infants or 25% to 35% of oral or IV
digitalizing dose for all other pediatric patients b)(elixir) for rapid digitalization, give ORALLY in divided doses; (premature) 20 to 30 mcg/kg;
(full-term) 25 to 35 mcg/kg; (1 to 24 mo) 35 to 60 mcg/kg; (2 to 5 y) 30 to 40 mcg/kg; (5 to 10 y) 20 to 35 mcg/kg; (over 10 y) 10 to 15 mcg/kg;
for daily maintenance doses or for gradual digitalization, give 20% to 30% of oral digitalizing dose for premature infants or 25% to 35% of oral
digitalizing dose for all other pediatric patients c)(solution) older than 2 years; maintenance dose, 10 mcg/kg/day ORALLY, adjust as
necessary
d)(tablet) daily maintenance dose, give ORALLY in divided doses; (2 to 5 y of age) 10 to 15 mcg/kg; (5 to 10 y of age) 7 to 10 mcg/kg; (over
10 y of age) 3 to 5 mcg/kg
CONTRA-INDICATIONS: hypersensitivity to digoxin products, ventricular fibrillation
ADVERSE EFFECTS: Cardiac dysrhythmia
THERAPEUTIC USE: Digoxin/Digitalis Antidote
DOSE: Adult - Digoxin toxicity, a)acute ingestion of unknown amounts, 10 vials (380 mg) IV, observe response; repeat with 10 vials as
needed; LIFE THREATENING, 20 VIALS (760 mg) IV b)acute ingestion of known amount digOXIN, each vial (38 mg) IV will bind
approximately 0.5 mg digOXIN; bioavailability of digOXIN is 0.8 for 0.25 mg tablets OR 1 for 0.2 Lanoxicaps; use the following formula, dose
(in vials) = digOXIN ingested (mg) X bioavailability / 0.5 mg of digOXIN bound per vial c)chronic digOXIN toxicity, 6 vials (228 mg) IV OR use
the following formula: dose (in vials) = (serum digOXIN concentration in ng/mL) x (wt in kg)/100. Pedia - Digoxin toxicity, a)acute ingestion of
unknown amounts, 10 vials (380 mg); observe response; repeat with 10 vials as needed; LIFE THREATENING, 20 vials (760 mg) IV b)acute
ingestion of known amount digOXIN, each vial (38 mg) IV will bind approximately 0.5 mg digOXIN; bioavailability of digOXIN is 0.8 for 0.25
mg tablets OR 1 for 0.2 Lanoxicaps; use the following formula, dose (in vials) = digOXIN ingested (mg) X bioavailability / 0.5 mg of digOXIN
bound per vial c)chronic digOXIN toxicity, (infants and small children) single vial (38 mg) IV initially OR use the following formula: number of
vials needed = (serum digOXIN concentration in ng/mL) x (wt in kg)/100, then dose (in mg) = number of vials X 38 mg per vial
CONTRA-INDICATIONS:none known
THERAPEUTIC USE: Opioid
DOSE: Adult - one to three tablets (10 to 30 milligrams) three times daily for treatment of COUGH. Smaller doses may also be effective and
up to 50 milligrams three times daily is possible. Pedia - aged 6 to 12 years old is 5 to 10 milligrams one to three times daily; aged 2 to 5
years of age is 2.5 to 5 milligrams one to three times daily
CONTRA-INDICATIONS: Disease states where respiratory depression would compromise the patient, Long term use in patients with chronic
constipation, Sustained-release capsules in patients younger than 12 years of age, Hypersensitivity to dihydrocodeine or other opioids
THERAPEUTIC USE: Antianginal, Antihypertensive, Benzothiazepine, Calcium Channel Blocker, Cardiovascular Agent
DOSE: Adult – Hypertension a)(sustained release) initial 60-120 mg ORALLY twice daily; usual dose 120-180 mg twice daily, MAX 360
mg/day b)(extended release, Cap) initial 120-240 mg ORALLY once daily; titrate after 14 days; usual dose, 240-360 mg ORALLY once daily,
MAX 540 mg/day c)(extended release Tab) initial 180-240 mg ORALLY once daily; dose range 120-540 once daily, MAX 540 mg/day. Pedia not FDA-approved in pediatric patients, Hypertension (TAB, regular release): 1.5-2 mg/kg ORALLY daily in 3-4 divided doses; MAX 3.5 mg/kg
daily has been used
CONTRA-INDICATIONS: acute MI with pulmonary congestion on x-ray, administration of IV beta-blockers within a few hours of IV diltiazem,
atrial fibrillation or flutter associated with an accessory bypass tract (Wolff-Parkinson-White or short PR syndromes); risk of potentially fatal
heart rate fluctuations, cardiogenic shock, heart block, second or third-degree atrioventricular without a functioning ventricular pacemaker,
hypersensitivity to diltiazem, hypotension, symptomatic, newborns; some injections contain benzyl alcohol, sick sinus syndrome without a
functioning ventricular pacemaker, ventricular tachycardia; may lead to hemodynamic deterioration and ventricular fibrillation
ADVERSE EFFECTS: Cardiac dysrhythmia
THERAPEUTIC USE: Antiemetic, Antihistamine, Antivertigo, Ethanolamine (class), Respiratory Agent
DOSE: Adult - Motion sickness; Treatment and Prophylaxis a)50-100 mg ORALLY 30 min prior to travel; repeat every 4-6hrs; maximum
dose: 400 mg/day b)50-100 mg IM every 4-6 hrs as needed c)50 mg IV over 2 min (dilute in 10 mL NS before giving). Pedia - not for use in
children less than 2 years of age, Motion sickness; Treatment and Prophylaxis a)(2-6 yrs) 12.5-25 mg ORALLY every 6-8 hrs; maximum dose:
75 mg/day b)(6-12 yrs) 25-50 mg ORALLY every 6-8 hrs; maximum dose: 150 mg/day c)1.25 mg/kg or 37.5 mg/m(2) IM every 6 hrs;
maximum dose: 300 mg/day
CONTRA-INDICATIONS: hypersensitivity to dimenhydrinate or diphenhydramine
22
PRODUCT
DESCRIPTION
Dimethindine Maleate
Dinoprostone
TRADE
NAME
Fenistil
Propess
Prostin E2
DOSAGE
FORM/STRENGTH
Drops 1mg/mL
Syrup 0.1mg/mL
Inj. 10mg/mL
Vag. Pessary 10mg
Vaginal Tablet 3mg
Diosmin/Hesperidine
Daflon
Tablet 500mg
Diphenhydramine HCl
Exylin Pedia
Syrup 7mg/5mL
Diphtheria Pertussis Tetanus
& Type B Vaccine
Tetract-Hib
Injection
Diphtheria Tetanus Vaccine
D.T. Vax
Injection Adult
Injection Pedia
Dipivefrine HCl
Propine
Eye Drops 0.1%
PRODUCT INFORMATION
THERAPEUTIC USE: Alkylamine, Antihistamine, Less-Sedating
DOSE: Adult - Immediate Release Tablet, is 1 to 2 milligrams three times daily; Syrup- 1 tsp.(5 mL) of a 0.123-mg/mL syrup up to 9 times
daily. Pedia – Drops: a)The usual dose for infants is 0.25 mg (or 5 drops of a 1 mg/mL solution) three times daily. Dimethindene is
contraindicated in infants under one month old and should be used cautiously in infants under one year, due to an increased risk of sleep
apnea b)children 1 to 8 years old is 0.5 to 0.75 mg (or 10 to 15 drops of a 1 mg/mL solution) three times daily c)children 9 years old and older
is 1 mg (20 drops of a 1 mg/mL solution) three times daily.
CONTRA-INDICATIONS: Hypersensitivity, Premature infants and neonates, Lactation, Prostate hypertrophy, Bladder obstruction,
Hypersensitivity to parabens (contained in the topical gel, oral drops and oral syrup), Cardiac arrhythmias, Alcohol abuse
THERAPEUTIC USE: Endocrine-Metabolic Agent, Prostaglandin, Uterine Stimulant
DOSE: Adult – Abortion, insert 20 mg suppository high into the vagina; patient to remain supine for 10 min; dose may be repeated at 3- to 5h intervals until abortion occurs; Cervical ripening procedure - Induction of labor a)insert the contents of one syringe (0.5 mg) into the cervical
canal just below the level of the internal os; patient to remain in the supine position for at least 15-30 min; repeat dose of 0.5 mg may be given
after 6 hours; MAX 1.5 mg/24 hr b)Vaginal Insert: 10 mg placed transversely in the posterior fornix of the vagina; patient to remain in the
recumbent position for 2 h following insertion; remove upon onset of active labor or 12 h after insertion. Pedia - Safety and effectiveness in
children not established, however, safety and efficacy in adolescents are expected to be the same as in adult women (vaginal insert)
CONTRA-INDICATIONS: active cardiac, pulmonary, renal, or hepatic disease, acute pelvic inflammatory disease, cephalopelvic disproportion
- suspected or definite, fetal distress - suspected or definite, hypersensitivity to prostraglandins or constituents of the products, multipara with
6 or more previous term pregnancies, previous cesarean section or major uterine surgery, simultaneous IV oxytocic drugs, term pregnancy,
unexplained vaginal bleeding during pregnancy
ADVERSE EFFECTS: Decreased diastolic arterial pressure, Fetal distress, Fetus or newborn affected by hypertonic labor, Hypertonic uterine
dysfunction, Without fetal distress, Myocardial infarction, Rupture of uterus
THERAPEUTIC USE: Capillary Hemorrhage, Diabetes mellitus adjunct, Heavy legs, Hemorrhoids, Intermenstrual spotting due to IUD,
lymphedema, peripheral venous insufficiency, premenstrual syndrome, stasis ulcer, thromboembolic disorder post-operative prophylaxis.
Dose: Adult - Thromboembolic disorder, Postoperative; Prophylaxis ,1000 mg (two 450mg/50mg tablets) every 8 hours the day before
surgery, 1000mg 6 hours before surgery, and 1000 mg daily on postoperative days 4 to 15 was administered in combination with lowmolecular-weight heparin
CONTRA-INDICATIONS: Hypersensitivity to diosmin
THERAPEUTIC USE: Analgesic, Antihistamine Ethanolamine/Acetaminophen Combination, Antipruritic, Antitussive/Expectorant
Combination, Antivertigo, Ethanolamine (class), Respiratory Agent, Sleep Aid
DOSE: Adult - Allergic rhinitis, 25 to 50 mg ORALLY every 4 to 6 h; maximum dose: 300 mg/day or 10 to 50 mg IM/IV every 2 to 3 h;
maximum parenteral dose: 400 mg/day. Pedia - Not recommended in infants or neonates. Allergic rhinitisa)(up to 6 y) 6.25 to 12.5 mg
ORALLY every 4 to 6 h b)(6 to 12 y) 12.5 to 25 mg ORALLY every 4 to 6 h; maximum dose: 150 mg/day c)(12 y and older) 25 to 50 mg
ORALLY every 4 to 6 h; maximum dose: 300 mg/day d)5 mg/kg/day or 150 mg/m(2)/day IM/IV divided in 4 doses, MAX 300 mg/day
CONTRA-INDICATIONS: hypersensitivity to diphenhydramine, newborns or premature infants, nursing mothers
ADVERSE EFFECTS: Anaphylaxis
THERAPEUTIC USE: Indicated for active immunization against Diphtheria, tetanus, pertussis, Hepatitis B & diseases caused by H.
Influenzae type B of all infants from the age og 6weeks onwards.
DOSE: Recommended dose 0.5mL of the vaccine must be administered. Primary vaccination schedule consists of three doses to be
administered at intervals of at least 4weeks within the first 6months of life. The first dose can be administered at 6weeks of age.
CONTRA-INDICATIONS: Hypersensitivity to any component of the vaccine, encephalopathy.
ADVERSE EFFECTS: Redness, swelling and pain on the site of injection. Fever, irritability, unusual crying, drowsiness, feeding problems,
diarrhea and vomiting.
THERAPEUTIC USE: Vaccine
DOSE: Pedia – (6 wks to less than 7 y of age) primary series and booster, 0.5mL IM x 5 doses; doses given at 2, 4, and 6 mo of age, and
boosters at 15 to 20 mo and at 4 to 6 y of age; recommended intervals: between first 3 doses is 8 wks (4 wk minimum), between dose 3 and 4
is 6 to 12 mo, dose 5 before entry into kindergarten or elementary school (but is not needed if dose 4 was given after 4 th birthday)
CONTRA-INDICATIONS: encephalopathy within 7 days of previous pertussis-containing vaccine, hypersensitivity or serious allergic reaction
to any vaccine component, history of gelatin or thimerosal allergy, progressive neurologic disorder (eg. Infantile spasm, uncontrolled epilepsy,
progressive encephalopathy); defer vaccination until neurologic status is clarified and stabilized
ADVERSE EFFECTS: Anaphylaxis, Crying, Persistent, Fever, Seizure
THERAPEUTIC USE: Adrenergic, Alkylarylamine, Antiglaucoma, Sympathomimetic
DOSE: Adult – Open-angle glaucoma, 1 drop of 0.1% solution TOPICALLY in affected eye(s) every 12 h. Pedia – safety and effectiveness
23
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Dipyridamole
Persantin
Inj. 5mg/mL
Tablet 25mg
Tablet 75mg
Dobutamine HCl
Dobutrex
Injection 250mg
Domperidone
Dompy
Tablet 10mg
Motilium
Dopamine HCl
Intropin
Inj. 200mg/5mL
Dorzolamide
Trusopt
Eye Drops 2%
Doxapram HCl
Dopram
Inj. 20mg/mL
Doxorubicin
Adriblastina
Inj. 10mg/5mL
Inj. 50mg/25mL
Doxycycline Hyclate
Doxycin
Doxydar
Vibramycin
Capsule 100mg
PRODUCT INFORMATION
have not been established in pediatric patients
CONTRA-INDICATIONS: hypersensitivity to dipivefrin, narrow-angle glaucoma
ADVERSE EFFECTS: Cardiac dysrhythmia, Follicular conjunctivitis, Hypertension, Tachyarrhythmia
THERAPEUTIC USE: Diagnostic Agent, Cardiac Function, Phosphodiesterase Inhibitor, Platelet Aggregation Inhibitor
DOSE: Adult – Heart valve replacement – Thromboembolic disorder; Prophylaxis 75-100 mg ORALLY 4 times daily as an adjunct to warfarin
therapy; Radionuclide myocardial perfusion study - 0.142 mg/kg/min IV for 4 min (0.57 mg/kg total) prior to thallium; maximum 60 mg. Pedia –
safety and effectiveness in the pediatric population have not been established
CONTRA-INDICATIONS: hypersensitivity to dipyridamole products and any components of the product
ADVERSE EFFECTS: Angina, Bronchospasm, Myocardial infarction,Ventricular arrhythmia
THERAPEUTIC USE: Adrenergic, Vasopressor
DOSE: Adult – Decreased cardiac output & Heart failure initial, 0.5-1 mcg/kg/min IV; maintenance, 2.5-20 mcg/kg/min IV; titrate according to
response; MAX dose, 40 mcg/kg/min IV. Pedia – not FDA approved in children, Decreased cardiac output 2-20 mcg/kg/min IV; titrate
according to response; MAX dose, 40 mcg/kg/min IV
CONTRA-INDICATIONS: hypersensitivity to dobutamine, idiopathic hypertrophic subaortic stenosis
ADVERSE EFFECTS: Cardiac dysrhythmia, Eosinophilic myocarditis, Thrombocytopenia
THERAPEUTIC USE: Antiemetic, Dopamine Antagonist
DOSE: Adult – Indigestion, Postprandial Usual dose, 10 to 20 milligrams up to three times daily, before meals and at night, symptomatically.
Pedia - Usual dose, 200 to 400 micrograms per kilogram body-weight every 4 to 8 hours
CONTRA-INDICATIONS: Hypersensitivity to domperidone
THERAPEUTIC USE: Adrenergic, Vasopressor
DOSE: Adult – initial, 2 to 5 mcg/kg/min IV; increase in 5 to 10 mcg/kg/min increments; MAX 50 mcg/kg/min IV. Pedia – not FDA approved in
children. Hypotension, acute, initial, 2 to 5 mcg/kg/min IV; increase in 5 to 10 mcg/kg/min increments; MAX 30 mcg/kg/min IV
CONTRA-INDICATIONS: hypersensitivity to dopamine, pheochromocytoma, tachyarrhythmias/ventricular fibrillation
ADVERSE EFFECTS: Ectopic beats, Gangrenous disorder, Ventricular arrhythmia, Wide QRS complex
THERAPEUTIC USE: Antiglaucoma, Carbonic Anhydrase Inhibitor
DOSE: Adult – Raised intraocular pressure, In patients with ocular hypertension or open-angle glaucoma, 1 drop TOPICALLY in affected
eye(s) 3 times daily.
Pedia – safety and effectiveness not established in pediatric patients
CONTRA-INDICATIONS: hypersensitivity to dorzolamide products
ADVERSE EFFECTS: Immune hypersensitivity reaction, Ocular, Iridocyclitis, Rash, Urolithiasis
THERAPEUTIC USE: Stimulant, Respiratory
DOSE: Adult – Chronic obstructive pulmonary disease – Hypercapnia, acute, 1 to 2 mg/min IV continuous infusion (0.5 to 1 ml/min of a 2
mg/mL solution), may increase to 3 mg/min as needed; MAX infusion time 2 h. Pedia – not FDA approved in children under 12 yr of age;
Apnea of prematurity 0.5 to 2.5 mg/kg/h IV infusion
CONTRA-INDICATIONS: cardiovascular disorders, doxapram formulation available in the US contains benzyl alcohol; it is contraindicated in
newborns, epilepsy or convulsive disorder, head injury or cerebral vascular accident, hypersensitivity to doxapram products, mechanical
ventilatory disorders, severe hypertension
ADVERSE EFFECTS: Cardiac dysrhythmia, Chest pain, Dyspnea, Hemolysis, Thrombophlebitis, Wheezing
THERAPEUTIC USE: Anthracycline, Antineoplastic Agent
DOSE: Adult & Pedia – Acute lymphoid leukemia a)(single agent): 60 to 75 mg/m(2) IV every 21 days b)(in combination with other
chemotherapy agents): 40 to 60 mg/m(2) IV every 21 to 28 days.
CONTRA-INDICATIONS: myelosuppression, previous complete cumulative doses of doxorubicin, daunorubicin, idarubicin, and other
anthracyclines and anthracenes
ADVERSE EFFECTS: Cardiac dysrhythmia, Congestive heart failure, Myelosuppression
THERAPEUTIC USE: Amebicide Intestinal, Antiacne, Antibacterial, Antibiotic, Antimalarial, Antiprotozoal, Dental Agent, Tetracycline (class)
DOSE: Adult – Acinetobacter infection, 100 mg ORALLY every 12 hr on day 1 then 100 mg/day ORALLY in 1-2 divided doses; severe
infections, 100 mg ORALLY every 12 hours. Pedia - over 8 years, (under 45 kg) 4.4 mg/kg ORALLY in 1-2 divided doses on day 1 then 2.24.4 mg/kg/day ORALLY in 1-2 divided doses; (over 8 years, over 45 kg) use adult dose
CONTRA-INDICATIONS: hypersensitivity to doxycycline/tetracycline products
ADVERSE EFFECTS: Bulging fontanelle
24
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Dydrogesterone
Duphaston
Tablet 10mg
Edrophonium
Tensilon
Inj. 10mg/mL
Enalapril Maleate
Enoxaparin Sodium
Renitec
Riapril
Clexane
Ephedrine HCl
Syrup 0.1mg/mL
Tablet 10mg
Injection 2000iu
Injection 4000iu
Injection 8000iu
Inj. 50mg/mL
Epirubicin HCl
Farmorubicin
Inj. 10mg/5mL
Inj. 50mg/25mL
Epoetin Alfa
Eprex
Injection 1000iu
Injection 4000iu
PRODUCT INFORMATION
THERAPEUTIC USE: Treatment of progesterone deficiencies such as: dysmenorrheal, endometriosis, secondary amenorrhea, irregular
cycles, functional bleeding, premenstrual syndrome, threatened and habitual abortion associated with proven progesterone deficiency,
infertility due to luteal insufficiency. To counteract the effects of unopposed estrogen on the endometrium (HRT).
DOSE: Adult – Varies from 10 mg to 40 mg per day and depends on the indication for which it is prescribed.
THERAPEUTIC USE: Cholinesterase Inhibitor, Diagnostic Agent, Myasthenia Gravis
Nondepolarizing Muscle Relaxant Antagonist
DOSE: Adult – Myasthenia gravis; Diagnosis a)2 mg IV over 15 to 30 seconds, if no reaction in 45 seconds, give additional 8 mg b)in adults
with inaccessible veins, 10 mg IM. Pedia – Myasthenia gravis; a)(infants) 0.5 mg IV or 0.5 to 1 mg IM or SC b)(34 kg or less) 1 mg IV, if no
reaction in 45 seconds, may repeat at a rate of 1 mg every 30 to 45 seconds to maximum cumulative dose of 5 mg or 2 mg IM c)(over 34 kg)
2 mg IV, if no reaction in 45 seconds, may repeat at a rate of 1 mg every 30 to 45 seconds to maximum cumulative dose of 10 mg or 5 mg IM
CONTRA-INDICATIONS: hypersensitivity to edrophonium chloride or anticholinesterase agents, hypersensitivity to sulfite agents, intestinal or
urinary obstruction of the mechanical type
ADVERSE EFFECTS: Bronchospasm, Cardiac arrest, Respiratory tract paralysis
THERAPEUTIC USE: ACE Inhibitor, Antihypertensive, Cardiovascular Agent, Renal Protective Agent
DOSE: Adult – Heart failure, initial, 2.5 mg ORALLY once or twice daily; maintenance, 2.5-20 mg ORALLY twice daily; MAX 20 mg daily in
divided doses. Pedia – Hypertension 6 to 16 years: initial, 0.08 mg/kg ORALLY once daily (up to 5 mg), MAX 0.58 mg/kg or 40 mg daily
CONTRA-INDICATIONS: ACE-inhibitor induced angioedema, hereditary or idiopathic angioedema, hypersensitivity to enalapril/other ACE
inhibitors, pregnancy
ADVERSE EFFECTS: Angioedema, Intestinal angioedema, Liver failure, Syncope
THERAPEUTIC USE: Anticoagulant, Low Molecular Weight Heparin
DOSE: Adult – 40 mg SUBQ every 24 hours; give initial dose 2 hours prior to surgery and continue for 7 to 10 days. Pedia – Not FDA
approved in children
CONTRA-INDICATIONS: active major bleeding, hypersensitivity to enoxaparin, heparin, pork products, hypersensitivity to benzyl alcohol,
thrombocytopenia associated with a positive test for antiplatelet antibody in the presence of enoxaparin.
ADVERSE EFFECTS: Anaphylactoid reaction, Atrial fibrillation, Eczematous drug eruption, Heart failure, Hematoma, Spinal, Hemorrhage,
Major, Increased liver function test, Pneumonia, Pulmonary edema, Skin necrosis, Thrombocytopenia
THERAPEUTIC USE: Adrenergic, Alkylarylamine, Bronchodilator, CNS Stimulant, Decongestant,, Sympathomimetic, Vasopressor
DOSE: Adult - Complication of anesthesia - Drug-induced hypotension usual dose, 25 to 50 mg (range, 10 to 50 mg) injected SUBQ/IM/IV;
Nasal congestion, 25 to 50 mg ORALLY every 6 h as needed; 0.5% solution or 0.6% jelly Intranasally every 4 h
CONTRA-INDICATIONS: anesthesia with cyclopropane or halothane, diabetes hypersensitivity to ephedrine/sympathomimetic amines,
hypertension or other cardiovascular disorders, pregnancy with maternal blood pressure above 130/80, thyrotoxicosis
THERAPEUTIC USE: Anthracycline, Antineoplastic Agent
DOSE: Adult – Breast cancer, Adjuvant therapy for axillary node-positive disease a)initial starting dose, 100 to 120 mg/m(2) IV given every 3
to 4 weeks b)60 mg/m(2) IV on days 1 and 8 repeated every 28 days for 6 cycles in combination with cyclophosphamide and 5-fluorouracil
c)100 mg/m(2) on day 1 repeated every 21 days for 6 cycles in combination with cyclophosphamide and 5-fluorouracil.
Pedia – safety & efficacy have not been established in pediatric patients.
CONTRA-INDICATIONS: hypersensitivity to anthracenediones, hypersensitivity to epirubicin or other anthracyclines, neutrophil count less
than 1500 cells/mm(3), prior cumulative max dose of anthracyclines, severe hepatic dysfunction, severe myocardial insufficiency, recent MI,
severe arrhythmias.
ADVERSE EFFECTS: Abnormal ECG, Acute myeloid leukemia, secondary, Anaphylaxis, Cardiotoxicity, Possibly fatal CHF, Hyperuricemia,
Immune hypersensitivity reaction, Myelosuppression, Possibly severe, Tissue necrosis, Local, Tumor lysis syndrome
THERAPEUTIC USE: Erythropoietic, Hematopoietic
DOSE: Adult – Anemia in neoplastic disease, due to chemotherapy (non-myeloid malignancy) a)(three times per week dosing) 150 units/kg
subcutaneously 3 times per week; if no response after 8 weeks, may increase to 300 units/kg 3 times per week; discontinue after the
completion of the chemotherapy course b)(once weekly dosing) 40,000 units subcutaneously once weekly; if no response after 4 weeks, may
increase to 60,000 units subcutaneously once weekly; discontinue after the completion of the chemotherapy course. Pedia – safety and
efficacy of epoetin alfa has not been established in pediatric patients less than 1 month old with chronic renal failure who are on dialysis;
Anemia in neoplastic disease, due to chemotherapy (non-myeloid malignancy), 600 units/kg (MAX, 40,000 units) IV once weekly; if no
response after 4 weeks, may increase to 900 units/kg (MAX, 60,000 units) IV weekly; discontinue after the completion of the chemotherapy
course
CONTRA-INDICATIONS: hypersensitivity to human albumin, hypersensitivity to mammalian cell-derived products, hypertension,
uncontrolled; hypertensive encephalopathy and seizures have been observed
25
PRODUCT
DESCRIPTION
TRADE
NAME
Erythrodar
Eye Oint. 5mg/g
Susp. 200mg/5mL
Tablet 250mg
Erythromycin
Lactobionate
Erythrocin
Erythrodar
Injection 500mg
Injection 1gram
Esmolol HCl
Brevibloc
Inj. 10mg/mL
Ethambutol
Myambutol
Tablet 100mg
Tablet 400mg
Erythromycin
Erythrocin
DOSAGE
FORM/STRENGTH
Ethanolamine
Injection 5%
Etoposide
VP – 16
Inj. 100mg/5mL
Fat Emulsion
Lipofundin
Inj. 20%, 100mL
Inj. 20%, 250mL
Inj. 20%, 500mL
PRODUCT INFORMATION
ADVERSE EFFECTS: Cerebrovascular accident, Congestive heart failure, Deep venous thrombosis, Hypertension, Left ventricular failure,
acute, Myocardial infarction, Pulmonary embolism, Seizure, Thrombotic disorder, Thrombotic microangiopathy, Thrombus due to any device,
implant &/or graft, Transient ischemic attack
THERAPEUTIC USE: Amebicide Intestinal, Antiacne, Antibacterial, Antibiotic, Macrolide
DOSE: Adult – 250 mg ORALLY every 6 h or 500 mg ORALLY every 12 h; MAX 4 g/day or 250 mg ORALLY every 6 h or 333 mg ORALLY
every 8 h or 500 mg ORALLY every 12 h; MAX 4 g/day, depending on type and severity of infection.
Pedia – 30 to 50 mg/kg/day ORALLY divided every 6 to 8 h; MAX 4 g/day as base, depending on type and severity of infection.
CONTRA-INDICATIONS: concomitant therapy with astemizole, cisapride, pimozide, or terfenadine, hypersensitivity to erythromycin or any
component of the product
THERAPEUTIC USE: Amebicide Intestinal, Antiacne, Antibacterial, Antibiotic, Macrolide
DOSE: Adult & Pedia - 15 to 20 mg/kg/day IV in divided doses; MAX 4 g/day, depending on type and severity of infection.
CONTRA-INDICATIONS: concomitant therapy with astemizole, cisapride, pimozide, or terfenadine, hypersensitivity to erythromycin products.
THERAPEUTIC USE: Antiarrhythmic, Group II, Beta-Adrenergic Blocker, Cardioselective, Cardiovascular Agent
DOSE: Adult – Hypertension, Intraoperative – Tachyarrhythmia, Intraoperative a)(immediate control) initial, 80 mg IV bolus over 30 seconds
followed by 150 mcg/kg/min IV infusion b)(immediate control) titration, may titrate up to 300 mcg/kg/min. Pedia – safety and effectiveness not
established
CONTRA-INDICATIONS: cardiogenic shock, hypersensitivity to esmolol, overt cardiac failure, second and third degree AV block, severe
sinus bradycardia
ADVERSE EFFECTS: Bronchospasm, Pulmonary edema, Seizure
THERAPEUTIC USE: Antitubercular
DOSE: Adult – should not be used alone as initial or retreatment, Pulmonary tuberculosis; Adjunct a)initial, 15 mg/kg ORALLY once daily as
combination therapy with other antitubercular agents (such as isoniazid, rifampin, pyrazinamide) b)retreatment, 25 mg/kg ORALLY once daily
for 60 days then 15 mg/kg ORALLY once daily as combination therapy with other antitubercular agents (such as isoniazid, rifampin,
pyrazinamide) c)NOT routinely recommended for preventive therapy for tuberculosis. Pedia – not recommended for children less than 13 y.
Pulmonary tuberculosis; Adjunct initial, (over 13 y) 15 mg/kg ORALLY once daily as combination therapy with other antitubercular agents.
CONTRA-INDICATIONS: hypersensitivity to ethambutol products, patients with known optic neuritis, unless clinical judgment determines that
it may be used, patients unable to appreciate and report visual side effects or changes in vision.
ADVERSE EFFECTS: Anaphylactoid reaction, Blindness &/or vision impairment level, Neutropenia, Optic neuritis, Peripheral neuropathy,
Thrombocytopenia
THERAPEUTIC USE: Sclerosing Agent
DOSE: Adult – Bleeding esophageal varices, 1.5 to 5 mL per varix IV at the time of the acute bleeding episode and then after 1 week, 6
weeks, 3 months, and 6 months as indicated; MAX dose per treatment session, 20 mL. Pedia- safety & efficacy not established in children
CONTRA-INDICATIONS: hypersensitivity to ethanolamine oleate, oleic acid, or ethanolamine
ADVERSE EFFECTS: Acute renal failure, Anaphylaxis, Esophageal perforation, Esophageal stricture, Pulmonary embolism
THERAPEUTIC USE: Antineoplastic Agent, Mitotic Inhibitor
DOSE: Adult – Small cell carcinoma of lung, in combination therapy with other approved chemotherapeutic agents as first-line therapy
a)Range, 35 mg/m(2)/day IV for 4 days, to 50 mg/m(2)/day IV for 5 days; in combination with other approved chemotherapeutic agents;
repeat at 3-4 week intervals b)ORAL dose is 2 times the IV dose rounded to the nearest 50 mg. Pedia - safety and effectiveness in children
have not been established
CONTRA-INDICATIONS: hypersensitivity to podophyllum
ADVERSE EFFECTS: Acute leukemia, Congestive heart failure, Hepatotoxicity, Immune hypersensitivity reaction, Myelosuppression, Doselimiting, Myocardial infarction, Stevens-Johnson syndrome, Toxic epidermal necrolysis
THERAPEUTIC USE: Parenteral Lipids
DOSE: Adult – Total parenteral nutrition, doses should be individualized based upon the caloric requirements of the patient; daily dose
should not exceed 2.5g fat/kg of body weight and should not exceed 60% of the total daily caloric input. Pedia – Total parenteral nutrition
a)older patients: doses should be individualized based upon the caloric requirements of the patient; daily dose should not exceed 3 g fat/kg of
body weight and should not exceed 60% of the total daily caloric input b)premature infants, doses should be individualized based upon the
caloric requirements of the patient; suggested initial dosage, 0.5 g fat/kg of body weight per 24 h IV and may be increased in relation to the
infants' ability to eliminate fat up to a maximum of 3 g fat /kg per 24 h; rate should not exceed 1 g fat/kg in 4 h
CONTRA-INDICATIONS: abnormal fat metabolism, including pathological hyperlipidemia, lipid nephrosis, or acute pancreatitis with
hyperlipidemia
ADVERSE EFFECTS: Cholestasis, Dyspnea, Hepatomegaly, Pulmonary fat embolism, Splenomegaly, Thrombocytopenia
26
PRODUCT
DESCRIPTION
Fentanyl
TRADE
NAME
Durogesic
Sublimase
DOSAGE
FORM/STRENGTH
Inj. 0.1mg/2mL
Inj. 500mcg/10mL
Patch 25mcg/Hr
Patch 50mcg/Hr
Ferric Hydroxide
Polymaltose
Ferose
Ferrous Fumarate
Fumafer
Tablet 200mg
Ferrous Sulphate
Feromin
Tablet 190mg
Fertonic
Fibrinogen
Drops 25mg Iron
Syrup 50mg Iron
Injection 1gram
Filgrastim
Neupogen
Inj. 300mcg/mL
Flucloxacillin
Floxapen
Capsule 500mg
Injection 500mg
PRODUCT INFORMATION
THERAPEUTIC USE: Analgesic, Anesthetic Adjunct, Opioid
DOSE: Adult - transdermal system: only for use in the management of chronic, moderate to severe pain requiring around-the-clock opioid
therapy not managed by other means in patients who have demonstrated opioid tolerance and require a total daily dose equivalent to the
fentanyl 25 mcg/hr transdermal patch; management of acute or post-operative pain in opiate-naive patients is contraindicated. Pedia - the
safety of the fentanyl iontophoretic transdermal system has not been established in children
CONTRA-INDICATIONS: acute or postoperative pain; risk of life-threatening respiratory depression/hypoventilation, bronchial asthma, acute
or severe; risk of serious or life-threatening hypoventilation, hypersensitivity to fentanyl or any product or system components, mild or
intermittent pain management; risk of serious or life-threatening hypoventilation, opioid nontolerant patients; risk of life-threatening respiratory
depression, paralytic ileus, suspected or known, situations of significant respiratory depression and unmonitored settings that lack
resuscitative equipment
ADVERSE EFFECTS: Apnea, Cardiac dysrhythmia, Chest pain, Hypertension, Hypotension, Hypoventilation, Respiratory depression
THERAPEUTIC USE: Iron Supplement, Nutriceutical, Parenteral Mineral-Trace Mineral
DOSE: Adult – Iron deficiency anemia, ORAL, elemental iron 2-3 mg/kg DAILY (divided into 3 doses). Pedia – Iron deficiency anemia
a)(premature infants) 2 to 4 mg elemental iron/kg/day ORALLY (divided into 1 or 2 doses), MAX 15 mg/day b)(infants and children) 3 to 6 mg
elemental iron/kg/day ORALLY (divided into 1 to 3 doses)
CONTRA-INDICATIONS: anemia other than iron-deficiency anemia, hemochromatosis, hemosiderosis, hypersensitivity to iron products
ADVERSE EFFECTS: Immune hypersensitivity reaction
THERAPEUTIC USE: Iron Supplement, Nutriceutical, Parenteral Mineral-Trace Mineral
DOSE: Adult – Iron deficiency anemia, ORAL, elemental iron 2-3 mg/kg DAILY (divided into 3 doses). Pedia – Iron deficiency anemia
a)(premature infants) 2 to 4 mg elemental iron/kg/day ORALLY (divided into 1 or 2 doses), MAX 15 mg/day b)(infants and children) 3 to 6 mg
elemental iron/kg/day ORALLY (divided into 1 to 3 doses)
CONTRA-INDICATIONS: anemia other than iron-deficiency anemia, hemochromatosis, hemosiderosis, hypersensitivity to iron products
ADVERSE EFFECTS: Immune hypersensitivity reaction
THERAPEUTIC USE: Iron Supplement, Nutriceutical, Parenteral Mineral-Trace Mineral
DOSE: Adult – Iron deficiency anemia, ORAL, elemental iron 2-3 mg/kg DAILY (divided into 3 doses). Pedia – Iron deficiency anemia
a)(premature infants) 2 to 4 mg elemental iron/kg/day ORALLY (divided into 1 or 2 doses), MAX 15 mg/day b)(infants and children) 3 to 6 mg
elemental iron/kg/day ORALLY (divided into 1 to 3 doses)
CONTRA-INDICATIONS: anemia other than iron-deficiency anemia, hemochromatosis, hemosiderosis, hypersensitivity to iron products
ADVERSE EFFECTS: Immune hypersensitivity reaction
THERAPEUTIC USE: To control haemorrhage associated with low blood-fibrinogen concentration in afibrinogenaemia or
hypofirbrinogenaemia. It has also been used in disseminated intravascular coagulation.
DOSE: Adult - Generally, 1-2 grams is administered initially, with subsequent infusions as required. Pedia – the dosage should be selected
according to the body weight of the child and clinical need.
CONTRA-INDICATIONS: Hypersensitivity to constituents of the preparation.
ADVERSE EFFECTS: Anaphylactic reaction, potential risk of thromboembolic episodes.
THERAPEUTIC USE: Colony Stimulating Factor, Hematopoietic
DOSE: Adult & Pedia – Febrile neutropenia, In non-myeloid malignancies following myelosuppressive chemotherapy; Prophylaxis 5
mcg/kg/day SC/IV once daily; start at least 24 h after chemotherapy.
CONTRA-INDICATIONS: Hypersensitivity to E.coli derived proteins, filgrastim or any component of the product
ADVERSE EFFECTS: Acute respiratory distress syndrome, Hemoglobin SS disease with crisis, Rupture of spleen, Vasculitis of the skin
THERAPEUTIC USE: Penicillin, Penicillinase-Resistant
DOSE: Adult – oral doses of floxacillin have been 250 mg every 6 to 8 hours. However, higher doses (500 to 2000 mg every 8 hours) have
been used in some studied; IV dose of floxacillin is 250 to 500 mg every 6 hours. IM, a dose of 250 mg every 6 hours has been suggested.
Higher doses are indicated in more severe infections over 3 to 4 minutes.
Pedia – oral dose of floxacillin in children 2 to 10 years and under 2 years of age is 125 mg and 62.5 mg, respectively, every 6 hours; children
2 to 10 years of age, IV doses of 125 to 250 mg every 6 hours are suggested. An IM dose of 125 mg every 6 hours has been recommended
in this age group. For younger children (under 2 years of age), one-half of the above dose is suggested.
CONTRA-INDICATIONS: Hypersensitivity to FLOXACILLIN or other penicillins
27
PRODUCT
DESCRIPTION
TRADE
NAME
Diflucan
Capsule 50mg
Inj. 2mg/mL
Syrup 1mg/mL
Flucytosine
Ancotil
Inj. 10mg/mL
Fludarabine Phosphate
Fludara
Injection 50mg
Fluconazole
Fludrocortisone Acetate
Candivast
DOSAGE
FORM/STRENGTH
Cortilon
Florinef
Syrup 10mcg/mL
Tablet 100mcg
Flumazenil
Anexate
Inj. 100mcg/mL
Flumethasone/Salicylic Acid
Locasalen
Ointment
Fluorescein Sodium
Fluorets
Eye Minims 2%
Eye Strips 1mg
Injection 10%
PRODUCT INFORMATION
THERAPEUTIC USE: Antifungal, Triazole
DOSE: Adult – Candidiasis of the mouth, 200 mg ORALLY or IV on the first day, then 100 mg once daily; treatment should be continued for
at least 2 weeks to decrease the likelihood of relapse; Candidiasis of the esophagus, 200 mg ORALLY or IV on the first day, then 100 mg
once daily (MAX daily dose 400 mg); treatment should last for at least 3 weeks and for at least 2 weeks following resolution of symptoms.
Pedia – Candidiasis of the mouth, 6 mg/kg/day ORALLY or IV on day 1, then 3 mg/kg/day once daily for at least 2 weeks to decrease the
likelihood of relapse; Candidiasis of the esophagus, 6 mg/kg/day ORALLY or IV on day 1, then 3 mg/kg/day (MAX 12 mg/kg/day) once daily
for at least 3 weeks; continue treatment for 2 weeks following resolution of symptoms
CONTRA-INDICATIONS: hypersensitivity to fluconazole
ADVERSE EFFECTS: Anaphylaxis
THERAPEUTIC USE: Antifungal
DOSE: Adult – Candidiasis (septicemia, endocarditis, urinary tract infections, pulmonary infections) 50 to 150 mg/kg/day ORALLY divided
into 4 doses at 6-h intervals. Pedia – safety and efficacy in children not established
CONTRA-INDICATIONS: hypersensitivity to flucytosine
ADVERSE EFFECTS: Cardiotoxicity, Leukopenia, Thrombocytopenia
THERAPEUTIC USE: Antimetabolite, Antineoplastic Agent
DOSE: Adult – B-cell chronic lymphocytic leukemia, For patients who have not responded to or whose disease has progressed during
treatment with at least one standard alkylating-agent containing regimen, 25 mg/m(2) IV daily for 5 days, repeat every 28 days; dosage should
be adjusted based on hematologic or non-hematologic toxicity. Pedia – efficacy has not been established in any childhood malignancy
CONTRA-INDICATIONS: hypersensitivity to fludarabine products
ADVERSE EFFECTS: Aplasia of skin, Autoimmune hemolytic anemia, Edema, Fever, Graft versus host disease, Transfusion-associated,
with non-irradiated blood, Infectious disease, Myelosuppression, Neurotoxicity, Pneumonia
THERAPEUTIC USE: Adrenal Mineralocorticoid, Diagnostic Agent, Adrenocortical Function, Endocrine-Metabolic Agent
DOSE: Adult – Addison's disease – Adrenal insufficiency, 0.1 mg ORALLY 3 times/wk to 0.2 mg/day ORALLY. Pedia – Not FDA approved in
children. Addison's disease – Adrenal insufficiency a)infants, 0.1 to 0.2 mg/day ORALLY b)children, 0.05 to 0.1 mg/day ORALLY
CONTRA-INDICATIONS: hypersensitivity to fludrocortisones, systemic fungal infections
ADVERSE EFFECTS: Cardiomegaly, Congestive heart failure, Hypertension, Raised intracranial pressure, Secondary hypocortisolism,
Seizure, Thrombophlebitis
THERAPEUTIC USE: Benzodiazepine Antagonist, Toxicology-Antidote Agent
DOSE: Adult – Drug overdose, Benzodiazepine, known or suspected initial, 0.2 mg IV over 30 s; if desired level of consciousness not
obtained after an additional 30 s, give dose of 0.3 mg IV over 30 s; further doses of 0.5 mg IV over 30 s may be given at 1-min intervals if
needed to MAX total dose of 3 mg; patients with only partial response to 3 mg may require additional slow titration to a total dose of 5 mg; if
no response 5 min after receiving total dose of 5 mg, overdose is unlikely to be benzodiazepine and further treatment with flumazenil will not
help. Pedia – safety and efficacy in the reversal of conscious sedation in pediatric patients below the age of 1 year have not been established.
Reversal of benzodiazepine activity, children 1 year or older, 0.01 mg/kg (up to 0.2 mg) IV over 15 seconds; if adequate sedation reversal
does not occur after an additional 45 seconds, further injections of 0.01 mg/kg (up to 0.2 mg) may be repeated at 1-minute intervals, as
needed up to 4 times; maximum total dose 0.05 mg/kg or 1 mg, whichever is lower
CONTRA-INDICATIONS: hypersensitivity to flumazenil or benzodiazepines, patients who are showing signs of serious cyclic antidepressant
overdose, patients who have been given a benzodiazepine for control of a potentially life-threatening condition (eg, control of intracranial
pressure or status epilepticus).
ADVERSE EFFECTS: Cardiac dysrhythmia, Death, Usually in patients with serious underlying disease or who had ingested large amounts of
non-benzodiazepine drugs, (usually cyclic antidepressants), as part of an overdose, Seizure, In patients who are relying on benzodiazepines
to control seizures, are physically dependent on benzodiazepines, or who have ingested large doses of other drugs
THERAPEUTIC USE: Adrenal Glucocorticoid
DOSE: Adult & Pedia – Flumethasone cream 0.03% should be applied in a thin film to the affected area 3 to 4 times daily.
CONTRA-INDICATIONS: Hypersensitivity to flumethasone or components
THERAPEUTIC USE: Disclosing Agent
DOSE: Adult - Ophthalmic fluorescence imaging, inject contents of ampul or vial of 10% or 25% solution rapidly IV into the antecubital vein;
Applanation tonometry-place strip, which has been moistened with a drop of sterile water, at the fornix in the lower cul-de-sac close to the
punctum; patient should close lid tightly over strip until desired amount of staining is observed or retract upper lid and touch tip of strip to the
bulbar conjunctiva on the temporal side until adequate staining is achieved. Pedia – Safety & effectiveness not established in children
CONTRA-INDICATIONS: concomitant soft contact lens use, hypersensitivity to any component of fluorescein
ADVERSE EFFECTS: Anaphylaxis, Injection, Arterial ischemia, Basilar, Cardiac arrest, Injection site thrombophlebitis, Seizure, Shock
28
PRODUCT
DESCRIPTION
Fluorometholone
TRADE
NAME
FML
DOSAGE
FORM/STRENGTH
Eye Drops 0.1%
Inj. 250mg/5mL
Inj. 500mg/10mL
Fluorouracil
Fluticasone Propionate
Flixotide
Evohaler 125mcg
Evohaler 250mcg
Folic Acid
Folicum
Vitafol
Inj. 5mg/mL
Syrup 1mg/mL
Tablet 5mg
Fondaparinux
Arixtra
Inj. 2.5mg/0.5mL
Fosinopril
Monopril
Staril
Tablet 10mg
Tablet 20mg
PRODUCT INFORMATION
THERAPEUTIC USE: Adrenal Glucocorticoid, Ophthalmologic Agent
DOSE: Adult & Pedia – Inflammatory disorder of the eye a)ophthalmic ointment, initial, apply one-half inch ribbon into the conjunctival sac
every 4 hrs b)ophthalmic ointment, maintenance, apply one-half inch ribbon into the conjunctival sac 1 to 3 times daily c)ophthalmic
suspension: Instill 1 drop into the conjunctival sac 2 to 4 times daily.
CONTRA-INDICATIONS: epithelial herpes simplex keratitis, mycobacterial infections of the eye, fungal diseases of the ocular structures,
hypersensitivity to preparation components, vaccinia, varicella, or other viral diseases of the eye
ADVERSE EFFECTS: Glaucoma, Perforating scleral wound
THERAPEUTIC USE: Antimetabolite, Antineoplastic, Dermatological
DOSE: Adult – Carcinoma of pancreas, Palliative 12 mg/kg IV daily for 4 days, 6 mg/kg IV daily on days 6, 8, 10, 12 (maximum dose 800
mg/day); maintenance therapy- may be considered in patients tolerating fluorouracil toxicity by repeating the first course every 30 days, after
the last day of the previous treatment cycle. Alternatively, a single maintenance dose of 10-15 mg/kg/week may be given after toxic signs
resulting from the initial course of therapy have subsided; maximum dose 1 g/week. Pedia – Safety and effectiveness in children have not
been established
CONTRA-INIDICATIONS: Bone marrow depression, Dihydropyrimidine dehydrogenase enzyme deficiency, Hypersensitivity to fluorouracil,
Poor nutritional state, Pregnancy, existing or potential, Serious infection
ADVERSE EFFECTS: Anaphylaxis, Angina, Bleeding, Cerebellar syndrome, acute, Coronary arteriosclerosis, Eye / vision finding, Finding of
lacrimation, Gastrointestinal ulcer, Immune hypersensitivity reaction, Light intolerance, Myelosuppression, Anemia, eucopenia,
thrombocytopenia, Nystagmus, Stenosis of lacrimal system, Thrombophlebitis
THERAPEUTIC USE: Adrenal Glucocorticoid, Anti-Inflammatory, Corticosteroid
DOSE: Adult – Allergic rhinitis, Nasal Inhalation, initial, 2 sprays/nostril daily or 1 spray/nostril twice daily, MAX 2 sprays/nostril/day (200
mcg/day). Pedia - Allergic rhinitis Nasal Inhalation, 4 y and older, initial, 1 spray/nostril once daily, MAX 2 sprays/nostril daily (200 mcg/day)
CONTRA-INDICATIONS: hypersensitivity to fluticasone or other ingredients, severe allergy to milk proteins, status asthmaticus or other acute
episodes of asthma.
ADVERSE EFFECTS: Anaphylaxis, Glaucoma, Immune hypersensitivity reaction, Secondary hypocortisolism
THERAPEUTIC USE: Nutritive Agent, Vitamin B
DOSE: Adult – Folic acid deficiency, up to 1 mg/day IM, IV, ORAL, SC; resistant cases may require larger doses; maintenance, 0.4 mg/day
ORALLY; for pregnant and lactating women, 0.8 mg/day ORALLY; never less than 0.1 mg/day. Pedia - ORAL, IM, IV, SC, up to 1 mg/day;
resistant cases may require larger doses, maintenance, infants, 0.1 mg/day; age under 4 y, up to 0.3 mg/day; age 4 y or older, 0.4 mg/day
CONTRA-INDICATIONS: hypersensitivity to folic acid products
ADVERSE EFFECTS: Allergy
THERAPEUTIC USE: Anticoagulant, Factor Xa Inhibitor
DOSE: Adult – Postoperative deep vein thrombosis, Hip repair or replacement, knee replacement, or abdominal surgery; Prophylaxis 2.5 mg
SUBQ once daily after hemostasis has been established (initial dose should be given 6-8 hrs post-op); usual duration of therapy is 5 to 9
days; for hip fracture patients an extended course of up to 24 days is recommended. Pedia – safety and efficacy in pediatrics have not been
established
CONTRA-INDICATIONS: active major bleeding; risk of uncontrollable hemorrhage, bacterial endocarditis, body weight less than 50 kg for
prophylactic therapy of hip fracture, hip replacement or knee replacement surgery, or abdominal surgery; increased risk for major bleeding
episodes, fondaparinux-related thrombocytopenia, hypersensitivity to fondaparinux, severe renal impairment (creatinine clearance less than
30 mL/min); increased risk for major bleeding episodes
ADVERSE EFFECTS: Anemia, Bleeding, Major, in those greater than 75 years old, Bleeding, Major, in those less than 65 years old,
Bleeding, Major, with normal renal function, Bleeding, Major, with severe renal impairment, Increased liver aminotransferase level,
Asymptomatic, Thrombocytopenia, Less than 50,000/mm(3)
THERAPEUTIC USE: ACE Inhibitor, Antihypertensive, Cardiovascular Agent, Renal Protective Agent
DOSE: Adult – Congestive heart failure; Adjunct initial, 5 to 10 mg ORALLY once daily; maintenance, 20 to 40 mg ORALLY daily; MAX 40
mg daily; Hypertension – initial, 10 mg ORALLY once daily; maintenance, 20 to 40 mg ORALLY once daily or in 2 divided doses; MAX 80 mg
daily; Myocardial infarction – initial, 5 mg ORALLY once daily; maintenance, 5 to 20 mg ORALLY daily; MAX 20 mg/daily. Pedia –
Hypertension, (children ages 6 to 16 years weighing more than 50 kg) 5 to 10 mg ORALLY once daily, MAX 40 mg/day
CONTRA-INDICATIONS: hypersensitivity to fosinopril/other ACE inhibitors
ADVERSE EFFECTS: Angioedema, Head and Neck, Intestinal angioedema, Liver failure
29
PRODUCT
DESCRIPTION
TRADE
NAME
Diusemide
Furosemide
Lasix
Salurin
DOSAGE
FORM/STRENGTH
Inj. 20mg/2mL
Inj. 50mg/5mL
Syrup 1mg/mL
Tablet 40mg
Fusidate Sodium
Balad
Fucidin
Fusibact
Injection 500mg
Ointment 2%
Tablet 250mg
Fusidic Acid
Fucithalmic
Eye Drops 1%
Ganciclovir
Cymevene
Injection 500mg
Gemcitabine HCl
Gemzar
Injection 200mg
Gemfibrozil
Lopid
Tablet 600mg
Low – Lip
Garamycin
Gentamicin
Gentacin
Eye/Ear Drops
0.3%
Eye Ointment 0.3%
Injection 20mg/2mL
PRODUCT INFORMATION
THERAPEUTIC USE: Cardiovascular Agent, Diuretic, Loop
DOSE: Adult – Congestive heart failure – Edema a)initial, 20 to 40 mg IV over 1 to 2 min; may repeat same dose 2 hours later or may be
increased by 20 mg until desired response; this individually determined dose may be given once or twice daily b)initial, 20 to 40 mg IM; may
repeat same dose 2 hours later or may be increased by 20 mg until desired response; this individually determined dose may be given once or
twice daily c)initial, 20 to 80 mg ORALLY daily, may repeat in 6 to 8 hours; MAX 600 mg/day ORALLY d)titrate to maintenance, may increase
by 20 to 40 mg ORALLY at 6 to 8 hours intervals after the previous dose; this individual dose may be given once or twice daily; MAX 600
mg/day ORALLY e)IV infusion, administer at a rate not greater than 4 mg/min. Pedia - a)premature neonates less than 29 wk gestation, 1 to
2 mg/kg/dose ORALLY every 24 hours; may increase to 6 mg/kg/dose b)premature neonates less than 29 wk gestation, 1 mg/kg/dose IV
every 24 hours c)neonates, 1 to 3 mg/kg ORALLY every 8 hours as needed d)neonates, 1 to 3 mg/kg IV over 3 min; may repeat same dose
every 8 hours e)infants and children, initial, 2 mg/kg/dose ORALLY; may increase by 1 to 2 mg/kg/dose no sooner than 6 to 8 hours following
the previous dose. MAX 6 mg/kg/dose ORALLY
CONTRA-INDICATIONS: hypersensitivity to furosemide or sulfonamides, anuria
ADVERSE EFFECTS: Agranulocytosis, Aplastic anemia, Erythema multiforme, Hemolytic anemia, Hypotension, Leukopenia, Pancreatitis,
Scaling eczema, Stevens-Johnson syndrome, Thrombocytopenia
THERAPEUTIC USE: Infection of skin & soft tissue, infective conjunctivitis, osteomyelitis
DOSE: Adult – IV dose in adults is 500 mg sodium fusidate (equivalent 480 mg fusidic acid) 3 times daily, with doses not to exceed 2 gm
daily; Pedia – IV dose in children is 20 mg sodium fusidate/kg/day, equivalent to 19.2 mg/kg/day fusidic acid, divided into 3 equal doses and
infused over a 2 to 4 hour period into a wide bore vein with good blood flow
THERAPEUTIC USE: Infection of skin & soft tissue, infective conjunctivitis, osteomyelitis
DOSE: Adult & Pedia – For skin and soft tissue infections the minimum duration of therapy should be 1 to 2 weeks, for acute osteomyelitis a
minimum of 2 to 4 weeks, and chronic osteomyelitis several months of therapy may be required.
CONTRA-INDICATIONS: Hypersensitivity to fusidic acid and/or its salts
THERAPEUTIC USE: Antiviral, Guanosine Nucleoside Analog, Viral DNA Polymerase Inhibitor
DOSE: Adult – Cytomegalovirus infection, Transplantation; Prophylaxis a)5 mg/kg IV over 1 hr every 12 hr for 7-14 days, then 5 mg/kg IV
once a day 7 days a week, or 6 mg/kg IV once a day 5 days a week; duration of therapy dependent on degree and duration of
immunosuppression b)solid organ transplant, 1 g ORALLY 3 times a day. Pedia – not FDA-approved for pediatric patients; use with caution in
this population due to the probability of long-term carcinogenicity and reproductive toxicity. Cytomegalovirus infection; Prophylaxis – HIV
infection, Advanced a)(primary prophylaxis) 30 mg/kg ORALLY 3 times a day b)(secondary prophylaxis) 5 mg/kg IV once daily
CONTRA-INDICATIONS: hypersensitivity to ganciclovir/acyclovir products, patients with severe neutropenia (ANC less than 500/microliter) or
severe thrombocytopenia (platelets less than 25,000/microliter), intravitreal implant; any contraindication for ocular surgery including infection
or severe thrombocytopenia
THERAPEUTIC USE: Antimetabolite, Antineoplastic Agent
DOSE: Adult – Carcinoma of pancreas, As first line therapy in locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV)
disease, or for patients previously treated with 5-fluorouracil a)initial, 1000 mg/m(2) IV over 30 min weekly for 7 wk followed by 1 wk rest
b)subsequent, 1000 mg/m(2) IV weekly for 3 consecutive weeks out of every 4 weeks. Pedia - safety and effectiveness in children have not
been established
CONTRA-INDICATIONS: hypersensitivity to gemcitabine
ADVERSE EFFECTS: Acute respiratory distress syndrome, Cardiac dysrhythmia, Congestive heart failure, Hemolytic uremic syndrome,
Hepatotoxicity, Hypertension, Interstitial pneumonia, Liver failure, Myelosuppression, Dose-limiting, Myocardial infarction, Pulmonary edema,
Pulmonary fibrosis, Renal failure, Respiratory failure, Reversible posterior leukoencephalopathy syndrome, Seizure, Thrombotic
microangiopathy, Tissue necrosis, Vasculitis
THERAPEUTIC USE: Antihyperlipidemic, Fibric Acid
DOSE: Adult – 600 mg ORALLY twice daily 30 minutes before the morning and evening meal. Pedia – safety and efficacy not established in
pediatric patients
CONTRA-INDICATIONS: Concomitant gemfibrozil and cerivastatin, Pre-existing gallbladder disease, Hepatic dysfunction, including primary
biliary cirrhosis, Hypersensitivity to gemfibrozil, Severe renal impairment
ADVERSE EFFECTS: Liver function tests abnormal, Rhabdomyolysis, Especially when coadministered with a statin
THERAPEUTIC USE: Aminoglycoside, Antibacterial, Antibiotic
DOSE: Adult – Bacterial endocarditis a)(traditional dosing) 3 mg/kg/d IV in equally divided doses every 8 h or up to 5 mg/kg/d IV in 3 or 4
equally divided doses; adjust dose based on serum concentrations b)(once daily dosing, not FDA approved) 4 to 7 mg/kg/day IV once every
24 h; adjust dosage based on serum concentrations.
Pedia – Bacterial sepsis of newborn a)(neonates, less than 28 weeks gestational age) 2.5 mg/kg IV every 24-36 h b)(neonates, 28-32 weeks
30
PRODUCT
DESCRIPTION
TRADE
NAME
Gentam
Gentamicin
/ Betamethasone
Garasone
Glibenclamide
(Glyburide)
Daonil
Diatab
Euglucon
Glibil
Glynase
Gliclazide
Diamicron
Glaze
Glizide
Glipizide
Glucagon
Glucose
Amaryl
Diapride
Minidiab
PRODUCT INFORMATION
Injection 80mg/2mL gestational age) 2.5 mg/kg IV every 18 h c)(neonates, 33-42 weeks gestational age) 2.5 mg/kg IV every 12 h d)(term neonates over 1 week of
Eye/Ear Drops
Crystals
Solution 1%
Gentian Violet
Glimepiride
DOSAGE
FORM/STRENGTH
Tablet 5mg
Tablet 80mg
Tablet 2mg
Tablet 3mg
Tablet 5mg
Sucrazide
Injection 1unit
(1mg)
Powder 50grams
Powder 75grams
Powder 100grams
Powder 450grams
age, infants and children less than 5 years of age) 2.5 mg/kg IV every 8 h e)(children 5 years and older) 2-2.5 mg/kg IV every 8 h
CONTRA-INDICATIONS: hypersensitivity to gentamicin/aminoglycosides
ADVERSE EFFECTS: Nephrotoxicity, Neuromuscular blockade finding, Ototoxicity, Respiratory tract paralysis, Concomitant anesthesia,
muscle relaxants
THERAPEUTIC USE: Aminoglycoside, Antibacterial, Antibiotic
DOSE: Adult – Eye infection a)ophthalmic ointment 0.3%, apply a small amount (half-inch ribbon) 2 to 3 times a day b)ophthalmic solution
0.3%, instill 1 to 2 drops into the affected eye every 4 h, up to 2 drops every hour for severe infections
CONTRA-INDICATIONS: hypersensitivity to gentamicin/aminoglycosides
THERAPEUTIC USE: Antifungal, Antisepsis skin cleansing procedure
DOSE: Adult - Antisepsis Skin cleansing procedure, apply to affected area once or twice daily
CONTRA-INDICATIONS: hypersensitivity to gentian violet, patients with porphyria, use on ulcerative lesions or open wounds
THERAPEUTIC USE: 2nd Generation Sulfonylurea, Hypoglycemic
DOSE: Adult – Diabetes mellitus type 2 a)(regular) initial, 2.5-5 mg ORALLY once daily b)(regular) maintenance, 1.25-20 mg ORALLY once
daily or in 2 divided doses, MAX 20 mg/day c)(micronized glyburide): initial, 1.5-3 mg ORALLY once daily d)(micronized glyburide):
maintenance, 0.75-12 mg ORALLY once daily or in 2 divided doses, MAX 12 mg/day. Pedia – safety and efficacy not established in pediatric
patients
CONTRA-INDICATIONS: diabetic ketoacidosis, hypersensitivity to glyburide
ADVERSE EFFECTS: Hypoglycemia
THERAPEUTIC USE: 2nd Generation Sulfonylurea, Hypoglycemic
DOSE: Adult – initial doses of 40 or 80 mg orally daily with breakfast. The dose is increased in increments of 40 or 80 mg (usually weekly)
until adequate glycemic control is achieved. The drug can be given once daily, although twice-daily therapy (with meals) may be indicated in
some patients. Maximum doses have usually been 320 mg daily
CONTRA-INDICATIONS: Diabetic ketoacidosis, Hypersensitivity to gliclazide or other sulfonylureas, Type I diabetes as sole therapy
THERAPEUTIC USE: 2nd Generation Sulfonylurea, Hypoglycemic
DOSE: Adult – Diabetes mellitus type 2 a)initial, 1 to 2 mg ORALLY once daily b)maintenance, 1 to 4 mg ORALLY once daily, MAX 8 mg
daily. Pedia – not FDA-approved in pediatric patients.Diabetes mellitus type 2 a)initial, 1 mg ORALLY once daily b)maintenance, 1 to 8 mg
ORALLY once daily, MAX 8 mg daily
CONTRA-INDICATIONS: diabetic ketoacidosis, hypersensitivity to glimepiride products, pregnancy complicated by diabetes mellitus
ADVERSE EFFECTS: Hypoglycemia
THERAPEUTIC USE: 2nd Generation Sulfonylurea, Hypoglycemic
DOSE: Adult – Diabetes mellitus type 2 a)(Glucotrol): initial, 5 mg ORALLY once daily b)(Glucotrol): maintenance, MAX 40 mg daily (if dose
exceeds 15 mg, divide into at least 2 doses) c)(Glucotrol-XL): initial: 5 mg ORALLY once daily d)(Glucotrol-XL): maintenance: 5-10 mg
ORALLY daily, MAX 20 mg daily. Pedia – safety and efficacy not established in pediatric patients
CONTRA-INDICATIONS: diabetic ketoacidosis, hypersensitivity to glipizide
ADVERSE EFFECTS: Hypoglycemia, Stevens-Johnson syndrome
THERAPEUTIC USE: Beta-Adrenergic Blocker Antagonist, Diagnostic Agent, Gastric Function, Gastrointestinal Agent, Glucose Regulation,
Antihypoglycemic
DOSE: Adult – Hypoglycemia 1 mg (1 unit) IM,IV,SC; Radiography of gastrointestinal tract a)(IV) 0.25 to 2 mg (0.25 to 2 units) IV 1 min
before procedure b)(IM) 1 to 2 mg (1 to 2 units) IM 4 to 10 min before procedure. Pedia – Hypoglycemia a)(weight <20 kg (<44 pounds)): 0.02
to 0.03 mg/kg/dose or 0.5 mg/dose IM,IV,SC; MAX 1 mg/dose b)(weight >20 kg (>44 pounds): 1 mg (1 unit) IV, IM, SC
CONTRA-INDICATIONS: hypersensitivity to glucagon, known pheochromocytoma
THERAPEUTIC USE: Diagnostic Agent, Nutritive Agent, Osmotherapy Agent, Parenteral Solution
DOSE: Adult – Glucose tolerance test a)Diabetes mellitus (diagnosis): 75 g anhydrous glucose (dextrose) dissolved in water ORALLY, as
one-time dose for oral glucose tolerance test b)Gestational diabetes mellitus (diagnosis), one-step approach: 100 g anhydrous glucose
(dextrose) dissolved in water ORALLY, as one-time dose for oral glucose tolerance test c)Gestational diabetes mellitus (diagnosis), two-step
approach: 50 g anhydrous glucose (dextrose) dissolved in water ORALLY as one-time dose for glucose challenge test, then perform the 100g oral glucose tolerance test on those who exceeded the threshold value on the glucose challenge test
CONTRA-INDICATIONS: a)Do not use concentrated solutions of dextrose in patients with: anuria, diabetic coma and hyperglycemia,
intracranial or intraspinal hemorrhage, delirium tremens in dehydrated patients, glucose-galactose malabsorption syndrome b)Allergy to corn
or corn products
31
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Glycerin
Laxolyne
Liquid
Supp. Adult
Supp. Pedia
Glyceryl Trinitrate
Deponit NT
Minitran
Nitroderm TTS
Tridil
Inj. 50mg/10mL
Inj. 50mg/50mL
Patch 5mg
Patch 10mg
Glycopyrronium Bromide
Inj. 0.2mg/mL
Goserelin Acetate
Zoladex Depot
Inj. 3.6mg
Granisetron HCl
Kytril
Inj. 1mg/mL
Tablet 1mg
Guaphan
Guaifenesin
Resyl
Syrup
100mg/5mL
Robitussin
Haemophilus Influenza
Type B Conjugated Vaccine
Hibtiter
Inj. 10mcg/0.5mL
PRODUCT INFORMATION
THERAPEUTIC USE: Antiglaucoma, Cardiovascular Agent, Diuretic, Osmotic, Gastrointestinal Agent, Laxative, Hyperosmotic, Laxative,
Stool Softener, Lubricant, Ocular Protectant, Dental, Protectant, Dermatological
DOSE: Adult – is 3 grams suppositories should be retained for 15 minutes; liquid glycerin is administered rectally, gently insert stem with
steady pressure with the tip pointing toward the navel and squeeze the unit until almost all the liquid has been delivered; a small amount of
liquid will remain. Pedia – younger than 6 years of age of glycerin suppositories to promote fecal evacuation is 1 to 1.5 grams; suppositories
should be retained for 15 minutes
CONTRA-INDICATIONS: Hypersensitivity to any component in the preparation, Well-established anuria, Severe dehydration, Frank or
impending acute pulmonary edema, Severe cardiac decompensation
THERAPEUTIC USE: Antianginal, Coronary Vasodilator, Nitrate
DOSE: Adult – Pulmonary edema a)initial, 5 to 10 mcg/min IV, titrate in increments of 5 mcg/min every 3 to 5 min to total dose of 100 to 200
mcg/min until desired hemodynamic effect obtained; systolic arterial pressure should be kept in the range of 90 to 100 mmHg b)SL tablet; 0.3
to 0.4 mg every 5 min x 3. Pedia – safety and efficacy not established in children. Pulmonary edema, initial, 0.5 to 20 mcg/kg/min IV; MAX, 60
mcg/kg/min
CONTRA-INDICATIONS: anemia, severe, concurrent use of phosphodiesterase inhibitors such as sildenafil or vardenafil (increased
hypotensive effect), constrictive pericarditis, early myocardial infarction, hypersensitivity to adhesives, hypersensitivity to organic nitrates,
increased intracranial pressure, pericardial tamponade, restrictive cardiomyopathy, symptomatic hypotension
ADVERSE EFFECTS: Blood coagulation disorder with prolonged bleeding time, Methemoglobinemia, Rebound hypertension, Uncommon,
Scaling eczema, Syncope, Thrombocytopenia, Unstable angina
THERAPEUTIC USE: Antimuscarinic, Cholinergic Antagonist, Gastrointestinal Agent
DOSE: Adult – Cardiac dysrhythmia, Vagal reflex associated, surgically-induced or drug-induced – Surgical procedure, 0.1 mg IV as a single
dose, repeat every 2 to 3 min as needed. Pedia - a)glycopyrrolate injection contains benzyl alcohol; do not use in patients less than 1 month
of age b)safety and effectiveness in pediatric patients below the age of 16 years have not been established
CONTRA-INDICATIONS: gastrointestinal obstruction, glaucoma, hypersensitivity to glycopyrrolates, myasthenia gravis, newborns less than 1
month of age, obstructive uropathy, paralytic ileus or intestinal atony, severe ulcerative colitis or toxic megacolon, unstable cardiovascular
status in acute hemorrhage
ADVERSE EFFECTS: Allergic reaction, acute, Anaphylaxis, Cardiac arrest, Cardiac dysrhythmia, Malignant hyperthermia, Seizure,
Tachyarrhythmia
THERAPEUTIC USE: Antineoplastic Agent, Luteinizing Hormone Releasing Hormone Agonist
DOSE: Adult – Breast cancer, For palliation of advanced disease in pre- and peri-menopausal women, 3.6 mg SubQ every 28 days for longterm therapy
CONTRA-INDICATIONS: hypersensitivity to goserelin products, leutenizing hormone-releasing hormone (LHRH) or LHRH analogues, 10.8
mg depot dose in women
ADVERSE EFFECTS: Deep venous thrombosis
THERAPEUTIC USE: Antiemetic, Serotonin Receptor Antagonist, 5-HT3
DOSE: Adult – Chemo-induced nausea and vomiting; Prophylaxis a)2mg orally 1hr before chemo or 1mg orally 1 hr before and 1mg 12 hr
after chemo b)10 mcg/kg IV 30 min before chemo. Pedia - 2 yrs or older, 10 to 40 mcg/kg/dose IV 30 min before chemo.
CONTRA-INDICATIONS: hypersensitivity to granisetron or any of its components
THERAPEUTIC USE: Expectorant
DOSE: Adult – Sputum abnormal – amount a)liquid/syrup/immediate-release, 200 to 400 mg orally every 4 h; max.dose, 2400 mg/day
b)sustained-release, 600 to 1200 mg orally every 12 h; max.dose, 2400 mg/day. Pedia – a)(12 y and older) liquid/syrup/immediate-release,
200 to 400 mg orally every 4 h; max.dose, 2400 mg/day b)(12 y and older) sustained-release, 600 to 1200 mg orally every 12 h; max.dose,
2400 mg/day c)(6 to 12 y) liquid/syrup, 100 to 200 mg orally every 4 h; max.dose, 1200 mg/day d)(2 to 6 y) liquid/syrup, 50 to 100 mg orally
every 4 h; max.dose, 600 mg/day e)(under 2 y) dose should be individualized, common dosage is 25 to -50 mg orally every 4 h; max. dose,
300 mg/day
CONTRA-INDICATIONS: hypersensitivity to guaifenesin products
THERAPEUTIC USE: For the prevention of invasive Haemophilus influenzae tybe infections (meningitis, septicaemia, cellulitis, arthritis,
epiglottitis) in infants from 2months of age.
DOSE: Pedia – Before 6 months of age, 3 successive 0.5mL doses at one or two month intervals followed by a booster injection at 18months
of age; 6 – 12 months, two 0.5mL doses at a 1month interval followed by a booster injection (0.5mL) at 18months of age; From 1 to 5 years, a
single 0.5mL dose.
CONTRA-INDICATIONS: Hypersensitivity of one of the ingredients of the vaccine, particularly tetanus protein or allergy appearing after a
previous injection of conjugated Haemophilus influenzae type b vaccine
32
PRODUCT
DESCRIPTION
Haloperidol
TRADE
NAME
Haldol
Serenace
DOSAGE
FORM/STRENGTH
Drops 2mg/mL
Inj. 5mg/mL
Tablet 1.5mg
Tablet 5mg
Halothane
Anesthane
Inhalation
Heparenoid
Hirudoid
Lasonil
Prelloran
Ointment 0.8%
Inj. 1000iu/mL
Inj. 5000iu/mL
Inj. 25,000iu/mL
Heparin Sodium
Hepatitis B Immunoglobulin
Hepatect
Injection
Hepatitis B Vaccine
Engerix-B
Injection Adult
Injection Pedia
Human Antitetanus
Immunoglobulin
Tetagam P
Injection
250iu/mL
Pregnyl
Injection
PRODUCT INFORMATION
THERAPEUTIC USE: Antipsychotic, Butyrophenone, Dopamine Antagonist
DOSE: Adult – Schizophrenia a)2 to 5 mg IM, may repeat every 4 to 8 h depending on patient response; increase to every 1 h if needed
b)0.5 to 2 mg (moderate symptoms) or 3 to 5 mg (severe symptoms) orally 2 to 3 times daily. Pedia – Not FDA approved in children less than
3 years of age. Schizophrenia a)3 to 12 y (weight range 15 to 40 kg), 0.05 mg/kg/day orally in 2 to 3 divided doses, may increase by 0.5
mg/day at 5 to 7 day intervals to therapeutic effect; Max. daily dose 0.15 mg/kg/day b)12 y and older, 0.5 to 2 mg (moderate symptoms) or 3
to 5 mg (severe symptoms) orally 2 to 3 times daily
CONTRA-INDICATIONS: comatose states, hypersensitivity to haloperidol, Parkinson's disease, toxic central nervous system depression,
severe
ADVERSE EFFECTS: Agranulocytosis, Dead – sudden death, Neuroleptic malignant syndrome, Paralytic ileus, Priapism, Prolonged QT
interval, Seizure, Tardive dyskinesia, Torsades de pointes
THERAPEUTIC USE: Haloalkane, Volatile Liquid
DOSE: Adult – Inhalation route, For induction of ANESTHESIA, halothane doses vary from patient to patient. Usual concentrations have
been 0.5% to 3% in oxygen or nitrous oxide/oxygen. Pedia – For induction of anesthesia, a concentration of 0.5% to 2.5% in nitrous
oxide/oxygen has been used in children
CONTRA-INDICATIONS: Hypersensitivity to halothane or other halogenated volatile anesthetics, Obstetrical anesthesia unless uterine
relaxation is required, Patients with known or suspected susceptibility to malignant hyperthermia, Patients who have developed jaundice or
other signs of acute hepatic damage after previous exposure to halothane
THERAPEUTIC USE: Bruising, Injuries to unbroken skin (soft tissue injuries), Sprains
ADVERSE EFFECTS: Flushing of the skin due to widening of the small blood vessels, Allergy to one or more of the ingredients
(hypersensitivity)
PRECAUTIONS: Broken skin or open wounds, Children under 12 years of age, Infected wounds or ulcers, Large areas of skin, Lining of the
body's cavities (mucous membranes)
THERAPEUTIC USE: Anticoagulant, Heparin (class)
DOSE: Adult – Acute coronary syndrome, 60 to 70 units/kg IV bolus (maximum 5000 units) then 12 to 15 units/kg/hr (maximum 1000
units/hr). Pedia – use of 100 unit/mL heparin flush not recommended for use in neonates; do not use solutions preserved with benzyl alcohol
in neonates. Anticoagulant therapy – Collection of blood specimen for laboratory,70 to 150 units/10 to 20 mL sample of whole blood
CONTRA-INDICATIONS: active bleeding, uncontrollable; except when due to disseminated intravascular coagulation, instances in which
blood coagulation tests cannot be performed at necessary intervals, severe thrombocytopenia
ADVERSE EFFECTS: Anaphylaxis, Hemorrhage, Heparin-induced thrombocytopenia with thrombosis, Delayed, Immune hypersensitivity
reaction, Increased liver aminotransferase level, Osteoporosis, With long-term, high-dose administration
THERAPEUTIC USE: Vaccine
DOSE: Adult – Hepatitis B, Post-exposure; Prophylaxis, household exposure, blood exposure (sharing toothbrushes, razors); 0.06 mL/kg IM
as a single dose within 14 days of exposure, plus hepatitis B vaccine series. Pedia – Hepatitis B, Post-exposure; Prophylaxis, household
exposure in infants less than 12 months of age, acute hepatitis B infection in mother or caregiver – 0.5 mL IM as a single dose plus hepatitis B
vaccine
CONTRA-INDICATIONS: anaphylactic or severe systematic reactions to parenteral human globulin, IgA deficiency; increased risk of
anaphylactoid reaction
THERAPEUTIC USE: Vaccine
DOSE: Adult – Prophylaxis, 10 mcg (1mL) IM or 20 mcg (1 mL) IM x 3 doses at 0, 1, and 6 months. Pedia – Prophylaxis a)(0-19 yrs of age)
Recombivax HB®, pediatric/adolescent formulation; 5 mcg (0.5 mL) IM x 3 doses at 0, 1, and 6 months b)(11-15 yrs of age) Recombivax
HB®, adult formulation; 10 mcg (1 mL) IM x 2 doses at 0, and 4-6 months c)(0-19 yrs of age) Engerix-B®; 10 mcg (0.5 mL) IM x 3 doses at 0,
1, and 6 months
CONTRA-INDICATIONS: hypersensitivity to any hepatitis-containing vaccine, hypersensitivity to yeast or any component of the vaccine
ADVERSE EFFECTS: Anaphylaxis, Pancytopenia
THERAPEUTIC USE: Prophylaxis in persons with recent injuries and whose prior vaccination regimen was incomplete or is unknown.
Therapy of clinically manifest tetanus.
DOSE: Adult & Pedia – prophylaxis of tetanus, 250 IU and 0.5mL of an adsorbed tetanus vaccine or an adequate tetanus diphtheria
combination vaccine. The dose can be raised to 500 IU (simultaneously with tetanus vaccination) in other cases.
CONTRA-INDICATIONS: Hypersensitivity to products containing homologous immunoglobulins, particularly in patients with IgA deficiency
and concurrent presence of antibodies to IgA.
THERAPEUTIC USE: Diagnostic Agent, Endocrine-Metabolic Agent, Gonadotropin
DOSE: Adult – Cryptorchidism, 4000 units IM 3 times weekly for 3 weeks; OR 5000 units every second day for 4 doses; OR 15 injections of
33
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Human Chorionic
Gonadotrophin
Hyaluronidase
Hylase
Injection 1500iu
Hydralazine
Apresoline
Inj. 20mg/mL
Syrup 2mg/mL
Tablet 25mg
Hydrochlorothiazide
Esidrex
Syrup 5mg/mL
Tablet 25mg
Hydrocortisone
Alfacort
Cortiderm
Hydrocortone
Hydrosone
Hydrocortisone Na
Succinate
Solu-Cortef
Hydrogen Peroxide
Cream 1%
Syrup 2.5mg/mL
Tablet 10mg
Tablet 20mg
Inj. 100mg/2mL
Injection 250mg
Solution 3%
Solution 6%
PRODUCT INFORMATION
500 to 1000 units over a period of 6 wks; OR 500 units 3 times weekly for 4 to 6 wks repeated 1 month later using 1000 units dose if
ineffective; therapy is usually started between 4 and 9 years of age. Pedia – Cryptorchidism (4 y and older) 4000 units IM 3 times weekly for 3
weeks; OR 5000 units every second day for 4 doses; OR 15 injections of 500 to 1000 units over a period of 6 wks; OR 500 units 3 times
weekly for 4 to 6 wks repeated 1 month later using 1000 units dose if ineffective; therapy is usually started between 4 and 9 years of age
CONTRA-INDICATIONS: precocious puberty, prostate cancer or other androgen-dependent cancer, hypersensitivity to chorionic
gonadotropin
THERAPEUTIC USE: Dermatological Agent, Enzyme, Tissue Permeability Modifier
DOSE: Adult – Hypersensitivity test: Intradermal injection of 0.02 mL (3 units) of a 150-unit/mL solution; positive reaction shows wheal and
pseudopods and itching within 5 min, lasting for 20-30 min; typical dose, add 150 units (range 50 to 300 units) to the injection solution. Pedia
- typical dose, add 150 units (range 50 to 300 units) to the injection solution; (children less than 3 yrs) MAX volume of a single clysis not to
exceed 200 mL; (premature/very young infants) MAX clysis not to exceed 25 mL/kg daily; rate of infusion not to exceed 2 mL/min
CONTRA-INDICATIONS: Hypersensitivity to hyaluronidase products
ADVERSE EFFECTS: Anaphylaxis
THERAPEUTIC USE: Antihypertensive, Peripheral Vasodilator, Peripheral Vasodilator
DOSE: Adult – Essential hypertension, initial, 10 mg ORALLY four times daily for the first 2 to 4 days; increase to 25 mg ORALLY four times
daily for remainder of first wk; second and subsequent wk, increase to 50 mg ORALLY four times daily; titrate to lowest effective maintenance
dose; MAX dose 300 mg/day; emergency therapy: 20 to 40 mg/dose IM/IV bolus as needed. Pedia – Essential hypertension, 0.75 mg/kg/day
ORALLY in 4 divided doses; increase dose gradually over 3 to 4 weeks, MAX dose 7.5 mg/kg or 200 mg daily; emergency therapy: 1.7 to 3.5
mg/kg/day IM/IV bolus in 4 to 6 divided doses
CONTRA-INDICATIONS: dissecting aortic aneurysm, hypersensitivity to hydralazine
ADVERSE EFFECTS: Agranulocytosis, Hepatotoxicity, Leukopenia, Lupus pneumonia, Systemic lupus erythematosus
THERAPEUTIC USE: Cardiovascular Agent, Diuretic, Thiazide
DOSE: Adult – Hypertension a)initial, 12.5 to 25 mg ORALLY once daily b)titration, allow 2-3 wk to achieve optimum antihypertensive effect
c)titrate to maintenance, may increase to 50-100 mg ORALLY daily in single or divided doses. Pedia – Hypertension a)1 to 2 mg/kg ORALLY
daily in single or two divided doses; infants less than 6 months old, may require doses up to 3 mg/kg ORALLY daily in two divided doses
b)infants up to 2 yrs old: MAX dose, not to exceed 37.5 mg ORALLY daily c)children 2-12 yrs old: MAX dose, not to exceed 100 mg ORALLY
daily
CONTRA-INDICATIONS: anuria, hypersensitivity to hydrochlorothiazide or sulfonamides
ADVERSE EFFECTS: Angle-closure glaucoma, Cardiac dysrhythmia, Disorder of hematopoietic structure, Hepatotoxicity, Pancreatitis,
Pulmonary edema, Scaling eczema, Stevens-Johnson syndrome, Systemic lupus erythematosus, Toxic epidermal necrolysis
THERAPEUTIC USE: Adrenal Glucocorticoid, Anti-Inflammatory, Corticosteroid, Endocrine-Metabolic Agent, Gastrointestinal Agent,
Hemorrhoidal Anti-Inflammatory, Immune Suppressant, Otic Agent
DOSE: Adult – Allergic disorder, 20 to 240 mg per day ORALLY; Disorder of skin, ORAL; 20 to 240 mg per day, TOPICAL; apply to affected
area as a thin film 2 to 4 times daily. Pedia – Disorder of skin TOPICAL: apply to affected area as a thin film 2 to 4 times daily; Nephrotic
syndrome, Idiopathic or due to lupus erythematosus; 240 mg/m(2) ORALLY daily; MAX 320 mg/day; divided 3 times/day for 4 wk, then 160
mg/m(2) every other day for 4 wk
CONTRA-INDICATIONS: hypersensitivity to hydrocortisone or any of its components, live or live attenuated vaccines, systemic fungal
infections
ADVERSE EFFECTS: Adrenal insufficiency, Cataract, Cushing's syndrome, Disorder of fluid &/or electrolyte, Drug-induced adrenocortical
insufficiency, HPA, Glaucoma, Hyperglycemia, Pulmonary tuberculosis
THERAPEUTIC USE: Adrenal Glucocorticoid, Anti-Inflammatory, Corticosteroid, Endocrine-Metabolic Agent, Gastrointestinal Agent,
Hemorrhoidal Anti-Inflammatory, Immune Suppressant, Otic Agent
DOSE: Adult – Adrenal insufficiency – Surgical procedure, 100 to 500 mg IM or IV over 30 seconds to 10 min every 2 to 6 hours.
CONTRA-INDICATIONS: hypersensitivity to hydrocortisone or any of its components, live or live attenuated vaccines, systemic fungal
infections
ADVERSE EFFECTS: Adrenal insufficiency, Cataract, Cushing's syndrome, Disorder of fluid &/or electrolyte, Drug-induced adrenocortical
insufficiency, HPA, Glaucoma,
THERAPEUTIC USE: Antiseptic, Disinfectant
DOSE: Adult – Oral hygiene finding, Cleansing minor wounds or minor gum inflammation a)rinse in mouth with 10 mL for approximately 1
min, then spit out; use up to 4 times daily (after meals and at bedtime) b)gel, apply topically several drops to affected area of mouth; remain
in place at least one minute then spit out; use up to 4 times daily (after meals and at bedtime). Pedia – Oral hygiene finding, Cleansing minor
wounds or minor gum inflammation a)(2 y or older) rinse in mouth with 10 mL for approximately 1 min, then spit out; use up to 4 times daily
34
PRODUCT
DESCRIPTION
TRADE
NAME
Injection
1mg/mL
Hydromorphone
Hydroxychloroquine Sulphate
Hydroxyurea
DOSAGE
FORM/STRENGTH
Hydroquine
Tablet 200mg
Plaquenil
Hydrea
Capsule 500mg
Buscopan
Hyoscine-N-Butyl Bromide
Scopinal
Inj. 20mg/mL
Tablet 10mg
Spasmopan
Hypromellose
Ibuprofen
Artificial Tears
Eye Drops 0.3%
Tears Naturale
Advil
Brufen
Dolgit
Profinal
Sabopen
Syrup
100mg/5mL
Tablet 400mg
PRODUCT INFORMATION
(after meals and at bedtime) b)(2 y or older) gel, apply topically several drops to affected area of mouth; remain in place at least one minute
then spit out; use up to 4 times daily (after meals and at bedtime)
CONTRA-INDICATIONS: Injection or instillation into closed body cavities from which the released oxygen has no free exit
THERAPEUTIC USE: Analgesic, Anesthetic Adjunct, Opioid
DOSE: Adult - Chronic pain (Moderate to Severe) 3 to 4 mg IM/SC every 3 to 4 h; opioid tolerant patients, 1 to 14 mg IM/SubQ. Pedia - Pain,
acute (Moderate to Severe) adolescents, initial (opiate-naive patients) 0.2 to 0.6 mg IV (slow) every 2 to 3 h as needed; usual, 1 to 2 mg/dose
IM/IV/SubQ every 4 to 6 h; children, 0.015 mg/kg/dose IV every 4 to 6 h.
CONTRA-INDICATIONS: bronchial asthma, acute or severe, depressed ventilatory function; such as COPD, cor pulmonale, emphysema,
kyphoscoliosis, hypersensitivity to hydromorphone, intracranial lesion associated with increased intracranial pressure, obstretical analgesia,
paralytic ileus, known or suspected, patients not already receiving large amounts of parenteral opioids, respiratory depression in the absence
of resuscitative equipment, status asthmaticus, use of extended-release capsules on an as needed basis
ADVERSE EFFECTS: Apnea, Confusion, Disorder of cardiovascular system, Hypotension, Myoclonus, Respiratory depression, Seizure
THERAPEUTIC USE: Aminoquinoline, Antimalarial, Antirheumatic
DOSE: Adult – Malaria a)suppression: 400 mg (310 mg base) ORALLY once weekly on the same day; begin 2 weeks prior to entering an
endemic area and continue for 8 weeks after leaving the endemic area b)loading dose (if unable to start suppressive therapy 2 weeks prior):
800 mg (620 mg base) ORALLY initially, followed by normal suppressive therapy c)acute attack: 800 mg (620 mg base) ORALLY initially,
then 400 mg (310 mg base) in 6 to 8 hours and 400 mg once daily for 2 days OR a single dose of 800 mg ORALLY. Pedia – Malaria
a)suppression: 5 mg base/kg ORALLY once weekly on the same day; begin 2 weeks prior to entering an endemic area and continue for 8
weeks after leaving the endemic area b)loading dose (if unable to start suppressive therapy 2 weeks prior): 10 mg base/kg ORALLY in two
divided doses 6 hours apart, followed by normal suppressive therapy c)acute attack: 10 mg base/kg (MAX 620 mg base) ORALLY (first dose),
followed by 5 mg base/kg (MAX 310 mg base) ORALLY in 6 hours (second dose), then 18 hours after second dose (third dose), then 24
hours after third dose (fourth dose)
CONTRA-INDICATIONS: hypersensitivity to 4-aminoquinoline compound, long-term use in children, retinal or visual field changes from prior
4-aminoquinoline compound
ADVERSE EFFECTS: Agranulocytosis, Ototoxicity, Retinopathy, Torsades de pointes
THERAPEUTIC USE: Antimetabolite, Antineoplastic Agent
DOSE: Adult – Chronic myeloid leukemia, Resistant, Continuous therapy, 20 to 30 mg/kg ORALLY given as a single daily dose; continue
administration for a minimum of 6 weeks to assess effectiveness and continue indefinitely if effective.
Pedia - safety and efficacy not established in pediatric patients.
CONTRA-INDICATIONS: hypersensitivity to hydroxyurea products, severe bone marrow depression
ADVERSE EFFECTS: Gangrenous disorder, Genetic mutation, Long-term use, Secondary leukemia, Long-term use, Skin ulcer
THERAPEUTIC USE: Anesthetic Adjunct, Antiemetic, Antimuscarinic, Antivertigo, Gastrointestinal Agent, Mydriatic-Cycloplegic
DOSE: Adult – Increased intestinal motility, 0.4 to 0.8 mg; Mania 0.6 mg IM/IV/SC.
Pedia – not FDA approved in pediatric patients. Preoperative sedation a)Injection: (age 6 months to 3 years) 0.1-0.15 mg IM/IV/SC
b)Injection: (age 3 to 6 years) 0.2-0.3mg IMIV/SC; Vomiting – Injection: 6 mcg/kg/dose SC
CONTRA-INDICATIONS: chronic lung disease; repeated administration may increase the risk of adverse events, hepatic impairment,
hypersensitivity/idiosyncrasy to scopolamine hydrobromide, other belladonna alkaloids or anticholinergic drugs, or barbiturates, narrow-angle
(angle-closure) glaucoma, prostatic hypertrophy, pyloric obstruction renal impairment
ADVERSE EFFECTS: Confusion, Systemic absorption, Dry skin, Systemic absorption Hallucinations, Somnolence, Systemic,
Tachyarrhythmia Xerostomia, Systemic absorption of ophthalmic formulation
THERAPEUTIC USE: Diagnostic Agent, Lubricant, Ocular, Surgical Aid, Ocular
DOSE: Adult – Gonioscopy; Diagnosis, 2.5% OPHTHALMIC solution used as needed to fill the gonioscopic prism; Operative procedure on
anterior chamber of eye – instill a 2% OPHTHALMIC solution into the anterior chamber, as needed, using a 20-gauge or larger cannula;
Xerophthalmia – instill 1 drop 0.3% to 1% OPHTHALMIC solution into affected eye(s) 3 to 4 times daily, as needed. Pedia – Xerophthalmia
(adolescents) instill 1 drop 0.3% to 1% OPHTHALMIC solution into affected eye(s) 3 to 4 times daily, as needed
CONTRA-INDICATIONS: hypersensitivity to hypromellose
THERAPEUTIC USE: Analgesic, Antimigraine, Antirheumatic, Central Nervous System Agent, Musculoskeletal Agent, NSAID, Propionic Acid
(class)
DOSE: Adult – Pain over-the-counter dosing, 200 to 400 mg ORALLY every 4 to 6 hours as needed, MAX 1200 mg/day; do not take longer
than 10 days unless directed by a physician. Pedia – Pain over-the-counter dosing, 6 months-12 years old, 5 to 10 mg/kg ORALLY every 6 to
8 hours as needed, MAX 4 doses/day; 12 years and older, 200 to 400 mg ORALLY every 4 to 6 hours as needed, MAX 1200 mg/day; do not
give longer than 10 days unless directed by a physician
35
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Sapofen
Ointment 10%
Powder
Ichthammol
Idarubicin
Zavedos
Injection
10mg/10mL
Ifosfamide
Holoxan
Injection 1gram
Injection 2grams
Imipenem-Cilastatin
Tienam
Injection 500mg
Imipramine HCl
Tofranil
Tablet 10mg
Tablet 25mg
PRODUCT INFORMATION
CONTRA-INDICATIONS: treatment of peri-operative pain in setting of coronary artery bypass graft, bleeding, especially those with active
intracranial hemorrhage or gastrointestinal bleeding, coagulation defects, congenital heart disease in whom patency of the ductus arteriosus
is necessary for satisfactory pulmonary or systemic blood flow, hypersensitivity to ibuprofen, infection that is untreated, proven or suspected,
necrotizing enterocolitis, present or suspected, patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin
or other nonsteroidal anti-inflammatory agents; severe, even fatal, anaphylactic-like reactions have been reported renal function impairment,
significant, thrombocytopenia
ADVERSE EFFECTS: Acute renal failure, Agranulocytosis, Amblyopia, Anaphylactoid reaction, Anemia, Aseptic meningitis , Cerebrovascular
accident, Confusion, Congestive heart failure, Depression, Erythema multiforme, Gastrointestinal hemorrhage, perforation & ulcer, Hearing
loss, Hematuria, Hemolytic anemia, Hepatitis, Hypertension, Inflammatory disorder of digestive tract, Jaundice, Melena, Myocardial infarction,
Neutropenia, Pancreatitis, Renal azotemia, Scaling eczema, Stevens-Johnson syndrome, Thrombocytopenia, Thrombotic tendency
observations, Toxic epidermal necrolysis
THERAPEUTIC USE: An irritant & local antibacterial agent. It is used alone or in combination with other antiseptics for the treatment of skin
disorders such as erysipelas, psoariasis and lupus erythematosus, and to promote healing in chronic inflammations.
DOSE: Topical to the skin as a 10% ointment.
THERAPEUTIC USE: Anthracycline, Antineoplastic Agent
DOSE: Adult – Acute myeloid leukemia, In combination with other approved antileukemic agents, induction, 12 mg/m(2) IV over 10 to 15 min
daily for 3 days in combination with cytarabine; cytarabine can be dosed as 100 mg/m(2) every day by continuous infusion for 7 days or as 25
mg/m(2) IV bolus followed by 200 mg/m(2) every day by continuous infusion for 5 days. Pedia – Safety and effectiveness in children have not
been established. Acute lymphoid leukemia 8 to 10 mg/m(2) IV daily for 3 days has been used
CONTRA-INDICATIONS: hypersensitivity to idarubicin or other anthracyclines, marked myelosuppression induced by previous treatment with
other antitumor agents or by radiotherapy, previous treatment with complete cumulative doses of DOXORUBICIN or daunorubicin, idarubicin,
or other anthracyclines
ADVERSE EFFECTS: Cardiac dysrhythmia, Chest pain, Congestive heart failure, Hepatotoxicity, Infectious disease, Inflammatory disease of
mucous membrane, Myelosuppression, Myocardial infarction, Nephrotoxicity
THERAPEUTIC USE: Alkylating Agent, Antineoplastic Agent, Nitrogen Mustard
DOSE: Adult – Testicular cancer, Germ cell; third-line, in combination with other antineoplastic agents, 1.2 g/m(2) IV daily for 5 days
repeated every 3 weeks; use with a prophylactic agent for hemorrhagic cystitis. Pedia – Safety and effectiveness in children have not been
established
CONTRA-INDICATIONS: hypersensitivity to ifosfamide or mesna products, severe bone marrow depression
ADVERSE EFFECTS: Disorder of urinary tract, Metabolic acidosis, Myelosuppression, Nephrotoxicity, Neurotoxicity
THERAPEUTIC USE: Antibiotic
DOSE: Adult – Bacterial endocarditis a)mild infection: (fully susceptible organisms) 250 mg IV every 6 h; (moderately susceptible organisms
including P. aeruginosa) 500 mg IV every 6 h; maximum 50 mg/kg/day b)moderate infection (fully susceptible organisms) 500 mg IV every 6
to 8 h; (moderately susceptible organisms including P. aeruginosa) 500 mg IV every 6 h or 1 g IV every 8 h; maximum 50 mg/kg/day c)severe
infection (fully susceptible organisms) 500 mg IV every 6 h; (moderately susceptible organisms including P. aeruginosa) 1 g IV every 8 h or 1
g IV every 6 h; maximum 50 mg/kg/day. Pedia – Safety and efficacy of the intramuscular product in children under 12 years of age have not
been established. Bacterial endocarditis a)(less than 1 week of age) 25 mg/kg IV every 12 h; maximum 2 g/day for fully susceptible
organisms, maximum 4 g/day for moderately susceptible organisms including P. aeruginosa b)(1 to 4 weeks of age) 25 mg/kg IV every 8 h;
maximum 2 g/day for fully susceptible organisms, maximum 4 g/day for moderately susceptible organisms including P. aeruginosa c)(4 weeks
to 3 months of age) 25 mg/kg IV every 6 h; maximum 2 g/day for fully susceptible organisms, maximum 4 g/day for moderately susceptible
organisms including P. aeruginosa d)(3 months of age and older) 15 to 25 mg/kg IV every 6 h; maximum 2 g/day for fully susceptible
organisms, maximum 4 g/day for moderately susceptible organisms including P. aeruginosa
CONTRA-INDICATIONS: hypersensitivity to imipenem or cilastatin, or any component of the product, hypersensitivity to local anesthetics of
the amide type and in patients with severe shock or heart block; IM product diluted with lidocaine
ADVERSE EFFECTS: Anaphylaxis, Seizure
THERAPEUTIC USE: Antidepressant Tricyclic, Urinary Enuresis Agent
DOSE: Adult – Depression a)(hospitalized patients) 100 mg ORALLY per day in divided doses; may increase up to a MAX of 300 mg/day
b)(outpatients) 75 mg ORALLY per day; may increase up to a MAX of 200 mg/day; usual maintenance dose, 50 to 150 mg/day. Pedia –
safety and effectiveness in children with nocturnal enuresis below the age of 6 years have not been established; effectiveness in pediatric
patients for any other condition has not been established. Nocturnal enuresis a)(children 6 to 12 y) initial, 25 mg ORALLY 1 h before bedtime,
may increase in 25 mg increments to MAX dose of 50 mg/d or 2.5 mg/kg/d b)(children over 12 y) initial, 25 mg ORALLY 1 h before bedtime,
may increase in 25 mg increments to MAX dose of 75 mg/d or 2.5 mg/kg/d
36
PRODUCT
DESCRIPTION
Immunoglobulin Varicella
Zoster
TRADE
NAME
Varitect
DOSAGE
FORM/STRENGTH
Injection
Injection
2.5grams
Injection 5grams
Immunoglobulin Human
Indapamide
Natrilix
SR Tablet 1.5mg
Tablet 2.5mg
Indomethacin
Indocid
Capsule 25mg
Injection 1mg
Supp. 100mg
Insulin Isophane (NPH)
Insulatard NPH
Inj. 100u/mL
Insulin Soluble (Regular)
Interferon Alfa-2b
Human Actrapid
Humulin
Intron – A
Inj. 100u/mL
Injection 3miu
PRODUCT INFORMATION
CONTRA-INDICATIONS: coadministration with a MAOI or use within 14 days of discontinuing a MAOI; may cause serious reactions,
hypersensitivity to dibenzazepines; risk of cross-sensitivity reactions, hypersensitivity to imipramine hydrochloride myocardial infarction,
during the acute recovery period
ADVERSE EFFECTS: Agranulocytosis, Atrioventricular conduction pattern – finding, Cardiac dysrhythmia, Cerebrovascular accident,
Decreased liver function, Depression, worsening, Heart block, Hypertension, Jaundice, Myocardial infarction, Orthostatic hypotension,
Palpitations, Psychotic disorder, Seizure, Suicidal thoughts, Suicide, Syncope
THERAPEUTIC USE: Immune Serum
DOSE: Adult – Varicella; Prophylaxis, 125 international units/10 kg IM or IV; MAX dose, 625 international units and MIN dose, 125
international units. Pedia –
Prophylaxis, 125 international units/10 kg IM or IV; MAX dose, 625 international units and MIN dose, 125 international units
CONTRA-INDICATIONS: IgA deficiency; potential to develop IgA antibodies and subsequent anaphylactoid reaction, history of anaphylactic
or other severe systemic reaction to immune globulins, hypersensitivity to any ingredient in the formulation or component of the container,
known immunity to varicella zoster virus
ADVERSE EFFECTS: Anaphylaxis
THERAPEUTIC USE: Immune Serum
DOSE: Adult & Pedia – FDA-approved indications vary by specific product. Bacterial infectious disease; Prophylaxis – B-cell chronic
lymphocytic leukemia 400 mg/kg IV every 3 to 4 weeks.
CONTRA-INDICATIONS: history of severe systemic allergic reaction to human immunoglobulin products, selective IgA deficiency, severe
thrombocytopenia or any coagulation disorder which would contraindicate intramuscular injections
ADVERSE EFFECTS: Acute renal failure, Acute respiratory distress syndrome, Anaphylaxis, Aseptic meningitis, Bullous dermatosis,
Erythema multiforme, Hemolytic anemia, Hepatitis, Hypokalemic nephropathy, Myocardial infarction, Pulmonary edema, Renal tubular
disorder, Proximal, Stevens-Johnson syndrome, Thrombotic disorder, Tubular necrosis, acute
THERAPEUTIC USE: Cardiovascular Agent, Diuretic, Thiazide Related
DOSE: Adult – Congestive heart failure – Edema, initial, 2.5 mg ORALLY once daily in the morning; may increase to 5 mg ORALLY once
daily after 1 wk; Hypertension initial, 1.25 mg ORALLY once daily in the morning; titration, allow 4 wk to achieve optimum antihypertensive
effect; maintenance, 2.5 to 5 mg ORALLY once daily.
Pedia – safety and effectiveness not established in children
CONTRA-INDICATIONS: anuria, hypersensitivity to indapamide or sulfonamides
ADVERSE EFFECTS: Cardiac dysrhythmia, Stevens-Johnson syndrome, Toxic epidermal necrolysis
THERAPEUTIC USE: Acetic Acid (class), Analgesic, Antimigraine, Antipyretic, Antirheumatic, Central Nervous System Agent,
Musculoskeletal Agent, NSAID
DOSE: Adult – maximum recommended oral or rectal dose is 200 mg/day. Pedia – Patent ductus arteriosus a)less than 48 hours old, 0.2
mg/kg IV followed by 0.1 mg/kg IV every 12 to 24 hours for 2 doses b)2 to 7 days old, 0.2 mg/kg IV every 12 to 24 hours for 3 doses c)over 7
days old, 0.2 mg/kg IV followed by 0.25 mg/kg every 12 to 24 hours for 2 doses d)if the ductus arteriosus re-opens, a second course of 1 to 3
doses may be given
CONTRA-INDICATIONS: treatment of peri-operative pain in setting of coronary artery bypass graft, history of recent rectal bleeding or
proctitis, hypersensitivity to indomethacin, neonates with active bleeding, infection, necrotizing enterocolitis, severe renal failure,
thrombocytopenia, or coagulation defects, patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or
other nonsteroidal anti-inflammatory agents; severe, even fatal, anaphylactic-like reactions have been reported
THERAPEUTIC USE: Antidiabetic, Diagnostic Agent, Pituitary Function, Gastrointestinal Agent
DOSE: Adult – the average daily insulin requirement in diabetes therapy ranges between 0.5 and 1.0 IU/Kg, dependent on the individual
patient.
CONTRA-INDICATIONS: Hypoglycaemia, hypersensitivity to human insulin or any of the excipients.
ADVERSE EFFECTS: Hypoglycaemia, edema and refraction anomalies may occur, hypersensitivity reactions.
THERAPEUTIC USE: Antidiabetic, Diagnostic Agent, Pituitary Function, Gastrointestinal Agent
DOSE: Adult & Pedia – Diabetic ketoacidosis, initial, 0.15 unit/kg IV, followed by continuous infusion of 0.1 unit/kg/hour; if no biochemical
response in 2 to 4 hours, double infusion rate; when glucose level falls to 250 mg/dL or less, halve infusion rate or add dextrose 5% infusion
to maintain blood glucose between 200 and 250 mg/dL; continue until acidosis is corrected.
CONTRA-INDICATIONS: hypoglycemia, systemic allergic reactions
ADVERSE EFFECTS: Hypoglycemia (Severe)
THERAPEUTIC USE: Antineoplastic Agent, Antiproliferative Agent, Antiviral, Immunological Agent
DOSE: Adult – Type B viral hepatitis, chronic, With compensated liver disease, 5 million international units IM/SUBQ daily OR 10 million
37
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Iodine
Crystals
Tincture 2%
Ipecacuanha (Ipecac)
Solution
Inhaler 20mcg
Nebs. Soln.500mcg
Ipratropium Bromide
Atrovent
Irbesartan
Aprovel
Tablet 150mg
Tablet 300mg
Iron Hydroxide
Ferosac
Injection
100mg/5mL
Isoflurane
Floran
Forane
Inhalation
PRODUCT INFORMATION
international units IM/SUBQ 3 times a week for 16 weeks. Pedia – safety and efficacy in pediatric patients less than 18 years of age have not
been established other than for chronic hepatitis B. Type B viral hepatitis, chronic, With compensated liver disease, (age 1 to 17 yr) 3 million
international units /m(2) SUBQ 3 times a week for the first week, then 6 million international units/m(2) SUBQ 3 times a week; total duration of
therapy 16 to 24 wk; MAX 10 million international units 3 times a week
CONTRA-INDICATIONS: autoimmune hepatitis, liver disease, decompensated, prior hypersensitivity to any interferon alfa preparations or
components
ADVERSE EFFECTS: Allergic reaction, acute, Serious, Aplastic anemia, Autoimmune disease, Cotton wool spots, Hepatotoxicity, Increased
liver enzymes, Nephrotic syndrome, Neutropenia, Pancreatitis, Pneumonia, Pneumonitis, Psychotic disorder,Pulmonary infiltrate, Renal
failure, Retinal hemorrhage, Retinal vascular occlusion, Thrombocytopenia
THERAPEUTIC USE: Antibacterial Cleansing Agent, Antithyroid Agent, Expectorant, Iodide Supplement, Parenteral Mineral-Trace Mineral,
Radiation Emergency, Thyroid Blocking Agent
DOSE: Adult & Pedia – Disinfection a)2% aqueous solution TOPICALLY for minor wounds b)2% tincture TOPICALLY on intact skin c)2% in
glycerin TOPICALLY on mucous membranes; Thyroid storm – 5 to 10 drops of Lugol's solution (8 mg iodide/drop) or 1 to 2 drops of saturated
solution of potassium iodide (50 mg of iodide/drop) 3 times a day mixed in water or juice.
CONTRA-INDICATIONS: hypersensitivity to iodine, burn patients
THERAPEUTIC USE: Emetic, Nutriceutical
DOSE: Adult – Poisoning, acute a)In patients 12 years of age or older, the usual dose of ipecac syrup in accidental POISONING is 30 mL
orally followed by 8 or more ounces of water b)Ipecac has been used as an expectorant in doses containing approximately 0.4 to 1.2
milligrams of total alkaloids. This is equivalent to 0.3 to 1mL of ipecac syrup. Pedia – Oral – 1 to 12 years of age, In children over 1 year of
age, the recommended dose of ipecac syrup is 3 teaspoonsful (15 milliliters). If vomiting does not occur within 20 minutes, a similar dose is
repeated once. If the patient does not vomit within 30 minutes, the dosage should be recovered by gastric lavage
CONTRA-INDICATIONS: ingestion of petroleum distillate, ingestion of strong acids or bases, ingestion of strychnine, unconsciousness or
absence of gag reflex
ADVERSE EFFECTS: Cardiomyopathy, Chronic use
THERAPEUTIC USE: Anticholinergic, Bronchodilator, Nasal Agent
DOSE: Adult – Chronic obstructive pulmonary disease a)(inhalation aerosol) 2 INHALATIONS 4 times per day; MAX 12 inhalations/day
b)(inhalation solution 0.02%) 500 mcg NEBULIZED 3 to 4 times per day; separate doses by 6 to 8 hours. Pedia – Inhalation aerosol not FDAapproved for children under 12 yr of age; Chronic obstructive pulmonary disease – (inhalation solution 0.02%) 12 y of age and older, 500 mcg
NEBULIZED 3 to 4 times/day per day; separate doses by 6 to 8 hours
CONTRA-INDICATIONS: hypersensitivity to ipratropium products, hypersensitivity to soya lecithin or related food products
ADVERSE EFFECTS: Immune hypersensitivity reaction, Angioedema, bronchospasm, urticaria, anaphylaxis, oropharyngeal edema, Paralytic
ileus
THERAPEUTIC USE: Angiotensin II Receptor Antagonist, Cardiovascular Agent, Renal Protective Agent
DOSE: Adult – Diabetic nephropathy target maintenance dose, 300 mg ORALLY once daily Hypertension – 150 mg ORALLY once daily;
may titrate to MAX of 300 mg once daily
CONTRA-INDICATIONS: hypersensitivity to irbesartan products, pregnancy
ADVERSE EFFECTS: Angioedema, face, lips, throat, Rhabdomyolysis
THERAPEUTIC USE: Dermatological Agent, Iron Supplement, Nutriceutical, Parenteral Mineral-Trace Mineral
DOSE: Adult – Iron deficiency anemia – IV or IM, dose in mL (50 mg elemental iron/mL)= 0.0442 [desired hemoglobin-observed hemoglobin]
x lean body weight in kg + (0.26 x lean body wt); give 2 mL or less once daily until total dose has been reached. Pedia – Iron deficiency
anemia a)children weighing over 15 kg, IV or IM, same formula as for adults b)children weighing 5-15 kg, IV or IM, dose in mL (50 mg
elemental iron/mL)= 0.0442 (desired hemoglobin – observed hemoglobin) x weight (kg) + (0.26 x weight); give 2 mL or less once daily until
total dose has been reached
CONTRA-INDICATIONS: anemias not associated with iron deficiency, hypersensitivity to the product
ADVERSE EFFECTS: Anaphylaxis, Chest pain, Dyspnea, Headache, Hematuria, Hypotension, Leukocytosis, Respiratory arrest, Seizure
THERAPEUTIC USE: Haloalkane, Volatile Liquid
DOSE: Adult – General anesthesia a)induction, 1.5 to 3% isoflurane with oxygen or oxygen-nitrous oxide mixture b)maintenance, 1 to 2.5%
with nitrous oxide, additional 0.5 to 1% with oxygen alone. Pedia – safety in children under 2 yr of age has not been established
CONTRA-INDICATIONS: hypersensitivity to isoflurane or other halogenated agents, malignant hyperthermia, known or suspected genetic
susceptibility
ADVERSE EFFECTS: Decreased liver function, Malignant hyperthermia, Respiratory depression
38
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Isoniazid
Syrup 10mg/mL
Tablet 100mg
Tablet 300mg
Isopropyl Alcohol
Solution 70%
Isoproterenol HCl
(Isoprenaline)
Isoproterenol
Injection 1:5000
Isosorbide Dinitrate
Isoket
Isoket Retard
Isomack
Isordil
SL Tablet 5mg
SR Tablet 40mg
Tablet 10mg
Tablet 20mg
Itraconazole
Sporanox
Capsule 100mg
Ketamine HCl
Ketalar
Tekam
Injection
50mg/mL
Ketoconazole
Nizoral
Cream 2%
Tablet 200mg
L-Thyroxine Sodium
Eltroxin
Syrup
PRODUCT INFORMATION
THERAPEUTIC USE: Antitubercular, Isonicotinic Acid
DOSE: Adult – Tuberculosis, 5 mg/kg ORALLY/IV/IM once daily (MAX 300 mg/dose) OR 15 mg/kg ORALLY/IV/IM 1 to 3 times per week
(MAX 900 mg/dose) in combination with other antitubercular drugs. Pedia – Tuberculosis, 10 to 15 mg/kg ORALLY daily (MAX 300 mg/dose)
OR 20 to 30 mg/kg ORALLY twice per week (MAX dose 900 mg) in combination with other antitubercular drugs
CONTRA-INDICATIONS: drug fever, chills, arthritis, or other adverse reaction to isoniazid, hepatic injury due to isoniazid, hypersensitivity to
isoniazid, including drug-induced hepatitis, liver disease, acute
ADVERSE EFFECTS: Agranulocytosis, Anemia, Megaloblastic anemia, Seizure, Systemic lupus erythematosus, Thrombocytopenia
THERAPEUTIC USE: Antibacterial Cleansing Agent, Toxicology-Antidote Agent
CONTRA-INDICATIONS: Patients with epilepsy, urinary tract infections, and those with prior addiction, ETHANOL in DEXTROSE solutions
should not be used in diabetic coma
THERAPEUTIC USE: Adrenergic, Bronchodilator, Sympathomimetic, Vasopressor
DOSE: Adult – Cardiac arrest a)IM, 0.2 mg, followed by 0.02 to 1 mg, depending on response b)IV, 2 to 10 mcg/min, titrate to response
c)SC, 0.2 mg, followed by 0.15 to 0.2 mg, depending on response
CONTRA-INDICATIONS: angina pectoris, digitalis-induced tachycardia or heart block, hypersensitivity to isoproterenol products,
tachyarrhythmias
ADVERSE EFFECTS: Coronary arteriosclerosis
THERAPEUTIC USE: Antianginal, Coronary Vasodilator, Nitrate
DOSE: Adult – Angina; Prophylaxis a)ORAL (immediate release forms), initial 5 to 20 mg ORALLY 2 to 3 times daily; maintenance 10 to 40
mg ORALLY 2 to 3 times daily; a daily dose-free interval of at least 14 h is recommended to minimize tolerance b)SUBLINGUAL, 2.5 to 5 mg
SL 15 min before expected activity. Pedia – safety and efficacy not established in pediatric patients
CONTRA-INDICATIONS: hypersensitivity to organic nitrates
ADVERSE EFFECTS: Methemoglobinemia, Rebound hypertension, Syncope, Unstable angina
THERAPEUTIC USE: Antifungal, Triazole
DOSE: Adult – Aspergillosis a)oral, 200mg to 400mg daily b)IV, 200mg infused over one hour twice daily for 4 doses, then 200 mg once
daily c)life-threatening situations, oral, 200mg 3 times daily for 3 days, then oral 200 mg daily; treatment should continue for at least 3 months
d)life-threatening situations, IV, 200 mg 2daily for 4 doses, then IV 200 mg daily; continue for at least 3 months. Pedia – Limited data: oral
solution, 6 months-12 yr, 5mg/kg/day for 2 wk; oral capsule, 3-16 yr, 100 mg/day
CONTRA-INDICATIONS: Coadministration with cisapride, dofetilide, oral midazolam, pimozide, levacetylmethadol (levomethadyl), quinidine,
lovastatin, simvastatin, or triazolam, Coadministration with ergot alkaloids metabolized by CYP3A4, such as dihydroergotamine, ergometrine
(ergonovine), ergotamine and methylergometrine (methylergonovine), Congestive heart failure or history of congestive heart failure
(itraconazole capsules for treatment of onychomycosis),Pregnant women or women contemplating pregnancy (itraconazole capsules for
treatment of onychomycosis),Previous hypersensitivity to itraconazole
ADVERSE EFFECTS: Anaphylaxis, Congestive heart failure, IV, Hepatotoxicity, Neutropenic disorder, Stevens-Johnson syndrome
THERAPEUTIC USE: Anesthetic Adjunct
DOSE: Adult – General anesthesia; Adjunct a)induction, 1 to 4.5 mg (base)/kg IV single dose b)induction, 1 to 2 mg/kg IV infusion at 0.5
mg/kg/min; in addition to diazepam 2-5 mg IV over 1 min c)induction, 6.5 to 13 mg (base)/kg IM d)maintenance, 0.1 to 0.5 mg (base)/min IV
infusion, repeat as needed; augmented with diazepam 2-5 mg IV e)maintenance, 0.01 to 0.03 mg/kg/min continuous IV infusion
f)maintenance, increments of one-half to the full induction dose may be repeated as needed. Pedia – not FDA approved in children under age
16 yr, General anesthesia; Adjunct a)induction, 5 to 10 mg (base)/kg IM; range, 4 to 13 mg/kg b)induction, 1 to 2 mg/kg IV; range, 0.5-4.5
mg/kg c)maintenance, 0.01 to 0.03 mg/kg/min continuous IV infusion d)maintenance, increments of one-half to the full induction dose may be
repeated as needed
CONTRA-INDICATIONS: hypersensitivity to ketamine products, conditions where hypertension is hazardous
ADVERSE EFFECTS: Increased blood pressure, Increased muscle function, Respiratory depression, Tachyarrhythmia
THERAPEUTIC USE: Antifungal, Antiseborrheic, Imidazole, Steroid Synthesis Inhibitor
DOSE: Adult – Candidal vulvovaginitis, 200 to 400 mg ORALLY once daily; minimum treatment for candidiasis is 1-2 weeks; Candidiasis of
skin – apply 2% cream TOPICALLY once daily for 2 weeks. Pedia – Candidal vulvovaginitis – age 2 yr and older, 3.3 to 6.6 mg/kg ORALLY
once daily; minimum treatment for candidiasis is 1-2 weeks
CONTRA-INDICATIONS: hypersensitivity to ketoconazole products, concurrent use with astemizole or terfenadine, concurrent use with
cisapride or oral triazolam
ADVERSE EFFECTS: Anaphylaxis, Hepatotoxicity
THERAPEUTIC USE: Diagnostic Agent, Thyroid Function, Thyroid Supplement
DOSE: Adult – Hypothyroidism a)1.7 mcg/kg/day ORALLY in a single daily dose (usual maintenance dose is 100-125 mcg/day 70 kg adult)
39
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
25mcg/mL
Tablet 25 mcg
Tablet 50mcg
Tablet 100mcg
Labetalol
Trandate
Lactose
Lactulose
Inj. 5mg/mL
Syrup 10mg/mL
Tablet 100mg
Tablet 200mg
Powder 50grams
Duphalac
Rialac
Syrup
Latanoprost
Xalatan
Eye Drops
50mcg/mL
Letrozole
Femara
Tablet 2.5mg
Levetiracetam
Keppra
Tablet 500mg
Levobunolol HCl
Betagan
Eye Drops 0.5%
PRODUCT INFORMATION
b)severe hypothyroidism, initial: 12.5 to 25 mcg/day with increases of 25 mcg/day every 2 to 4 weeks. Pedia - Hypothyroidism a)(0 to 3
months) 10 to 15mcg/kg/day b)(3 to 6 months) 8 to 10mcg/kg/day c)(6 to 12 months) 6 to 8mcg/kg/day d)(1 to 5 yrs) 5 to 6mcg/kg/day e)(6 to
12 yrs) 4 to 5mcg/kg/day f)(over 12 yrs, growth and puberty incomplete) 2 to 3 mcg/kg/day g)(growth and puberty complete) 1.7 mcg/kg/day
CONTRA-INDICATIONS: acute MI, hypersensitivity to thyroid hormone, treatment of obesity, uncorrected adrenal cortical insufficiency,
untreated angina, untreated hypertension, untreated thyrotoxicosis
ADVERSE EFFECTS: Myocardial infarction, Osteopenia, Pseudotumor cerebri, Seizure
THERAPEUTIC USE: Alpha/Beta-Adrenergic Blocker, Antianginal, Antihypertensive
DOSE: Adult – Hypertension a)initial, 100 mg ORALLY twice daily b)titration, may increase dose in increments of 100 mg ORALLY twice
daily every 2-3 days c)maintenance, 200-400 mg ORALLY twice daily d)IV to ORAL conversion, initial, 200 mg ORALLY, followed in 6-12hr
by 200-400 mg ORALLY depending on BP response. Pedia – Not FDA approved in children. Hypertension a)initial, 1-3 mg/kg/day ORALLY in
2 divided doses; MAX 10-12 mg/kg/day ORALLY up to 1200 mg/day in 2 divided doses b)ages 3-15yr, initial bolus, 0.2-1 mg/kg IV c)ages 315yr, continuous infusion, 0.25-1.5 mg/kg/hr IV
CONTRA-INDICATIONS: bronchial asthma or chronic obstructive pulmonary disease, cardiogenic shock, conditions associated with severe
and prolonged hypotension, hypersensitivity to labetalol, overt cardiac failure, second and third degree AV block, severe sinus bradycardia
ADVERSE EFFECTS: Bronchospasm, Hepatotoxicity (Severe), Hyperkalemia, Ventricular arrhythmia
THERAPEUTIC USE: Widely used in pharmaceutical manufacturing. In the production of capsules or tablets it may be employed as a diluent,
bulking agent, filler or excipient and in powders as a bulking agent.
ADVERSE EFFECTS: Lactose intolerance occurs due to a deficiency of the intestinal enzyme lactase. Ingestion of lactose by patients with
lactase deficiency leads to a clinical syndrome of abdominal pain, diarrhea, distension and flatulence.
THERAPEUTIC USE: Gastrointestinal Agent, Laxative, Hyperosmotic
DOSE: Adult – Constipation, 15 to 45 mL (20 grams/30 mL) ORALLY 3 to 4 times daily for 24 to 48 hours; MAX 40 grams/day; Hepatic
encephalopathy; Treatment and Prophylaxis, initially, 30 to 45 mL (20 grams/30 mL) ORALLY 3 to 4 times daily, then adjusted every 1 to 2
days to achieve 2 to 3 soft formed stools/day or 300 mL (200 grams) mixed with 700 mL of water or saline RECTALLY as a retention enema
(retain for 30 to 60 min) every 4 to 6 hours as needed. Pedia – Constipation a)(infants) 2.5 to 10 mL/day (20 grams/30 mL) ORALLY in 3 to 4
divided doses b)(children) 40 to 90 mL/day (20 grams/30 mL) ORALLY in 3 to 4 divided doses
CONTRA-INDICATIONS: hypersensitivity to lactulose products, galactosemia, patients requiring a galactose free diet
ADVERSE EFFECTS: Hypernatremia, Hypokalemia
THERAPEUTIC USE: Antiglaucoma, Prostaglandin
DOSE: Adult – Ocular hypertension – Raised intraocular pressure, 1 drop in affected eye(s) once daily, in the evening; Open-angle glaucoma
– Raised intraocular pressure, 1 drop in affected eye(s) once daily, in the evening
CONTRA-INDICATIONS: hypersensitivity to latanoprost or benzalkonium chloride
ADVERSE EFFECTS: Macular retinal edema
THERAPEUTIC USE: Antineoplastic Agent, Aromatase Inhibitor, Endocrine-Metabolic Agent
DOSE: Adult – Breast cancer, Neoadjuvant, postmenopausal, hormone receptor-positive, 2.5 mg ORALLY once daily for 3 to 8 months prior
to surgery. Pedia – safety and effectiveness not established in children
CONTRA-INDICATIONS: hypersensitivity to letrozole or any component of the product, premenopausal endocrine status; potential for
maternal and fetal toxicity and fetal malformations
ADVERSE EFFECTS: Fracture of bone, Heart failure, Myocardial infarction, Pancytopenia, Pleural effusion, Pulmonary embolism,
Thromboembolic disorder
THERAPEUTIC USE: Anticonvulsant
DOSE: Adult – Myoclonic seizure; Adjunct, initial, 500 mg ORALLY twice daily; increase daily doses by 1000 mg every 2 weeks to reach a
target dose of 3000 mg/day. Pedia – (tablets, oral solution) safety and efficacy not established in children less than 4 years of age. Partial
seizure; Adjunct, (4 -15 years of age) 10 mg/kg ORALLY twice daily; may increase dosage by 20 mg/kg/day in 2 divided doses every 2 weeks
to a MAX of 60 mg/kg/day (in 2 divided doses)
ADVERSE EFFECTS: Suicidal intent, Suicide
THERAPEUTIC USE: Antiglaucoma, Beta-Adrenergic Blocker, Nonselective
DOSE: Adult – Raised intraocular pressure, In patients with open-angle glaucoma or ocular hypertension a)(0.25% solution) 1-2 drops in
affected eye(s) twice daily b)(0.5% solution) 1-2 drops in affected eye(s) once daily; MAX 1 drop twice a day. Pedia – Safety and efficacy not
established in children
CONTRA-INDICATIONS: bronchial asthma or chronic obstructive pulmonary disease, cardiogenic shock, hypersensitivity to levobunolol,
overt cardiac failure, second and third degree AV block, severe sinus bradycardia
40
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Levodopa/Carbidopa
Sinemet
Tablet 110mg
Tablet 275mg
Levosimendan
Simdax
Inj. 2.5mg/mL
Lidocaine HCl
Lidocaine
/Hydrocortisone
Xylocaine
Xylocard
Xyloproct
Liquid Parafin
Ointment
Injection 1%
Injection 2%
Lidocaine/Adrenaline
Lidocaine/Prilocaine
Gel 2%
Injection 1%
Injection 2%
Injection 20%
Ointment 5%
Spray 10%
Syringe 2%
Viscous 2%
Emla
Lacri – Lube
Mineral Oil
Cream 5%
Eye Ointment
Oil 60mL
PRODUCT INFORMATION
THERAPEUTIC USE: Antiparkinsonian
DOSE: Adult – Parkinson's disease, Idiopathic a)25/100 TAB; initial, 1 TAB ORALLY 3 times a day; increase by 1 TAB daily or every other
day to 8 TABS daily b)10/100 TAB; initial, 1 TAB ORALLY 3 or 4 times daily; increase by 1 TAB daily or every other day to 8 TABS daily
c)50/200 (sustained release) TAB, 1 TAB ORALLY twice daily at an interval of at least 6 hr d)(sustained release) titration, doses and dosing
intervals may be increased or decreased depending upon therapeutic response; most patients adequately treated with doses that provide
400-1600 mg of levodopa per day, administered as divided doses at intervals of 4-8 hr during the waking day; dosage adjustment interval at
least 3 days. Pedia – safety and efficacy not established in pediatric patients
CONTRA-INDICATIONS: hypersensitivity to levodopa/carbidopa products, history of melanoma, undiagnosed skin lesions, narrow-angle
glaucoma, nonselective MAO inhibitors concurrently or less than 2 wks prior
ADVERSE EFFECTS: Dyskinesia, Heart disease, Orthostatic hypotension, Psychotic disorder
DOSE: Intravenous route a)In a dose-ranging, comparative pharmacodynamic study involving patients with CONGESTIVE HEART
FAILURE, the optimal dosing regimen was determined to be an initial bolus of levosimendan 6 to 24 micrograms/kilogram (mcg/kg) delivered
over 10 minutes, followed by a continuous infusion of levosimendan 0.05 to 0.2 mcg/kg/minute b)A continuous infusion of levosimendan 0.1
microgram/kilogram/minute improved hemodynamics in a small series (n=10) of critically ill patients with CARDIOGENIC SHOCK requiring
catecholamines. No bolus dose was given
CONTRA-INDICATIONS: Prior hypersensitivity to levosimendan or racemic simendan
THERAPEUTIC USE: Amino Amide, Anesthetic, Local, Antiarrhythmic, Group IB
DOSE: Adult – Local anesthetic intravenous regional block a)10 to 60 mL of a 0.5% solution IV for a total dose of 50 to 300 mg b)the
maximum individual dose should not exceed 4 mg/kg and the maximum total dose of 300 mg should not be exceeded Local anesthetic
intravenous regional block
CONTRA-INDICATIONS: sensitivity to local anesthetics of the amide type or to any other component of the product
ADVERSE EFFECTS: Cardiac arrest, Cardiac dysrhythmia, Heart block, Loss of consciousness, Methemoglobinemia, Seizure, Tremor
THERAPEUTIC USE: For the treatment of pain, itching and discomfort arising from irritated anorectal tissues e.g. haemorrhoids, pruritus ani,
proctitis, milder forms of anal fissures, postoperative pain relief.
DOSE: Apply the ointment several times a day in a thin layer to the affected area. Intrarectal use, apply the ointment with the special
applicator. Cleanse the applicator thoroughly after use. A daily dose of 6grams of ointment is well within safety limits. The duration of
treatment may vary between ten day and three weeks.
CONTRA-INDICATIONS: Known hypersensitivity to local anesthetics of the amide type or to other components of the product. For infections
caused by viruses, bacteria, pathogenic fungi or parasites, topical glucocorticoids should not be used without concomitant causal therapy.
ADVERSE EFFECTS: Allergic reactions
THERAPEUTIC USE: Local infiltration anaesthesia, Regional anaesthesia, Intra or Peri-articular infiltration, Sympathetic infiltration
DOSE: Adult – the maximum dose should not exceed 500mg, when using epidural anesthesia in obstetric it is advisable to reduce the dose
by one-half. Pedia – An adrenaline concentration of 1/400,000 should not be exceeded. It is therefore necessary to dilute formulations
containing Adrenaline.
THERAPEUTIC USE: Anesthetic, Amino Amide Combination, Anesthetic, Local
DOSE: Adult – Topical local anesthetic, Genital mucous membranes, females, apply a thick layer (5-10 g) of CREAM for 5-10 min, perform
local anesthetic infiltration immediately after removal of cream. Pedia – Topical local anesthetic to skin
a)(age 0-3 months or weight <5 kg) MAX dose, 1 g; MAX application area, 10 cm(2); MAX application time, 1 hr b)(age 3-12 months, weight
>5 kg) MAX dose, 2 g MAX application area, 20 cm(2); MAX application time, 4 hr c)(age 1-6 yr, weight >10 kg) MAX dose, 10 g MAX
application area, 100 cm(2); MAX application time, 4 hr d)(age 7-12 yr, weight >20 kg) MAX dose, 20 g; MAX application area, 200 cm(2);
MAX application time, 4 hr
CONTRA-INDICATIONS: hypersensitivity to local amide-type anesthetics or to any component of the product
ADVERSE EFFECTS: Central nervous system finding, Depression/excitation, Methemoglobinemia, Myocardial dysfunction, Seizure
THERAPEUTIC USE: Emollient, Laxative
DOSE: Adult – Constipation a)15 to 45 mL ORALLY once daily at bedtime, MAX 45 mL b)enema: empty contents of 1 bottle (133 mL) into
RECTUM once; Dry skin, apply to damp skin as needed. Pedia – Constipation a)(5 to 11 yr) 5 to 15 mL ORALLY once daily at bedtime b)(12
yr and older) enema: empty contents of 1 bottle (133 mL) into RECTUM once c)(2 to 11 yr) enema: empty contents of 1-half bottle (66.5 mL)
into RECTUM once; Dry skin, apply to skin directly after bath
41
PRODUCT
DESCRIPTION
TRADE
NAME
Loperamide HCl
Imodium
Loratadine
Clara
Claritin
Loratan
Lorine
DOSAGE
FORM/STRENGTH
Capsule 2mg
Syrup 5mg/5mL
Tablet 10mg
Lorazepam
Ativan
Inj. 4mg/2mL
Tablet 1mg
Tablet 2mg
Macrogols
/Polyethylene Glycol
Cololyt
Granules
Magnesium Citrate
Epimag
Powder 5grams
Magnesium Sulphate
Injection 10%
Injection 50%
Powder
Syrup
100mg/mL
PRODUCT INFORMATION
CONTRA-INDICATIONS: appendicitis, children less than 2 yr of age, children less than 6 yr of age, colostomy/ileostomy, diverticulitis,
hypersensitivity to mineral oil products, ulcerative colitis, rectal bleeding
ADVERSE EFFECTS: Pneumonitis due to inhalation of oil or essence, Rectal hemorrhage
THERAPEUTIC USE: Antidiarrheal
DOSE: Adult – Diarrhea, acute, 4 mg ORALLY followed by 2 mg after each loose stool up to a maximum of 16 mg/day. Pedia – Diarrhea,
acute a)first day dosage; (2 to 5 y, 13 to 20 kg) 1 mg ORALLY 3 times daily b)first day dosage; (6 to 8 y, 20 to 30 kg) 2 mg ORALLY twice
daily c)first day dosage; (8 to 12 y, greater than 30 kg) 2 mg ORALLY 3 times daily d)subsequent daily dosage; (2 to 12 y) 1mg/10kg of body
weight ORALLY only after a loose stool, total daily dose should not exceed dosages for the first day
CONTRA-INDICATIONS: abdominal pain in the absence of diarrhea, bacterial enterocolitis, caused by invasive organisms including
Salmonella, Shigella, and Campylobacter; do not use as primary therapy, dysentery, acute; do not use as primary therapy, hypersensitivity to
loperamide or to any of the excipients, infants below 24 months of age, pseudomembranous colitis, associated with the use of broad spectrum
antibiotics; do not use as primary therapy, ulcerative colitis, acute; do not use as primary therapy
ADVERSE EFFECTS: Necrotizing enterocolitis in fetus OR newborn
THERAPEUTIC USE: Antihistamine, Less-Sedating, Piperidine, Respiratory Agent
DOSE: Adult – Asthma (allergic asthma) 10 to 20 mg ORALLY once daily has been used for up to 8 weeks. Pedia – Seasonal allergic
rhinitis a)(2 to 5 y) 5 mg ORALLY once daily b)(6 y and older) 10 mg orally once daily
CONTRA-INDICATIONS: hypersensitivity to loratadine or any of its ingredients
ADVERSE EFFECTS: Decreased liver function
THERAPEUTIC USE: Antianxiety, Anticonvulsant, Benzodiazepine, Short or Intermediate Acting, Skeletal Muscle Relaxant
DOSE: Adult – Anxiety a)initial, 2 to 3 mg/day ORALLY divided into 2 to 3 daily doses b)maintenance, 2 to 6 mg/day ORALLY divided into 2
to 3 daily doses; MAX dose 10 mg/day. Pedia – Safety and effectiveness of lorazepam tablets in children less than 12 years old have not
been established. Safety and effectiveness of lorazepam injection in children less than 18 years old have not been established. Status
epilepticus 0.05 to 0.1 mg/kg IV (MAX 4 mg/dose)
CONTRA-INDICATIONS: hypersensitivity to benzodiazepines or any component of the product (oral and injection), polyethylene glycol,
propylene glycol, or benzyl alcohol, intra-arterial administration; may produce arteriospasm resulting in gangrene, narrow-angle glaucoma,
acute, respiratory insufficiency, severe; in the absence of resuscitative equipment, sleep apnea syndrome.
ADVERSE EFFECTS: Acidosis
THERAPEUTIC USE: Indicated for cleansing the bowel by means of total gut perfusion and whole bowel irrigation in preparation for
gastrointestinal examination and surgery.
DOSE: The typical dosage per patient is 3 to 4 liters. The total volume can be drunk on the eve of the examination, especially before double
contrast enemas. Alternatively the dose can be divided into 1 liter on the eve and 2liters in the morning of the day of examination.
Recommended ingestion rate ranges from 1.2 liters to 1.8 liters per hour (200 to 300mL every 10minutes). It should preferably be drunk cool.
The addition of sugarless flavorings or lemon juice is possible. Patients should fast for three or four hours before ingestion begins. Patients
should never be given solid food less than two hours prior to administration.
ADVERSE EFFECTS: Nausea and flatulence, vomiting, rectal irritation.
THERAPEUTIC USE: Antacid, Magnesium Containing, Anticonvulsant, Anti-Inflammatory, Laxative, Hyperosmotic & Stimulant, Magnesium
Supplement, Nutriceutical, Parenteral Mineral-Trace Mineral, Renal-Urologic Agent
DOSE: Adult – Hypomagnesemia; Prophylaxis, 400 mg ORALLY daily with meals; Preparation of bowel for procedure – 150 to 300 mL
(1.745 g/30 mL solution) ORALLY once, may repeat as needed. Pedia – Preparation of bowel for procedure, (6-12 yr): 0.5 mL/kg (1.745 g/30
mL solution) up to a maximum of 200 mL every 4-6 hours until stools are clear
CONTRA-INDICATIONS: abdominal pain, nausea/vomiting, rectal bleeding, heart block, low-salt diet, severe renal disease
ADVERSE EFFECTS: Hypermagnesemia, Hypoventilation
DOSE: Adult – Hypomagnesemia; Treatment and Prophylaxis a)mild hypomagnesemia; 1 g (magnesium sulfate 50% solution) IM every 6
hours for 4 doses b)severe hypomagnesemia; up to 250 mg/kg (magnesium sulfate 50% solution) IM in 4 hours OR 5 g in 1 L of D5W or NS
by slow IV infusion over 3 hours c)TPN, maintenance; 1 to 3 g (8 to 24 mEq) magnesium sulfate daily given parenterally. Pedia –
Hypomagnesemia; Treatment and Prophylaxis a)neonates, magnesium sulfate 25 to 50 mg/kg IV every 8 to 12 hours for 2 to 3 doses
b)children, magnesium sulfate 25 to 50 mg/kg IV every 4 to 6 hours for 3 to 4 doses; MAX single dose is 2000 mg c)TPN, maintenance;
infants; 0.25 to 1.25 g (2 to 10 mEq) magnesium sulfate daily given parenterally
CONTRA-INDICATIONS: heart block, parenteral administration, myocardial damage, parenteral administration
ADVERSE EFFECTS: Abnormal ECG, Blood coagulation disorder with prolonged bleeding time, Central nervous system depression, Heart
block, Hyporeflexia, Hypotension, Respiratory tract paralysis, Vasodilatation
42
PRODUCT
DESCRIPTION
Maprotiline HCl
TRADE
NAME
Ludiomil
Measles/Mumps
/Rubella Vaccine
DOSAGE
FORM/STRENGTH
Tablet 10mg
Tablet 25mg
Injection
Medazole
Mebendazole
Vermox
Susp. 20mg/mL
Tablet 100mg
Wormazol
Medroxyprogesterone
Acetate
Provera
Tablet 5mg
Fenam
Mefenamic Acid
Fendol
Mafepain
Capsule 250mg
Syrup
50mg/5mL
Ponstan
Megestrol Acetate
Megace
Tablet 40mg
PRODUCT INFORMATION
THERAPEUTIC USE: Antidepressant Tetracyclic
DOSE: Adult – Bipolar disorder, depressed phase a)outpatients: 75 mg/day ORALLY (2-3 divided doses) for 2 weeks; may increase in 25 mg
increments up to a MAX of 225 mg/day in single or divided doses b)inpatients: 100-150 mg/day ORALLY (2-3 divided doses) for 2 weeks;
may increase in 25 mg increments up to a MAX of 225 mg/day in single or divided doses c)maintenance: 75-150 mg/day ORALLY in single or
divided doses. Pedia – safety and efficacy have not been established in patients below 18 years of age
CONTRA-INDICATIONS: coadministration with a MAOI or use within 14 days of discontinuing a MAOI, hypersensitivity to maprotiline
hydrochloride, myocardial infarction (MI), during the acute recovery period, seizure disorder
ADVERSE EFFECTS: Decreased liver function, Depression, Worsening, Granulocytopenic disorder, Jaundice, Mania, Neutropenia, Seizure,
Suicidal thoughts, Suicide
THERAPEUTIC USE: Vaccine
DOSE: Adult – Measles-mumps-rubella vaccination, 0.5 mL SC. Pedia – Safety and effectiveness of measles vaccine in infants below the
age of 6 months have not been established. Safety and effectiveness of mumps and rubella vaccine in infants less than 12 months of age
have not been established. Measles-mumps-rubella vaccination 0.5 mL SC at 12 to 15 months and at 4 to 6 years of age
CONTRA-INDICATIONS: alkylating agents, antimetabolites, cerebrospinal fluid leaks, clinical judgment with respect to immunosuppressive
treatment is indicated (eg, in general, short-term steroid therapy or alternate-day therapy are not significantly immunosuppressive, and there
is no contraindication in these settings), corticosteroid use in large amounts immunodeficiency, congenital, leukemia, lymphoma, or
generalized malignancy, patients with active, untreated tuberculosis (potential exacerbation), patients with moderate-to-severe
immunodeficiency conditions, including those receiving immunosuppressive therapy (potential for viral replication and/or reduced vaccine
efficacy); HIV-infected patients can be immunized if they are not severely immunosuppressed; leukemia patients in remission can be
vaccinated if they have not received chemotherapy in the previous three months, pregnancy should be avoided for 4 weeks; pregnancy
should be avoided for 3 months postvaccination based on manufacturer recommendations, prior hypersensitivity to any component of
combined measles, mumps, and rubella vaccines, including gelatin: Neomycin is component of MMR-II®; neomycin sensitivity is a
contraindication only in patients with a history of anaphylaxis following topical or systemic use; a history of contact dermatitis is not a
contraindication, radiation therapy, severe febrile illness
ADVERSE EFFECTS: Anaphylaxis, Encephalitis, Guillain-Barre syndrome, Association with vaccine unlikely, Optic neuritis, Polyneuritis,
Polyneuropathy, Stevens-Johnson syndrome, Thrombocytopenia
THERAPEUTIC USE: Anthelmintic, Benzimidazole
DOSE: Adult – Ancylostomiasis and necatoriasis, 100 mg ORALLY twice daily for 3 consecutive days; drug regimen may be repeated in 3
wks if necessary. Pedia – Ancylostomiasis and necatoriasis, (over 2 y) 100 mg ORALLY twice daily for 3 consecutive days; drug regimen may
be repeated in 3 wks if necessary
CONTRA-INDICATIONS: hypersensitivity to mebendazole products
ADVERSE EFFECTS: Hepatitis, Seizure
THERAPEUTIC USE: Antineoplastic Agent, Contraceptive, Progestin, Endocrine-Metabolic Agent
DOSE: Adult – Abnormal uterine bleeding unrelated to menstrual cycle, Hormonal imbalance-induced, 5-10 mg ORALLY daily for 5-10 days
beginning on day 16 or 21 of the menstrual cycle; to produce optimum secretory transformation of the primed endometrium, 10 mg ORALLY
daily for 10 days beginning on day 16 of the cycle. Pedia – Safety and efficacy not established in children
CONTRA-INDICATIONS: as a diagnostic test for pregnancy, malignancy of breast or genital organs, pregnancy, sensitivity to
medroxyprogesterone acetate or any of its ingredients, liver dysfunction or disease, missed abortion, thrombophlebitis, thromboembolic
disorders, cerebral apoplexy, or a history of these conditions, undiagnosed vaginal bleeding
ADVERSE EFFECTS: Anaphylaxis, Decreased bone mineral density, Deep venous thrombosis, Jaundice, Osteoporosis, Pulmonary
embolism, Thrombophlebitis
THERAPEUTIC USE: Analgesic, Antimigraine, Central Nervous System Agent, Fenamate, NSAID
DOSE: Adult – Pain, initial dose 500 mg, followed by 250 mg every 6 hours as needed, usually not longer than 1 week. Pedia – safety and
efficacy for pediatric patients younger than 14 years have not been established
CONTRA-INDICATIONS: treatment of peri-operative pain in setting of coronary artery bypass graft, hypersensitivity to mefenamic acid,
patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory agents;
severe, even fatal, anaphylactic-like reactions have been reported
ADVERSE EFFECTS: Acute renal failure, Bronchospasm, Cerebrovascular accident, Gastrointestinal perforation, Gastrointestinal ulcer,
Hepatitis, Hypertension, Inflammatory disorder of digestive tract, Jaundice, Liver failure, Myocardial infarction, Scaling eczema, StevensJohnson syndrome, Thrombotic tendency observations, Toxic epidermal necrolysis
THERAPEUTIC USE: Endocrine-Metabolic Agent, Progestin
DOSE: Adult – Breast cancer, palliative treatment of advanced disease (recurrent, inoperable, or metastatic), 40 mg ORALLY FOUR times
43
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Tablet 160mg
Meloxicam
Coxicam
Mobic
Moven
Supp. 15mg
Tablet 7.5mg
Tablet 15mg
Melphalan
Alkeran
Tablet 2mg
Meningococcal Vaccine
ACWY
Injection
Mercaptopurine
Puri – Nethol
Tablet 50mg
Meropenem
Meronem
Injection 500mg
Injection 1gram
Asacol
Mesalazine
Pentasa
Salofalk
SR Tablet
500mg
PRODUCT INFORMATION
daily. Pedia – safety and effectiveness not established in children
CONTRA-INDICATIONS: history of hypersensitivity to megestrol acetate or any component of the formulation, known or suspected
pregnancy
ADVERSE EFFECTS: Adrenal insufficiency, Anemia, Deep venous thrombosis, Pulmonary embolism, Thrombophlebitis
THERAPEUTIC USE: Analgesic, Antirheumatic, Central Nervous System Agent, Musculoskeletal Agent, NSAID, Oxicam
DOSE: Adult – Rheumatoid arthritis, 7.5 mg ORALLY once a day, MAX 15 mg ORALLY once a day. Pedia – safety and efficacy in children
less than 18 years old have not been established. Juvenile rheumatoid arthritis, polyarticular – Pauciarticular juvenile rheumatoid arthritis, (2
years and older) 0.125 mg/kg ORALLY once daily; MAX 7.5 mg daily; dosing should be individualized based on the weight of the child.
CONTRA-INDICATIONS: treatment of peri-operative pain in setting of coronary artery bypass graft, hypersensitivity to meloxicam, patients
who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory agents; severe,
even fatal, anaphylactic-like reactions have been reported
THERAPEUTIC USE: Alkylating Agent, Antineoplastic Agent, Nitrogen Mustard,
DOSE : Adult – Multiple myeloma, Palliative treatment, 6 mg/day ORALLY for 2 to 3 wk, then 4 wk off, then restart at 2 mg/day when white
blood cell and platelet counts are rising; other regimens include 0.25 mg/kg/day for 4 consecutive days (0.2 mg/kg/day for 5 days) in
combination with prednisone- total dose of 1 mg/kg/course repeated every 4 to 6 weeks if granulocyte/platelet counts have returned to
normal; 10 mg/day for 7 to 10 days with a maintenance dose of 2 mg/day; 0.15 mg/kg/day for 7 days with a maintenance dose of 0.05
mg/kg/day or less. Pedia – safety & efficacy have not been established in pediatric patients
CONTRA-INDICATIONS: Hypersensitivity to melphalan products, Previous resistance to the drug
ADVERSE EFFECTS: Anaphylaxis, Hemolytic anemia, Hepatitis, Immune hypersensitivity reaction, Jaundice, Liver function tests abnormal,
Myelosuppression, Pulmonary fibrosis
Pulmonary infiltrate, Secondary malignant neoplastic disease, Sterility, Vasculitis
THERAPEUTIC USE: Vaccine
DOSE: Adult – Meningococcal infectious disease; Prophylaxis, primary or revaccination, 0.5 mL SUBQ as a single dose. Pedia – safety and
effectiveness in children below the age of 2 y have not been established; Meningococcal infectious disease; Prophylaxis (2 y and older)
primary or revaccination, 0.5 mL SUBQ as a single dose
CONTRA-INDICATIONS: Any acute illness, Sensitivity to thimerosal or any other component of the vaccine
THERAPEUTIC USE: Antimetabolite, Antineoplastic Agent, Antirheumatic, Cytotoxic, Gastrointestinal Agent
DOSE: Adult – Acute lymphoid leukemia, As induction and maintenance therapy a)induction, 2.5 mg/kg/day (100-200 mg) ORALLY; if no
clinical improvement after 4 weeks, may increase dose to 5 mg/kg daily b)maintenance, 1.5-2.5 mg/kg/day ORALLY as single dose; usually
used in combination with methotrexate.
Pedia – Acute lymphoid leukemia, As induction and maintenance therapy a)induction, 2.5 mg/kg/day ORALLY; if no clinical improvement after
4 weeks, may increase dose to 5 mg/kg daily b)maintenance, 1.5-2.5 mg/kg/day ORALLY; usually used in combination with methotrexate
CONTRA-INDICATIONS: hypersensitivity to mercaptopurine/component of formulation, prior resistance to mercaptopurine or thioguanine,
should not be used unless acute leukemia diagnosis is established
ADVERSE EFFECTS: Hepatotoxicity, Hyperuricemia, Myelosuppression, Ulceration of intestine
THERAPEUTIC USE: Antibiotic, Beta-Lactam, Carbapenem
DOSE: Adult – Infectious disease of abdomen, Complicated, 1 g IV injection or infusion every 8 h. Pedia – Bacterial meningitis, 3 mo and
older, 40 mg/kg IV injection or infusion every 8 h, MAX dose 2 g every 8 h; Infection of skin &/or subcutaneous tissue, Complicated 3 mo and
older, 10 mg/kg IV infusion or injection every 8 h; MAX dose 500 mg every 8 h
CONTRA-INDICATIONS: hypersensitivity to meropenem or any component of its product, other drugs in the same class (carbapenems), or
other beta-lactam antibiotics
ADVERSE EFFECTS: Agranulocytosis, Angioedema, Erythema multiforme, Leukopenia, Neutropenia, Seizure, Most commonly in patients
with CNS disorders, Stevens-Johnson syndrome, Toxic epidermal necrolysis
THERAPEUTIC USE: Anti-Inflammatory, Gastrointestinal Agent, Salicylate, Non-Aspirin
DOSE: Adult - Ulcerative colitis, Active a)(controlled-release capsule) 1 gram ORALLY 4 times daily for up to 8 wks b)(Asacol® delayedrelease tablet) 800 mg ORALLY 3 times daily for 6 wks. Pedia – safety & efficacy has not been established in pediatric patients
CONTRA-INDICATIONS: hypersensitivity to mesalamine salicylates (including aspirin), or to any component of the tablets, capsules, rectal
suspension, or rectal suppositories, including the suppository vehicle (saturated vegetable fatty acid esters
ADVERSE EFFECTS: Agranulocytosis, Aplastic anemia, Hepatotoxicity, Leukopenia, Neutropenia, Pancreatitis, Pancytopenia, Pericarditis,
Renal impairment, Thrombocytopenia
44
PRODUCT
DESCRIPTION
Mesna
TRADE
NAME
Uromitexan
DOSAGE
FORM/STRENGTH
Injection
100mg/mL
Formit
Metformin
Glucophage
Tablet 500mg
Tablet 850mg
Metfor
Methotrexate
Inj. 50mg/5mL
Inj. 500mg/5mL
Intrathecal 5mg
Tablet 2.5mg
Methylcellulose
Powder
Solution 1%
Methyldopa
Methylene Blue
Aldomet
Syrup 25mg/mL
Tablet 250mg
Injection 1%
PRODUCT INFORMATION
THERAPEUTIC USE: Hemorrhagic Cystitis Inhibitor
DOSE: Adult – Hemorrhagic cystitis, Ifosfamide-induced; Prophylaxis – bolus IV regimen, IV bolus 20% of ifosfamide dose (w/w) at 0, 4, 8 h.
Pedia – safety and efficacy of mesna tablets have no been established in children
CONTRA-INDICATIONS: hypersensitivity to mesna/other thiol compounds
ADVERSE EFFECTS: Hypotension
THERAPEUTIC USE: Biguanide, Hypoglycemic
DOSE: Adult – Diabetes mellitus type 2 a)initial, 500 mg ORALLY twice daily or 850 mg ORALLY once daily b)maintenance, 1 to 2.55 g
ORALLY daily in 2-3 divided doses, MAX 2550 mg/day c)(extended release TAB) initial, 500 mg ORALLY once daily d)(extended release
TAB) maintenance, 1 to 2 g ORALLY once daily ; MAX 2000 mg/day e)(Fortamet® extended-release) initial, 500 mg to 1 g ORALLY once
daily f)(Fortamet® extended-release) maintenance, 1 to 2.5 g ORALLY once daily; MAX 2500 mg/day. Pedia – Diabetes mellitus type 2
a)(immediate release TAB or SOLN) 10-16 yr, initial 500 mg ORALLY twice daily b)(immediate release TAB or SOLN) 10-16 yr, maintenance,
titrate in 500 mg increments weekly, MAX 2000 mg/day in divided doses
CONTRA-INDICATIONS: hypersensitivity to metformin, iodinated contrast media, intravascular use in radiologic studies; possible acute
alteration of renal function resulting in increased risk of lactic acidosis, renal impairment (ie, serum creatinine 1.4 mg/dL or higher in females
or 1.5 mg/dL or higher in males), including that caused by cardiovascular collapse, acute myocardial infarction, or septicemia; increased risk
of lactic acidosis, metabolic acidosis, acute or chronic, including ketoacidosis; increased risk of lactic acidosis
ADVERSE EFFECTS: Lactic acidosis
THERAPEUTIC USE: Antimetabolite, Antineoplastic Agent, Antipsoriatic, Antirheumatic, Cytotoxic
DOSE: Adult – Non-Hodgkin's lymphoma, Advanced a)(Burkitt's lymphoma, stages I and II) 10 to 25 mg/day ORALLY for 4 to 8 days; (stage
III) in combination with other antineoplastic agents b)(lymphosarcoma, stage III) 0.625 to 2.5 mg/kg/day IV/IM in combination with other
antineoplastics. Pedia – the safety and effectiveness of methotrexate in pediatric patients has only been established for cancer chemotherapy
and polyarticular-course juvenile rheumatoid arthritis. Acute lymphoid leukemia a)induction, 3.3 mg/m(2)/day IV in combination with
corticosteroid therapy for 4-6 weeks has been given b)maintenance, 30 mg/m(2)/week administered in 2 divided IM or ORAL doses; 2.5
mg/kg IV every 14 days has also been used
CONTRA-INDICATIONS:pregnancy, breastfeeding, known hypersensitivity to methotrexate, patients with psoriasis/rheumatoid arthritis with
alcoholism, alcoholic liver disease, or other chronic liver disease, patients with psoriasis/rheumatoid arthritis with preexisting blood dyscrasias
or laboratory evidence of immunodeficiency syndromes
ADVERSE EFFECTS: Arachnoiditis, With intrathecal administration, Atrophy of liver
Cirrhosis of liver, Disorder of lung, Gastrointestinal hemorrhage, Hepatic fibrosis, Hepatic necrosis, Hyperuricemia, Increased liver function
test, Inflammatory disease of mucous membrane, Interstitial pneumonia, Acute, chronic, Kidney disease, Liver failure, Myelosuppression,
Renal failure, Skin ulcer
THERAPEUTIC USE: Diagnostic Agent, Lubricant, Ocular, Surgical Aid, Ocular
DOSE: Adult – Gonioscopy; Diagnosis, 2.5% OPHTHALMIC solution used as needed to fill the gonioscopic prism; Operative procedure on
anterior chamber of eye – instill a 2% OPHTHALMIC solution into the anterior chamber, as needed, using a 20-gauge or larger cannula;
Xerophthalmia – instill 1 drop 0.3% to 1% OPHTHALMIC solution into affected eye(s) 3 to 4 times daily, as needed. Pedia – Xerophthalmia
(adolescents) instill 1 drop 0.3% to 1% OPHTHALMIC solution into affected eye(s) 3 to 4 times daily, as needed
CONTRA-INDICATIONS: hypersensitivity to hypromellose
THERAPEUTIC USE: Alpha-Adrenergic Agonist, Antihypertensive, Cardiovascular Agent
DOSE: Adult – Hypertension a)initial, 250 mg ORALLY two-three times daily; may adjust dose at intervals of not less than every 2 days;
maintenance, 500-2000 mg ORALLY daily in 2-4 divided doses; MAX dose, 3000 mg daily b)250-500 mg IV every 6 hr; MAX dose, 1000 mg
IV every 6 hr. Pedia – Hypertension a)initial, 10 mg/kg ORALLY daily in 2-4 divided doses; MAX dose, 65 mg/kg or 3000 mg daily, whichever
is less b)20-40 mg/kg/day IV divided every 6 hr; MAX dose, 65 mg/kg or 3000 mg daily, whichever is less c)(neonates) 2.5-5 mg/kg ORALLY
or IV every 8 hr
CONTRA-INDICATIONS: current MAOI therapy, hypersensitivity to methyldopa, liver disease (with or without previous association with
methyldopa therapy)
ADVERSE EFFECTS: Bone marrow depression, Colitis, Congestive heart failure, Decreased liver function, Rarely fatal, Granulocytopenic
disorder, Hemolytic anemia, Immune hypersensitivity reaction, Leukopenia, Malignant lymphoma, Neutropenia, Pancreatitis, Parkinsonism,
Systemic lupus erythematosus, Thrombocytopenia
THERAPEUTIC USE: Antiseptic, Diagnostic Agent, Kidney Function, Toxicology-Antidote Agent
DOSE: Adult & Pedia – Drug-induced methemoglobinemia, 1 to 2 mg/kg (0.1 to 0.2 mL/kg of a 1% solution) IV very slowly over several min.
CONTRA-INDICATIONS: hypersensitivity to methylene blue, intraspinal injection, methemoglobinemia in cyanide poisoning
ADVERSE EFFECTS: Cardiac dysrhythmia, Hemolytic anemia, Malignant hyperthermia, Methemoglobinemia
45
PRODUCT
DESCRIPTION
Methylergometrine
Maleate
TRADE
NAME
Methergin
Methylparaben
DOSAGE
FORM/STRENGTH
Injection
0.2mg/mL
Powder
Methylphenidate
Ritalin
Tablet 10mg
Methylprednisolone Acetate
Depo Medrol
Injection 40mg
Inj. 80mg/2mL
Methylprednisolone
Sodium Succinate
Solu – Medrol
Injection 40mg
Inj. 125mg/2mL
Injection 1gram
Metoclopramide
Plasil
Premosan
Primperan
Riamide
Inj. 10mg/2mL
Syrup 5mg/5mL
Tablet 10mg
Metronidazole
Amrizole
Anazol
Flagyl
Flazol
Negazole
Inj. 500mg
Susp. 200mg/5mL
Tablet 500mg
Vaginal Tab.500mg
PRODUCT INFORMATION
THERAPEUTIC USE: Ergot Alkaloid, Uterine Stimulant
DOSE: Adult – Postpartum hemorrhage, associated with uterine atony or subinvolution, 0.2 mg IM/IV (may be repeated at 2 to 4 h intervals
up to 5 doses) then 0.2 mg ORALLY 3 to 4 times a day as needed (MAX duration: 7 days). Pedia – safety and efficacy not established in
pediatric patients
CONTRA-INDICATIONS: hypersensitivity to methylergonovine products, concomitant use with potent CYP 3A4 inhibitors, pregnancy,
toxemia, uncontrolled hypertension
ADVERSE EFFECTS: Angina, Hypertensive episode, Myocardial infarction, Seizure
THERAPEUTIC USE: Preservative for galenicals in concentrations ranging from 0.05 to 0.25%. When desired to give a strong antiseptic
effect, 3 to 5 times the above concentration may be used.
DOSE: Topical to pharynx, 3mg in a troche.
THERAPEUTIC USE: Amphetamine Related, Central Nervous System Agent & Stimulant
DOSE: Adult – individualize dosage according to need and response of patient; Attention deficit hyperactivity disorder a)immediate-release
(IR), 10 to 60 mg/day ORALLY divided 2 to 3 times daily, preferably 30 to 45 min before meals
b)extended-release, no prior methylphenidate therapy, 18 mg ORALLY once daily in the morning; may adjust dosage at weekly intervals in 18
mg increments; MAX 54 mg/day. Pedia - Attention deficit hyperactivity disorder, (age 6 y and older) immediate-release, 5 mg ORALLY twice
daily (before breakfast and lunch); dose adjustments of 5 to 10 mg at weekly intervals; MAX 60 mg/day
CONTRA-INDICATIONS: marked agitation, anxiety, and tension; may aggravate symptoms glaucoma, hypersensitivity to methylphenidate or
other components of the products, monoamine oxidase inhibitors, such as isocarboxazid, phenelzine, selegiline, tranylcypromine, within 14
days of administration; may cause hypertensive crisis, tics, motor Tourette's syndrome, family history or diagnosis
ADVERSE EFFECTS: Contact dermatitis, Decreased body growth, Drug dependence, Lowered convulsive threshold, Psychotic disorder, Tic
THERAPEUTIC USE: Adrenal Glucocorticoid, Endocrine-Metabolic Agent, Immune Suppressant
DOSE: Adult – Adrenal insufficiency, 40 mg IM every other week; Rheumatoid arthritis a)IM, maintenance, 40-120 mg/wk b)INTRAARTICULAR, 20-80 mg for large joint; 10-40 mg for medium joint; 4-10 mg for small joint, may be repeated every 1-5 weeks or more. Pedia –
dosage will be reduced but should be governed more by the severity of the condition and response of the patient than by age or size. Allergic
disorder, dosage varies; administer the equivalent of a total daily oral dose as a single IM injection in a 24-h period
CONTRA-INDICATIONS: systemic fungal infection, administration of live or live, attenuated vaccine in patients receiving immunosuppressive
doses of corticosteroids premature infants, hypersensitivity to methylprednisolone or any component of the product
ADVERSE EFFECTS: Congestive heart failure, Drug-induced adrenocortical insufficiency, HPA, Glaucoma, Hyperglycemia, Osteoporosis,
Pulmonary tuberculosis, Raised intracranial pressure, Seizure
THERAPEUTIC USE: Adrenal Glucocorticoid, Endocrine-Metabolic Agent, Immune Suppressant
DOSE: Adult & Pedia – Allergic disorder, initial dose, 10 to 40 mg IV over several minutes, may repeat as IV or IM injections as needed
depending on patient's response; for high-dose therapy, 30 mg/kg IV over at least 30 min, may repeat every 4 to 6 h for up to 72 h.
CONTRA-INDICATIONS: hypersensitivity to any constituent of the product, premature infants (preparations containing benzyl alcohol),
systemic fungal infections, live vaccine or attenuated live vaccine in patients receiving immunosuppressive doses
ADVERSE EFFECTS: Cataract, Congestive heart failure, Cushing's syndrome, Glaucoma, Hyperglycemia, Osteoporosis, Primary
adrenocortical insufficiency, Pulmonary tuberculosis, Raised intracranial pressure, Seizure
THERAPEUTIC USE: Antiemetic, Diagnostic Agent, Dopamine Antagonist, Stimulant, Gastrointestinal
DOSE: Adult – Chemotherapy-induced nausea and vomiting; Prophylaxis, 1 to 2 mg/kg/dose IV over 15 min administered 30 min prior to
chemotherapy and then every 2 h for 2 doses, then every 3 h for 3 doses. Pedia – Postoperative nausea and vomiting, 0.25 mg/kg/dose IV
repeat every 6-8 hrs as needed
CONTRA-INDICATIONS: concomitant use of drugs with extrapyramidal adverse effects, gastrointestinal hemorrhage, obstruction
(mechanical), or perforation, hypersensitivity to metoclopramide products, pheochromocytoma, seizure disorders
ADVERSE EFFECTS: Cardiac dysrhythmia, Reversible, Neuroleptic malignant syndrome
THERAPEUTIC USE: Amebicide, Extraintestinal & Intestinal, Antiacne Antibacterial, Antibiotic, Antiprotozoal, Antiulcer, Helicobacter Pylori,
Nitroimidazole
DOSE: Adult – Abscess, Anaerobic, loading dose, 15 mg/kg IV over 1 h; maintenance dose, 7.5 mg/kg IV every 6 h, starting 6 h after loading
dose; MAX 4 g/day; 7.5 mg/kg ORALLY every 6 h; maximum 4 g/day. Pedia – Amebic dysentery, acute, 35-50 mg/kg/day ORALLY in 3
divided doses for 10 days; maximum 750 mg/dose
CONTRA-INDICATIONS: hypersensitivity to metronidazole or other nitroimidazole agents, hypersensitivity to parabens (gel formulations),
first trimester of pregnancy
ADVERSE EFFECTS: Leukopenia, Ototoxicity, Thrombocytopenia
46
PRODUCT
DESCRIPTION
Miconazole
TRADE
NAME
Daktarin
Miconaz
Mycoheal
DOSAGE
THERAPEUTIC USE: Antifungal, Imidazole
DOSE: Adult & 12years old – Candidal vulvovaginitis a)200 mg Vaginally at bedtime for 3 days b)100 mg Vaginally at bedtime for 7 days
Cream 2%
c)1200 mg VAGINALLY once; Tinea, Superficial, apply TOPICALLY to affected areas twice daily. Pedia – Tinea, Superficial, (2 y and older)
Vaginal Cream 2% apply TOPICALLY to affected areas twice daily
Inj. 2.5mg/0.5mL
Inj. 15mg/3mL
Midazolam
Dormicum
Milrinone
Primacor
Injection
10mg/10mL
Mineral Oil/Anhyd. Liquid
Lanolin/Petrolatum
Refresh PM
Eye Ointment
Syrup 1mg/mL
(30mL, 45mL,
60mL and 75mL)
Mirtazapine
Remeron
Tablet 30mg
Misoprostol
Cytotec
Tablet 200mcg
Mitomycin
Mitoxantrone HCl
Injection 10mg
Novantrone
PRODUCT INFORMATION
FORM/STRENGTH
Injection
2mg/mL
CONTRA-INDICATIONS:hypersensitivity to miconazole products
THERAPEUTIC USE: Anesthetic Adjunct, Benzodiazepine, Short or Intermediate Acting, Hypnotic
DOSE: Adult – Amnesia induction – Anxiety – Preoperative sedation a)good risk patients under the age of 60, 0.07 to 0.08 mg/kg IM
(approximately 5 mg) 1 h before surgery b)patients with chronic obstructive pulmonary disease, other higher risk surgical patients, patients 60
or more years of age, and patients who have received concomitant narcotics or other CNS depressants, 0.02 to 0.05 mg/kg IM (approximately
2 to 3 mg) 1 h before surgery c)older patients when the anticipated intensity and duration of sedation is less critical, 1 mg IM 1 h before
surgery. Pedia – Amnesia induction – Anxiety – Preoperative sedation a)0.1 to 0.15 mg/kg IM, 0.5 mg/kg for more anxious patients. MAX 10
mg b)(6 mos to 5 y of age) initial dose 0.05 to 0.1 mg/kg IV, a total dose of 0.6 mg/kg may be necessary. MAX 6 mg c)(6 to 12 y of age) initial
dose 0.025 to 0.05 mg/kg IV, a total dose of 0.4 mg/kg may be necessary. MAX 10 mg d)(12 y of age and older) same dose as adults. MAX
10 mg
CONTRA-INDICATIONS: hypersensitivity to midazolam or benzodiazepines, acute narrow-angle glaucoma, untreated open-angle glaucoma,
intrathecal or epidural administration (due to the presence of the preservative benzyl alcohol)
ADVERSE EFFECTS: Agitation, Apnea, Cardiac arrest, Usually in combinations with CNS depressant drug, Desaturation of blood, Pediatric
patients, Hypotensive episode, Involuntary movement, Respiratory arrest, With CNS depressant drugs, Respiratory depression, Respiratory
obstruction
THERAPEUTIC USE: Inotropic Agent, Vasodilator
DOSE: Adult – Congestive heart failure, initial loading dose, 50 mcg/kg IV over 10 min; maintenance, 0.375 to 0.75 mcg/kg/min continuous IV
infusion. Pedia – Not FDA approved in children. Decreased cardiac output – Operation on heart, after separation from cardiopulmonary
bypass, 50 mcg/kg IV over 15 min followed by 3 mcg/kg/min IV for 30 min; maintenance, 0.5 mcg/kg/min IV
CONTRA-INDICATIONS: hypersensitivity to milrinone lactate
ADVERSE EFFECTS: Liver function tests abnormal, Thrombocytopenia, Ventricular premature complex
THERAPEUTIC USE: Provides strong, soothing nighttime relief for more intense dry, irritated eyes. It is a preservative free lubricant eye
ointment that is ideal for use at bedtime.
THERAPEUTIC USE: Antidepressant, Tetracyclic
DOSE: Adult – Major depressive disorder, 15 mg/day ORALLY at bedtime; may increase in dose every 1-2 weeks to a max dose of 45
mg/day. Pedia - safety and effectiveness in pediatric patients have not been established
CONTRA-INDICATIONS: hypersensitivity to mirtazapine
ADVERSE EFFECTS: Agranulocytosis, Depression, worsening, Mania, Neutropenia, Seizure, Suicidal thoughts, Suicide
THERAPEUTIC USE: Antiulcer, Protectant, Endocrine-Metabolic Agent, Prostaglandin
DOSE: Adult – Abortion, 800 mcg VAGINALLY times one dose; Cervical ripening procedure – Induction of labor a)25 mcg VAGINALLY every
3 to 4 hours (maximum dose, 400 mcg) b)initial, 100 mcg ORALLY every 4 hours (maximum of 5 doses) c)initial, 50 mcg ORALLY every 4
hours for 2 doses, then 100 mcg every 4 hours until membrane rupture (maximum of 5 doses). Pedia – safety and efficacy have not been
established in pediatric patients
CONTRA-INDICATIONS: hypersensitivity to misoprostol or prostaglandins, pregnancy
ADVERSE EFFECTS: Anemia, Cardiac dysrhythmia
THERAPEUTIC USE: Antibiotic, Antineoplastic Agent
DOSE: Adult – Carcinoma of pancreas, Disseminated adenocarcinoma, in combination with other agents, 20 mg/m(2)/dose IV every 6 to 8
weeks
CONTRA-INDICATIONS: coagulation disorders or increase bleeding tendency, hypersensitivity to mitomycin, no dosages should be repeated
unless leukocyte count has returned to 4000/m(3) and platelet count to 100,000/m(3), renal impairment: do not give to patients with a SCr>1.7
mg/dL
ADVERSE EFFECTS: Hemolytic uremic syndrome, Myelosuppression,Nephrotoxicity
THERAPEUTIC USE: Antineoplastic Agent
DOSE: Adult - Acute myeloid leukemia, In combination with other approved agents a)induction, 12 mg/m(2) IV daily on days 1-3, in
combination with cytarabine 100 mg/m(2) daily as continuous IV infusion on days 1-7 b)re-induction, if incomplete response to first induction,
may give second induction dose, 12 mg/m(2) IV daily for 2 days in combination with cytarabine 100 mg/m(2) daily as continuous IV infusion
on days 1-5 c)consolidation, 12 mg/m(2) IV daily on days 1 and 2, in combination with cytarabine 100 mg/m(2) daily as continuous IV infusion
47
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Mivacurium Chloride
Mivacron
Injection
2mg/mL
Monobasic Na Phosphate/
Dibasic Na Phosphate
Fleet Enema
Enema Adult
Enema Pedia
Morphine Sulphate
MST
Inj. 10mg/mL
Tablet 30mg
Tablet 60mg
Moxifloxacin HCl
Avalox
Vigamox
Eye Drops 0.5%
Injection 400mg
Tablet 400mg
Multivitamin
Mixavit
Injection Adult
Injection Pedia
Syrup
Tablet
Multivitamins/Iron
Polyvisol
Drops
PRODUCT INFORMATION
on days 1-5; the first course is usually started 6 wk after final induction dose and the second, 4 weeks after the first . Pedia – safety and
effectiveness not established in pediatric patients. Solid tumor configuration, 5-8 mg/m(2)/week IV; alternative dosing regimen 18-20 mg/m(2)
IV every 3-4 weeks
CONTRA-INDICATIONS: hypersensitivity to mitoxantrone products
ADVERSE EFFECTS: Acute myeloid leukemia, Secondary, Cardiotoxicity, Hepatotoxicity, Myelodysplasia of the spinal cord,
Myelosuppression
THERAPEUTIC USE: Musculoskeletal Agent, Neuromuscular Blocker, Non-Depolarizing
DOSE: Adult – dosage should be individualized, Induction of neuromuscular blockade, During surgery as an adjunct to general anesthesia
and to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation a)initial, for intubation,
0.15 mg/kg IV bolus over 5-15 sec or 0.2 mg/kg IV bolus over 30 sec OR 0.25 mg/kg IV bolus in divided doses (0.15 mg/kg followed in 30 sec
by 0.1 mg/kg) b)maintenance, 0.1 mg/kg IV bolus 15-25 min after initial dose c)maintenance, 9-10 mcg/kg/min continuous IV infusion after
initial dose, upon early evidence of spontaneous recovery d)maintenance, 4 mcg/kg/min continuous IV infusion if initiated simultaneously with
administration of initial dose. Pedia – dosage should be individualized, Induction of neuromuscular blockade, During surgery as an adjunct to
general anesthesia and to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation
a)(age 2-12 yr) initial, for intubation, 0.2 mg/kg IV bolus over 5-15 seconds b)(age 2-12 yr) maintenance, 0.1 mg/kg IV bolus c)(age 2-12 yr)
maintenance, 14 mcg/kg/min (range 5-31 mcg/kg/min) continuous IV infusion after initial dose, upon early evidence of spontaneous recovery
CONTRA-INDICATIONS: hypersensitivity to mivacurium products/benzylisoquinolinium, hypersensitivity to benzyl alcohol (multi-dose vials)
ADVERSE EFFECTS: Bradyarrhythmia, Cardiac dysrhythmia, Hypotension, Prolonged neuromuscular block, Tachyarrhythmia
THERAPEUTIC USE: Colorectal Agent, Laxative, Hyperosmotic, Phosphate Supplement
DOSE: Adult – one bottle (118mL delivered dose) or as directed by physician.
Pedia – one bottle (59mL delivered dose) or as directed by physician. Do not use on children under 2years of age unless directed by a
physician.
CONTRA-INDICATIONS: acute phosphate nephropathy, biopsy-proven, allergy or hypersensitivity to sodium phosphate salts or any product
component
ADVERSE EFFECTS: Phosphate nephropathy, acute, Prolonged QT interval, Renal failure, Tonic-clonic seizure
THERAPEUTIC USE: Analgesic, Analgesic Combination, Opioid, Anesthetic Adjunct Opioid
DOSE: Adult – Acute myocardial infarction – Pain, 2 to 10 mg IV administered slowly over 4 to 5 min, a strength of 2.5 to 15 mg may be
diluted in 4 to 5 mL of sterile water for injection; Pain (Moderate to Severe), 0.1 to 0.2 mg/kg SUBQ every 4 h, MAX 15 mg/dose; 0.05 to 0.1
mg/kg IV, MAX 10 mg/dose; (neonates) 0.1 mg/kg IV/SUBQ every 4 to 6 h
CONTRA-INDICATIONS: asthma, severe or acute, hypercarbia, hypersensitivity to morphine, morphine salts, or to any component of the
products, paralytic ileus, known or suspected, respiratory depression; in the absence of resuscitative equipment or in unmonitored settings,
upper airway obstruction
ADVERSE EFFECTS: Anaphylaxis, Cardiac arrest, Dyspnea, Finding of intracranial pressure, Myoclonus, Orthostatic hypotension, Other
specified circulatory disorder, circulatory depression, Respiratory depression, Shock, Syncope
THERAPEUTIC USE: Antibiotic, Fluoroquinolone
DOSE: Adult – Acute exacerbation of chronic obstructive pulmonary disease, 400 mg IV or ORALLY every 24 hr for 5 days; Bacterial
conjunctivitis, (0.5% ophthalmic solution) 1 drop to affected eye(s) 3 times a day for 7 days; Bacterial sinusitis, acute 400 mg IV or ORALLY
every 24 hr for 10 days. Pedia – safety and efficacy of oral and parenteral moxifloxacin in children less than 18 years of age have not been
established; Bacterial conjunctivitis, (0.5% ophthalmic solution; 1 year of age and older) 1 drop to affected eye(s) 3 times a day for 7 days
CONTRA-INDICATIONS: hypersensitivity to moxifloxacin hydrochloride or quinolone antibiotics
ADVERSE EFFECTS: Acute renal failure, Anaphylactoid reaction, Aplastic anemia, Extrinsic allergic alveolitis, Hemolytic anemia, Hepatic
necrosis, Hepatitis, Immune hypersensitivity reaction, Jaundice, Liver failure, Pancytopenia, Peripheral neuropathy, Prolonged QT interval,
Serum sickness due to drug, Stevens-Johnson syndrome, Thrombocytopenia, Torsades de pointes, Toxic epidermal necrolysis, Traumatic or
non-traumatic rupture of tendon
THERAPEUTIC USE: To avoid and correct inadequate vitamin intake which may result from an imbalanced or special diet, impaired
absorption, anorexia, slimming or therapy with drugs acting as vitamin antagonists.
DOSE: Adult – 1 tablet three times a day.
Pedia – above 4years, 1teaspoonful once daily; 2 to 4 years, 1/2 teaspoonful once daily. All doses above or as directed by the physician.
THERAPEUTIC USE: To avoid and correct inadequate vitamin intake which may result from an imbalanced or special diet, impaired
absorption, anorexia, slimming or therapy with drugs acting as vitamin antagonists.
DOSE: DROPS 0.3 – 0.6mL (1/2 – full dropper) daily or as directed by the physician.
48
PRODUCT
DESCRIPTION
Mupirocin
Naloxone Hydrochloride
TRADE
NAME
Bactroban
Narcan
Naxone
DOSAGE
FORM/STRENGTH
Nasal Ointment 2%
Ointment 2%
Injection
0.4mg/mL
Neomycin/Polymyxin
/Hydrocortisone
Otosporin
Ear Drops
Neomycin/Polymyxin
/Dexamethasone
Maxitrol
Eye Drops
Eye Ointment
Neostigmine Bromide
Prostigmin
Tablet 15mg
Neostigmine Methylsulphate
Prostigmin
Inj. 0.5mg/mL
Inj. 2.5mg/mL
Niclosamide
Yomesan
Tablet 500mg
PRODUCT INFORMATION
THERAPEUTIC USE: Antibacterial, Antibiotic
DOSE: Adult – Impetigo, apply 2% ointment TOPICALLY 3 times per day for 3-5 days, reevaluate if no response; Methicillin resistant
Staphylococcus aureus infection, Colonization, intranasal ointment, apply one-half of single-use 1 g tube into each nostril TOPICALLY twice
daily for 5 days. Pedia – Impetigo (2 months to 15 years of age) apply 2% ointment TOPICALLY 3 times a day for 3-5 days; reevaluate if no
response; Methicillin resistant Staphylococcus aureus infection, Colonization (12 years of age and older) intranasal ointment, apply one-half of
single-use 1 g tube into each nostril TOPICALLY twice daily for 5 days
CONTRA-INDICATIONS: hypersensitivity to mupirocin or any component of the product
THERAPEUTIC USE: Opioid Antagonist, Toxicology-Antidote Agent
DOSE: Adult – Methadone overdose, 0.4 to 2 mg IV, repeat every 2 to 3 min as needed; if no response after 10 mg, reconsider diagnosis of
opioid toxicity; may administer IM or SC if IV access not available. Pedia – Methadone overdose, a)(neonates) 0.01 mg/kg IV/IM/SC every 2
to 3 min to desired degree of reversal b)0.01 mg/kg IV, then 0.1 mg/kg if needed; may give IM/SC in divided doses if IV route not available
c)age less than 5 yr OR weight 20 kg or less, 0.1 mg/kg IV/IO/ET; age 5 yr and older OR weight greater than 20 kg, 2 mg
CONTRA-INDICATIONS: hypersensitivity to naloxone
ADVERSE EFFECTS: Cardiac dysrhythmia, Hepatotoxicity, Hypertension, Hypotension, Opioid withdrawal, Pulmonary edema, Ventricular
fibrillation
THERAPEUTIC USE: Aminoglycoside/Corticosteroid Combination, Anti-Infective/Anti-Inflammatory Combination
DOSE: Adult – Infection of external auditory canal, instill 4 drops OTICALLY in affected ear(s) 3 to 4 times a day; MAX duration 10 days.
Pedia – Ophthalmic suspension not FDA-approved in children, Infection of external auditory canal, 2 y and older, instill 3 drops OTICALLY in
affected ear(s) 3 to 4 times a day; MAX duration 10 days
CONTRA-INDICATIONS: Use in eyes or in external ear canal if eardrum is perforated, Use on tuberculous, fungal, or viral lesions,
Hypersensitivity to any of its components, Viral diseases of the cornea and conjunctiva, Mycobacterial infection, Fungal infections of the
ocular structures, Cutaneous viral infections such as herpes simplex virus or varicella zoster virus
THERAPEUTIC USE: Indicated in ocular inflammation when concurrent use of an antimicrobial is judged necessary.
DOSE: Eye Drops – 1 to 2 drops topically in the conjunctival sac. In severe disease, drops may be used hourly, being tapered to
discontinuation as the inflammation subsides; Eye Ointment – apply a small amount into the conjunctival sac up to 3 or 4 times daily or may
be used adjunctively with drops at bedtime.
CONTRA-INDICATIONS: Epithelial herpes simplex keratitis, vaccinia, varicella and many other viral diseases of the cornea & conjunctiva.
Hypersensitivity to a component of the medication.
THERAPEUTIC USE: Central Nervous System Agent, Cholinesterase Inhibitor, Immunological Agent, Nondepolarizing Muscle Relaxant
Antagonist
DOSE: Adult – Myasthenia gravis, 15 to 375 mg ORALLY daily; average dose, 150 mg ORALLY over 24 h; individualize interval between
doses and adjust as needed.
Pedia – safety and effectiveness not established in children
CONTRA-INDICATIONS: hypersensitivity to neostigmine or bromides, intestinal or urinary obstruction, peritonitis
ADVERSE EFFECTS: Anaphylaxis, Bronchospasm, Cardiac dysrhythmia, Respiratory arrest, Respiratory depression, Seizure
THERAPEUTIC USE: Central Nervous System Agent, Cholinesterase Inhibitor, Immunological Agent, Nondepolarizing Muscle Relaxant
Antagonist
DOSE: Adult – Abdominal distension – Postoperative complication; Treatment and prophylaxis, 0.25 mg SUBQ or IM as soon as possible
after operation, repeat every 4 to 6 h for 2 to 3 days; treatment, 0.5 mg SUBQ or IM as required
THERAPEUTIC USE: Anthelmintic
DOSE: Adult – usual oral dose 2 grams (4 tablets) as a single dose daily for 7 days. Hymenolepis nana does not need an intermediate host
before infecting humans, thus both the adult worm and the larva exist in the intestine. Therapy must be continued for 7 days to ensure the
infestation is eradicated. Pedia – In children weighing more than 34 kg (75 pounds) the recommended dose for taenia saginata, taenia
solium, and diphyllobothrium latum is 3 tablets (1.5 grams) chewed thoroughly as a single dose
CONTRA-INDICATIONS: Hypersensitivity to niclosamide
49
PRODUCT
DESCRIPTION
Nifedipine
Nitrazepam
Nitrofurantoin
Noradrenaline Acid
Tartrate
TRADE
NAME
Adalat
Adalat Retard
Coracten
Epilat
Epilat Retard
Nifecard
Nifecard Retard
Mogadon
Furadantin
Macrodantin
Levophed
Mikostat
Nystatin
Mycostatin
Rianest
Octreotide
Sandostatin
DOSAGE
FORM/STRENGTH
Capsule 10mg
Tablet 20mg
Tablet 5mg
Susp. 25mg/5mL
Tablet 100mg
Injection 1:1000
Ointment
100,000u/g
Susp.
100,000u/mL
Inj. 0.1mg/mL
Inj. 0.2mg/mL
PRODUCT INFORMATION
THERAPEUTIC USE: Antianginal, Antihypertensive, Antimigraine
Calcium Channel Blocker, Cardiovascular Agent, Dihydropyridine
DOSE: Adult – Hypertension (extended-release tablets) initial 30 to 60 mg ORALLY once daily; maintenance, 30 to 90 mg ORALLY once
daily, MAX 120 mg/day. Pedia – not FDA approved for pediatric patients. Hypertrophic cardiomyopathy 0.6-0.9 mg/kg/24hr ORALLY divided
into 3-4 doses
CONTRA-INDICATIONS: hypersensitivity to nifedipine or other calcium channel antagonists
ADVERSE EFFECTS: Angina, Increased, Myocardial infarction
THERAPEUTIC USE: Anticonvulsant, Benzodiazepine, Short or Intermediate Acting, Sedative-Hypnotic
DOSE: Adult - Oral route a)Doses most commonly used to treat INSOMNIA in clinical studies have been nitrazepam 5 to 10 mg at bedtime;
however, extreme hangover effects and side effects limit this dosage. b)Nitrazepam 5 milligrams at bedtime is considered an effective dose
for relieving anxiety induced sleep disorders before DENTAL PROCEDURES.Pedia – has been used extensively in the treatment of
EPILEPSY in children. Doses used in most clinical trials have ranged from 1 to 6 milligrams daily initially, with doses increasing up to 60 mg
daily
CONTRA-INDICATIONS: Hypersensitivity to nitrazepam
THERAPEUTIC USE: Antibiotic, Nitrofuran
DOSE: Adult – Urinary tract infectious disease, 50 to 100 mg ORALLY 4 times a day for 1 week or at least 3 days after urine is sterile. Pedia
– contraindicated in neonates below the age of 1 month. Urinary tract infectious disease (1 mo and older) 5 to 7 mg/kg/day in 4 divided doses
for 1 week or at least 3 days after urine is sterile
CONTRA-INDICATIONS: Known hypersensitivity to nitrofurantoin, Creatinine clearance less than 60 mL/min, Pregnancy at term, Infants less
than 1 month of age, Perinephric abscess or pyelonephritis, Prostate infection in elderly men
ADVERSE EFFECTS: Cholestatic jaundice syndrome, Hemolytic anemia, Hepatic necrosis, Hepatitis, Immune hypersensitivity reaction,
Interstitial lung disease, Neuropathy, Pulmonary fibrosis, Pulmonary toxicity
THERAPEUTIC USE: Adrenergic, Sympathomimetic, Vasopressor
DOSE: Adult – Hypotension, acute a)initial, 8 to 12 mcg/min IV and observe response; adjust rate of flow to establish a low normal BP
(systolic, 80 to 100 mmHg) b)maintenance, 2 to 4 mcg/min IV; doses up to 68 mg/day may be needed.
Pedia – safety and efficacy not established in pediatric patients; Hypotension, acute initial 0.1 mcg/kg/min IV, titrate to desired effect;
maintenance 0.05 to 0.3 mcg/kg/min, MAX 6 mcg/min
CONTRA-INDICATIONS: hypotension due to blood volume deficit
ADVERSE EFFECTS: Cardiac arrest, Cardiac dysrhythmia
THERAPEUTIC USE: Antifungal, Polyene
DOSE: Adult – Candidal vulvovaginitis 1 tablet (100,000 units) intravaginally daily for 2 wks; Candidiasis of skin, Cutaneous and
mucocutaneous infections; ointment or cream, apply liberally to affected areas topically twice daily until healing complete. Pedia Candidiasis of skin, Cutaneous and mucocutaneous infections, ointment or cream, apply liberally to affected areas topically twice daily until
healing complete; powder, apply to candidal lesions topically 2 to 3 times daily until healing complete; for fungal infections of the feet,
footwear should be dusted as well
CONTRA-INDICATIONS: hypersensitivity to nystatin products
THERAPEUTIC USE: Endocrine-Metabolic Agent, Somatostatin (class)
DOSE: Adult – Acromegaly, Inadequate response to or ineligible for surgery, radiation, or bromocriptine mesylate a)initial, 50 mcg SC/IV 3
times daily b)maintenance, 100-500 mcg SC/IV 3 times daily c)initial, 20 mg IM intragluteally at 4-week intervals for 3 months d)after initial 3
months, continue 20 mg IM intragluteally every 4 weeks if GH is </= 2.5 ng/mL, IGF-I is normal, and clinical symptoms have improved e)after
initial 3 months, increase to 30 mg IM intragluteally every 4 weeks if GH is > 2.5 ng/mL, IGF-I is elevated, and/or clinical symptoms
uncontrolled f)after initial 3 months, decrease to 10 mg IM intragluteally every 4 weeks if GH is </= 1 ng/mL, IGF-I is normal, and clinical
symptoms are controlled g)increase dose to 40 mg IM intragluteally every 4 weeks in patients whose GH, IGF-1, and symptoms are not
adequately controlled at 30 mg. Pedia – Safety and efficacy in children not established
CONTRA-INDICATIONS: sensitivity to octreotide or any of its components
ADVERSE EFFECTS: Cardiac dysrhythmia, Congestive heart failure, Worsening, Sinus bradycardia
50
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Ofloxacin
Eylox
Oflox
Oxacin
Eye Drops
Ofloxacin/Prednisolone
/Tetrahydrozoline
Loxtra
Eye Drops
Omeprazole
Hyposec
Losec
Omeral
Risek
Mups Tab 10mg
Ondansetron HCl
Dihydrate
Zofran
Inj. 4mg/2mL
Inj. 8mg/4mL
Tablet 4mg
Tablet 8mg
Oxybuprocaine
Benoxinate
Oxybutynin
Ditropan
Tablet 5mg
Oxytocin
Syntocinon
Inj. 5units/mL
Inj. 10units/mL
Eye Minims 0.4%
PRODUCT INFORMATION
THERAPEUTIC USE: Antibacterial, Antibiotic, Fluoroquinolone
DOSE: Adult – Bacterial conjunctivitis (ophthalmic) day 1 and 2, instill 1 to 2 drops in affected eye(s) every 2 to 4 h; day 3 to 7, instill 1 to 2
drops 4 times daily. Pedia – safety and efficacy in children less than 18 years of age have not been established (oral) Bacterial conjunctivitis,
(ophthalmic; 1 y of age and older) day 1 and 2, instill 1 to 2 drops in affected eye(s) every 2 to 4 h; day 3 to 7, instill 1 to 2 drops 4 times daily
THERAPEUTIC USE: For corticosteroid responsive inflammatory conditions of the conjunctiva, cornea and anterior segment of the eye where
bacterial infection or a risk of bacterial infection exists.
DOSE: Apply 1 to 2 drops three to four times daily in the affected eye(s).
CONTRA-INDICATIONS: Epithelial herpes simplex keratitis, vaccinia, varicella and many other viral diseases of the cornea and conjunctiva,
tuberculosis of the eye, fungal diseases of the ocular structures, hypersensitivity to any ingredient of the medication.
ADVERSE EFFECTS: Local irritation, including photophobia, blurred vision, dizziness, numbness, nausea and headache
THERAPEUTIC USE: Antiulcer, Gastrointestinal Agent, Proton Pump Inhibitor
DOSE: Adult – Duodenal ulcer disease, Dual therapy; Adjunct – Helicobacter pylori gastrointestinal tract infection, Dual therapy. Pedia –
Safety not established in pediatric patients. Erosive esophagitis, To maintain healing; Prophylaxis – Gastroesophageal reflux disease, To
maintain healing; Prophylaxis a)2 y and older, less than 20 kg, 10 mg ORALLY daily b)2 y and older, 20 kg or greater, 20 mg ORALLY daily
CONTRA-INDICATIONS: Hypersensitivity to omeprazole or to any of its components
ADVERSE EFFECTS: Hepatotoxicity, Hip fracture, Interstitial nephritis, Pancreatitis, Rhabdomyolysis
THERAPEUTIC USE: Antiemetic, Serotonin Receptor Antagonist, 5-HT3
DOSE: Adult – Chemotherapy-induced nausea and vomiting, Initial and repeat courses of moderately emetogenic chemotherapy;
Prophylaxis, 8 mg dissolved orally on tongue 30 min prior to chemotherapy and repeated in 8 hours, then 8 mg every 12 hours for 1 to 2 days
post chemotherapy. Pedia – Chemotherapy-induced nausea and vomiting, Initial and repeat courses of moderately emetogenic
chemotherapy; Prophylaxis a)(IV) 6 months and older, 0.15 mg/kg IV 30 min prior to chemotherapy, repeat 4 and 8 hours after the first dose
b)(oral) 4-11 y, 4 mg orally 30 min prior to chemotherapy, repeated 4 and 8 hours after the first dose, then every 8 hours for 1-2 days post
chemo c)(oral) 12 y and older, 8 mg ORALLY 30 min prior to chemo and repeat in 8 hours, then 8 mg every 12 hours for 1 to 2 days post
chemotherapy
CONTRA-INDICATIONS: hypersensitivity to ondansetron
ADVERSE EFFECTS: Bronchospasm, Cardiac dysrhythmia
THERAPEUTIC USE: Amino Ester, Anesthetic, Local
DOSE: Adult – Benoxinate should not be used on infected areas. For anesthesia during short ophthalmologic procedures, a 0.4% benoxinate
solution is recommended. Dosages are one to two drops for tonometry, two drops for the fitting of contact lenses and three to six drops for the
removal of foreign bodies from the corneal epithelium or minor surgery. The benoxinate drops should be instilled into the conjunctival sac at
30- to 90-second intervals. Pedia – Two drops of a 0.4% benoxinate solution demonstrated excellent efficacy in peri-operative analgesia in a
randomized study of 40 children aged 3 to 8 years undergoing strabismus surgery.
CONTRA-INDICATIONS: Known hypersensitivity to benoxinate or other anesthetics of the ester type
THERAPEUTIC USE: Antimuscarinic, Urinary Antispasmodic
DOSE: Adult – Bladder muscle dysfunction - overactive, With symptoms of urge urinary incontinence, urgency, and frequency, extended
release, 5 mg or 10 mg once daily at same time each day, dose may be increased in 5 mg increments at weekly intervals to MAX 30 mg daily.
Pedia – Bladder muscle dysfunction - overactive, With symptoms of urge urinary incontinence, urgency, and frequency, (age 6 y and older)
extended release, 5 mg orally once per day at same time each day; dose may be increased in 5-mg increments to a maximum of 20 mg/day
CONTRA-INDICATIONS: gastric retention, glaucoma, narrow-angle (uncontrolled), hypersensitivity to oxybutynin, urinary retention
THERAPEUTIC USE: Diagnostic Agent, Fetal Heart Rate Distress, Endocrine-Metabolic Agent, Pituitary Hormone, Posterior, Uterine
Stimulant
DOSE: Adult – Induction of labor, Medically indicated, initial, 0.5 to 1 milliunit/min IV (3 to 6 mL/h of a 10 units/1000 mL dilute oxytocin
solution); gradually increase dose in increments of 1 to 2 milliunits/min every 30 to 60 min until desired contraction pattern has been
established; once desired frequency of contractions has been reached and labor progressed to 5 to 6 cm dilation, the dose may be reduced
by similar increments
CONTRA-INDICATIONS: fetal distress where delivery is not imminent, hypersensitivity to the drug, obstetrical emergencies, significant
cephalopelvic disproportion, unfavorable fetal positions or presentations, where adequate uterine activity fails to achieve satisfactory
progress, where the uterus is already hyperactive or hypertonic, where vaginal delivery is contraindicated
ADVERSE EFFECTS: Afibrinogenemia, Fatal, in mother, Anaphylaxis, Mother, Brain damage, Permanent, Cardiac dysrhythmia, Mother and
fetus, Central nervous system deficit, Permanent, Coma, Mother, Convulsions in the newborn, Death, Mother, Fetal bradycardia,
Hypertensive episode, Mother, Low apgar score, At 5 minutes, Neonatal jaundice, Pelvic hematoma, Mother, Postpartum hemorrhage,
51
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Paclitaxel
Taxol
Inj. 30mg/5mL
Inj. 150mg/25mL
Pancuronium Bromide
Pavulon
Injection
4mg/2mL
Pantoprazole
Pantozol
Proton
Papaverine HCl
Vasorin
Paracetamol
Adol
Fevadol
Panadol
Tempra
Tylenol
Tylenol Forte
Paracetamol/Caffeine
/Codeine
Paracetamol/Orphenadrine
Citrate
Injection 40mg
Tablet 40mg
Injection
0.06g/2mL
Drops 100mg/mL
Supp.125mg
Supp. 250mg
Supp. 500mg
Syrup
120mg/5mL
Tablet 500mg
Fevadol Plus
Panadol Extra
Myogesic
Tablet
Tablet
PRODUCT INFORMATION
Mother, Retinal hemorrhage, Neonatal, Rupture of uterus, Mother, Subarachnoid hemorrhage, Mother, Ventricular premature beats, Mother
and fetus, Water intoxication syndrome
THERAPEUTIC USE: Antineoplastic Agent, Mitotic Inhibitor
DOSE: Adult – Breast cancer, Adjuvant, node-positive administered sequentially to the standard doxorubicin-containing regimen, 175
mg/m(2) IV over 3 hr every 3 wk for four courses given sequential to doxorubicin-containing combination chemotherapy.
Pedia – safety and efficacy not established in pediatric patients
CONTRA-INDICATIONS: hypersensitivity to taxol, Cremophor EL, neutropenia less than 1,500 cells/mm(3)-solid tumors, neutrophil count
<1,000 cells/mm(3)-Kaposi's sarcoma
ADVERSE EFFECTS: Anaphylaxis, Coronary artery stent thrombosis, Hypotension, Immune hypersensitivity reaction, Myelosuppression,
Neutropenic disorder
THERAPEUTIC USE: Musculoskeletal Agent, Neuromuscular Blocker, Non-Depolarizing
DOSE: Adult – dosage must be individualized. General anesthesia; Adjunct, initial, 0.04 to 0.1 mg/kg IV (endotracheal intubation, 0.06 to 0.1
mg/kg IV); later incremental doses starting at 0.01 mg/kg may be used. Pedia – dosage must be individualized. General anesthesia; Adjunct
a)(all ages except neonates) initial, 0.04 to 0.1 mg/kg IV (endotracheal intubation, 0.06 to 0.1 mg/kg IV); later incremental doses starting at
0.01 mg/kg may be used b)(neonates) administer a test dose of 0.02 mg/kg IV to measure responsiveness
CONTRA-INDICATIONS: hypersensitivity to pancuronium or bromide products
ADVERSE EFFECTS: Apnea, Bronchospasm, Hypertension, Prolonged neuromuscular block, Respiratory failure, Tachyarrhythmia
THERAPEUTIC USE: Antiulcer, Gastrointestinal Agent, Proton Pump Inhibitor
DOSE: Adult – Duodenal ulcer disease, 40-80 mg ORALLY once daily for 4-8 weeks; Zollinger-Ellison syndrome, 80 mg IV infusion every 12
hours, can increase to every 8 hours; MAX 240 mg/day; 40 mg ORALLY twice daily; MAX 240 mg daily. Pedia – Safety and efficacy not
established in children
CONTRA-INDICATIONS: hypersensitivity to pantoprazole products
ADVERSE EFFECTS: Hip fracture, Hyperglycemia, Rhabdomyolysis, Stevens-Johnson syndrome
THERAPEUTIC USE: Peripheral Vasodilator
DOSE: Adult – Erectile dysfunction a)initial, 30 mg INTRACAVERNOSAL over 1 to 2 min; may increase to 60 mg according to response
b)(combination therapy) 30 mg papaverine / 0.5 to 1 mg phentolamine INTRACAVERNOSAL c)do not use more than 3 times weekly or 2
days in succession. Pedia – not FDA approved in children
CONTRA-INDICATIONS: complete atrioventricular block, hypersensitivity to papaverine
ADVERSE EFFECTS: Acidosis, Hepatotoxicity, Priapism, Raised intracranial pressure
THERAPEUTIC USE: Acetaminophen Combination, Analgesic, Antipyretic
DOSE: Adult – Fever a)650 to 1000 mg ORALLY every 4 h as needed, maximum 4 g/day b)650 mg RECTALLY every 4 to 6 h; maximum 6
suppositories/24 h. Pedia – Fever a)10 to 15 mg/kg/dose ORALLY every 4 to 6 h, maximum 5 doses/day b)age 6 to 12 y, 325 mg ORALLY
every 4 to 6 h, maximum 2.6 g/24 h c)age 3 to 6 y, 120 to 125 mg RECTALLY every 4 to 6 h; maximum 720 mg/24 h d)age 1 to 3 y, 80 mg
RECTALLY every 4 h e)age 3 to 11 months, 80 mg RECTALLY every 6 h
CONTRA-INDICATIONS: hypersensitivity to acetaminophen
ADVERSE EFFECTS: Gastrointestinal hemorrhage, Hepatotoxicity, Nephrotoxicity, Pneumonitis
THERAPEUTIC USE: Analgesic, Opioid/Acetaminophen Combination
DOSE: Adult – Pain, Mild to moderately severe a)acetaminophen 300 to 1000 mg (MAX 4000 mg/day) / codeine 15 to 60 mg (MAX 360
mg/day) ORALLY every 4 hours as needed b)15 mL (1 tbsp) ORALLY every 4 hours as needed. Pedia – safety not established in children
under 3 years of age. Pain, Mild to moderately severe a)(3-6 yrs) 5 mL ORALLY 3 to 4 times a day b)(7-12 yrs) 10 mL ORALLY 3 to 4 times a
day c)for TABS, dose of codeine phosphate is 0.5 mg/kg
CONTRA-INDICATIONS: hypersensitivity to acetaminophen/codeine products
ADVERSE EFFECTS: Respiratory depression, At higher doses
THERAPEUTIC USE: Antimuscarinic, Skeletal Muscle Relaxant, Centrally Acting
DOSE: Adult – Musculoskeletal pain, 100 mg ORALLY twice daily in morning and evening; 60 mg IV/IM, may be repeated every 12 hr; switch
to oral form for maintenance. Pedia – safety and effectiveness have not been established for pediatric patients
CONTRA-INDICATIONS: cardiospasm (megaesophagus), glaucoma, hypersensitivity to orphenadrine, myasthenia gravis, prostatic
hypertrophy or obstruction of bladder neck, pyloric or duodenal obstruction, stenosing peptic ulcer
ADVERSE EFFECTS: Anaphylaxis, With IM injection, Palpitations, Tachyarrhythmia
52
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Paraffin Soft White Jelly
Vaseline
Gel
Peginterferon Alpha 2B
Peg – Intron
Injection
Pentazocine
Sosegon
Injection
30mg/mL
Pentoxifylline
Trental
Inj. 100mg/5mL
Tablet 400mg
Pethidine HCl
Demerol
Meperidine
Inj. 50mg/mL
Inj. 100mg/2mL
Phenazone/Benzocaine
/Glycerol
Auralgan
Ear Drops
Gardenal
Inj. 40mg/mL
Inj. 130mg/mL
Inj. 200mg/mL
Syrup 10mg/mL
(50mL & 100mL)
Tablet 15mg
Tablet 100mg
Phenobarbitone
Phenol
Injection 6%
Phenoxybenzamine HCl
Dibenylin
Capsule 10mg
Phentolamine Mesylate
Regitine
Injection
PRODUCT INFORMATION
THERAPEUTIC USE: As an emollient in the management of skin disorders. It is not readily absorbed by the skin. Sterile dressings containing
soft paraffin are used for wound dressing.
THERAPEUTIC USE: Indicated for the treatment of chronic hepatitis C in adults.
DOSE: Recommended dose is 0.5mcg/Kg administered SC once weekly for one year.
CONTRA-INDICATIONS: Hypersensitivity to the active substance or to any interferon or to any of the excipients, pregnancy, men whose
female partners are pregnant, autoimmune disease, decompensated liver disease.
ADVERSE EFFECTS: Headache, myalgia, pain/inflammation at injection site, fatigue, rigors, fever, depression, arthralgia, nausea, alopecia,
musculoskeletal pain, irritability, influenza like symptoms, insomnia, diarrhea, abdominal pain, asthenia, pharyngitis, weight decrease,
anorexia, anxiety, dizziness, pruritus.
THERAPEUTIC USE: Analgesic, Anesthetic Adjunct, Opioid Agonist/Antagonist
DOSE: Adult – Anesthesia; Adjunct, 30 mg IV, IM or SC every 3 to 4 hr as needed, MAX 360 mg/day; doses above 30 mg IV or 60 mg IM,
SC are not recommended. Pedia – Safety and effectiveness in children less than 12 yr of age not established. Anesthesia; Adjunct, single 0.5
mg/kg IM dose
CONTRA-INDICATIONS: hypersensitivity to pentazocine
ADVERSE EFFECTS: Dyspnea, Hallucinations, Injection site necrosis, Physical addiction, Respiratory depression, Toxic epidermal
necrolysis
THERAPEUTIC USE: Hemorheologic, Methylxanthine
DOSE: Adult – Intermittent claudication, 400 mg ORALLY three times a day with meals; Stasis ulcer – 800 mg ORALLY three times a day;
Vascular disorder of inner ear, 1600 mg/day ORALLY in 2-4 divided doses. Pedia – safety and effectiveness in pediatric patients have not
been established.
CONTRA-INDICATIONS: hypersensitivity to pentoxifylline or methylxanthines, recent cerebral hemorrhage, recent retinal hemorrhage
ADVERSE EFFECTS: Angina, Aplastic anemia, Cardiac dysrhythmia, Confusion, Depression, Edema, Hepatitis, Hypotension, Increased liver
function test, Jaundice, Leukopenia, Seizure, Thrombocytopenia
THERAPEUTIC USE: Analgesic, Anesthetic Adjunct, Opioid
DOSE: Adult – Obstetric pain, 50 to 100 mg IM/subQ every 1 to 3 hr as needed
CONTRA-INDICATIONS: hypersensitivity to meperidine, recent or concomitant MAOI
ADVERSE EFFECTS: Cardiac arrest, Disorder of cardiovascular system, Hypotension, Respiratory depression, Seizure, Syncope
THERAPEUTIC USE: Amino Ester, Anesthetic, Local,Smoking Cessation Agent
DOSE: Adult – Otitis – Topical local anesthetic, instill 4 to 5 drops of otic solution into external ear canal of affected ear(s), repeat every 1 to 2
h if necessary. Pedia – Otitis – Topical local anesthetic, (age 1 y and older) instill 4 to 5 drops of otic solution into external ear canal of
affected ear(s), repeat every 1 to 2 h if necessary.
CONTRA-INDICATIONS: hypersensitivity to benzocaine/ester-type local anesthetics, perforated tympanic membrane/ear discharge.
ADVERSE EFFECTS: Methemoglobinemia, More common in infants and young children
THERAPEUTIC USE: Anticonvulsant, Barbiturate, Long Acting, Gastrointestinal Agent, Sedative
DOSE: Adult – Epilepsy, 50 mg to 100 mg ORALLY 2 or 3 times daily OR 100 mg to 320 mg slow IV injection repeated if necessary up to a
MAX total dose of 600 mg/day.
Pedia – Epilepsy, 15 mg to 50 mg ORALLY 2 to 3 times daily
CONTRA-INDICATIONS: hypersensitivity to henobarbital products, porphyria, marked impairment of liver function, respiratory disease
(dyspnea or obstruction)
ADVERSE EFFECTS: Agranulocytosis, Injury of liver, Megaloblastic anemia, Osteopenia, Rickets, Scaling eczema, Stevens-Johnson
syndrome, Thrombocytopenia, Thrombophlebitis
THERAPEUTIC USE: Analgesic sclerosing agent, sclerosant in the treatment of hydroceles.
DOSE: Up to 10mL has been injected into the tissue around internal haemorrhoids.
PRECAUTIONS: Solution containing phenol should not be applied to large areas of skin or large wounds since sufficient phenol may be
absorbed to give rise to toxic symptoms.
THERAPEUTIC USE: Alpha-Adrenergic Blocker, Cardiovascular Agent
DOSE: Adult – Pheochromocytoma, To control hypertension and sweating, initial, 10 mg ORALLY twice daily; titrate to maintenance, may
increase dose every other day to 20-40 mg ORALLY 2-3 times daily. Pedia – Not FDA approved in children
CONTRA-INDICATIONS: any condition compromised by hypotension, hypersensitivity to phenoxybenzamine
ADVERSE EFFECTS: Seizure
THERAPEUTIC USE: Alpha-Adrenergic Blocker, Antihypertensive, Diagnostic Agent, Pheochromocytoma
53
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
10mg/mL
Phenylephrine HCl
Mydfrin
Prefrin
Eye Drops 2.5%
Eye Minims 10%
Inj. 10mg/mL
Phenytoin
Epanutin
Capsule 100mg
Inj. 250mg/5mL
Susp. 30mg/5mL
Phytomenadione
Konakion
Inj. 2mg/0.2mL
Inj. 10mg/mL
Tablet 10mg
Pilocarpine HCl
Isopto-Carpine
Eye Drops 1%
Eye Drops 2%
Eye Drops 4%
Pinaverium Bromide
Dicetel
Tablet 50mg
PRODUCT INFORMATION
DOSE: Adult – Erectile dysfunction, 40 to 80 mg ORALLY 1 h prior to sexual activity. Hypertensive episode, Pre- or intra-operative;
Treatment and Prophylaxis – Pheochromocytoma, preoperative, 5 mg IV or IM 1 to 2 h prior to surgery, may repeat as needed; intraoperative,
5 mg IV as needed. Pedia – Hypertensive episode, Pre- or intra-operative; Treatment and Prophylaxis – Pheochromocytoma; preoperative, 1
mg IV or IM 1 to 2 h prior to surgery, may repeat as needed; intraoperative, 1 mg IV as needed
CONTRA-INDICATIONS: hypersensitivity to phentolamine or mannitol, myocardial infarction, coronary artery disease, angina pectoris
ADVERSE EFFECTS: Cardiac dysrhythmia
THERAPEUTIC USE: Adrenergic, Alkylarylamine, Anesthetic Adjunct, Decongestant, Hemorrhoidal Agent, Mydriatic-Cycloplegic,
Sympathomimetic, Vasopressor
DOSE: Adult – Glaucoma (open-angle glaucoma) instill 1 drop of 2.5% ophthalmic solution TOPICALLY on the upper limbus of affected
eye(s) a few minutes after application of topical anesthetic; may repeat after 1 hour. Pedia – Mydriasis induction,1 drop of 2.5% ophthalmic
solution to the conjunctiva; may repeat in 1 hour if necessary
CONTRA-INDICATIONS: anatomical narrow-angle, hypersensitivity to phenylephrine products, infants/children of low body weight, narrow
angle glaucoma, severe hypertension, tachycardia
ADVERSE EFFECTS: Myocardial infarction, Pulmonary edema, Tachyarrhythmia, Ventricular arrhythmia
THERAPEUTIC USE: Antiarrhythmic, Group IB, Anticonvulsant, Hydantoin (class)
DOSE: Adult – Seizure, Generalized Tonic-Clonic and Complex Partial (psychomotor and temporal lobe) Seizures a)Extended-release
phenytoin sodium capsules: 100 mg ORALLY 3 times a day, usual maintenance dose is 100 mg ORALLY 3-4 times a day, doses up to 200
mg ORALLY 3 times a day may be used if necessary; patients established on 100 mg 3 times a day may take one 300 mg extended-release
capsules once daily b)Oral suspension: 125 mg (5 mL) 3 times daily; adjust dose every 7-10 days as necessary (MAX dose 625 mg/day)
c)Oral tablets (Infatabs®): 100 mg (2 tablets) 3 times daily, usual maintenance dose 300-400 mg/day (MAX dose 600 mg/day); Status
epilepticus – 10-15 mg/kg IV loading dose (not to exceed 50 mg/min), followed by maintenance doses of 100 mg ORALLY OR IV every 6-8
hr. Pedia – Seizure, Generalized Tonic-Clonic and Complex Partial (psychomotor and temporal lobe) Seizures, Extended-release phenytoin
sodium capsules, oral suspension, oral tablets (Infatabs®): 5 mg/kg/day divided equally into 2 or 3 doses to a subsequent maximum of 300
mg/day; usual maintenance dose is 4 to 8 mg/kg/day; children over the age of 6 years may require minimum adult dose (300 mg/day); Status
epilepticus – 15 to 20 mg/kg slow IV loading dose (not to exceed 1 to 3 mg/kg/min
CONTRA-INDICATIONS: hypersensitivity phenytoin, fosphenytoin, or hydantoins, sinus bradycardia, SA block, second and third degree AV
block and Adams-Stokes syndrome
ADVERSE EFFECTS: Agranulocytosis, Bullous dermatosis, Granulocytopenic disorder, Leukopenia, Liver damage, Lupus erythematosus,
Nephrotoxicity, Pancytopenia, Purpuric rash, Scaling eczema, Stevens-Johnson syndrome, Thrombocytopenia, Toxic epidermal necrolysis,
Toxic hepatitis
THERAPEUTIC USE: Nutritive Agent, Vitamin K
DOSE: Adult – Drug action reversal, Anticoagulant a)2.5 to 25 mg ORALLY (rarely up to 50 mg); if prothrombin time is not satisfactory within
12 to 48 h, repeat dose b)2.5 to 25 mg IV or SUBQ (rarely up to 50 mg); if prothrombin time is not satisfactory within 6 to 8 h, repeat dose.
Pedia – Hemorrhage of newborn; Prophylaxis a)(term infants), 0.5 to 1 mg IM within 1 h of birth b)(preterm infants) body weight at least 1 kg
at birth, 0.5 to 1 mg IM at birth c)(preterm infants) body weight less than 1 kg at birth, 0.3 mg/kg IM
CONTRA-INDICATIONS: hypersensitivity to phytonadione products
ADVERSE EFFECTS: Anaphylaxis, IV and IM use
THERAPEUTIC USE: Cholinergic, Dental Agent, Direct Acting Miotic
DOSE: Adult – Open-angle glaucoma a)(solution) 2 drops TOPICALLY in the affected eye(s) up to 3 or 4 times per day b)(gel) 0.5 inch
ribbon of 4% gel TOPICALLY in conjunctival sac once a day at bedtime c)(Ocusert Pilo®) 20 to 40 mcg/hr delivered via ocular system
TOPICALLY to the conjunctiva once every 7 days. Pedia – safety and effectiveness in pediatric patients has not been established
CONTRA-INDICATIONS: acute iritis or glaucoma after cataract extraction, hypersensitivity to pilocarpine products, narrow-angle (angleclosure) glaucoma, uncontrolled asthma (oral formulation)
ADVERSE EFFECTS: Retinal detachment, Ophthalmic formulation
THERAPEUTIC USE: Antimuscarinic, Calcium Channel Blocker
DOSE: Adult – 50-milligram dose given three times daily (with an increase up to 100 milligrams three times daily if deemed necessary) is
recommended by the manufacturer for irritable bowel syndrome and functional disorders of the biliary tract
CONTRA-INDICATIONS: Hypersensitivity to pinaverium bromide or bromides
54
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Piperacillin/Tazobactam
Tazocin
Injection
4.5grams
Piribedil
Trivastal
Tablet 50mg
Plasma Proteins
PPF
Injection 5%
Plegisol (Hospira's
Cardioplegic Solution)
Plegisol
Solution 1 Liter
Pneumococcal
Polysaccharide Vaccine
Pneumovax
Injection
0.5mL/Dose
Poliomyelitis Vaccine
Oral Vaccine
PRODUCT INFORMATION
THERAPEUTIC USE: Antibiotic
DOSE: Adult – Appendicitis (Moderate to Severe), Complicated by rupture or abscess, 3.375 g IV every 6 hours for 7 to 10 days. Pedia –
Safety and efficacy in pediatric patients have not been established. Appendicitis (Moderate to Severe), Complicated by rupture or abscess a)2
to 9 months of age; 80 mg piperacillin/ 10 mg tazobactam per kg IV every 8 hours for 7 to 10 days b)9 months of age and older, up to 40 kg
body weight; 100 mg piperacillin/ 12.5 mg tazobactam per kg IV every 8 hours for 7 to 10 days c)9 months of age and older, greater than 40
kg body weight; 3.375 g piperacillin/tazobactam IV every 6 hours for 7 to 10 days
CONTRA-INDICATIONS: hypersensitivity to penicillins, cephalosporins or beta-lactamase inhibitors
ADVERSE EFFECTS: Anaphylaxis
THERAPEUTIC USE: Dopamine Agonist
DOSE: Adult – Parkinson's disease, the optimal dose of piribedil in parkinsons disease is unclear. Oral doses have generally ranged from
120 to 240 mg daily. The daily dose has been given in 2 to 4 divided daily doses, although 6 to 9 doses/day have been employed by some
investigators; initiated in low doses, usually 40 to 60 mg daily, with dose increments of 20 mg every 2 to 7 days. The drug is frequently
administered with or after meals or with milk to improve gastrointestinal tolerance
CONTRA-INDICATIONS: Hypersensitivity to piribedil
THERAPEUTIC USE: Volume Expander
DOSE: Adult – Hypovolemia, 12.5-25 g (250-500 mL) IV, repeat as needed. Pedia – Safety and efficacy in children not established
CONTRA-INDICATIONS: cardiopulmonary bypass, congestive heart failure, hypersensitivity to albumin, hypoproteinemia associated with
chronic nephrosis, chronic cirrhosis, malabsorption, protein-losing enteropathies, pancreatic insufficiency, and undernutrition, increased or
normal intravascular volume, renal insufficiency, severe anemia
ADVERSE EFFECTS: Hypotension, Immune hypersensitivity reaction, Shaking, chills, urticaria
THERAPEUTIC USE: When suitably buffered in combination with ischemia and hypothermia is used to induce cardiac arrest during open
heart surgery.
DOSE: Suggested guide and is subject to variation according to the preference and experience of the surgeon. Add 10mL (840mg) of 8.4%
Sodium Bicarbonate to 1liter of plegisol in order to adjust the pH. Use 10mL of Hospira list 4900, 8.4% Sodium Bicarbonate Inj. USP, to
achieve the approximate pH of 7.8 when measured at Room Temp. Use of any other Sodium Bicarbonate Inj. May not achieve this pH due to
the varying pH's of Sodium Bicarbonate Inj. After this addition, the solution must be used within 24hr and should be cooled to 4ºC prior to use.
CONTRA-INDICATIONS: Must no be administered without the addition of 8.4% Sodium Bicarbonate Injection, USP, Hospira list 4900.
ADVERSE EFFECTS: Myocardial infarction, electrocardiographic abnormalities, arrhythmias, including ventricular fibrillation.
THERAPEUTIC USE: Vaccine
DOSE: Adult - Pneumococcal vaccination, 23-Valent vaccine; Prophylaxis, 0.5 mL IM or SC as single dose.
Pedia - Safety and effectiveness in children below the age of 2 years have not been established. Pneumococcal vaccination, 23-Valent
vaccine; Prophylaxis - (2 years and older) 0.5 mL IM or SC as single dose
CONTRA-INDICATIONS: hypersensitivity to pneumococcal vaccine components
ADVERSE EFFECTS: Anaphylactoid reaction, Angioedema, Hemolytic anemia, Thrombocytopenia, Transfusion reaction due to serum
protein reaction
THERAPEUTIC USE: Vaccine
DOSE: Adult - Poliomyelitis, acute; Prophylaxis a)unvaccinated adult, 0.5 mL IM or SUBQ x 3 doses given at 0, 1 to 2 mo, and 6 to 12 mo
b)unvaccinated adult, less than 3 mo, but more than 2 mo available before protection is needed; 0.5 mL IM or SUBQ x 3 doses given at least
1 month apart c)unvaccinated adult, 1 to 2 mo available before protection is needed; 0.5 mL IM or SUBQ x 2 doses given at least 1 mo apart
d)unvaccinated adult, less than 1 mo available before protection is needed; 0.5 mL IM or SUBQ as single dose e)incompletely vaccinated
adult, 0.5 mL IM or SUBQ; additional doses needed to complete a primary series should be given if time permits f)completely vaccinated
adults at increased risk of exposure, 0.5 mL IM or SUBQ as single dose. Pedia - Safety and effectiveness in infants below 6 weeks of age
have not been established. Poliomyelitis, acute; Prophylaxis a)unvaccinated child, 0.5 mL IM or SUBQ x 4 doses at 2, 4, and 6 to 18 mo of
age and booster at 4 to 6 years of age; do not give more frequently than 4 wks apart; first dose may be given as early as 6 wks of age
b)incompletely vaccinated child, children and adolescents with a previously incomplete series should receive additional 0.5 mL IM or SUBQ
doses to complete the series
CONTRA-INDICATIONS: acute febrile illness; defer vaccination, anaphylaxis or anaphylactic shock occurring within 24 hrs of administration
of one dose of vaccine; no further doses should be given, hypersensitivity to streptomycin, neomycin, polymixin B, hypersensitivity to polio
vaccine products, hypersensitivity to 2-phenoxyethanol and formaldehyde
ADVERSE EFFECTS: Anaphylaxis, Guillain-Barre syndrome, Association with vaccine unlikely, Paralytic poliomyelitis, vaccine-associated,
acute
55
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Resonium A
Polystyrene Na Sulphonate
Polyvinyl Alcohol
Sodium
Resonium
Liquifilm Tears
Powder
Eye Drops
Potassium Chloride
Inj. 20mEq/10mL
Inj. 40mEq/20mL
Powder
Syrup 1mEq/mL
Potassium Citrate
Powder
Potassium Citrate/
Sodium Citrate/Citric Acid
Polycitra
Solution
Potassium Iodide
Crystals
Potassium Permanganate
Crystals
PRODUCT INFORMATION
THERAPEUTIC USE: Exchange Resin, Hyperkalemia
DOSE: Adult – Hyperkalemia, 15 g orally 1 to 4 times daily as a slurry in water or syrup; 30 to 50 g Rectally every 6hr as a warm emulsion in
100 mL aqueous vehicle (sorbitol), retain 30-60 min and follow with a cleansing enema.
Pedia – Hyperkalemia, 1 g/kg/dose ORALLY every 6 hr; do not use ORALLY in neonates;1 g/kg/dose RECTALLY every 2-6 hr
CONTRA-INDICATIONS: hypersensitivity to sodium polystyrene sulfonate, hypokalemia, neonates with reduced GI motility (postoperatively
or drug-induced), obstructive bowel disease, oral administration in neonates
ADVERSE EFFECTS: Bronchopneumonia, Electrolytes abnormal, Fecal impaction, Rectal administration, Gastrointestinal necrosis, Colonic,
Hypocalcemia, Hypokalemia
THERAPEUTIC USE: Ocular Lubricant, it soothes and lubricates the dry eye and is useful as an eye drop throughout the day to provide
greater confort and longer wearing of hard contacts lenses.
DOSE: 1 drop in the eye as needed or as directed. If irritation persists or increases discontinue use.
NOTE: Not for use with soft contact lenses. Store between 15 - 30ºC. Keep container tightly closed. To avoid contamination, do not touch
dropper tip to any surface.
THERAPEUTIC USE: Nutriceutical, Parenteral Electrolyte, Potassium, Potassium Supplement
DOSE: Adult – Hypokalemia a)serum K less than 2 mEq/L, 20 to 40 mEq/h IV, with continuous cardiac monitoring; MAX 400 mEq/day
b)serum K greater than 2.5 mEq/L, 10 to 15 mEq/h IV; MAX 200 mEq/day c)serum K 3 to 3.5 mEq/L, ORAL, 40 to 100 mEq daily divided into
2 to 3 doses (no more than 20 mEq/dose); Hypokalemia; Prophylaxis, usual dose, 20 milliequivalents/day ORALLY. Pedia – Hypokalemia
a)intermittent IV, 0.5 to 1 mEq/kg/dose; infuse at 0.3 to 0.5 mEq/kg/h, MAX 1 mEq/kg/h and 30 mEq per dose; MAX 3 mEq/kg/day or 40
mEq/m(2)/day b)ORAL, 2 to 5 mEq/kg/day in divided doses
CONTRA-INDICATIONS: anticholinergic agents; gastrointestinal tract passage restrictions or delay may inhibit extended-release tablet
passage, cardiac patients with esophageal compression; extended-release tablets may cause esophageal ulceration due to enlarged left
atrium, concomitant pharmacologic agents in sufficient doses exerting anticholinergic effects; gastrointestinal tract passage restrictions or
delay may inhibit extended-release tablet passage, structural or pathological conditions causing gastrointestinal tract passage restrictions or
delay; may inhibit extended-release tablet passage, hyperkalemia; risk of cardiac arrest
ADVERSE EFFECTS: Abdominal pain, Abnormal ECG, Cardiac arrest, Gastrointestinal ulcer, Hyperkalemia
THERAPEUTIC USE: Parenteral Solution, Potassium Supplement, Urinary Alkalinizer, Urinary Stone Agent
DOSE: Adult – Nephrolithiasis, mild to moderate hypocitraturia (urinary citrate greater than 150 mg/day): 10 mEq potassium citrate ORALLY
three times daily with meals; severe hypocitraturia (urinary citrate less than 150 mg/day): 20 mEq potassium citrate ORALLY three times daily
OR 15 mEq ORALLY four times daily; with meals or within 30 min after meals or bedtime snack
CONTRA-INDICATIONS: Severe renal impairment with oliguria, azotemia, or anuria, Addison's disease, Adynamic episodica hereditaria,
Acute dehydration, Heat cramps, Severe myocardial damage, Potassium citrate in patients with hyperkalemia, Sodium citrate for patients on
sodium restricted diet, Potassium citrate in patients with peptic ulcer disease, Potassium citrate in patients with impaired potassium excretion,
Potassium citrate in patients taking potassium-sparing diuretics, Potassium citrate in patients using salt substitutes
THERAPEUTIC USE: Potassium Supplement, Urinary Alkalinizer, Urinary Stone Agent
DOSE: Adult – Nephrolithiasis, mild to moderate hypocitraturia (urinary citrate greater than 150 mg/day): 10 mEq potassium citrate ORALLY
three times daily with meals; severe hypocitraturia (urinary citrate less than 150 mg/day): 20 mEq potassium citrate ORALLY three times daily
OR 15 mEq ORALLY four times daily; with meals or within 30 min after meals or bedtime snack
CONTRA-INDICATIONS: Severe renal impairment with oliguria, azotemia, or anuria, Addison's disease, Adynamic episodica hereditaria,
Acute dehydration, Heat cramps, Severe myocardial damage, Potassium citrate in patients with hyperkalemia, Sodium citrate for patients on
sodium restricted diet, Potassium citrate in patients with peptic ulcer disease, Potassium citrate in patients with impaired potassium excretion,
Potassium citrate in patients taking potassium-sparing diuretics, Potassium citrate in patients using salt substitutes
THERAPEUTIC USE: Antibacterial Cleansing Agent, Antithyroid Agent, Expectorant, Iodine Supplement, Parenteral Mineral-Trace Mineral,
Radiation Emergency, Thyroid Blocking Agent
DOSE: Adult - Thyroid gland; Prophylaxis,130 mg ORALLY daily; Lymphocutaneous sporotrichosis, initial, 1 mL saturated solution ORALLY
3 times/day; increase by 0.5 mL/day to 9-12 mL/day; continue for 2-4 wk after all lesions heal. Pedia - Thyroid gland; Prophylaxis a)over 12 y
and weigh 150 lbs or greater, 130 mg ORALLY daily b)over 12 y and weigh 150 lbs or less, 65 mg orally daily c)3 to 12 y, 65 mg orally daily
d)1 mo to 3 y, 32.5 mg ORALLY daily e)birth to 1 mo, 16.25 mg ORALLY daily
CONTRA-INDICATIONS: hypersensitivity to iodide products, renal disorders, iodine-induced goiter
ADVERSE EFFECTS: Goiter, Prolonged or excessive use, Hypothyroidism, Prolonged or excessive use, Immune hypersensitivity reaction,
Thyroid adenoma, Prolonged or excessive use
THERAPEUTIC USE: Solutions are used as cleansing applications to wounds, ulcers, or abscesses and as wet dressing and in baths in
eczematous conditions and acute dermatoses especially where there is secondary infection. Solutions have also been used in bromhidrosis,
56
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Solution 1:8000
Solution 1:10,000
Inj. 15mM/5mL
Inj. 45mM/15mL
Potassium Phosphate
Praziquantel
Biltricide
Tablet 600mg
Prazosin HCl
Minipress
Tablet 1mg
Tablet 2mg
Tablet 5mg
Deltasone
Prednisolone
Gupisone
Pred-Forte
Primaquine Phosphate
Eye Drops 1%
Syrup 1mg/mL
Tablet 5mg
Tablet 20mg
Tablet 7.5mg
Procainamide HCl
Pronestyl
Injection
100mg/mL
Procaine Benzylpenicillin
Depocillin
Injection 2.4mu
Procarbazine
Natulan
Capsule 50mg
PRODUCT INFORMATION
in myotic infectiosn such as athlete's foot, and in poison ivy dermatitis.
DOSE: Topical, 1% solution 2 to 3 times a day or in a wet dressing.
ADVERSE EFFECTS: Crystals and concentrated solutions of Potassium Permanganate are caustic and even fairly dilute solutions are irritant
to tissues and stain skin brown, nausea, vomiting of a brownish colored material, corrosion, edema and brown coloration of the buccal
mucosa, gastrointestinal haemorrhage, liver & kidney damage and cardiovascular depression.
THERAPEUTIC USE: Treatment and prevention of hypophosphatemia or hypokalemia.
WARNING/PRECAUTIONS: Caution with renal insufficiency, cardiac disease, metabolic alkalosis, admixture of phosphate and calcium IV
fluid can result in calcium phosphate precipitation
THERAPEUTIC USE: Anthelmintic
DOSE: Adult & Pedia – Schistosomiasis, 20 mg/kg ORALLY 3 times over 1 day
CONTRA-INDICATIONS: Hypersensitivity to praziquantel, Ocular cysticercosis
ADVERSE EFFECTS: Cardiac dysrhythmia, Heart block, Seizure
THERAPEUTIC USE: Alpha-1 Adrenergic Blocker, Antihypertensive, Benign Prostatic Hypertrophy Agent, Cardiovascular Agent, ToxicologyAntidote Agent
DOSE: Adult – Hypertension, initial, not to exceed 1 mg ORALLY at bedtime; maintenance, 3-20 mg ORALLY daily (divided 2-3 times daily).
Pedia - Not FDA approved in children. Hypertension a)initial, 5 mcg/kg/dose ORALLY every 6 h b)titration, may increase to 25 mcg/kg/dose
ORALLY c)maintenance, 25-150 mcg/kg/24 hr ORALLY (divided every 6-8 h); MAX dose, 15 mg/day or 0.4 mg/kg/day ORALLY
CONTRA-INDICATIONS: hypersensitivity to prazosin or other quinazolines
ADVERSE EFFECTS: Hepatotoxicity, Pancreatitis, Systemic lupus erythematosus
THERAPEUTIC USE: Adrenal Glucocorticoid, Endocrine-Metabolic Agent, Immune Suppressant, Ophthalmologic Agent
DOSE: Adult - Allergic disorder 5-60 mg/day ORALLY
Pedia - Leprosy - Nerve injury, 1 mg/kg/day ORALLY for 1 month followed by 0.5 mg/kg/day for 3 months with further reductions of 5 mg
over a month thereafter for 6 to 8 months
CONTRA-INDICATIONS: Hypersensitivity, Ophthalmic products should not be used for the following: epithelial herpes simplex keratitis, acute
viral infections of the cornea or conjunctiva (eg, vaccinia, varicella), fungal eye infections, mycobacterial infections of the eye, Systemic fungal
infections
THERAPEUTIC USE: Aminoquinoline, Antimalarial
DOSE: Adult - Malaria, Prevention of relapse, 15 mg (base) orally once daily for 14 days or 45 mg (base)/week orally for 8 weeks; Malaria;
Prophylaxis, 30 mg (base) orally once daily; begin 1 day before departure and continue for 7 days after leaving malarious area. Pedia Malaria, Prevention of relapse, 0.3mg/kg/day (base) orally once daily for 14 days. Malaria; Prophylaxis, 0.5 mg (base) orally once daily; begin
1 day before departure and continue for 7 days after leaving malarious area
CONTRA-INDICATIONS: concomitant medications which cause bone marrow suppression, rheumatoid arthritis, lupus erythematosus,
hypersensitivity to primaquine, glucose-6-phosphate dehydrogenase deficiency, pregnancy
ADVERSE EFFECTS: Hemolytic anemia, Leukopenia, Methemoglobinemia
THERAPEUTIC USE: Antiarrhythmic, Group IA
DOSE: Adult - Advanced cardiac life support - Ventricular arrhythmia, non-VF/VT arrest, 20 mg/min IV until the arrhythmia is suppressed,
hypotension ensues, or the QRS complex is prolonged by 50% from its original duration; MAX dose 17 mg/kg; maintenance infusion rate is 1
to 4 mg/min. Pedia - safety and efficacy not established in children
CONTRA-INDICATIONS: complete heart block or second or third degree AV block, hypersensitivity to procainamide, procaine, or other estertype local anesthetics, systemic lupus erythematosus, torsades de pointes
ADVERSE EFFECTS: Agranulocytosis, Aplastic anemia, Blood coagulation disorder, Cardiac dysrhythmia, Hepatotoxicity, Systemic lupus
erythematosus
THERAPEUTIC USE: Antibiotic, Penicillin, Natural
DOSE: Adult – Anthrax, cutaneous, 600,000 to 1,000,000 units IM once a day; inhalational (post-exposure), 1,200,000 units IM every 12 h for
14 to 60 days.
Pedia – Anthrax inhalational (post-exposure), 25,000 units/kg IM every 12 h for 14 to 60 days; MAX dose 1,200,000 units
CONTRA-INDICATIONS: Hypersensitivity to penicillin/sulfites or procaine, Injection near artery or nerve
ADVERSE EFFECTS: Gangrenous disorder, Due to inadvertent intravascular administration, Injection site nerve damage, Jarisch
Herxheimer reaction, Myelitis, Due to inadvertent intravascular administration, Necrosis, Due to inadvertent intravascular administration,
Psychotic disorder, acute, Transient
THERAPEUTIC USE: Alkylating Agent, Antineoplastic Agent
DOSE: Adult - Non-Hodgkin's lymphoma, COPP regimen: 100 mg/m(2)/day ORALLY on days 1-10 in combination with cyclophosphamide
57
PRODUCT
DESCRIPTION
Promethazine HCl
Propofol
Propranolol HCl
TRADE
NAME
Histaloc
Phenergan
Protamine Sulphate
Inj. 50mg/2mL
Syrup 5mg/5mL
Diprivan
Inj. 200mg/20mL
Inj. 500mg/50mL
Inderal
Inj. 1mg/mL
Syrup 1mg/mL
Tablet 10mg
Tablet 40mg
Propyl Paraben
Propylthiouracil
DOSAGE
FORM/STRENGTH
Powder
PTU
Tablet 50mg
Injection 1%
PRODUCT INFORMATION
600 mg/m(2) IV days 1 and 8; vincristine 1.4 mg/m(2) IV on days 1 and 8 and prednisone 40 mg/m(2)/day ORALLY on days 1-14
CONTRA-INDICATIONS: hypersensitivity to procarbazine, inadequate bone marrow reserve
ADVERSE EFFECTS: Decreased liver function, Heinz bodies, Hemolysis, Myelosuppression, Neurotoxicity, Peripheral neuropathy,
Secondary malignant neoplastic disease, Nonlymphoid
THERAPEUTIC USE: Aliphatic, Antiemetic, Antihistamine, Antivertigo, Gastrointestinal Agent, Phenothiazine
DOSE: Adult – Allergy a)25 mg ORALLY at bedtime or 12.5 mg ORALLY before meals and at bedtime b)25 mg IV or IM, may repeat within
2 hrs if needed.
Pedia - Not for use in children less than 2 years of age. Allergy (2 yrs or older) 25 mg ORALLY at bedtime or 6.25-12.5 mg ORALLY three
times daily
CONTRA-INDICATIONS: Comatose states, Lower respiratory tract symptoms, including asthma, Patients with a history of an idiosyncratic
reaction or hypersensitivity to promethazine or other phenothiazines, Pediatric patients less than 2 years of age, Subcutaneous or intraarterial injection
ADVERSE EFFECTS: Agranulocytosis, Apnea, Jaundice, Leukopenia, Neuroleptic malignant syndrome, Respiratory depression,
Thrombocytopenia
THERAPEUTIC USE: Anesthetic, General
DOSE: Adult - General anesthesia a)(healthy adults less than 55 years of age) induction, 40 mg IV every 10 seconds until induction onset (2
to 2.5 mg/kg); dose varies for age and surgery type b)(healthy adults less than 55 years of age) maintenance, 100 to 200 mcg/kg/min IV
infusion (6 to 12 mg/kg/h); dose varies for age and surgery type c)(healthy adults less than 55 years of age) maintenance, 20 to 50 mg
increments IV bolus as needed . Pedia - General anesthesia a)(3 to 16 years) induction, 2.5 to 3.5 mg/kg IV over 20 to 30 seconds b)(2
months to 16 years) maintenance, 125 to 300 mcg/kg/min IV
CONTRA-INDICATIONS: hypersensitivity to propofol or its components, allergies to eggs, egg products, soybeans, or soy products
ADVERSE EFFECTS: Acute renal failure, Anaphylaxis, Apnea, Bacterial septicemia, Bradyarrhythmia, Heart failure, Hypertension, Peds,
Pancreatitis, Priapism, Propofol adverse reaction, Infusion syndrome, Respiratory acidosis, Seizure
THERAPEUTIC USE: Antianginal, Antiarrhythmic, Group II, Antihypertensive, Antimigraine, Beta-Adrenergic Blocker, Nonselective,
Cardiovascular Agent
DOSE: Adult - Angina pectoris, chronic a)immediate-release, 80 to 320 mg ORALLY daily (divided 2 to 4 times/day) b)long-acting, 80 to 160
mg ORALLY once daily. Pedia - Cardiac dysrhythmia a)immediate-release, 2 to 6 mg/kg ORALLY per 24 hr (divided every 6 to 8 hr)
b)immediate-release, maximum dose, 60 mg ORALLY per 24 hr c)0.1 mg/kg/dose IV, MAX 1 mg/dose, given by slow infusion over 5 min
CONTRA-INDICATIONS: bronchial asthma or chronic obstructive pulmonary disease, cardiogenic shock, hypersensitivity to propranolol,
overt cardiac failure, second and third degree AV block, severe sinus bradycardia
ADVERSE EFFECTS: Asthma, Bronchospasm, Congestive heart failure, Erythema multiforme, Myocardial infarction, Stevens-Johnson
syndrome, Toxic epidermal necrolysis
THERAPEUTIC USE: An antifungal preservative, preservative for galenicals in concentrations ranging from 0.05 to 0.25%. When desired to
give a strong antiseptic effect, 3 to 5 times the above concentration may be used.
THERAPEUTIC USE: Antithyroid Agent, Thionamide
DOSE:Adult - Hyperthyroidism a)initial, 300-400mg/day orally in divided doses every 8hrs; (initial doses as high as 600-900mg/day are
necessary) b)maintenance, 100-150mg/day orally in divided doses every 8-12hrs.
Pedia - safety and effectiveness not established in children under 6 years of age. Hyperthyroidism a)(6-10yrs) initial, 50-150 mg/day or 5-7
mg/kg/day ORALLY in divided doses every 6-8hrs b)(over 10yrs) initial, 150-300 mg/day or 5-7 mg/kg/day ORALLY in divided doses every 68hrs c)maintenance, 50 mg ORALLY twice daily or 1/3-2/3 of the initial dose
CONTRA-INDICATIONS: hypersensitivity to propylthiouracil
ADVERSE EFFECTS: Hepatic necrosis, Nephritis
THERAPEUTIC USE: Heparin Antagonist
DOSE: Adult - Toxicity of drug, Heparin a)1 mg IV for every 100 units of heparin remaining in patient; if 30 minutes have elapsed since the
injection of heparin one-half the dose may be sufficient; maximum 50 mg given over 10 minutes b) the dose can be given as a loading dose of
25 to 50 mg by slow IV injection, with the rest of the calculated dose over 8 to 16 hours by intravenous infusion c)25 to 50 mg IV should be
given immediately after the discontinuation of a continuous infusion of heparin. Pedia - safety and effectiveness in children have not been
established
CONTRA-INDICATIONS: hypersensitivity to protamine products
ADVERSE EFFECTS: Anaphylactoid reaction, Circulatory collapse, capillary leak, noncardiogenic pulmonary edema, Anaphylaxis,
Bradyarrhythmia, Hypotension
58
PRODUCT
DESCRIPTION
TRADE
NAME
Proteolytic Enzymes/
SpasmoMetixene/Dimethylpolysiloxane canulase
Pyrazinamide
PTB
Tebrazid
DOSAGE
FORM/STRENGTH
Tablet
Syrup
100mg/mL
Tablet 500mg
Pyridostigmine Bromide
Mestinon
Inj. 1mg/mL
Tablet 10mg
Tablet 60mg
Pyridoxine HCl
Benadon
Tablet 40mg
Pyrimethamine
/Sulphadoxine
Fansidar
Tablet
Quinine Di-Hydrochloride/
Quinine Sulphate
Inj. 300mg/mL
Tablet 300mg
Rabies Virus Vaccine
Injection
0.5mL/Dose
PRODUCT INFORMATION
THERAPEUTIC CATEGORY: Use for irritable colon, digestive dysfunctions following hepatobiliary diseases, enzyme deficiencies, functional
gastrointestinal disorders.
DOSE: Adult & children over 12years old – swallow whole 1bitab or, in cases of acute discomfort, 2bitabs before each meal.
CONTRA-INDICATIONS: Hypersensitivity to any of the components, narrow-angle glaucoma, intestinal atony.
ADVERSE EFFECTS: Dry mouth, disturbed visual accommodation, tachycardia; rarely nausea, abdominal pain.
THERAPEUTIC USE: Antitubercular
DOSE: Adult – Tuberculosis a)(40 to 55 kg) 1,000 mg ORALLY once daily OR 1,500 mg ORALLY 3 times a week OR 2,000 mg ORALLY 2
times a week in combination with other antitubercular agents b)(56 to 75 kg) 1,500 mg ORALLY once daily OR 2,500 mg ORALLY 3 times a
week OR 3,000 mg ORALLY 2 times a week in combination with other antitubercular agents c)(76 to 90 kg) 2,000 mg ORALLY once daily OR
3,000 mg ORALLY 3 times a week OR 4,000 mg ORALLY 2 times a week in combination with other antitubercular agents. Pedia Tuberculosis, 15 to 30 mg/kg ORALLY once daily (MAX 2,000 mg/day) OR 50 mg/kg ORALLY 2 times a week (MAX 4,000 mg/day) in
combination with other antitubercular agents
CONTRA-INDICATIONS: acute gout, hypersensitivity to pyrazinamide products, severe hepatic dysfunction
ADVERSE EFFECTS: Anemia, Hepatotoxicity
THERAPEUTIC USE: Central Nervous System Agent, Cholinesterase Inhibitor, Immunological Agent, Nerve Gas Antidote, Nondepolarizing
Muscle Relaxant Antagonist
DOSE: Adult - Myasthenia gravis a)average, 600 mg ORAL tablets or syrup daily, spaced to provide maximum relief when maximum strength
is needed b)180-540 mg ORAL slow-release tablets once or twice daily, spaced at least every 6hr.
Pedia - safety and effectiveness not established in children
CONTRA-INDICATIONS: hypersensitivity to pyridostigmine products or bromides, mechanical intestinal obstruction, urinary obstruction
ADVERSE EFFECTS: Bradyarrhythmia, Cholinergic crisis
THERAPEUTIC USE: Nutritive Agent, Toxicology-Antidote Agent, Vitamin B Combination
DOSE: Adult - Vitamin B6 deficiency; Treatment and Prophylaxis a)(recommended daily allowance) men and women, to 50 yr of age, 1.3
mg/day; men over 50 yr, 1.7 mg/day; women over 50, 1.5 mg/day; pregnancy 1.9 mg/day; lactation 2 mg/day b)(treatment) 10 to 20 mg/day
IM or IV for 3 wk; then 2 to 5 mg/day ORALLY for several wk. Pedia - Vitamin B6 deficiency; Treatment and Prophylaxis a)(recommended
daily allowance) age (0-6 months) 0.1 mg/day; (7-12 months) 0.3 mg/day; (1-3 yr) 0.5 mg/day; (4-8 yr) 0.6 mg/day; (9-13 yr) 1 mg/day; (males
14-18 yr) 1.3 mg/day; (females 14-18 yr) 1.2 mg/day b)(treatment) 5 to 25 mg/day ORALLY for 3 wk; then 1.5 to 5 mg/day ORALLY in a
multivitamin preparation
CONTRA-INDICATIONS: hypersensitivity to pyridoxine products
THERAPEUTIC USE: Antimalarial Sulfonamide Combination
DOSE: Adult - Malaria; Prophylaxis, 1 tablet ORALLY once weekly OR 2 tablets ORALLY once every 2 weeks; each tablet contains
sulfadoxine 500 mg/pyrimethamine 25 mg; start 1 to 2 days before arrival in endemic area and continue during stay and for 4 to 6 wk after
return. Pedia - Malaria; Prophylaxis, administer dose orally once weekly based on weight: (> 45 kg) 1 and 1/2 tablet; (31 to 45 kg) 1 tablet;
(21 to 30 kg) 3/4 tablet; (11 to 20 kg) 1/2 tablet; (5 to 10 kg) 1/4 tablet; each tablet contains sulfadoxine 500 mg/pyrimethamine 25 mg; start 1
to 2 days before arrival in endemic area and continue during stay and for 4 to 6 wk after return
CONTRA-INDICATIONS: blood dyscrasias, hypersensitivity to pyrimethamine or sulfonamides, infants - less than 2 months old, pregnancy or
breastfeeding, severe liver or renal disease
ADVERSE EFFECTS: Agranulocytosis, Aplastic anemia, Disorder of hematopoietic structure, Drug-induced eosinophilia, Hepatic necrosis,
Hepatitis, Nephrotoxicity, Stevens-Johnson syndrome, Thrombocytopenia, Toxic epidermal necrolysis
THERAPEUTIC USE: Antimalarial, Cinchona Alkaloid, Musculoskeletal Agent
DOSE: Adult – Malaria, 2 capsules (648 mg) every 8 hours for 7 days.
Pedia – Malaria over age 16 years, 2 capsules (648 mg) every 8 hours for 7 days
CONTRA-INDICATIONS: glucose-6-phosphate dehydrogenase deficiency, hypersensitivity to quinine, myasthenia gravis
ADVERSE EFFECTS: Disseminated intravascular coagulation, DIC, Hemolytic uremic syndrome, Hepatotoxicity, Interstitial nephritis,
Ototoxicity, Thrombocytopenia
THERAPEUTIC USE: Vaccine
DOSE: Adult - Rabies, Post-exposure; Prophylaxis a)(not previously vaccinated) 1 mL IM x 5 doses, one each on days 0, 3, 7, 14 and 28 in
conjunction with the administration of Human Rabies Immune Globulin (HRIG) on day 0; begin with the administration of HRIG 20
international units/kg IM b)(previously vaccinated) 1 mL IM x 2 doses, one each on day 0 and 3 (HRIG should not be given). Pedia - Rabies,
Post-exposure; Prophylaxis a)(not previously vaccinated) 1 mL IM x 5 doses, one each on days 0, 3, 7, 14 and 28 in conjunction with the
administration of Human Rabies Immune Globulin (HRIG) on day 0; begin with the administration of HRIG 20 international units/kg IM
b)(previously vaccinated) 1 mL IM x 2 doses, one each on day 0 and 3 (HRIG should not be given)
59
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Ranitidine
Nadine
Ranid
Rantag
Zantac
Inj. 50mg/2mL
Syrup 15mg/mL
Tablet 150mg
Rehydration Solution
Babylyte
Solution 240mL
Reteplase
Rapilysin
Injection 10units
Ribavirin
Rebetol
Capsule 200mg
Rifampicin
Rifadin
Capsule 150mg
Capsule 300mg
Syrup 20mg/mL
Risperidone
Risperdal
Solution
1mg/mL
Tablet 2mg
PRODUCT INFORMATION
CONTRA-INDICATIONS: hypersensitivity to processed bovine gelatin, chicken protein, neomycin, chlortetracycline and amphotericin B in
trace amounts (pre-exposure), no specific contraindications (post-exposure immunization)
ADVERSE EFFECTS: Anaphylaxis, Encephalitis, Guillain-Barre syndrome, Meningitis, Multiple sclerosis, Myelitis, Paralysis, Transient,
Retrobulbar neuritis
THERAPEUTIC USE: Antiulcer, Protectant, Gastric Acid Secretion Inhibitor, Histamine H2 Antagonist
DOSE: Adult - Duodenal ulcer disease, 150 mg ORALLY twice daily or 300 mg once daily after the evening meal or at bedtime; 50 mg IV/IM
every 6-8 hours or 6.25 mg/h IV continuous infusion.Pedia - Duodenal ulcer disease a)(1 month of age or older) 2 to 4 mg/kg ORALLY twice
daily, MAX 300 mg/day b)(1 month of age or older) 2 to 4 mg/kg/day IV in divided doses every 6-8 hours, MAX 50 mg every 6-8 hours.
CONTRA-INDICATIONS: hypersensitivity to ranitidine or any of its ingredients
ADVERSE EFFECTS: Anemia, Necrotizing enterocolitis in fetus or newborn, Pancreatitis, Thrombocytopenia
THERAPEUTIC USE: Indicated as a maintenance fluid for infants and young children to prevent dehydration in mild or moderate diarrhea.
DOSE: Children under 2years of age – before use consult the physician; Children over 2years of age – Offer babylyte every 3 or 4hours.
One to two liters should be taken each day while the diarrhea continues. If the diarrhea continues for more than 24hours or there is vomiting
or fever consult your doctor.
CONTRA-INDICATIONS: Patients with intractable vomiting, adynamic ileus, intestinal obstruction or bowel perforation.
THERAPEUTIC USE: Blood Modifier Agent, Tissue Plasminogen Activator
DOSE: Adult - Acute myocardial infarction, 10 unit IV bolus, 2 doses given 30 minutes apart. Pedia - safety and efficacy in children have not
been established
CONTRA-INDICATIONS: hypersensitivity to reteplase, active internal bleeding, severe uncontrolled hypertension, recent intracranial or spinal
surgery or trauma, known bleeding diathesis, history of cerebrovascular accident, intracranial neoplasm, arteriovenous malformation, or
aneurysm
ADVERSE EFFECTS: Cardiac dysrhythmia, Reperfusion, Cholesterol embolus syndrome, Gastrointestinal hemorrhage, Immune
hypersensitivity reaction, Intracranial hemorrhage
THERAPEUTIC USE: Antiviral, Guanosine Nucleoside Analog, Viral RNA Polymerase Inhibitor
DOSE: Adult - Hepatitis C, chronic, In patients with compensated liver disease
a)in combination with interferon alfa-2b, 75 kg or less, 400 mg ORALLY every morning and 600 mg ORALLY every evening b)in combination
with interferon alfa-2b, greater than 75 kg, 600 mg ORALLY twice a day c)in combination with peg-interferon alfa-2b, 400 mg ORALLY every
morning and 400 mg ORALLY every evening.
Pedia - Hepatitis C, chronic, In patients with compensated liver disease. a)greater than 61 kg, use adult dosing b)in combination with
interferon alfa-2b, 25 to 36 kg, 200 mg ORALLY twice a day c)in combination with interferon alfa-2b, 37 to 49 kg, 200 mg ORALLY every
morning and 400 mg ORALLY every evening d)in combination with interferon alfa-2b, 50 to 61 kg, 400 mg ORALLY twice a day
CONTRA-INDICATIONS: cardiac disease, significant or unstable; potential worsening due to drug-induced anemia, pregnancy or pregnant
partner of male patient; may cause birth defects and/or death of the exposed fetus, hemoglobinopathy (such as thalassemia major and sicklecell anemia), hepatic decompensation, in cirrhotic chronic hepatitis C patients coinfected with HIV before or during therapy, hepatitis,
autoimmune; ribavirin may worsen hepatitis, hypersensitivity to ribavirin or any component of the product, renal function impairment
ADVERSE EFFECTS: Bacterial infectious disease, oral, in combination with peginterferon alfa-2a, Bradyarrhythmia, Inhalation, Cardiac
arrest, Complication of respiratory therapy procedure, Drug precipitation, Hemolytic anemia, Cardiac and pulmonary events have occurred,
Hepatotoxicity, Hyperammonemia, Hyperbilirubinemia, Hypotension, Increased erythrocyte destruction, Liver failure, oral, in combination with
peginterferon alfa 2a, Pancreatitis, Fatal and nonfatal, Respiratory complication, Suicide, oral, in combination with peginterferon alfa-2a,
Thrombotic thrombocytopenic purpura
THERAPEUTIC USE: Antitubercular, Rifamycin
DOSE: Adult – Tuberculosis, initially, 10 mg/kg/day (in combination with isoniazid and pyrazinamide) ORALLY or IV for 2 mo; MAX 600
mg/day; then 10 mg/kg/day (in combination with isoniazid) for 4 mo or longer as needed. Pedia – Tuberculosis, initially, 10 to 20 mg/kg/day
(in combination with isoniazid and pyrazinamide) ORALLY or IV for 2 mo; MAX 600 mg/day; then 10 to 20 mg/kg/day (in combination with
isoniazid) for 4 mo or longer as needed.
CONTRA-INDICATIONS: hypersensitivity to rifampin or other rifamycins, presence of active Neisseria meningitidis infection
ADVERSE EFFECTS: Hepatotoxicity, Thrombocytopenia, High-dose therapy
THERAPEUTIC USE: Antipsychotic, Benzisoxazole
DOSE: Adult -Manic bipolar I disorder, a)(monotherapy or in combination with lithium or valproate) initial, 2 to 3 mg ORALLY once a day
b)(monotherapy or in combination with lithium or valproate) maintenance, dosage adjustments should be made in increments of 1 mg/day at
intervals of at least 24 hours; doses higher than 6 mg/day have not been evaluated in clinical trials. Pedia - safety and effectiveness in
pediatric patients less than 13 years of age with schizophrenia or less than 10 years with bipolar mania have not been established, safety and
60
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Ritodrine HCl
Yutopar
Injection
50mg/5mL
Rocuronium Bromide
Esmeron
Injection
50mg/5mL
Rubella Vaccine
Salbutamol
Injection 0.5mL
Butalin
Ventolin
Salicylic Acid
Salicylic Acid/Lactic Acid
/Lauromacrogol
Scorpion Antivenom
Inhaler 100mcg
Solution
5mg/mL
Powder
Collomack
Solution
Injection
PRODUCT INFORMATION
effectiveness in pediatric patients less than 5 years of age with autistic disorder have not been established; Manic bipolar I disorder - (10
years and older) initial, 0.5 mg ORALLY once daily as a single dose in the morning or evening; adjust dosage at intervals not less than 24
hours and in increments of 0.5 to 1 mg/day up to a maximum recommended dose of 2.5 mg/day
CONTRA-INDICATIONS: hypersensitivity to risperidone or to any product component
ADVERSE EFFECTS: Death, Hypothermia, Leukopenia, Neuroleptic malignant syndrome, Pancreatitis, Priapism, Purpuric disorder, Seizure,
Suicidal intent, Syncope, Tardive dyskinesia, Thrombocytopenia
THERAPEUTIC USE: Beta-2 Adrenergic Agonist, Uterine Relaxant
DOSE: Adult - IV route, For use in PREMATURE LABOR, the manufacturer recommends an initial dose of 0.05 mg (50 mcg)/min. The dose
is gradually increased by 0.05 mg (50 mcg/min every 10 min until the desired response is attained. The effective dose is usually between 150
to 350 mcg/min. The infusion should be continued for 12 to 24 hours after uterine contractions cease. Ten mg orally may be administered 30
min before the termination of the infusion, and then every 2 hours for the next 24 hours. Thereafter 10 to 20 mg every 4 to 6 hours can be
given for as long as it is desirable to prolong the pregnancy. Maximum dose - Intravenous infusions of ritodrine should not exceed 350 mg/min
CONTRA-INDICATIONS: Contraindicated for use before the 20th week of pregnancy, Hypersensitivity to ritodrine, Pre-existing maternal
medical conditions such as hypovolemia, cardiac arrhythmias associated with tachycardia or digitalis intoxication, uncontrolled hypertension,
pheochromocytoma, and bronchial asthma already treated by beta-mimetics and/or steroids, Conditions of the mother or fetus in which
continuation of pregnancy would be hazardous; including antepartum hemorrhage, eclampsia and severe pre-eclampsia, intrauterine fetal
death, chorioamnionitis, maternal cardiac disease, pulmonary hypertension, maternal hyperthyroidism, and uncontrolled maternal diabetes
mellitus
THERAPEUTIC USE: Musculoskeletal Agent, Neuromuscular Blocker, Non-Depolarizing
DOSE: Adult - General anesthesia; Adjunct - Induction of neuromuscular blockade, During surgery or mechanical ventilation, initial, 0.6
mg/kg IV, maintenance, 0.1 to 0.2 mg/kg IV push, repeat as needed OR 0.01 to 0.012 mg/kg/minute continuous IV infusion. Pedia - General
anesthesia; Adjunct - Induction of neuromuscular blockade, During surgery or mechanical ventilation, 3 mo to 14 y, initial, 0.6 mg/kg/dose IV;
3 mo to 14 y, maintenance, 0.075 to 0.125 mg/kg IV push as needed OR 0.012 mg/kg/min continuous IV infusion.
CONTRA-INDICATIONS: hypersensitivity to rocuronium products
ADVERSE EFFECTS: Anaphylaxis, Cardiac dysrhythmia, Hypertension, Hypotension, Tachyarrhythmia
THERAPEUTIC USE: Vaccine
DOSE: Adult - Prophylaxis, 0.5 mL SC x 1 dose. Pedia - safety and effectiveness in infants below the age of 12 mo have not been
established. Rubella; Prophylaxis, (12 mo and older) 0.5 mL SC x 1 dose
CONTRA-INDICATIONS: Active febrile infection, Acute febrile illness, Active, untreated TB, Blood dyscrasias, leukemia, lymphomas, bone
marrow malignancy, Family history of congenital or hereditary immunodeficiency, Anaphylactic reactions to topical or systemic neomycin,
Hypersensitivity to vaccine components, including gelatin, Primary or acquired immunodeficiency including immunocompromised HIV,
Immunosuppressive therapy, Pregnancy should be avoided for 28 days postvaccination based on Advisory Committee on Immunization
Practices
ADVERSE EFFECTS: Anaphylaxis, Encephalitis, Guillain-Barre syndrome, Association with vaccine unlikely, Optic neuritis, Polyneuritis,
Polyneuropathy, Stevens-Johnson syndrome, Thrombocytopenia
THERAPEUTIC USE: Beta-2 Adrenergic Agonist, Bronchodilator, Cardiovascular Agent, Sympathomimetic
DOSE: Adult - Asthma; Treatment and Prophylaxis, 2 INHALATIONS every 4-6 h or 1 INHALATION every 4 h; Exercise-induced asthma;
Prophylaxis, 2 INHALATIONS 15 min before exercise. Pedia - Asthma; Treatment and Prophylaxis, 4 y and older, 2 INHALATIONS every 4-6
h or 1 INHALATION every 4 h; Exercise-induced asthma; Prophylaxis, 4 y and older, 2 INHALATIONS 15 min before exercise
CONTRA-INDICATIONS: hypersensitivity to albuterol or any of its components
ADVERSE EFFECTS: Erythema multiforme, Stevens-Johnson syndrome
THERAPEUTIC USE: Analgesic, Antiacne Keratolytic, Antipsoriatic, Antipyretic, Antirheumatic, Antiseborrheic, Keratolytic, NSAID, Salicylate,
Non-Aspirin
DOSE: Adult - Acne vulgaris, apply TOPICALLY in concentrations of 0.5% to 10%; Psoriasis - apply TOPICALLY in concentrations of 3% to
6%; Removal of wart- apply TOPICALLY once or twice daily in concentrations of 5% to 40% for up to 12 weeks
Pedia – Psoriasis, apply TOPICALLY in concentrations up to 6%.
CONTRA-INDICATIONS: age less than 2 yrs, diabetes, hypersensitivity to salicylic acid, impaired circulation
THERAPEUTIC USE: Keratolytic, anti callous preparations, corns, hard skins and for warts.
DOSE: Apply 1drop night and morning to affected area only for several days.
ADVERSE EFFECTS: Local irritation
THERAPEUTIC USE: The polyvalent antivenom is highly specific in neutralizing the venoms of the Saudi yellow scorpion and black scorpion.
The antivenow has also a wide spectrum of activity and can neutralize the venoms of many of the Middle east and North African scorpions.
61
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Laxal
Senna Glycosides
Pursennid
Tablet 12mg
Sennalax
Sevoflurane
Sevorane
Inhalation
Silver Nitrate
Grafco
Stick 95%
Silver Sulphadiazine
Flamazine
Cream 1%
Simvastatin
Simvast
Zocor
Tablet 10mg
Tablet 20mg
Snake Antivenom Serum
Injection
Sodium Bicarbonate
Injection 4.2%
Injection 8.4%
Powder
Syrup 1mEq/mL
Tablet 325mg
PRODUCT INFORMATION
DOSE: Adult & Pedia – Five 1mL ampoules are to be diluted in 20-50mL half normal saline and infused IV slowly over a period of 30minutes.
The dose is to be repeated if necessary, up to 20 x 1mL ampoules. One quarter normal saline is to be used for infants & children up to 6years
old. Children must be given the same dose of antivenom as adults.
ADVERSE EFFECTS: Anaphylactic reaction
THERAPEUTIC USE: Anthraquinone laxatives are used primarily for short-term treatment of constipation and to evacuate the colon for rectal
and bowel examination.
DOSE: Adult – usual recommended dose is sennosides 15 to 17 milligrams (mg) once a day, ideally before bedtime, up to a maximum of 34
to 50 mg twice a day. Pedia – Ages 2 to 6 The recommended initial dosage in children between 2 and 6 years of age is 4.3 mg sennosides
once a day, preferably at bedtime. The maximum recommended dosage is 8.6 mg sennosides twice a day; Ages 6 to 12 – recommended
initial dosage in children between 6 and 12 years of age is 8.5 to 15 mg sennosides once a day, preferably at bedtime. The maximum
recommended dosage is 17 to 25 mg sennosides twice a day.
CONTRA-INDICATIONS: Stimulant laxatives are contraindicated in patients with the following conditions: acute surgical abdomen; bowel
obstruction; fecal impaction; hypersensitivity to anthraquinone laxatives or to any of the ingredients; nausea, vomiting, or other symptoms of
appendicitis; or undiagnosed abdominal pain.
THERAPEUTIC USE: Haloalkane, Volatile Liquid
DOSE: Adult – General anesthesia, 0.5% to 3% concentration with or without concomitant use of nitrous oxide. Pedia – General anesthesia,
0.5% to 3% concentration with or without concomitant use of nitrous oxide
CONTRA-INDICATIONS: hypersensitivity to sevoflurane or other halogenated agents, malignant hyperthermia, known or suspected
susceptibility; sevoflurane may trigger reaction
ADVERSE EFFECTS: Bradyarrhythmia, Hepatic necrosis, Hypotension, Laryngeal spasm, Liver failure, Malignant hyperthermia, Respiratory
depression, Seizure, Tachyarrhythmia
THERAPEUTIC USE: Antibacterial, Antiseptic, Dressing Agent, Keratolytic, Trace Mineral Supplement
DOSE: Adult – Chronic granulomatous disease, TOPICAL, apply 10% solution with cotton applicator to wart or lesion 2-3 times per wk for 2-3
wk as needed. TOPICAL, apply ointment to affected area and cover with apertured pad for 5 days.
Pedia – Gonococcal conjunctivitis neonatorum, 2 drops of 1% solution each eye immediately after delivery
CONTRA-INDICATIONS: hypersensitivity to silver nitrate products
ADVERSE EFFECTS: Methemoglobinemia
THERAPEUTIC USE: Antibacterial, Sulfonamide
DOSE: Adult – Burn, TOPICAL, apply 1% cream in 1/16-inch layer once or twice daily until healing or skin grafting. Pedia – safety and
effectiveness not established in children
CONTRA-INDICATIONS: hypersensitivity to silver or sulfonamide products, pregnancy (approaching term), preterm infants or newborns
under 2 months
ADVERSE EFFECTS: Disorder of hematopoietic structure, Leukopenia
THERAPEUTIC USE: Antihyperlipidemic, HMG-COA Reductase Inhibitor
DOSE: Adult – Hypercholesterolemia, initial, 20 to 40 mg orally once every evening; dose range, 5 to 80 mg ORALLY daily. Pedia – safety
and efficacy have not been studied in pediatric patients under 10 years of age. Familial hypercholesterolemia – heterozygous, adolescents 10
to 17 years of age: initial, 10 mg orally daily in the evening; maintenance, 10 to 40 mg orally daily; MAX 40 mg/day
CONTRA-INDICATIONS: active liver disease or elevated liver enzymes, hypersensitivity to simvastatin products, pregnancy and lactation
ADVERSE EFFECTS: Compartment syndrome of lower leg, Drug-induced myopathy, Hepatotoxicity, Rhabdomyolysis, Rupture of tendon
THERAPEUTIC USE: The polyvalent antivenom is highly specific in neutralizing the toxic effects of the six Saudi snake venoms. Neutralize
effectively the haemorrhagic and myonecrotic activities of the viper snake venoms and the neuromascular blocking and cardiotoxic effects of
the elapid snake venoms.
DOSE: Adult & Pedia – 40mL antivenom are diluted in approximately 5mL isotonic physiological fluid,/Kg body weight and infused IV slowly
over a period of 30 – 60 minutes. Alternatively, IV undiluted at a rate of 4mL/min. Children must be given the same dose as Adults.
ADVERSE EFFECTS: Allergic Reactions.
THERAPEUTIC USE: Antacid, Sodium Bicarbonate Containing, Parenteral Electrolyte, Sodium, Sodium Supplement
DOSE: Adult – Oral route, Sodium bicarbonate 1 gram equals 11.9 milliequivalents sodium and 11.9 milliequivalents bicarbonate. The usual
adult dose is 325 milligrams to 2 grams orally 4 times per day. Maximum daily dose in patients less than 60 years is 16 grams and greater
than 60 years is 8 grams/day; IV route, a)Hypertonic solutions of sodium bicarbonate must be diluted to isotonicity (1.5%) with sterile water,
sodium chloride, dextrose 5%, or other standard electrolyte solutions before administration b)Undiluted hypertonic 8.4% sodium bicarbonate
may be given by intravenous injection during cardiac arrest c)Flush intravenous lines before and after sodium bicarbonate infusion. Pedia –
62
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Tablet 500mg
Sodium Chloride
Inj. 2.5mEq/mL
Inj. 5.13mEq/mL
Powder
Syrup
2.5mEq/mL
Sodium Citrate
Powder
Sodium Cromoglycate
Opticrom
Eye Drops 2%
Sodium Hyaluronate
Healon
Injection
10mg/mL
Sodium Nitroprusside
Sodium Phosphate
Nipride
Nipruss
Injection
50mg/2mL
Injection
3mM/mL
PRODUCT INFORMATION
IV route a)In pediatric patients, use of sodium bicarbonate is recommended for symptomatic patients with HYPERKALEMIA,
HYPERMAGNESEMIA, TRICYCLIC ANTIDEPRESSANT OVERDOSE, or overdose from other sodium channel blocking agents and may be
considered for the patient with PROLONGED CARDIAC ARREST or shock associated with documented severe METABOLIC ACIDOSIS.
Pediatric dosing recommendations include an initial dose of 1 milliequivalents/kilogram (1 milliliter (mL)/kg of 8.4% solution) intravenously or
intraosseously. To limit the osmotic load in neonates, a dilute solution (0.5 mEq/mL; 4.2% solution) may be used. Subsequent doses should
be based on blood gas analysis or after every 10 minutes of continued arrest b)For neonates and children under 2 years, do not administer
more than 8 milliequivalents/kilogram/day; use a 4.2% solution or dilute the 8.4% solution to 0.5 milliequivalent/milliliter for slow
administration. Rapid injection (10 milliliter/minute) may produce hypernatremia, a decrease in cerebrospinal fluid pressure and possible
intracranial hemorrhage
CONTRA-INDICATIONS: Respiratory alkalosis, Hypocalcemia, Hypochloremia, Do not use Neutralizing Additive Solution 4.2% as a systemic
alkalinizer
THERAPEUTIC USE: Antiasthma, Dermatological Agent, Dressing Agent, Eye Wash
Irrigant, Moisturizer, Nutriceutical, Osmotherapy Agent
Parenteral Electrolyte, Sodium, Respiratory Agent, Sodium Supplement, Wound Care Agent
DOSE: Adult – Aldosterone measurement, urine a)Oral doses used have included: 12 gm/d ORALLY for 3 d, b)25 ml/kg of normal saline IV
infused over 4 hours for 3 d; Plasma aldosterone level; Intravenous doses used have included: 2-3 L of normal saline IV infused over 4-6 h
CONTRA-INDICATIONS: Hypernatremia or fluid retention, Hypersensitivity, Sodium chloride solutions with preservatives in newborns, for
injection or flushing of intravenous lines or mixing medications, Hypertonic saline abortifacient in pregnancies less than 15 weeks or more
than 24 weeks gestation or in presence of increased intra-amniotic pressure, as with contractions or hypertonic uterus, Hypertonic saline
abortifacient in patients with major systemic disorders, such as diabetes mellitus, renal, hepatic, or sickle cell disease; prior to uterine or
cervical surgery; in the presence of pelvic adhesions
THERAPEUTIC USE: Urinary Alkalinizer, Urinary Stone Agent and mild astringent
THERAPEUTIC USE: Antiasthma, Gastrointestinal Agent, Mast Cell Stabilizer, Nasal Agent, Ophthalmologic Agent
DOSE: Adult - Allergic rhinitis, NASAL INHALATION, 1 spray/nostril 3-6 times/day; Asthma; Prophylaxis, ORAL INHALATION, 20 mg 4
times/day (nebulizer) or 2 puffs (800 mcg/spray) 4 times/day (metered inhaler), then 3-4 times/day. Pedia - Allergic rhinitis, NASAL
INHALATION (2 y and older), 1 spray/nostril 3-6 times/day, Asthma; Prophylaxis, ORAL INHALATION, 20 mg 4 times/day (2 years and older;
nebulizer) or 2 puffs (800 mcg/spray) 4 times a day (5 years and older; metered inhaler), then 3-4 times/day
CONTRA-INDICATIONS: hypersensitivity to cromolyn products
ADVERSE EFFECTS: Anaphylaxis, Bronchospasm
THERAPEUTIC USE: Cartilaginous Defect Repair Agent, Dermatological Agent, Ophthalmologic Agent, Protectant, Dermatological, Surgical
Aid, Ocular
DOSE: Adult - Cataract surgery; Adjunct a sufficient amount of sodium hyaluronate is slowly and carefully introduced (using a cannula or
needle) into the anterior chamber; injection can be performed either before or after delivery of the lens.
Pedia - safety and effectiveness in children have not been established.
CONTRA-INDICATIONS: hypersensitivity to hyaluronan, active knee joint infections or skin disease at injection site, allergy to avian proteins,
feathers, and egg products
ADVERSE EFFECTS: Inflammatory disorder, Postoperative, including iritis, hypopyon, endophthalmitis, Pseudogout, Raised intraocular
pressure, Postoperative, likely if hyaluronate not removed as completely as possible after surgery, Septic arthritis
THERAPEUTIC USE: Antihypertensive, Peripheral Vasodilator, Coronary Vasodilator, Peripheral Vasodilator
DOSE: Adult & Pedia - Congestive heart failure, initial, 0.3 mcg/kg/min IV infusion, titrate every few min to desired effect; usual dose, 3
mcg/kg/min IV; MAX dose 10 mcg/kg/min.
CONTRA-INDICATIONS: compensatory hypertension (aortic coarctation or atriovenous shunting), congestive heart failure associated with
reduced peripheral vascular resistance, hypersensitivity to nitroprusside, optic atrophy, surgery patients with inadequate cerebral circulation,
symptomatic hypotension, tobacco amblyopia
ADVERSE EFFECTS: Bowel obstruction, Cardiac dysrhythmia, Cyanide poisoning, Hemorrhage, Excessive, decreased platelet aggregation,
Hypotensive episode, Excessive, Metabolic acidosis, Methemoglobinemia, Raised intracranial pressure, Toxicity of drug, Thiocyanate
THERAPEUTIC USE: Indicated as a source of Phosphorous, for addition to large volume IV fluids, to prevent or correct hypophosphatemia in
patients with restricted or no oral intake. It is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the
patient cannot be met by standard electrolyte or nutrient solutions.
DOSE: The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium, phosphorus and calcium
levels should be monitored as a guide to dosage. In TPN approximately 12 to 15 mM of Phosphorus (equivalent to 372 to 465mg elemental
63
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Sodium Stibogluconate
Pentostam
Injection
100mg/mL
Sodium Tetradecyl
Sulphate
STD
Injection 3%
Depakine
Syrup
200mg/3.5mL
Tablet 200mg
Tablet 500mg
Sodium Valproate
Depakine
Chrono
Spironolactone
Aldactone
Syrup 1mg/mL
Tablet 25mg
Tablet 100mg
Sterculia
Normacol Plus
Granules 62%
PRODUCT INFORMATION
phosphorus) per liter bottle of TPN solution containing 250 grams dextrose is usually adequate to maintain normal serum phosphorus. For
infants receiving TPN is 1.5 to 2 mM P/Kg/Day.
CONTRA-INDICATIONS: High Phosphorus or low calcium levels may be encountered and in patients with hypernatremia.
ADVERSE EFFECTS: Possible Phosphorus intoxication results in a reduction of serum calcium and the symptoms are those hypocalcemic
tetany.
THERAPEUTIC USE: Cutaneous leishmaniasis, visceral leishmaniasis
DOSE: Adult - 10-day course (n=19) of sodium stibogluconate 20 mg/kg/day was as effective as a 20-day course in the treatment of
cutaneous leishmaniasis.
Pedia - Recommended intravenous or intramuscular doses of sodium stibogluconate in children are 20 mg of antimony/kg IV or IM once daily
for 20 to 28 days. A longer duration may be necessary for some forms of VISCERAL LEISHMANIASIS, or the African form of the disease
CONTRA-INDICATIONS: Hypersensitivity to SODIUM STIBOGLUCONATE
THERAPEUTIC USE: Sclerosing Agent
DOSE: Adult - Venous varices, 0.5 to 2 mL (preferably 1 mL) IV into the vein intended for sclerosis; the 1% solution is used most often, with
the 3% solution being reserved for larger varicosities; MAX single treatment, do not exceed 10 mL
CONTRA-INDICATIONS: Acute cellulitis, Acute infections, Acute superficial thrombophlebitis, Allergic conditions, Bedridden patients, Huge
superficial veins with wide open communications to deeper veins, Phlebitis migrans, Previous hypersensitivity reactions to the drug,
Significant valvular or deep vein incompetence, Uncontrolled systemic diseases, Varicosities caused by abdominal and pelvic tumors unless
the tumor has been removed
ADVERSE EFFECTS: Anaphylaxis, death reported, Deep venous thrombosis, Necrosis, following extravasation, Pulmonary embolism, Skin
necrosis, following extravasation
THERAPEUTIC USE: Anticonvulsant, Antimigraine, Valproic Acid (class)
DOSE: Adult - Complex partial epileptic seizure a)monotherapy, 10 to 15 mg/kg/day IV, may increase dosage 5 to 10 mg/kg/week to achieve
optimal clinical response (MAX 60 mg/kg/day or less with a therapeutic range of 50 to 100 mcg/mL) b)conversion to monotherapy, 10 to 15
mg/kg/day IV, may increase dosage 5 to 10 mg/kg/week to achieve optimal clinical response (MAX 60 mg/kg/day or less with a therapeutic
range of 50 to 100 mcg/mL); reduce concomitant antiepilepsy drug dosage by approximately 25% every 2 weeks (reduction may be started at
initiation of therapy or delayed by 1 to 2 weeks if there is a concern that seizures are likely to occur with a reduction) c)adjunct, may be added
to the patient's regimen at an initial dosage of 10 to 15 mg/kg/day IV, may increase dosage 5 to 10 mg/kg/week to achieve optimal clinical
response (MAX 60 mg/kg/day or less with a therapeutic range of 50 to 100 mcg/mL). Pedia - safety and effectiveness in pediatric patients
under age 10 have not been established; for children 10 years of age and older, dose as an adult. Complex partial epileptic seizure a)(10 yrs
and older) monotherapy, 10 to 15 mg/kg/day IV, may increase dosage 5 to 10 mg/kg/week to achieve optimal clinical response (MAX 60
mg/kg/day or less with a therapeutic range of 50 to 100 mcg/mL) b)(10 yrs and older) conversion to monotherapy, 10 to 15 mg/kg/day IV, may
increase dosage 5 to 10 mg/kg/week to achieve optimal clinical response (MAX 60 mg/kg/day or less with a therapeutic range of 50 to 100
mcg/mL); reduce concomitant antiepilepsy drug dosage by approximately 25% every 2 weeks (reduction may be started at initiation of therapy
or delayed by 1 to 2 weeks if there is a concern that seizures are likely to occur with a reduction) c)(10 yrs and older) adjunct, may be added
to the patient's regimen at an initial dosage of 10 to 15 mg/kg/day IV, may increase dosage 5 to 10 mg/kg/week to achieve optimal clinical
response (MAX 60 mg/kg/day or less with a therapeutic range of 50 to 100 mcg/mL)
CONTRA-INDICATIONS: hepatic disease or significant hepatic dysfunction, hypersensitivity to valproate sodium, valproic acid, or divalproex
sodium, known urea cycle disorders; hyperammonemic encephalopathy, including fatalities, has occurred
ADVERSE EFFECTS: Liver failure, Children under the age of two years are at increased risk, Pancreatitis, Life-threatening,
Thrombocytopenia, Dose-related
THERAPEUTIC USE: Aldosterone Receptor Antagonist, Antiandrogen, Cardiovascular Agent, Diuretic, Potassium Sparing
DOSE: Adult - Edema - Nephrotic syndrome, initial, 100 mg/day ORALLY (range 25 to 200 mg/day) in single or divided doses; after 5 days,
adjust dosage (MAX 400 mg/day); then if response is inadequate after 5 days, consider adding another diuretic; in some patients, alternateday dosing has been effective. Pedia – NEONATES a)The suggested dosage regimen of spironolactone is 0.5 to 1 mg/kg orally every 8
hours; CHILDREN Usual oral dose of spironolactone in children is 1 to 3 mg/kg/day (1.5 mg/lb) in a single or 2 to 4 divided doses up to a
maximum dose of 200 milligrams/24 hours. The dose should be reduced to 1 to 2 mg/kg for maintenance or when used in combination with
other diuretics
CONTRA-INDICATIONS: anuria, hyperkalemia, hypersensitivity to spironolactone products, renal insufficiency, acute
ADVERSE EFFECTS: Agranulocytosis, Breast cancer, Cause and effect not established, Gastric hemorrhage, Gastritis, Hyperkalemia
(Severe), Metabolic acidosis, Skin ulcer, Systemic lupus erythematosus
THERAPEUTIC USE: Treatment of constipation, particularly simple or idiopathic constipation and constipation arising in pregnancy.
Management of colostomies and ileostomies.
64
PRODUCT
DESCRIPTION
Streptokinase
TRADE
NAME
Streptase
Streptomycin
DOSAGE
FORM/STRENGTH
Injection
750,000units
Injection 1gram
Gastrofatt
Sucralfate
Ulcar
Tablet 500mg
Ulsaheal
Sucrose
Sufentanil
Powder
Sufenta Forte
Injection
0.25mg/5mL
Blephamide
Sulphacetamide
Isopto-Cetamide
Eye Drops 10%
Eye Drops 15%
Riacetamide
PRODUCT INFORMATION
DOSE: Adult – 1 or 2 sachets once or twice daily after meals. Pedia - (6 to 12 years) one half of the adult dose; Under 6 years – only at the
discretion of the doctor. The granules should be placed dry on the tongue and, without chewing or crushing, swallowed immediately with
plenty of liquid (water or a cool drink).
CONTRA-INDICATIONS: Intestinal obstruction, faecal impaction and total atony of the colon.
ADVERSE EFFECTS: Occasionaly mild abdominal distention, oesophageal obstruction is possible if the product is taken in overdosage or if it
is not adequately washed down with fluid.
THERAPEUTIC USE: Thrombolytic, Tissue Plasminogen Activator
DOSE: Adult - Thromboembolic disorder, Arterial, loading dose, 250,000 international units IV over 30 min, then 100,000 international units/h
for 24 hr. Pedia - Thromboembolic disorder, Arterial, loading dose, 1000 international units/kg IV over 5-30 min; continuous infusion, 1000
international units/kg/h for up to 24 h
CONTRA-INDICATIONS: hypersensitivity to streptokinase products, severe uncontrolled hypertension, active internal bleeding, recent
intracranial or intraspinal surgery or trauma (within 2 months), intracranial neoplasm, arteriovenous malformation, or aneurysm, known
bleeding diathesis, history of cerebrovascular accident (within 2 months)
ADVERSE EFFECTS: Anaphylactoid reaction, Anaphylaxis, Bleeding, Major, Bradyarrhythmia, Cardiac dysrhythmia, Reperfusion,
Cholesterol embolus syndrome, Non-cardiogenic pulmonary edema, Polyneuropathy, Tachyarrhythmia
THERAPEUTIC USE: Aminoglycoside, Antibiotic, Antitubercular
DOSE: Adult – Tuberculosis, 15 mg/kg/day IM once a day (maximum 1 g/day), or 25-30 mg/kg/dose 2-3 times weekly (maximum 1.5 g/dose)
in combination with other antitubercular antibiotics for the first 2 months of therapy; maximum total dose 120 g/course. Pedia –Tuberculosis,
20-40 mg/kg IM once a day (maximum 1 g/day), or 25-30 mg/kg IM 2-3 times weekly (maximum 1.5 g/day) in combination with other
antitubercular antibiotics for the first 2 months of therapy; maximum total dose 120 g/course.
CONTRA-INDICATIONS: hypersensitivity to streptomycin/aminoglycosides, hypersensitivity to sulfites
ADVERSE EFFECTS: Arachnoiditis, Disorder of inner ear, Disorder of optic nerve, Encephalopathy, Nephrotoxicity, Neuromuscular blockade
finding Concomitant anesthesia, muscle relaxants, Peripheral neuritis, Respiratory tract paralysis Concomitant anesthesia, muscle relaxants
THERAPEUTIC USE: Antiulcer, Protectant
DOSE: Adult - Duodenal ulcer disease, Active, treatment, 1 gram ORALLY 4 times daily or 2 grams twice daily for 4 to 8 weeks. Pedia safety and efficacy in pediatric patients not established. Duodenal ulcer disease, Active, treatment, 40 to 80 mg/kg/day ORALLY divided every
6 hours OR 0.5 to 1 gram 4 times daily
CONTRA-INDICATIONS: hypersensitivity to sucralfate products
ADVERSE EFFECTS: Aluminum toxicity, Renal impaired patients, Bezoar
THERAPEUTIC USE: Principally as a pharmaceutical necessity for making syrups and lozenges. It gives viscosity and consistency to fluids.
THERAPEUTIC USE: Analgesic, Anesthetic Adjunct, Opioid
DOSE: Adult - dosage should be individualized, General anesthesia primary anesthetic agent, 8-30 mcg/kg IV with 100% oxygen and a
muscle relaxant, then 0.5-10 mcg/kg as needed in response to signs of lightening of anesthesia; MAX 30 mcg/kg/procedure; analgesic
adjunct to balanced general anesthesia, 1-8 mcg/kg IV (approximately 1 mcg/kg/hr of estimated surgical duration); 75% given prior to
intubation, then incrementally as 10-50 mcg IV as needed in response to signs of lightening of analgesia. Pedia - General anesthesia,
cardiovascular surgery (age under 12 yr) 10-25 mcg/kg with 100% oxygen, additional doses up to 25-50 mcg for maintenance of anesthesia
CONTRA-INDICATIONS: hypersensitivity to sufentanil, intolerance to opioid agonists
ADVERSE EFFECTS: Anaphylaxis, Cardiac arrest, Hypertension, Muscle rigidity, Respiratory depression
THERAPEUTIC USE: Antiacne Antibacterial, Antibiotic, Antiseborrheic, Dermatological Agent, Sulfonamide
DOSE: Adult – Bacterial infection of eye, Superficial infections including conjunctivitis a)ophthalmic solution, 1-2 drops into conjunctival
sac(s) of affected eye(s) every 2-3 hr initially; taper by increasing time intervals as condition responds; usual duration 7-10 days. Pedia –
Bacterial infection of eye, Superficial infections including conjunctivitis a)(2 months of age and older) ophthalmic solution, 1-2 drops into
conjunctival sac(s) of affected eye(s) every 2-3 hr initially; taper by increasing time intervals as condition responds; usual duration 7-10 days
CONTRA-INDICATIONS: hypersensitivity to sulfonamide products
Sulpiride
Dogmatil
Genprid
Capsule 50mg
THERAPEUTIC USE: Dopamine Antagonist
DOSE: Adult – oral dose of sulpiride in the treatment of Schizophrenia is 200 to 400mg twice daily, with gradual increases based on clinical
response to a max. of 1200 mg daily
CONTRA-INDICATIONS: Hypersensitivity to sulpiride, Pheochromocytoma, Parkinson's disease
Sulprostone
Nalador
Injection
500mcg
THERAPEUTIC USE: Prostaglandin
DOSE: Adult – Cervical ripening procedure, Intracervical application of 50 to 100 mcg of sulprostone gel has been used to induce cervical
priming prior to first-trimester abortion. The drug was given 6 to 8 hours prior to curettage
65
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
PRODUCT INFORMATION
CONTRA-INDICATIONS: Hypersensitivity to sulprostone, Acute pelvic inflammatory disease, Uterine scars
Suxamethonium Chloride
Anectine
Midarine
Injection
100mg/2mL
Tamoxifen Citrate
Nolvadex
Tablet 10mg
Teicoplanin
Targocid
Injection 200mg
Injection
10,000units
Tenecteplase
Terbinafine HCl
Lamifen
Lamisil
Injection
40iu/0.5mL
Tetanus Toxoid (Purified)
Tetracosactrin
Tablet 250mg
Synacthen
Inj. 250mcg/mL
Inj. 1mg/mL
THERAPEUTIC USE: Musculoskeletal Agent, Neuromuscular Blocker, Depolarizing, Skeletal Muscle Relaxant
DOSE: Adult – Induction of neuromuscular blockade, Adjunct to general anesthesia, to facilitate endotracheal intubation, and to provide
skeletal muscle relaxation during surgery or mechanical ventilation a)short procedures, 0.6 mg/kg IV (range 0.3 to 1.1 mg/kg) over 10 to 30
seconds b)long procedures, 2.5 to 4.3 mg/min continuous IV infusion c)long procedures, 0.3 to 1.1 mg/kg IV initially followed by 0.04 to 0.07
mg/kg at appropriate intervals d)3 to 4 mg/kg IM, if suitable vein is inaccessible; MAX 150 mg. Pedia – emergency tracheal intubation, infants
and small pediatric patients, 2 mg/kg IV
CONTRA-INDICATIONS: acute phase of major trauma/major burns, extensive denervation of skeletal muscle, hypersensitivity to
succinylcholine, personal or familial history of malignant hyperthermia, skeletal muscle myopathies, upper motor neuron injury
ADVERSE EFFECTS: Apnea, Bradyarrhythmia, Especially in children, Cardiac arrest
Cardiac dysrhythmia, Especially in children, Hyperkalemia, Immune hypersensitivity reaction, Malignant hyperthermia, Prolonged
neuromuscular block, Respiratory depression, Rhabdomyolysis, With myoglobinemia, in children, Tachyarrhythmia
THERAPEUTIC USE: Antiestrogen
DOSE: Adult – Adjuvant treatment for breast cancer, 20 to 40 mg ORALLY daily for 5 years. Pedia – safety and efficacy beyond one year of
therapy has not been established in girls aged 2 to 10 years treated for McCune-Albright Syndrome and precocious puberty
CONTRA-INDICATIONS: concomitant coumarin-type anticoagulant therapy; deep vein thrombosis, hypersensitivity to tamoxifen citrate or
any component of the product, pulmonary embolus
ADVERSE EFFECTS: Cataract surgery, Cerebrovascular accident, Malignant neoplasm of endometrium of corpus uteri, Pulmonary
embolism, Sarcoma of uterus
THERAPEUTIC USE: Antibiotic, Glycopeptide
DOSE: Adult – IM and IV in clinical trials in loading doses of 12 mg/kg, with 3 to 6 mg/kg/day as a single daily maintenance dose. The loading
dose can be given as 2 doses at 12 hour intervals. Alternatively, 400 to 600 mg of IV teicoplanin can be given as a single loading dose, and
followed with 200 to 600 mg either IV or IM once daily for maintenance therapy. Pedia – IV was effective and well tolerated when dosed at 3
to 6 mg/kg/day in children 2 to 12 years old for the treatment of gram-positive infections
CONTRA-INDICATIONS: Hypersensitivity to teicoplanin
ADVERSE EFFECTS: Hypersensitivity reaction
THERAPEUTIC USE: Thrombolytic, Tissue Plasminogen Activator
DOSE: Adult – Acute myocardial infarction, less than 60 kg, give 30 mg; 60 to 69 kg, give 35 mg; 70 to 79 kg, give 40 mg; 80 to 89 kg, give
45 mg; 90 kg or above, give 50 mg; administer single IV bolus over 5 seconds. Pedia - safety and efficacy have not been established in
pediatric patients
CONTRA-INDICATIONS: active internal bleeding, hypersensitivity to tenecteplase, history of cerebrovascular accident, intracranial or
intraspinal surgery or trauma within 2 months intracranial neoplasm, arteriovenous malformation, or aneurysm, known bleeding diathesis,
severe uncontrolled hypertension, intracranial aneurysm
ADVERSE EFFECTS: Anaphylaxis, Bleeding, Major, Cardiac dysrhythmia, Reperfusion, Cerebrovascular accident, Cholesterol embolus
syndrome, Immune hypersensitivity reaction, Intracranial hemorrhage
THERAPEUTIC USE: Allylamine, Antifungal
DOSE: Adult – Onychomycosis due to dermatophyte; ORAL, 250 mg daily for 6 wk for fingernails; 12 wk for toenails. Pedia – Tinea capitis,
less than 25 kg, 125 mg/day ORALLY; 25 to 35 kg, 187.5 mg/day ORALLY; greater than 35 kg, 250 mg/day ORALLY
CONTRA-INDICATIONS: hypersensitivity to terbinafine products
ADVERSE EFFECTS: Agranulocytosis, Cutaneous lupus erythematosus, Erythema multiforme, Liver failure, Neutropenic disorder,
Pancytopenia, Stevens-Johnson syndrome, Systemic lupus erythematosus, Toxic epidermal necrolysis
THERAPEUTIC USE: Toxoid
DOSE: Adult – Tetanus; Prophylaxis, 0.5 mL IM x 3 doses given at 0 and 4-8 weeks, and at 6-12 months after second dose; booster dose
every 10 years. Pedia – Not for use in children less than 7 years of age. Tetanus; Prophylaxis, (7 years and older) 0.5 mL IM x 3 doses given
at 0 and 4-8 weeks, and at 6-12 months after second dose; booster dose every 10 years
CONTRA-INDICATIONS: febrile illness or acute infection; defer vaccination, history of systemic allergic or neurologic reactions to previous
injection of the vaccine; only passive immunization should be given using Tetanus Immune Globulin (Human) (TIG),
hypersensitivity to any component of the vaccine, including thimerosal
ADVERSE EFFECTS: Anaphylaxis, Arthus type urticaria
THERAPEUTIC USE: Diagnostic Agent, Adrenocortical Function, Endocrine-Metabolic Agent, Pituitary Hormone, Anterior
DOSE: Adult – Adrenal insufficiency, Standard-dose; Diagnosis a)0.25 to 0.75 mg IM or IV over 2 min, diluted in NS b)IV infusion 0.04 mg/h
66
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Synacthen
Depot
Tetracycline
Theophylline
Hostacycline
Laticyn
Teracin
Eye Ointment 1%
Ointment 3%
Tablet 250mg
Quibron-T/SR
Tablet 300mg
Theoped
Thioguanine
Lanvis
Tablet 40mg
Thiopentone Sodium
(Thiopental)
Intraval
Injection 500mg
Thrombin
Tianeptine
Tigecycline
Topical 5000iu
Stablon
Tygacil
Tablet 12.5mg
Injection 50mg
PRODUCT INFORMATION
over 6 h, diluted in glucose or saline solutions. Pedia – Adrenal insufficiency, Standard-dose; Diagnosis a)(2 y of age or less) 0.125 mg IM or
IV over 2 min, diluted in NS b)(over 2 y) 0.25 to 0.75 mg IM or IV over 2 min, diluted in NS
CONTRA-INDICATIONS: history of hypersensitivity to cosyntropin
ADVERSE EFFECTS: Immune hypersensitivity reaction, Pancreatitis
THERAPEUTIC USE: Amebicide, Intestinal, Antiacne, Antibacterial, Antibiotic, Antiprotozoal, Antiulcer, Helicobacter Pylori
DOSE: Adult – Amebic infection, 1 g/day ORALLY divided in 2 to 4 equal doses; severe, 500 mg ORALLY 4 times daily. Pedia – Amebic
infection (older than 8 years) 25 to 50 mg/kg/day ORALLY divided in 4 equal doses
CONTRA-INDICATIONS: hypersensitivity to tetracycline products, last half of pregnancy/infancy/childhood up to 8 years of age
ADVERSE EFFECTS: Bulging fontanelle
THERAPEUTIC USE: Bronchodilator, Methylxanthine
DOSE: Adult – extended-release 12 h formulation, initial, 300 mg/day ORALLY divided every 12 h; after 3 days if tolerated, 400 mg/day
ORALLY divided every 12 h; after 3 more days if tolerated, 600 mg/day ORALLY divided every 12 h. Pedia – extended-release 12 h
formulation, less than 45 kg, initial, 12 to 14 mg/kg/day (MAX 300 mg/day) ORALLY divided every 12 h; after 3 days if tolerated, 16 mg/kg/day
(MAX 400 mg/day) ORALLY divided every 12 h; after 3 more days if tolerated, 20 mg/kg/day (MAX 600 mg/day) ORALLY divided every 12 hr.
CONTRA-INDICATIONS: hypersensitivity to theophylline, or to any product component, known allergy to corn or corn products; in dextrose
containing solutions.
ADVERSE EFFECTS: Atrial fibrillation, Intracranial hemorrhage, Seizure, Stevens-Johnson syndrome, Tachyarrhythmia
THERAPEUTIC USE: Antimetabolite, Antineoplastic Agent
DOSE: Adult – Acute myeloid leukemia, Induction and consolidation therapy only, single agent, 2 mg/kg/day ORALLY; after 4 wk may
increase to 3 mg/kg/day if no improvement or myelosuppression; adjust accordingly for combination therapy. Pedia – Acute myeloid
leukemia, Induction and consolidation therapy only, single agent, 2 mg/kg/day ORALLY; after 4 wk may increase to 3 mg/kg/day if no
improvement or myelosuppression; adjust accordingly for combination therapy
CONTRA-INDICATIONS: Patients whose disease has demonstrated prior resistance to thioguanine or mercaptopurine
ADVERSE EFFECTS: Gastrointestinal necrosis, With combination regimens, Hepatotoxicity, Hyperuricemia, Infectious disease, Jaundice,
Liver function tests abnormal, Myelosuppression, Perforation of intestine
THERAPEUTIC USE: Anesthetic Adjunct, Barbiturate, Short Acting
DOSE: Adult – General anesthesia, slow induction, 50 to 75 mg (2 to 3 mL of 2.5% solution) slow IV, single dose at 20 to 40 sec intervals;
rapid induction, 210 to 280 mg (3 to 4 mg/kg) IV divided in 2 to 4 doses; maintenance, 25 to 50 mg IV repeated as needed or continuous IV
infusion of 0.2% or 0.4% solution. Pedia – not FDA approved for use in pediatric patients. General anesthesia a)induction, (neonate) 3 to 4
mg/kg; (1 to 6 month) 5 to 8 mg/kg IV; (1 to 15 y) 5 to 6 mg/kg IV b)(age 1 to 15 y) maintenance, intermittent IV 1mg/kg as needed
CONTRA-INDICATIONS: absence of suitable veins for intravenous administration, acute intermittent porphyria or variegate porphyria,
hypersensitivity to thiopental products/barbiturate
ADVERSE EFFECTS: Anaphylaxis, Apnea, Finding of intracranial pressure, Hemolytic anemia, Laryngeal spasm, Myocardial dysfunction,
Radial neuropathy, Respiratory depression
THERAPEUTIC USE: Hemostatic
DOSE: Adult - Control of hemorrhage, mild/moderate, apply 100 units/mL TOPICALLY as needed; severe, apply 1000 units/mL TOPICALLY
as needed. Pedia - safety and efficacy in children have not been established
CONTRA-INDICATIONS: hypersensitivity to thrombin or components of bovine origin, direct circulatory injection; extensive intravascular
clotting and even death may occur.
ADVERSE EFFECTS: Antibody development
THERAPEUTIC USE: Antidepressant, Tricyclic, Dibenzothiazepine
DOSE: Adult – Depression, 25 to 50mg daily effective (usually 3 divided doses; 2 or 4 times daily in some studies)
CONTRA-INDICATIONS: Prior hypersensitivity to tianeptine
THERAPEUTIC USE: Antibiotic, Glycylcycline
DOSE: Adult – Infection of skin &/or subcutaneous tissue, Complicated, initial dose is 100 mg IV followed by 50 mg IV every 12 hours;
duration is for 5 to 14 days depending on the severity and site of infection and clinical and bacteriological progress; Infectious disease of
abdomen, Complicated, initial dose is 100 mg IV followed by 50 mg IV every 12 hours; duration is for 5 to 14 days depending on the severity
and site of infection and clinical and bacteriological progress. Pedia – not recommended in patients under 18 years of age; safety and efficacy
not established
CONTRA-INDICATIONS: hypersensitivity to tigecycline
ADVERSE EFFECTS: Pancreatitis, acute
67
PRODUCT
DESCRIPTION
Timolol Maleate
TRADE
NAME
Apimol
Ocumol
DOSAGE
FORM/STRENGTH
Eye Drops 0.25%
Eye Drops 0.5%
Tinzaparin Sodium
Innohep
Injection 3500iu
Injection 4500iu
Inj. 14,000iu
Inj. 20,000iu
Tirofiban
Aggrastat
Injection
0.25mg/mL
Tobramycin
/Dexamethasone
Tobradex
Eye Ointment
Tocopherol
Evion
Capsule 400mg
Tablet 100mg
Tolterodine
Detrusitol
Tablet 2mg
Topiramate
Topamax
Tablet 25mg
Tablet 100mg
Tablet 200mg
PRODUCT INFORMATION
THERAPEUTIC USE: Antianginal, Antiglaucoma, Antihypertensive, Antimigraine, Beta-Adrenergic Blocker, Nonselective, Cardiovascular
Agent
DOSE: Adult – Open-angle glaucoma a)1 drop (0.25%-0.5%) in affected eye(s) once or twice daily b)1 drop (0.25%-0.5%) in affected eye(s)
once daily c)1 drop (0.5% solution) in affected eye(s) once daily in the morning. Pedia – Open-angle glaucoma, 1 drop (0.25%-0.5% gelforming solution) in affected eye(s) once daily
CONTRA-INDICATIONS: bronchial asthma or chronic obstructive pulmonary disease, cardiogenic shock, hypersensitivity to timolol, overt
cardiac failure, second and third degree AV block, severe sinus bradycardia
ADVERSE EFFECTS: Bronchospasm, Cardiac dysrhythmia, Myocardial infarction
THERAPEUTIC USE: Anticoagulant, Low Molecular Weight Heparin
DOSE: Adult – 100 international units antifactor Xa activity equals 1 mg tinzaparin sodium Deep venous thrombosis, In conjunction with
warfarin, 175 international units anti-Xa/kg SC once daily for at least 6 days and until the patient is adequately anticoagulated with warfarin.
Pedia – safety and efficacy in children have not been established
CONTRA-INDICATIONS: active major bleeding, hypersensitivity to tinzaparin, heparin, sulfites, pork prod, history of heparin-induced
thrombocytopenia, history of tinzaparin-induced thrombocytopenia
ADVERSE EFFECTS: Anaphylaxis, Granulocytopenic disorder, Hemorrhage, Major, Pancytopenia, Priapism, Thrombocytopenia
THERAPEUTIC USE: Glycoprotein Iib/IIIa Inhibitor, Platelet Aggregation Inhibitor
DOSE: Adult – Acute coronary syndrome, 0.4 mcg/kg/min IV for 30 min then 0.1 mcg/kg/min for 12-24 hr after angioplasty/atherectomy.
Pedia – safety and efficacy in pediatric patients have not been established
CONTRA-INDICATIONS: aortic dissection, bleeding, major surgery, trauma, stroke within 30 days, concomitant use of another parenteral
GPIIb/IIIa inhibitor, hemorrhagic stroke, history of intracranial hemorrhage, neoplasm, arteriovenous malformation, or aneurysm,
hypersensitivity to tirofiban or other product components, pericarditis, severe hypertension, thrombocytopenia following prior tirofiban
administration
ADVERSE EFFECTS: Bleeding, Major, Dissecting aneurysm of coronary artery, Thrombocytopenia
THERAPEUTIC USE: Aminoglycoside/Corticosteroid Combination
DOSE: Adult – Bacterial infection of eye; Treatment and Prophylaxis – Inflammatory disorder of the eye, Steroid-responsive a)ophthalmic
ointment, apply one-half inch ribbon OPHTHALMICALLY into conjunctival sac(s) 3 to 4 times daily b)ophthalmic suspension, initial, 1 to 2
drops OPHTHALMICALLY every 2 h for 24 to 48 h, then 1 to 2 drops every 4 to 6 h. Pedia – Bacterial infection of eye; Treatment and
Prophylaxis – Inflammatory disorder of the eye, Steroid-responsive a)2 y and older, ophthalmic ointment, apply one-half inch ribbon
OPHTHALMICALLY into conjunctival sac(s) 3 to 4 times daily b)2 y and older, ophthalmic suspension, initial, 1 to 2 drops
OPHTHALMICALLY every 2 h for 24 to 48 h, then 1 to 2 drops every 4 to 6 h
CONTRA-INDICATIONS: viral or mycobacterial infection of the eye, fungal diseases of the eye, hypersensitivity to tobramycin or
dexamethasone
ADVERSE EFFECTS: Glaucoma, Raised intraocular pressure, Secondary infection
THERAPEUTIC USE: Colorectal Agent, Emollient, Nutritive Agent, Protectant, Dermatological, Vitamin E (class)
DOSE: Adult – Vitamin E deficiency is 4 to 5 times the Recommended Dietary Allowance (RDA) (15 milligrams/day for adults). Doses as high
as 300 milligrams may be necessary. Pedia – Vitamin E deficiency a)Premature or low-birth-weight neonates: vitamin E 25 to 50 units/day
results in normal plasma tocopherol levels in 1 week b)Children with malabsorption syndrome: water-miscible vitamin E 1 unit/kilogram/day
(to raise plasma tocopherol to within the normal range within 2 months and to maintain normal plasma concentrations)
CONTRA-INDICATIONS: Intravenous use in infants
THERAPEUTIC USE: Antimuscarinic, Urinary Antispasmodic
DOSE: Adult – Bladder muscle dysfunction – overactive, With symptoms of urinary frequency, urgency, or urge incontinence a)2 mg
ORALLY twice daily (immediate-release); may adjust dose to 1 mg twice daily (immediate-release) depending on tolerability and response b)4
mg ORALLY once daily (extended-release); may adjust dose to 2 mg once daily (extended-release) depending on tolerability and response.
Pedia – safety and effectiveness in pediatric patients has not been established
CONTRA-INDICATIONS: gastric retention, hypersensitivity to tolterodine products, uncontrolled narrow-angle glaucoma, urinary retention
ADVERSE EFFECTS: Anaphylactoid reaction, Angioedema, Dementia, Memory impairment
THERAPEUTIC USE: Anticonvulsant, Fructopyranose Sulfamate
DOSE: Adult & Pedia – Partial seizure, Initial monotherapy, 1st week, 25 mg ORALLY twice daily (morning and evening); 2nd week, 50 mg
ORALLY twice daily; 3rd week, 75 mg ORALLY twice daily; 4th week, 100 mg ORALLY twice daily; 5th week, 150 mg ORALLY twice daily; 6th
week (maximum dose) 200 mg ORALLY twice daily. Pedia – Efficacy in seizures not established in children under 2 years of age. Pedia –
Partial seizure, Initial monotherapy
CONTRA-INDICATIONS: Hypersensitivity to topiramate
68
PRODUCT
DESCRIPTION
Trace Elements
TRADE
NAME
Peditrace
Tracutil
Tragacanth
Injection Adult
Injection Pedia
Powder
Tramadol HCl
Tramal
Tranexamic Acid
Cyklokapron
Tretinoin
DOSAGE
FORM/STRENGTH
Caspule 50mg
Inj. 100mg/2mL
SR Tablet 100mg
Inj. 100mg/mL
Tablet 500mg
Acretine
Retin-A
Cream 0.05%
Triamcinolone
Acetonide
Kenacort
Injection
40mg/mL
Trihexyphenidyl HCl
Artane
Tablet 2mg
Tablet 5mg
PRODUCT INFORMATION
ADVERSE EFFECTS: Anemia, Body temperature above normal, Dyspnea, Hepatitis,
Hyperammonemia, With or without encephalopathy, Hyperchloremia, Hypohidrosis, Leukopenia, Liver failure, Metabolic acidosis, normal
anion gap (NAG),Nephrolithiasis
Pancreatitis, Renal tubular acidosis
THERAPEUTIC USE: Intended to meet the basal requirement of trace elements during IV nutrition of Adults, children and infants.
DOSE: Adult – recommended daily dose in patients with basal requirements is 10mL (1ampoule), moderately increased requirements the
daily dose may be up to 20mL (2amp.) accompanied by monitoring of the trace element status. Pedia – 1mL/Kg/Day to a max. dose of 15mL
CONTRA-INDICATIONS: Wilson's disease
THERAPEUTIC USE: Suspending agents in lotions, mixtures and extemporaneous preparations and prescriptions. It is used with emulsifying
agents largely to increase consistency and retard creaming. It is sometimes used as a demulcent in sore throat and the jelly-like product
formed when the gum is allowed to swell in water serves as a basis for pharmaceutical jellies, also used in various confectionery products and
as a pill excipient.
THERAPEUTIC USE: Analgesic, Opioid
DOSE: Adult - Pain, Moderate to moderately severe a)(immediate-release) titration schedule, 25 mg/day ORALLY every morning, titrated in
25 mg increments as separate doses every 3 days to reach 25 mg 4 times daily; then, may increase total daily dose by 50 mg as tolerated to
reach 50 mg 4 times daily; after titration, 50 to 100 mg ORALLY every 4-6 as needed can be used; MAX 400 mg/day b)(immediate-release)
rapid analgesic onset, 50 to 100 mg ORALLY every 4-6 h; MAX 400 mg/day c)(extended-release) 100 mg ORALLY once daily, may titrate up
by 100-mg increments every 5 days if necessary; MAX 300 mg/day. Pedia - safety and efficacy in patients under 16 years of age has not
been established a dosage of 50 to 100 milligrams (mg) every 4 to 6 hours can be administered as needed, to a maximum of 400 mg/day
CONTRA-INDICATIONS: hypersensitivity to tramadol, any other components of the product, or opioids, intoxication with alcohol, hypnotics,
narcotics, centrally acting analgesics, opioids, or psychotropic drugs; may worsen central nervous system and respiratory depression
ADVERSE EFFECTS: Anaphylactoid reaction, Dyspnea, Hallucinations, Impaired cognition, Orthostatic hypotension, Seizure, Syncope,
Tachyarrhythmia
THERAPEUTIC USE: Hemostatic
DOSE: Adult - Gastrointestinal hemorrhage, 1 gm IV every 4-6 hours for 2-3 days followed by 1.5 gm ORALLY 3-4 times a day for 3-7 days.
Pedia - Hemophilia - Hemorrhage; Prophylaxis - Tooth extraction; pre-op, 10 mg/kg IV as a single dose with replacement therapy immediately
prior to extraction or 25 mg/kg ORALLY 3-4 times a day beginning one day before surgery
CONTRA-INDICATIONS: active intravascular clotting process, acquired defective color vision, subarachnoid hemorrhage, hypersensitivity to
tranexamic acid
ADVERSE EFFECTS: Thrombotic disorder
THERAPEUTIC USE: Antiacne, Antineoplastic Agent, Dermatological Agent, Retinoid
DOSE: Adult - Acne vulgaris, apply 0.025%-0.1% cream or 0.05% LIQ topically at bedtime; Hyperpigmentation of skin, Facial mottling; with
comprehensive skin care and sunlight avoidance programs; Adjunct - apply 0.05% cream at bedtime.
Pedia - Acute promyelocytic leukemia, FAB M3, Induction therapy in patients who are refractory to, or have relapsed from, anthracycline
chemotherapy, 1 y and older, 45 mg/m(2)/day ORALLY (divided twice daily) for 90 days or 30 days past complete remission whichever comes
first
CONTRA-INDICATIONS: hypersensitivity to tretinoin or parabens
ADVERSE EFFECTS: Disorder of skin pigmentation, Topical, Dyspnea, Fever, Leukocytosis, Oral, Pericardial effusion, Pleural effusion,
Pseudotumor cerebri, Oral; especially pediatrics, Pulmonary infiltrate, Retinoid adverse reaction, Headache, N/V, fever, skin dryness, bone
pain, Weight gain
THERAPEUTIC USE: Adrenal Glucocorticoid, Anti-Inflammatory, Corticosteroid, Intermediate, Dental Agent, Endocrine-Metabolic Agent,
Immune Suppressant
DOSE: Adult - Acquired hemolytic anemia, IM, initial, 2.5 to 60 mg/day injected deeply into the gluteal muscle, doses can be adjusted
between 20 to 80 mg/day as needed. Pedia - Acquired hemolytic anemia, 6 to 12 y, IM, initial, 40 mg/day injected deeply into the gluteal
muscle, dose may vary upon severity of symptoms
CONTRA-INDICATIONS: hypersensitivity to triamcinolone acetonide or any other ingredients in the preparation, local viral, fungal, or
bacterial infections, status asthmaticus, acute asthma
ADVERSE EFFECTS: Cataract, Glaucoma, Hyperglycemia, Primary adrenocortical insufficiency, Pulmonary tuberculosis
THERAPEUTIC USE: Anticholinergic, Antiparkinsonian
DOSE: Adult - Parkinson's disease, initial, 1 mg/day ORALLY on first day, then increase in 2 mg increments at 3 to 5 day intervals; 6 to 10
mg normal daily dose; 12 to 15 mg/day postencephalitic; maintenance, 5 to 15 mg ORALLY DAILY (divided 3 to 4 times daily). Pedia - safety
and efficacy have not been established in pediatric patients
69
PRODUCT
DESCRIPTION
TRADE
NAME
DOSAGE
FORM/STRENGTH
Triprolidine/Pseudoephedrine
Actifed
Flucare
Sedofan
Tropicamide
Mydriacyl
Eye Drops 0.5%
Eye Drops 1%
Eye Minims 0.5%
Tropisetron
Navoban
Capsule 5mg
Inj. 5mg/5mL
Injection 2iu
Injection 10iu
Tuberculin
Ursodeoxycholic Acid
Vancomycin
Varicella Zoster
Virus Vaccine
Syrup
Urdox
Tablet 300mg
Ursofalk
Vancoled
Injection 500mg
Vancolon
Varilrix
Injection
PRODUCT INFORMATION
CONTRA-INDICATIONS: glaucoma, narrow-angle, hypersensitivity to trihexyphenidyl or any of tablet or elixir ingredients, under 3 years of
age, tardive dyskinesias
ADVERSE EFFECTS: Angle-closure glaucoma, Disorientated, Raised intraocular pressure
THERAPEUTIC USE: For the symptomatioc relief of upper respiratory tract disorders which are benefited by a combination of a histamine
receptor antagonist and a nasal decongestant, includes allergic rhinitis, vasomotor rhinitis, common cold and influenza.
DOSE: Adult – 10mL three times daily. Pedia (6 -12 years) 5mL three times daily; (2 to 5years) – 2.5mL three times daily; (6months – under
2years) 1.25mL three times daily.
CONTRA-INDICATIONS: Severe hypertension, monoamine oxidase inhibitors, antibacterial agent Furazolidone, exhibited intolerance to it or
to any of its constituents.
ADEVERSE EFFECTS: CNS depression, drowsiness, sleep disturbances, skin rashes, tachycardia, dryness of the mouth, urinary retention.
THERAPEUTIC USE: Antimuscarinic, Mydriatic-Cycloplegic
DOSE: Adult - Cycloplegia - Mydriasis induction a)examination of fundus, 1 to 2 drops 0.5% solution in the eye(s) 15 to 20 min prior to exam
b)refractive procedures, 1 to 2 drops 1% solution in the eye(s), may be repeated in 5 min. Pedia - Cycloplegia - Mydriasis induction
a)examination of fundus, 1 to 2 drops of 0.5% solution in the eye(s) 15 to 20 min prior to exam b)refractive procedures, 1 to 2 drops of 0.5%
or 1% solution in the eye(s), may be repeated in 5 min
CONTRA-INDICATIONS: primary glaucoma or a tendency toward glaucoma, sensitivity to tropicamide
ADVERSE EFFECTS: Abnormal behavior, Systemic absorption, Cardiac arrest, Confusion, Increased heart rate, Light intolerance, Psychotic
disorder, Raised intraocular pressure, Xerostomia
THERAPEUTIC USE: Serotonin Receptor Antagonist, 5-HT3
DOSE: Adult - Chemotherapy-induced nausea and vomiting, 5 mg IV on the day of chemotherapy (15 minutes prior to chemotherapy
regimens), followed by oral doses of 5 mg every 6 to 24 hours on subsequent days (for up to 7 days). Pedia -Postoperative nausea and
vomiting; Prophylaxis, single dose of tropisetron (0.1mg/kg up to a maximum of 5 mg) was more effective than placebo in preventing
postoperative nausea and vomiting in children using morphine patient-controlled analgesia (PCA). After induction of anesthesia, tropisetron
was given intravenously. At the end of surgery.
CONTRA-INDICATIONS: Hypersensitivity to tropisetron
THERAPEUTIC USE: Diagnostic Agent, Tuberculin
DOSE: Adult - Tuberculosis; Diagnosis, Mantoux test, inject 0.1 mL (5 tuberculin units) INTRADERMALLY. Pedia - Tuberculosis; Diagnosis,
Mantoux test, inject 0.1 mL (5 tuberculin units) INTRADERMALLY
CONTRA-INDICATIONS: hypersensitivity to tuberculin purified protein derivative, previous severe reaction (eg, vesiculation, ulceration,
necrosis)
ADVERSE EFFECTS: Injection site disorder, Vesiculation, Necrosis, Skin ulcer
THERAPEUTIC USE: Gastrointestinal Agent
DOSE: Adult - Chemodissolution of bile duct stone, 8 to 10 mg/kg/day ORALLY divided into 2 to 3 doses; Gallstone, During rapid weight loss;
Prophylaxis, 300 mg. Pedia - safety and effectiveness pediatric patients have not been established
CONTRA-INDICATIONS: hypersensitivity to bile acids or ursodiol, calcified cholesterol stones, radiopaque stones, radiolucent bile pigment
stones, compelling reason for cholecystectomy
THERAPEUTIC USE: Antibiotic, Glycopeptide
DOSE: Adult - Staphylococcal enterocolitis, 500mg to 2g orally daily divided every 6 to 8 hours for 7 to 10 days; Staphylococcal infectious
disease, methicillin-resistant, 2 grams/day IV divided every 6-12 hr administered over at least 60 minutes. Pedia - Staphylococcal
enterocolitis, 40mg/kg/day orally divided every 6 to 8 hr for 7 to 10 days; max. is 2 g daily; Staphylococcal infectious disease, methicillinresistant, 10mg/kg IV every 6 hr administered over at least 60 min.; max. 2 g/day; infants and neonates, initial, 15 mg/kg IV, followed by 10
mg/kg IV every 12 hr (administered over at least 60 min.) for neonates in the 1st week of life, and every 8hr from the second to 4th week of life
CONTRA-INDICATIONS: hypersensitivity to vancomycin products, solutions containing dextrose (pre-mixed solutions in GALAXY plastic
container); may be contraindicated in patients with known corn or corn product allergies
ADVERSE EFFECTS: Anaphylaxis, Nephrotoxicity, Neutropenia, Ototoxicity, Thrombocytopenia
THERAPEUTIC USE: Vaccine
DOSE: Adult - Varicella, Varivax(R); Prophylaxis, 0.5 mL SUBQ x 2 doses, at 0 and 4 to 8 wks. Pedia - safety and effectiveness in children
below the age of 12 months have not been established. Varicella, Prophylaxis a)(13 y and older) 0.5 mL SUBQ x 2 doses, at 0 and 4 to 8 wks
b)(12 mo to 12 y) 0.5 mL SUBQ; the ACIP recommends the first dose at 12 to 18 mo and a second dose at 4 to 6 y
CONTRA-INDICATIONS: anaphylactoid/anaphylactic reaction to neomycin, anaphylactoid/anaphylactic reaction to gelatin, blood dyscrasias,
cerebrospinal fluid leaks, concurrent immunosuppressive therapy, family history of congenital or hereditary immunodeficiency, unless the
immune competence of the potential vaccine recipient is demonstrated, febrile illness, active including febrile respiratory illness, HIV-
70
PRODUCT
DESCRIPTION
Vasopressin
Vecuronium Bromide
Verapamil HCl
TRADE
NAME
Lypressin
DOSAGE
FORM/STRENGTH
Injection 20u/mL
Pitressin
Norcuron
Isoptin
Isoptin SR
Injection 10mg
Inj. 2.5mg/mL
Syrup 50mg/mL
Tablet 40mg
Tablet 120mg
Vinblastine Sulphate
Velbe
Injection
10mg/10mL
Vincristine Sulfate
Oncovin
Inj. 1mg/mL
Injection 2mg
PRODUCT INFORMATION
infection or AIDS, immunodeficiency states, history of primary or acquired; including cellular immune deficiencies, hypogammaglobulinemic
and dysgammaglobulinemic states, and congenital immunodeficiency, lymphoma, leukemia, generalized malignancy, bone marrow
malignancy or lymphatic system malignancy, pregnancy or may become pregnant within 3 months of receiving the vaccine, tuberculosis,
active untreated
ADVERSE EFFECTS: Anaphylaxis, Ataxia, Bell's palsy, Encephalitis, Exacerbation of asthma, Guillain-Barre syndrome, Polymyalgia
rheumatica, Seizure, Non-febrile, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Transverse myelopathy syndrome
THERAPEUTIC USE: Endocrine-Metabolic Agent, GI Agent, Vasopressin (class)
DOSE: Adult - Abdominal distension; Prophylaxis - Postoperative complication, initial, 5 units IM (0.25 mL) postoperatively; increase to 10
units (0.5 mL) at subsequent injections repeated at 3- or 4-hour intervals if necessary. Pedia - reduce dose proportionately for pediatric
patients. Abdominal distension; Prophylaxis - Postoperative complication - for pediatric patients a proportionate reduction of the adult dose is
recommended; adult dose: initial, 5 units IM (0.25 mL) postoperatively; increase to 10 units (0.5 mL) at subsequent injections repeated at 3- or
4-hour intervals if necessary.
CONTRA-INDICATIONS: anaphylaxis or hypersensitivity to the drug or its components
ADVERSE EFFECTS: Anaphylaxis, Cardiac arrest, Cardiac dysrhythmia, Coronary arteriosclerosis, Decreased cardiac output, Gangrenous
disorder, Stenosis of bronchus, Water intoxication syndrome
THERAPEUTIC USE: Musculoskeletal Agent, Neuromuscular Blocker, Non-Depolarizing
DOSE: Adult - dosage must be individualized. Anesthesia, During surgery as an adjunct to general anesthesia to facilitate tracheal intubation
or mechanical ventilation; Adjunct a)initial, 0.08-0.1 mg/kg IV bolus b)maintenance, 0.01-0.015 mg/kg IV 25-40 min after initial dose, repeat
every 12-15 min as needed c)1 mcg/kg/min continuous IV infusion 20-40 min after initial intubation dose, after early evidence of spontaneous
recovery; then adjust to maintain 90% suppression of twitch response; range 0.8-1.2 mcg/kg/min. Pedia - dosage must be individualized
Safety and effectiveness not established in pediatric patients 7 weeks of age or younger. Anesthesia, During surgery as an adjunct to general
anesthesia to facilitate tracheal intubation or mechanical ventilation; Adjunct a)(age 8 weeks-1 yr) more sensitive on a mg/kg basis than adults
and recovery may take 1.5 times longer b)(age 1-10 yr) dosage must be individualized; may require slightly higher initial dose and slightly
more frequent supplemental doses than adults c)(age 10-16 yr) initial, 0.08-0.1 mg/kg IV bolus d)(age 10-16 yr) maintenance, 0.01-0.015
mg/kg IV 25-40 min after initial dose, repeat every 12-15 min as needed; may require more frequent supplementation than adults
CONTRA-INDICATIONS: hypersensitivity to vecuronium products
ADVERSE EFFECTS: Anaphylaxis, Apnea, Bronchospasm, Hypotension, Muscle weakness Prolonged, Prolonged neuromuscular block,
Tachyarrhythmia
THERAPEUTIC USE: Antianginal, Antiarrhythmic, Group IV, Antihypertensive, Antimigraine, Calcium Channel Blocker, Cardiovascular Agent,
Phenylalkylamine
DOSE: Adult – Angina a)(extended-release) initial, 180 mg ORALLY once daily at bedtime; titrate to 480 mg at bedtime; MAX 540 mg at
bedtime b)(immediate-release) 80 mg to 120 mg ORALLY three times daily. Pedia - oral formulations are not FDA approved in children under
18 yr. Atrial arrhythmia a)(less than 1 yr old) 0.1-0.2 mg/kg IV over 2 min, may repeat dose after 30 min b)(1-15 yr old) 0.1-0.3 mg/kg IV over
2 min (MAX 5 mg), may repeat dose after 30 min (MAX 10 mg)
CONTRA-INDICATIONS: atrial fibrillation/flutter associated with accessory bypass tract, cardiogenic shock, congestive heart failure, second
or third-degree atrioventricular block, hypersensitivity to verapamil/other calcium channel antagonists, sick sinus syndrome, symptomatic
hypotension, ventricular tachycardia, wide-complex
ADVERSE EFFECTS: Angina, Myocardial infarction, Syncope
THERAPEUTIC USE: Antineoplastic Agent, Mitotic Inhibitor
DOSE: Adult - Breast cancer, Unresponsive to endocrine surgery and hormonal therapy, first dose 3.7 mg/m(2) IV, second dose 5.5 mg/m(2)
IV, third dose 7.4 mg/m(2) IV, fourth dose 9.25 mg/m(2) IV, fifth dose 11.1 mg/m(2) IV, at weekly intervals; increase dose weekly until MAX
dose of 18.5 mg/m(2), target WBC count reduction to 3000 cells/mm(3); weekly maintenance dose 1 increment smaller than final initial dose.
Pedia - Choriocarcinoma, Unresponsive to other chemotherapeutic agents, 3 mg/m(2) when used in combination chemotherapy regimens;
dose modifications should be guided by hematologic tolerance
CONTRA-INDICATIONS: bacterial infection, significant granulocytopenia, unless result of disease being treated
ADVERSE EFFECTS: Azoospermia, Hypertension, Hyperuricemia, Leukopenia, Dose-limiting, Myelosuppression, Neurotoxicity
THERAPEUTIC USE: Antineoplastic Agent, Mitotic Inhibitor
DOSE: Adult - Acute leukemia, usual dose is 1.4 mg/m(2)/wk IV (MAX 2 mg; dose limit depends on patient, physician, protocol, and
institution). Pedia - Acute leukemia a)10 kg or less, 0.05 mg/kg IV once weekly, varies per protocol b)over 10 kg, 1.5 to 2 mg/m(2) IV once
weekly, varies per protocol.
CONTRA-INDICATIONS: Charcot-Marie-Tooth syndrome, hypersensitivity to vincristine/products, intrathecal use
ADVERSE EFFECTS: Myelosuppression, Neuromyopathy
71
PRODUCT
DESCRIPTION
Vitamin B Complex
Vitamin B12
Warfarin
Xylometazoline
TRADE
NAME
Neurobion
Tri - B
DOSAGE
FORM/STRENGTH
Injection
Tablet
Cynovit
Injection
1000mcg/mL
Coumadin
Tablet 1mg
Tablet 2mg
Tablet 2.5mg
Tablet 3mg
Tablet 5mg
Tablet 10mg
Decozal
Otrivin
Nasal Drops 0.05%
Nasal Drops 0.1%
Nasal Spray 0.1%
Xylose
Powder 5grams
Zinc Oxide
Ointment 10%
Powder
Zinc Sulphate
Powder
Syrup 4mg/mL
PRODUCT INFORMATION
THERAPEUTIC USE: Dietary supplements, Nutritional, B Vitamins Combinations
DOSE: Adult - Oral 1 to 2 tablets three times daily. Ampoule – initial treatment 1amp daily by deep IM injection. After subsidence of the acute
symptoms and in less severe cases, 2 or 3 ampoules weekly.
ADVERSE EFFECTS: Rare hypersensitivity reactions
THERAPEUTIC USE: Diagnostic Agent, Vitamin B12 Absorption, Nutritive Agent, Vitamin B
DOSE: Adult – B12 deficiency a)normal absorption, 1000 mcg/day orally; if oral route not adequate, initial treatment same as for pernicious
anemia; chronic treatment should be with oral B12 preparation b)malabsorption, 100 mcg IM or deep SC injection daily for 6 or 7 days; if
clinical improvement and reticulocyte response, give same amount on alternate days for 7 doses; then every 3 to 4 days for another 2 to 3 wk;
then 100 mcg monthly for life. Pedia - Cobalamin deficiency, 1000mcg/day orally, IM route is preferred; 30 to 50 mcg IM daily for 2 or more
wk; then 100 mcg monthly to sustain remission; Pernicious anemia - 30 to 50mcg IM daily for 2 or more wk; then 100 mcg monthly to sustain
remission
CONTRA-INDICATIONS: hypersensitivity to cobalt, B12 products, or any component of the product
ADVERSE EFFECTS: Anaphylaxis, Angioedema, Congestive heart failure, Peripheral vascular disease, Pulmonary edema
THERAPEUTIC USE: Anticoagulant, Coumarin (class)
DOSE: Adult - Atrial fibrillation - Thromboembolic disorder, initial, 2 to 5 mg orally/IV once a day; adjust dose based on the results of INR;
usual maintenance, 2 to 10 mg orally/IV once a day. Pedia - safety and efficacy in pediatrics patients have not been established, although the
use of warfarin for the treatment or prophylaxis of thrombosis is well established; more frequent INR determinations are recommended in
pediatric patients
CONTRA-INDICATIONS: abortion, eclampsia, preeclampsia, threatened, alcoholism; lack of patient cooperation, anesthesia, major regional
or lumbar block, aneurysms; cerebral, dissecting aorta, bacterial endocarditis, bleeding tendencies of the gastrointestinal, genitourinary, or
respiratory tract, blood dyscrasias, cerebrovascular hemorrhage, gastrointestinal, genitourinary or respiratory tract ulcerations or overt
bleeding, hemorrhage, cerebrovascular, hemorrhagic tendencies, hypersensitivity to warfarin or any component of the product, inadequate
laboratory facilities, malignant hypertension, pericarditis and pericardial effusion, pregnancy, known or suspected, psychosis; lack of patient
cooperation, senility; lack of patient cooperation, spinal puncture and other procedures with potential for uncontrollable bleeding, surgery of
central nervous system or eye, recent or potential, traumatic surgery resulting in large open surface, recent or potential
ADVERSE EFFECTS: Cholesterol embolus syndrome, Hemorrhage, Hepatitis, Hypersensitivity reaction, Intraocular hemorrhage, Tissue
necrosis
THERAPEUTIC USE: Decongestant, Imidazoline
DOSE: Adult – Rhinitis, for adults and children 12 years old or more, the recommended dose of xylometazoline 0.1% nasal solution is 2 to 3
drops in each nostril every 8 to 10 hours. The nasal spray (0.1%) is administered as 1 to 2 inhalations in each nostril every 8 to 10 hours.
Should not be employed for longer than 3 to 5 days due to the risk of rebound congestion. Pedia – Rhinitis, In 2 to 12 years of age, 2 or 3
drops of xylometazoline 0.05% solution should be instilled in each nostril every 8 to 10 hours. Dropper dosage forms are preferred over
sprays in children less than 6 years old since dosing can be more easily controlled; In children 6 months to 2 years of age, the usual pediatric
dose of xylometazoline 0.05% solution is 2 to 3 drops in each nostril every 8 to 10 hours; Should not be employed for longer than 3 to 5 days
to prevent the occurrence of rebound congestion
CONTRA-INDICATIONS: Hypersensitivity to Xylometazoline or other adrenergic agents, Narrow-angle glaucoma, Rhinitis sicca, Children
under age 6 years
THERAPEUTIC USE: Diagnosis for intestinal malabsorption and steatorrhea
DOSE: Adult - 5 or 25g dose in 200 to 300 mL (maxi 500 mL) of water for evaluating malabsorptive syndromes.
Pedia - 500 mg/kg as a 5 to 10% solution in water, or 14.5 grams/square meter body surface in a 10% aqueous solution; Maximum pediatric
dosage is 25 grams
CONTRA-INDICATIONS: Absolute contraindications and precautions to this agent have not been determined; no information found at the
time of this review
ADVERSE EFFECTS: Nause, Intestinal bloating, Borborygmi, Vomiting, Cramping, Abdominal discomfort & Diarrhea.
THERAPEUTIC USE: Prevention and soothing relief of nappy rash and redness of the skin. It is also recommended for use in minor burns
and wounds.
DOSE: Apply it evenly at every nappy change, particularly to the folds of the skin. Whereas for minor burns or wounds, clean and dry the
affected area, apply it evenly to the affected area as necessary.
THERAPEUTIC USE: Antipruritic, Hemorrhoidal Agent, Parenteral Mineral-Trace Mineral, Protectant, Dermatological, Throat Agent, Zinc
Supplement
DOSE: Adult - Zinc deficiency, 25 to 50 mg elemental zinc orally per day. Pedia - Zinc deficiency, 0.5 to 1 mg elemental zinc/kg orally daily,
divided 1 to 3 times/day
72
PRODUCT
DESCRIPTION
Zoledronic Acid
TRADE
NAME
Zometa
DOSAGE
FORM/STRENGTH
Injection 4mg
PRODUCT INFORMATION
THERAPEUTIC USE: Bisphosphonate , Calcium Regulator
DOSE: Adult - Bone metastasis - 4mg IV infused over 15min every 3-4 wk; administer with an oral calcium supplement of 500mg and a
multiple vitamin containing 400 IU of vitamin D. Pedia - safety and effectiveness not established in children
CONTRA-INDICATIONS: hypersensitivity to Zoledronic Acid or any of its excipients, hypocalcemia
ADVERSE EFFECTS: Aseptic necrosis of bone, of the jaw, Hyperkalemia, Hypocalcemia, Nephrotoxicity, Pleural effusion
73